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Abstract 
Malaria is one of the most common infectious diseases in the world. In 
particular, Plasmodium falciparum malaria is responsible for more deaths than any 
other parasitic disease. Although there are preventative measures against malaria, it is 
hoped that a vaccine can soon be developed that will have long term benefits in 
malaria control. In order to design a safe and effective vaccine, there needs to be a 
more thorough understanding of the mechanisms involved in anti-malarial immunity 
and which immune responses are protective or pathogenic. 
Individuals living in malaria-endemic areas develop clinical immunity. Although 
these individuals do not have complete sterilising immunity, they are able to control 
infection (as shown by the absence of clinical symptoms in the presence of parasites) 
and limit parasite replication. In contrast, unexposed, or naive, individuals inevitably 
develop clinical illness when infected with malaria. Elucidating the differences between 
these two patterns of response is the key to developing prevention strategies. 
It is now widely accepted that clinical symptoms develop as a result of an 
excessive inflammatory response to malaria antigen. I hypothesise that inflammation 
is primarily due to a "Th-1 -like" response and that the development of clinical immunity 
is associated with the downregulation of pro-inflammatory cytokines. I further 
hypothesise that immune responses of naïve and clinically immune individuals are 
mediated by different populations of mononuclear cells. 
In order to test these hypotheses, I first developed specific and sensitive 
methods to measure cytokine production. I then compared proliferative responses and 
IFN-y production of peripheral blood mononuclear cells (PBMCs) to P. falciparum 
schizont extract (PfSE) from malaria naive, malaria-exposed (but not clinically immune) 
and malaria-immune individuals. In order to determine how PfSE-induced IFN-y 
production is regulated, I have also measured IL-12 p40, IL-12 p70 and IL-10 from 
PfSE-stimulated PBMCs and investigated the role of neutralising antibody to IL-12 in 
modulating IFN-y production. Finally, a combination of cell surface staining and 
intracellular cytokine staining was used in order to determine the phenotypes of cells 
responding to PfSE. 
Cells from all individuals proliferated vigorously in response to PfSE, but there 
were no significant differences between any of the groups. Cells from naïve individuals 
produced moderate levels of IFN-y which were mainly IL-12-dependent. Intracellular 
cytokine staining analysis indicated that IFN-y was primarily produced by 	T cells, 
although significant proportions of 'yö+ I cells and NK cells also produced IFN-'y. IFN-y 
levels were significantly higher in PBMC cultures of exposed individuals than in cell 
cultures from naïve individuals and were only partially IL-12-dependent. In contrast, 
minimal levels of IFN-y were produced from PfSE-stimulated cells of immune 
individuals and were significantly lower than those found in either naïve or exposed 
populations. Neutralising antibodies to IL-12 reduced IFN-y to background levels in cell 
cultures of immune donors. Although these data indicate that IL-12 does play a role in 
mediating IFN-y responses, no significant differences were found in malaria-specific 
IL-12 p40 protein levels or mRNA transcripts between any of the groups. There was 
also no significant difference between the groups in IL-b 0 production, suggesting that 
this cytokine does not play a major role in modulating PfSE-stimulated IFN-y 
production. 
In cell cultures from all 3 groups, PfSE-stimulated cells were predominantly 
I cells although there were also activated NK cells and B lymphocytes. CD4+ c4+ 
CD45RO+ cells were the predominant population of lymphoblasts in cell cultures of 
naïve individuals, although S+ cells also responded to PfSE. Although exposed 
individuals had the same predominant cell phenotype responding to PfSE, they also 
had significantly higher numbers of responding CD8+ cells than naïve individuals. The 
data from this study strongly supports the idea that the downregulation of inflammatory 
cytokines is a critical component of clinical immunity and that this may be dependent 
on the cell population which is activated. 
These findings have important implications for the development of antimalarial 
vaccines; vaccination protocols should avoid the induction of strong pro-inflammatory 
immune responses in naïve individuals and should seek to target antigens recognised 
by the CD8+ population which may be associated with protective clinical immunity. 
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Chapter 1: Introduction 
1.1 What is malaria? 
1.1.1 Plasmodium life cycle 
Malaria is a mosquito-borne infectious disease caused by protozoan parasites of 
the genus Plasmodium. Plasmodium falciparum is the most common and most 
pathogenic type of the 4 species which infect humans. Plasmodium has 4 different 
growth stages (figure 1.1), 2 in mosquitoes (sexual and asexual) and 2 in humans (both 
asexual). After an infectious bite, sporozoites migrate to the liver where they undergo 
growth and reproduction. Infection is asymptomatic (3, 175, 210). After about 8 or 9 
days, merozoites, the asexual erythrocyte stage which causes the clinical symptoms of 
malaria (208), are released and then infect red blood cells (RBCs). Fever occurs when 
schizont-infected erythrocytes burst and release merozoites which parasitise new 
RBCs. It is thought that toxins released at schizont burst, such as 
glycosylphosphatidylinositol (GPI)(1 17, 305), stimulate macrophages (Mø) to produce 
tumour necrosis factor alpha (TNF-a) which in turn mediates fever by upregulating the 
inflammatory response (188, 190, 192). However, the extent to which these toxins 
alone can mediate all the pathology of malaria has recently come into question (308). 
1.1.2 Malaria: the problem 
Malaria is the second most common infectious disease in the world. It is 
estimated that over 300 million cases and over 3 million malaria-related deaths occur 
every year, with the majority of cases occurring in sub-Saharan Africa (280). The 
majority of deaths occur in children, and malaria is a major cause of illness and death in 
pregnant women (100). In particular, severe anaemia and/or cerebral malaria are the 
common clinical manifestations of P. falciparum (218, 222, 229, 233, 280). Mortality is 
caused only by P. falciparum, because illnesses such as cerebral malaria are thought to 
result from sequestration (adherence of infected RBCs to endothelial cells), a 
phenomenon which does not occur with other Plasmodium infections (175). 
Currently, the only forms of personal protection against malaria are prophylactic 
drugs, such as chioroquine and mefloquine, or prevention of direct contact with 
mosquitoes via use of insecticide-impregnated bed nets and mosquito repellents. 
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These forms of protection are highly problematic for several reasons. The emergence 
of drug-resistant strains of Plasmodium has reduced the efficacy of many 
chemoprophylactic regimens. Also, in underdeveloped countries where the highest 
prevalence of malaria occurs, individuals are unable to afford the high cost of medical 
treatment. Although the initiation of impregnated bed net programs has been 
successful in reducing the number of malaria-related deaths (64), there is a risk that 
individuals who are no longer constantly exposed may have lower natural immunity to 
malaria. 
With all of these problems, combined with the fact that the incidence of malaria 
is increasing, it is hoped that a vaccine, or measures which can lessen malaria 
pathogenesis, can soon be developed. DNA vaccinations conferred partial protection 
to Plasmodium yoelii infection in mice (78), and pre-immunisation with an attenuated 
Salmonella typhi vaccine expressing the circumsporozoite protein of P. falciparum 
elicited strong proliferative and interferon-gamma (IFN-7) responses in vitro (324). But 
vaccine development has been highly problematic because of antigenic polymorphism 
and antigenic variation and because specific antigens (Ag) are presented at different 
stages of the parasite life cycle (77, 187, 280). It has been suggested that development 
of a multi-stage vaccine would be preferred, because protective immune responses to 
different stages of the parasite life cycle would be induced (77). In order to develop 
such a vaccine, there needs to be a better understanding of parasite-host interaction 
and of what immune responses would be beneficial. 
1.1.3 The epidemiology of malaria 
In highly endemic areas of stable, perennial malaria, infants less than one year 
of age have few clinical episodes of malaria (6, 40, 108, 213, 347). This phenomenon 
may be attributable to factors such as the presence of fetal haemoglobin (256) or 
transplacental transfer of maternal immunoglobulin (44). However, this innate 
immunity wanes with age, and children under the age of 5 have the highest risk of 
clinical attacks, whereas all ages are affected in areas of low endemicity (low, 
unstable, seasonal transmission) (233). Those individuals who survive past childhood 
develop premunition, a state of non-sterilising immunity where there is an absence of 
clinical symptoms when parasites are present in the bloodstream (222, 233, 360). It is 
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generally thought that repeated and constant exposure is required for acquired 
immunity (222). However, Deloron et al. demonstrated that malarial immunity is long 
lasting even without constant exposure (73). It has also been hypothesised that 
individuals develop anti-toxic (lack of clinical symptoms) and anti-parasitic (inhibition of 
parasite replication) immunity separately (268). This point has been challenged by 
studies which demonstrated that very few children with asymptomatic infection had 
high parasite counts (155) and that febrile temperatures were always associated with 
high parasite density across all age groups (262). 
The immune mechanisms that cause clinical illness and subsequent clinical 
immunity are not fully understood in human malaria infection. It is thought that clinical 
disease is a result of an excessive inflammatory response and that downregulation of 
this response leads to immunity (discussed in section 1.2.2). Understanding the 
factors which underlie premunition may be the first step in developing preventative 
measures against malaria. 
1.2 The innate immune response and malaria infection 
1.2.1 Innate versus adaptive immunity 
There are two main parts to immunity: innate and adaptive. Innate, or natural, 
immunity works in an antigen non-specific manner by recognising common components 
of pathogens. Innate defence mechanisms are in place before infection, are rapidly 
activated and are not enhanced by prior exposure; that is to say, there is no 
immunological memory (18, 94, 95). The innate immune system provides a first line of 
defence against invading organisms. 
Adaptive, or acquired, immunity is exquisitely Ag specific and may be long 
lasting. This line of defence is specifically induced by foreign Ag and relies upon clonal 
expansion of I and B lymphocytes (94, 95); as a result, adaptive immunity is not as 
immediate as innate immunity. Each successive exposure to such Ag enhances the 
immune response; i.e. immunological memory has developed, and results in more rapid 
secondary and subsequent responses. 
The first interaction with an invading pathogen is via the innate immune system. 
Cells such as Mø (macrophages) and natural killer (NK) cells can directly lyse and/or 
phagocytose foreign pathogens (23). But more importantly, these cells produce 
'ru 
cytokines which affect the differentiation and proliferation of B and I lymphocytes (94, 
95, 227, 333). Thus, the interaction between the innate immune system and a 
pathogen is involved in the initiation of subsequent adaptive immune responses. 
1.2.2 Innate immunity and malaria 
Malaria parasites activate IFN-y production from NK cells which in turn stimulates 
Mø to produce TNF-ct and to attack parasites (189). These responses are essential in 
limiting primary infection. In mouse models, IFN-y inhibited parasite replication (98) and 
IFN-'y and TNF-a conferred protection against malaria via a nitric oxide (NO)-dependent 
pathway (151, 309, 320). Elevated serum levels of lFNj' and TNF-a correlate with an 
absence of parasitemia (74) and rapid cure (182) respectively in human malaria. 
However, overproduction of these cytokines may be what causes clinical illness. 
Mice infected with Plasmodium berghei (P. berghei) ANKA failed to develop cerebral 
malaria when IFN-y and TNF-a were neutralised (293). In humans, plasma 
concentrations of these cytokines were higher in symptomatic than in asymptomatic 
infections (118, 193, 238, 356). Taken together, these observations suggest that there 
is 	critical balance of the quantity, timing, location and context (i.e. cytokine milieu) of 
cytokine production, which determine if these responses are pathogenic or beneficial. 
Thus, the immune system is involved both in protective immunity and pathogenesis. 
1.3 Components of P. falciparum antigen 
1.3.1 Early in vitro studies with P. falciparum antigen 
Individuals who live in endemic areas are continuously exposed to malaria. 
When cultured in vitro, their peripheral blood mononuclear cells (PBMCs) proliferate 
vigorously to malaria Ag (114, 281). More interestingly, it has also been shown that 
cells (studies have primarily used T cells) from individuals who have never been 
previously exposed to malaria, can also be induced to proliferate in response to 
plasmodial antigens (14, 20, 62, 63, 75, 97, 105, 112, 115, 119, 159, 290, 366, 370). 
The question that remains to be answered is: how is malaria recognised by these T 
cells? There are three different stimuli which are able to activate T lymphocytes: 
mitogens, superantigens and classical recall antigens. 
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1.3.2 Mitogens 
Mitogens, which tend to be molecules derived from plant or bacterial cell walls, 
generate a significant lymphoproliferative response in T and B cells with the highest in 
vitro proliferation usually seen between 2 and 4 days. Mitogens bind directly to cell 
surface receptors without needing to be processed and presented on major 
histocompatability complexes (MHC). For example, phytohaemagglutinin (PHA), a 
plant lectin, binds directly to the CD3-T cell receptor (TcR) complex which is expressed 
by all T cells, whatever their Ag specificity, and transduces a proliferative signal (1). 
Thus, there is a rapid, non-specific, polyclonal activation of cells in response to 
mitogens. 
Studies done in the late 70s-early 80s showed that P. falciparum extracts 
generated non-specific blast transformation in vitro of PBMCs from immune as well as 
non-immune donors (14, 105, 119, 366). Because unsensitised individuals were also 
able to respond, it was thought at the time that the primary mechanism was mitogenic. 
However, it was agreed that P. falciparum extracts also exhibited some antigenic 
activity. 
1.3.3 Superantigens 
Superantigens are interesting in that they have some characteristics of both 
mitogens and antigens. The most common superantigens, staphylococcal 
enterotoxins, are able to stimulate a significant proportion of T cells by cross-linking 
MHC with the variable portion of (Vu) of the T cell receptor beta chain (101). 
Superantigens are not processed and presented on MHC but do require MHC 
expression as they bind to MHC class II outside the peptide-binding site (101). Maximal 
in vitro proliferation is usually seen between 3 and 6 days. They are not able to 
stimulate as large a proportion of T cells as mitogens, because different superantigens 
stimulate cell with different Vp chains (1). 
Behr et al. hypothesised that P. falciparum extracts are superantigenic rather 
than antigenic in nature, because the kinetics of the response they induce are most 
similar to those produced by enterotoxins (20). In addition, P. falciparum extracts 
induced a significant increase in gamma-delta T (y+)  cells in cultures from malaria-
unexposed donors (20). This is characteristic of the response to staphylococcal 
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enterotoxin B (SEB) but not to purified protein derivative of Mycobacterium tuberculosis 
(PPD), a classical recall Ag. Other studies also concluded that P. falciparum extracts 
had superantigenic components, because extracts stimulated a proportion of naïve (i.e. 
unprimed) I cells (97, 115). However as discussed in the next section (1.3.4), most 
studies demonstrate that P. falciparum extracts stimulate T cells in the same manner as 
a classical recall Ag. 
13.4 Classical recall antigens 
Antigens need to be processed and presented on MHC in order to be recognised 
by T cells. Maximal in vitro proliferation to Ag, such as PPD, is usually seen between 6 
and 9 days. After primary stimulation, Ag-specific clones of T cells proliferate and a 
high frequency of memory T cells are produced that have exquisite specificity to a 
particular Ag. Thus, there is a much smaller proportion of T cells being activated in a 
recall antigenic response (1-5%) than in response to a superantigen (10-30%) or 
mitogen (100%). 
There is a clear consensus that P. falciparum extracts are also antigenic in 
nature in the classical sense. In contrast to the results from Behr et al.'s study, others 
have demonstrated that proliferative kinetics are similar to other recall antigens (62, 63). 
Second, a number of studies also proved that responses to P. falciparum are not only 
MHC-dependent but are MHC-restricted (i.e. HLA-dependent restriction of T cell 
proliferation), a crucial component of Ag presentation (114, 159, 290). 
If P. falciparum is truly antigenic in nature, why does the immune system 
respond so vigorously, if it has had no previous exposure? It is hypothesised that the 
responding cells are in fact memory cells. Memory cells are believed to be maintained 
at high frequency in peripheral blood through cross-reactive stimulation with other 
environmental Ag. Currier et al. and Bender et al. generated malaria-specific T cell 
clones from non-exposed individuals and found that these cells were able to proliferate 
in response to a number of common environmental organisms (24, 62, 63). This 
hypothesis is further supported by the fact that similar cross-reactive responses are 
found with yeast and other parasitic infections such as Leishmania (275), 
Paracoccidioides brasiliensis ( 239, 240) and Ttypanosoma cruzi (266). 
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1.4 Cellular responses to malaria infection 
1.4.1 Primary immune cells 
1.4.1.1 Macrophages 
Macrophages (Mø) are mononuclear phagocytes, which provide one of the first 
lines of defence in innate immunity (1). They also act as Ag presenting cells (APC) to 
CD4 cells, therefore stimulating the adaptive immune response (267). They are closely 
related to blood monocytes. 
Mø produce a number of inflammatory cytokines, such as interleukin-1 (IL-1), 
interleukin-6 (IL-6) and TNF-a, and oxidative metabolites (NO discussed in section 
1.5.3.4) which have been implicated in the pathogenesis of malaria (153, 190, 261), 
particularly TN F-a which is a mediator of fever paroxysms in acute P. falciparum 
infection (32, 55, 191, 194). Mø also produce interleukin-12 (IL-12), a cytokine which 
recruits NK cell for destruction of foreign pathogens, stimulates IFN-y production by NK 
cells, and mediates I cell differentiation down a Thi pathway (142, 144, 164, 301). 
IL-12 may play an important role in malaria infection because it can stimulate a Mø-
mediated inflammatory response via IFN-y and TNF-a (61). 
Mø also regulate inflammatory responses by producing anti-inflammatory 
cytokines such as interleukin 10 (IL-10) and transforming growth factor beta (TGF-p) 
(66, 141). These cytokines decrease inflammatory cytokine production from PBMCs of 
P. falciparum-infected individuals (135) and in mice infected with Plasmodium berghei 
(252). 
1.4.1.2 NK cells 
NK cells are large granulocytic lymphocytes which represent about 15% of the 
total circulating lymphocytes in peripheral blood (1). Human stimulatory (CDI6 and 
CD56) as well as inhibitory (KIR and CD94) NK cell Ag receptors mediate cytotoxicity 
when target cells fail to express MHC class I proteins on their cell surface (39, 123, 
147, 209, 277, 278, 307) 
One of their primary functions is to lyse foreign pathogens or infected cells (123, 
278). NK cells in conjunction with Mø, provide the first line of defence in innate 
immunity. NK cells also facilitate the development of ThO cells into Thi cells via IFN-y 
production (323). Most importantly, they are a major source of IFN-y which is essential 
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in activating Mø to kill invading pathogens during the early stages of infection (143, 289, 
302, 307). IFN-y production by NK cells confers resistance in both Toxoplasma gondii 
and Plasmodium chabaudi infection (143, 236), but decreases resistance in mice 
infected with Listeria (331) 
1.4.2 T lymphocytes 
1.4.2.1 CD8+ TceIIs 
CD8+ I cells, or cytotoxic T cells, lyse infected cells which express processed 
foreign Ag in association with MHC class I molecules. They also protect against 
parasitic infections such as Toxoplasma gondii through the production of IFN-y (321). 
In malaria vaccination studies in mice, protection against exoerythrocytic stages of 
P. yoelii was absolutely dependent on IFN-y from CD8+ cells (78). CD8+ cells are 
major IFN-y producers and probably produce more IFN-y than CD4+ on a cell to cell 
basis (363). 
At first it was thought that CD8+ cells did not play a role in acute malaria 
infection, because infected red blood cells do not express MHC class I molecules. 
However, CD8+ cells may have some suppresser activity. While some studies showed 
that the removal of CD8+ I cells from PBMC cultures had no effect on lymphocyte 
proliferative responses to malaria Ag (136), others have clearly shown an increase in 
responsiveness in the absence of CD8+ cells (285). Although the exact mechanism of 
suppression is not known, CD8+ cells may be producing downregulatory cytokines such 
as TGF-13, a cytokine which is able to suppress proliferative responses (348). 
1.4.2.2 Naïve and memo!y CD4+ a/i-i- T cells 
Greater than 90% of all circulating T cells bear T cell receptor (IcR) composed 
of a and 13  chains (239, 365). CD4+ cells, or helper T (Th) cells activate both Mø and 
B cell growth and differentiation (1). They may be further divided into subsets on the 
basis of cytokine secretion (see section 1.5.2). CD4+ a13+ cells are required for 
maximal yB+  cell activation (84, 199, 291, 319). 
Numerous in vitm studies demonstrate that CD4+ 43+ memory cells are the 
predominant cell population which proliferate in PBMCs from previously unexposed 
individuals exposed to different fungal, bacterial, and parasitic organisms, including 
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P. falciparum (62, 63, 75, 239, 240, 266, 290, 370). The majority of these cells express 
the RO isoform of CD45 (CD45RO+) (75, 239, 266) which is indicative of previously 
activated or memory cells (125, 159). These studies have led to the hypothesis that 
common pathogens or commensal or environmental organisms carry antigenic epitopes 
which cross-react with those of other organisms such that malaria-reactive T cell clones 
can be expanded by exposure to non-malarial antigens (63). 
However some studies have also shown that cells bearing CD45RA, normally a 
naive cell marker, can also respond to malaria Ag. Goodier et al. suggested that the 
Ag preparation used in these experiments must contain some superantigenic elements 
since both memory and naive cells proliferate (115). In studies by Fern etal., 
CD45RA+ is the only subset which expanded (97). These results suggest a large 
number of antigenic epitopes can be presented by MHC class II molecules, and this 
results in an unusually extensive I cell response. Alternatively, the CD45RA+ 
population identified by Fern et al. may have represented activated cells which had 
reverted to the naïve phenotype (125). 
Depending on the type of infection and what stage the infection has reached, 
CD4+ c4+ cells may stimulate an Ab-mediated or a cell-mediated inflammatory 
response. CD4+ cells, clonally expanded in vitro with P. yoelii and then transferred into 
reconstituted nude mice, were found to mediate a complete clearance of infection 
through IFN-y (9). CD4+ c4H- cells are also potent producers of interleukin-2 (IL-2) 
which in turn activates 78+ cell-mediated production of IFN-y. However, if CD4+ a43+ 
cells produce too much IFN-'y, pathology may result from excessive production of other 
inflammatory cytokines such as TNF-cL (293). However, CD4+ cells can also produce 
anti-inflammatory cytokines such as IL-4 which downregulate or inhibit the downstream 
effects of inflammatory cytokines or which help mediate Ab production. Murine 
Plasmodium chabaudi chabaudi AS infection (197) and human P. falciparum infection is 
resolved by antibody production (57) 
1.4.2.3 y8+ T cells 
T cells also recognise Ag through a TcR composed of y and 6 chains, but only 6-
8% of lymphocytes in human peripheral blood express yo receptors. (365). A small 
proportion of 76 cells are CD4+ or CD8+, but most are CD4-ICD8-. In adult humans, 
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two-thirds of these cells express the Vy9 and V62 chains (112, 365). However, 
V79V62+ cells are not the major subset of 76 cells in cord blood or in intestinal epithelia 
(69, 112), suggesting that these cells may be expanded by constant antigenic 
exposure. Although the V79 V2 is the largest subset in healthy individuals, and is 
usually the one which is expanded during malaria infection (20), in one report the 
Vy9 V1 subset was shown to be preferentially expanded during P. falciparum infection 
(51). 
y8+ cells differ from a+ T cells in the way they recognise Ag, since 78+ cells are 
able to recognise nonpeptidic substances. Though some a+  cells are able to do the 
same (165), they are MHC restricted, whereas y&f cells are not (35, 69, 106, 107). y+ 
cells can recognise protein Ag in one of three ways. First, they can recognise 
processed peptide in a classical MHC-restricted fashion; Haregewoin et al. found that 
73+ clones are unable to respond to HLA mismatched APC (127). Second, they 
recognise Ag in a MHC-dependent manner; that is, MHC must be present but does not 
have to be HLA-matched. For example, Schild et al. showed that a 3+ clone specific 
for one MHC was able to cross-react with other MHC molecules (304). Finally, yö+ cells 
recognise extracellular peptides or non-peptide Ag which bind directly to the TcR 
without the need for MHC presentation (35, 294). Ag recognition involves the Ag 
receptor, but yö+ cells recognise conformational epitopes in an 'immunoglobulin-type' 
manner (294, 304). 
yö+ cells may play a role in immunosurveillance, because they are able to detect 
and destroy infected cells and because of their high prevalence in epithelial locations 
(127, 294). Elloso etal. showed that y&- cells inhibit P. falciparum merozoites from 
infecting erythrocytes in vitro, thereby inhibiting active malaria infection (85). In 
a3+ TcR-deficient mice, y3+ cells are able to lyse T. gondii -infected Mø (163). More 
importantly 'y&'- cells participate in the inflammatory response through the production of 
pro-inflammatory cytokines such as IFN-y (17, 54, 106, 107, 116). yö+ cells produced 
high levels of lFN-y, which mediated the clearance of murine T. gondii infection (163). 
In vitro studies showed that human y6+  cells are stimulated to produce IFN-y against 
malaria Ag (116, 264) and concluded that 'y+ may have an immunopathologic role. 
There is a significant increase in the proportion of yö-i- cells in peripheral blood 
during acute malaria infection (137, 242, 260, 291, 295), although in two studies, no 
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increase in y+  cell proportions were found during infection in individuals who have lived 
all their lives in malaria endemic areas (145, 260). Thus y+ cell expansion may be a 
feature of acute malaria in non-immune or semi-immune individuals but the response 
may be down-regulated in clinically immune individuals. It has also been found that y6+ 
cells are preferentially expanded in vitro when stimulated with P. falciparum Ag (20, 
115, 198). These results seem to contradict the evidence that CD4+ c3+ cells were 
preferentially expanded in response to malaria Ag (62, 63, 75, 290, 370). One reason 
for this discrepancy may be the source of malaria Ag used in the assays. Waterfall et 
al. demonstrated that CD4+ c43+ cells are preferentially expanded when cells are 
cultured with a freeze-thaw schizont extract, while y+ cells are expanded in the 
presence of either live schizonts or schizont extract plus IL-2 (354). Elloso et al. also 
demonstrated that + cells only responded in the presence of CD4+ ct3+ cells (84). 
These results imply that CD4+ c4+ cells may be the crucial cells stimulated, because 
76+ cell expansion requires CD4+ a+  cells for endogenous IL-2. 
1.4.3 B cells 
B cells represent only 15% of the total circulating lymphocytes in peripheral 
blood, but are much more abundant in lymph node (25%) and spleen (45%) (1). B cells 
may contribute to humoral immunity against malaria by generating Ag-specific 
antibodies but may also act as antigen-presenting cells for CD4+ cells. Vice versa, 
CD4+ cells produce T helper 2 (Th-2)-like cytokines (i.e. interluekin-4 (IL-4)) and 
T helper 1 (Th-1)-like cytokines (i.e. IFN-'y) which stimulate B cell production of 
neutralising and complement fixing antibodies respectively (2). The study of 
immunoglobulin production in malaria infection was pioneered by Cohen and McGregor 
in the early 1960s when they were able to demonstrate complete sterilising immunity to 
P. falciparum infection in African individuals who had received serum from immune 
individuals (57). Immunity by passive transfer of lgG in immune serum to non-immune 
adults has also been confirmed by Druilhe et al. (79). Antibodies are thought to confer 
protection against malaria by neutralising parasites (i.e. inhibiting merozoite RBC 
invasion) through Ab-dependent cellular cytotoxicity (221) or through interactions with 
malaria 'toxins'. Although early acute infection is controlled primarily by pro-
inflammatory cytokines, complete resolution of parasitemia requires antibody help in 
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mice infected with P. c. chabaudi (196, 330). In humans studies, higher levels of lgG 
and 1gM are found in individuals living in malaria-endemic areas (222), though these 
antibodies may not all be parasite specific. Riley et al. also found that Ab responses to 
merozoite surface protein-1 (MSP-1) increase with age (281). Finally, Luty et al. 
demonstrated that elevated levels of specific IgGi and IgG3 were associated with lower 
or absent parasitemia in Gabonese schoolchildren (211). Taken together, these results 
suggest a protective role for B cells in malarial infection. 
1.5 Cytokines mediating the immune response to malaria 
1.5.1 Introduction 
Cytokines are hormone-like proteins which provide a communication network 
within the immune system and mediate almost every aspect of innate and adaptive 
immunity. Monokines are the subset of cytokines which are mainly produced by 
mononuclear phagocytes. They control the effector functions of these cells and act as 
co-stimulators for lymphocyte activation. Lymphokines are the subset of cytokines 
which are produced by activated T lymphocytes; they regulate activation, growth, and 
differentiation of lymphocyte subsets. However, lymphokines also activate and regulate 
the inflammatory response. 
The cytokine network is a complex series of interactions whose picture still 
remains incomplete. There are numerous cytokines which are produced when cells are 
stimulated with P. falciparum (116, 128, 349), many of which have overlapping and 
redundant functions. The question of whether infection is cleared or disease is 
exacerbated depends on the balance of the overall cytokine milieu. 
1.5.2 The Thi vs. Th2 paradigm 
Studies in mice have demonstrated that CD4 T cells can be divided into Thi and 
Th2 cell subsets based on the cytokines they produce and their primary functions. Thi 
cells produce lFN-y and IL-2 and mediate cellular immunity, whereas Th2 cells produce 
IL-4, IL-5, IL-b, and IL-13 (IL-10 only in mice) and promote growth and differentiation 
of B lymphocytes (2, 91, 258, 288, 318). It is likely that this dichotomy also occurs in 
CD8 cells, as has been recently suggested in Schistosoma mansoni infection (91). It 
was originally thought that Thi responses were mainly protective against bacterial, 
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protozoal and fungal pathogens while Th2 responses were mainly protective against 
helminth infections, although more recent studies have shown that both Thi and Th2 
cytokines mediate immune responses in many different types of infections (8, 301, 
362). Recent studies have also shown that the Thi vs. Th2 paradigm holds true for 
human CD4 cells, although the range of cytokines is less polarised (71, 86). For 
example, in humans IL-6 and IL-10 are produced by both Thi and Th2 cells (318, 324). 
Activated T cells are believed to express an early undifferentiated phenotype 
(ThO), which produces both types of cytokines (i.e. IFN-y and IL-4) before further 
differentiation into Thi or Th2 cells (86, 253). However, differentiated phenotypes do 
not always remain stable. For example, Sornasse et al. and Szabo et aL demonstrated 
that Th2 cells were able to revert to ThO or Thi cells under the influence of IL-12 (318) 
or IFN-y (323). Although categorising Th cells based on the cytokines they produce is 
extremely helpful in describing immune responses, recent studies indicate that immune 
responses are not as polarised as has been thought (8). Rather it is the balance 
between cytokines that determine which effector mechanisms will predominate. 
There is some evidence that ThO cells include a distinct population of 
differentiated cells which do not function as precursors for Thi and Th2 cells and 
which produce both Thi and Th2 cytokines. A number of studies have identified cells 
producing a combination of IL-2, IL-4, IL-5, and IFN-y (86, 234, 253, 265). 
Finally, cells that produce only TGF-P have been designated Th3 cells. Th3 
cells are downregulatory cells which immunosuppress Thi and Th2 cellular responses 
via production of TGF-13 (171, 220, 338, 361). 
The nature of the Ag and the cytokine environment determine the pathway of 
differentiation of a naive Th cell. Sartono et al. found that cells from lymphatic fitariasis 
patients produced Thi cytokines when stimulated with PPD and Th2 cytokines when 
stimulated with worm Ag in vitro (299). Type 1 cytokines, IL-12 and IFN-y, and type 2 
cytokines, predominantly IL-4, will drive naive Th cells to differentiate into Thi and Th2 
cells respectively, while reciprocally downregulating the other class of cytokines (323). 
The following sections describe some of the cytokines which have been 
identified as important in the context of malaria infection, focusing particularly on their 
roles in inflammatory responses. 
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1.5.3 Inflammatory cytokines 
1.5.3.1 Cytokines produced by macrophages 
IL-i 
IL-1 (IL-la and IL-1f3) are produced by Mø to act both upon lymphocytes and 
upon Mø themselves. IL-1 stimulates a Mø-mediated inflammatory response, and like 
TNF-a, is also an endogenous pyrogen which mediates fever production by increasing 
prostaglandin synthesis by hypothalamic cells (1, 191). IL-1 acts as a co-stimulator for 
NO production by Mø (287) and for IFN-y production by NK cells and I lymphocytes 
(66, 121, 142). 
IL-1f3 and IL-12 mediate resistance via an IFN-y pathway to T. gondiiin vivo in 
mice with severe combined immunodeficiency (SCID) (142). A similar pathway could 
operate in malaria. However, elevated serum concentrations of IL-1 receptor 
antagonist, a soluble factor which competes with IL-1 for IL-1 receptors, were found in 
Gambian children with cerebral malaria and acute P. falciparum malaria but not 
asymptomatic infection, indicating that an overproduction of this inflammatory cytokine 
may be detrimental to the host (153, 154). Thus the balance of IL-1 production may be 
critical with low levels being beneficial and promoting parasite clearance and high levels 
promoting disease. 
IL-6 
IL-6 is also a Mø-derived pyrogen that helps stimulate the inflammatory 
response, although it is also considered to be a Th2 cytokine in mice and has an 
important role in B cell differentiation (I). IL-6, in conjunction with TNF-a, is a crucial 
cytokine in fever induction and innate protection against malaria parasites (182, 191). 
An early increase of serum IL-6 was demonstrated in protected vaccinees immunised 
with P. falciparum sporozoites (128). However, higher levels of IL-6 were found in 
individuals with complicated P. falciparum malaria and cerebral malaria compared to 
asymptomatic and aparasitemic individuals (15, 153, 182, 238). 
TNF-a 
TN F-a is an inflammatory cytokine which is produced primarily by Mø following 
contact with microbial pathogens (190) but also by NK cells and T lymphocytes. TNF-a 
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activates Mø and cytotoxic T cells for cellular killing, stimulates IL-1 and IL-6 production 
from Mø and acts as a co-stimulator of IFN-y production by NK cells (311, 335). TNF-a 
contributes to both protection and pathology in different diseases. 
TNF-a-mediated IFN-y production from NK cells has been found to be necessary 
in clearing infections of Listeria monocytogenes, T. gondii, and P. c. chabaudi AS (121, 
311, 320, 335). Although low levels early on in infection correlate with resistance, 
excessive levels of TNF-a late in P. c. chabaudi infection correlate with susceptibility in 
B6 mice, (152). 
In humans, TN F-a is the primary endogenous pyrogen which causes fever in 
P. falciparum infection (55, 328). Kwiatkowski hypothesised that fever induced by TNF-
a may be beneficial to the host, because elevated temperatures kill off the mature 
erythrocytic stages of the parasite (188, 190). It has also been demonstrated that 
monocyte-mediated Ab-dependent killing of P. falciparum is dependent on TNF-a (37). 
Kremsner et al. were able to correlate elevated levels of TNF-a with a more rapid 
clinical and parasitologic cure in patients with mild P. falciparum malaria (182). 
However, excessive levels of TN F-a can play a pivotal role in the pathogenesis of 
infectious disease. Groenveld et al. found high levels of numerous inflammatory 
cytokines, including TNF-a, in patients with severe sepsis (120). Elevated levels of 
TNF-a and TNF-a receptor 1 were found in individuals with acute and severe P. 
falciparum infection compared with individuals with asymptomatic infection (118, 154, 
155, 193, 261). 
TNF-a may be the major pathogenic cytokine in severe malaria. TNF-a 
suppresses bone marrow stem cell division and has been implicated in severe malarial 
anaemia (186). TNF-a increases lactate and decreases glucose levels which, if in 
excess, can lead to hypoglycaemia (56). Finally, TNF-a upregulates the adhesion 
molecules, intercellular adhesion molecule-1 (ICAM-1) (28, 225), endothelial leukocyte 
adhesion molecule 1 (ELAM-1) and vascular cell adhesion molecule 1 (VCAM-1) (248). 
It has been hypothesised that cerebral malaria is caused by the adherence of 
parasitised RBCs to these adhesion molecules in brain capillaries, causing reduced 
blood flow and hypoxia (248). 
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IL-12 
IL-12, originally called NK cell stimulatory factor, is composed of 2 subunits, p35 
and p40 which give rise to the biologically active p70 heterodimer. The p35 subunit is 
constitutively expressed by a number of cell types, while p40 is only produced by cells 
producing bioactive IL-12 (43, 124, 212, 243). It is produced primarily by monocytes, 
dendritic cells and Mø (124). 
IL-4, IL-b, and TGF-13 downregulate the production of IL-12 (219, 237, 301), and 
IFN-y, which is itself upregulated by IL-12, upregulates IL-12 (113, 315, 333), although 
IL-12 can be produced independently of IFN-y (130). IL-12 stimulates the production of 
all lgG isotypes (195, 230, 237), acts as a co-stimulator for I lymphocyte proliferation 
(132) and most importantly, activates the inflammatory response by enhancing NK cell 
maturation, cellular cytotoxicity and IFN-y production (25, 26, 130, 237, 301). IL-12 also 
potentiates innate inflammatory response by driving ThO cells to differentiate into Thi 
cells, which also produce IFN-y (13, 72, 306, 340). 
IL-12 is produced in response to bacterial and parasitic infections, including 
Leishmania braziliensis, M. tuberculosis and P. c. chabaudi AS (316, 320, 326). Flynn 
et al. demonstrated that lL-12 is necessary for clearance of M. tuberculosis infection in 
BALB/c mice (102). Resistance to Leishmania major infection is correlated with the 
ability to produce IL-12 (21, 122), and IL-12 enhances the efficacy of a pertussis whole-
cell vaccine (217). However, Taha et al. demonstrated that IL-12 levels increased in 
patients with active clinical tuberculosis, possibly indicating a detrimental effect of IL-12 
(326). 
Administration of recombinant IL-12 before sporozoite challenge conferred 
complete sterile protection against P. cynomolgi infection in monkeys (138). In resistant 
mice, the appearance of Thi cells and high levels of IEN-y, mediated by IL-12, predicts 
survival of the host and a relatively mild infection of P. c. chabaudi AS while the exact 
opposite occurs if Th2 cells are preferentially expanded (309, 320). Other studies have 
shown that IL-12 mediates killing not only of infected erythrocytes but also of infected 
hepatocytes (61). However, excessive levels of IL-12 may be pathogenic. Yoshimoto 
et al. demonstrated that IL-12 mediated clearance of blood stage P. berghei XAT (an 
attenuated strain) (369), but that in lethal P. berghei infection, IL-12 was involved in liver 
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damage and death (368). No data is available on whether the same is true for human 
malaria infection. 
1.5.3.2 Cytokines produced by lymphocytes 
IL-2 
IL-2 is mainly produced by the Thi subset of CD4+ and CD8+ cells. IL-2 is a 
potent stimulator of NK cells (334), but mainly induces the proliferation, differentiation, 
and activation of T lymphocytes (i.e. CD4+, CD8+ and 76+ cells). It binds to the IL-2 
receptor complex on I cells which causes the cells to move from Cl to S phase (332). 
yö+ T cells proliferate in response to IL-2, or other cytokines that signal through the IL-2 
receptor, when CD4+ a+ cells are stimulated with P. falciparum Ag in vitro (84). 
However, the role of IL-2 in pathogenesis is not clear. Mice susceptible to cerebral 
malaria had lower mRNA levels of IL-2 as compared to resistant mice (67), and IL-2 
knockout mice had exacerbated P. c. chabaudi and P. yoelii infection as compared to 
controls (341). The absence of, or low levels of, IL-2 have been correlated with severe 
P. falciparum infection in vivo and human immunodeficiency virus HIV infection in vitro 
(135) (357). However, it should be noted that measuring IL-2 in plasma or cell culture 
supernatants is not a good indicator of how much IL-2 is being produced, because it 
rapidly binds to IL-2 receptors (IL-2R) and is removed from the fluid phase (1). Thus, 
soluble IL-2R is a better marker of IL-2 production. 
IFN-y 
IFN-y, or macrophage activating factor, is a non-covalently linked homodimer 
which has a number of structural variants (255). IFN-y is produced by NK cells and T 
cells (both c3+ and 'yb-'- cells (1), and its primary roles are Mø activation and 
differentiation of ThU to Thi cells (113). Although IFN-'y can be produced via an IL-12-
independent pathway (300). IL-12 and IFN-T stimulate and regulate each other through 
a positive feedback loop to both NK cells and Thi cells, leading an amplification of the 
inflammatory response (315). 
Immunity to various diseases, particularly those caused by intracellular 
pathogens, has been shown to be dependent on IFN-y. NK cell production of IFN-y is 
essential in clearing L. major, L. monocytogenes, and T. gondii infections (301, 311, 
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335), and resistance against P. c. chabaudiAS requires IFN-y (309, 320). P. yoelii 
specific T cell clones which produce IFN-y are protective when adoptively transferred 
into nude mice (9). Studies in monkeys have shown that IEN-y is able to confer 
protection by inhibiting malaria parasite development in hepatocytes (216). 
However, overproduction of IFN-y may exacerbate the pathology of diseases 
such as malaria and tuberculosis in humans (75, 326). IFN-y overproduction, secondary 
to lipopolysaccharide (LPS)-induced IL-1 2, is responsible for endotoxic-induced shock 
(334). In one mouse malaria model, IFN-y receptor-deficient mice did not get cerebral 
malaria (293) and IFN-7 mRNA levels were higher in susceptible mice compared to 
controls (67). IEN-y induced death when it was administered in the late stage of 
Plasmodium vinckei malaria (181). As with other inflammatory cytokines, pathology 
versus protection is dependent upon how much, where and when IFN-y is produced. 
1.5.3.3 Roles for IL-15 and IL- 18 
IL-15 
IL-15 is an inflammatory cytokine which is mainly produced by Mø, although it is 
also produced by other types of cells. It has many functions which overlap those of 
IL-2, because IL-15 shares some of the same receptor components. It may act when 
IL-2 is downregulated (325). IL-15, alone and in conjunction with IL-12, controls the 
survival and apoptosis of NK cells (45, 289). It stimulates the production of IFN-y by NK 
cells and c3+ and yö+ T lymphocytes (106, 143, 160). 1L-15 is often associated with 
Thi-mediated clearance of intracellular pathogens such as T. gondii, because of its 
ability to induce IFN-'y (143). No studies have been done on the role of IL-15 in malaria 
infection. 
IL-IS 
Recently, IL-18, formerly known as IFN-y-inducing factor (lGlF), was discovered 
(250). It is produced mainly by Mø in an inactive form which is converted to the active 
form by caspase 1 (249). IL-18 induces NK cell production of IFN-'y and acts as a co-
stimulator in the activation of ThI cells (232). IL-12 and IL-18 can activate NK cells 
independently of each other which may explain IL-12-independent IFN-y production 
from NK cells (179). However, the amount of IFN-y produced is much higher when both 
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IL-12 and IL-18 are present (179, 232). IL-18 has been associated with IFN-y-mediated 
clearance of the intracellular parasite, Trypanosoma cruzi (231). No data is available 
on the role of IL-18 in malaria infections. 
1.5.3.4 Nitric oxide in the inflammatory response 
NO is one of the primary reactive nitrogen intermediates which is produced by 
Mø during an inflammatory response. NO production is stimulated by TNF-a and IFN-'y 
induction of nitric oxide synthase (309, 320) and is downregulated by cytokines such 
as lL-4, IL-10 and TGF-3 (34, 76, 151, 343). NO takes part in the inflammatory 
response to a number of bacterial, viral and parasitic infections by cytostasis (157, 
158), but it is not clear how vital it is for parasitic killing. NO was required in clearing 
P. c. chabaudiAS ( 309, 320), P. vinckei (18 1) Tiypanosoma cruzi (110) and Klebsiella 
pneumoniae (337) infections in mice, but in human malaria infection, it has been 
suggested that overproduction of NO may cause cerebral malaria. NO levels were 
higher in patients with severe P. falciparum malaria than in patients with asymptomatic 
infection (247). However, higher levels of NO were found in malaria patients who 
healed their infections versus coma patients (59), and were correlated with rapid cure 
(182). In a study done in Tanzania, NO levels were inversely correlated with severity 
of disease in individuals acutely infected with P. falciparum malaria (11). 
1.5.4 Downregulatory cytokines 
1.5.4.1 IL-4 
IL-4 induces other CD4 cells to differentiate into Th2 cells by downregulating IL-
12 receptor (IL-12R) expression thereby rendering cells non-responsive to IL-12 (113, 
254). IL-4 is a B lymphocyte growth factor and has effects which are antagonistic to 
both IFN—y and IL-2 (235). Although some studies show that IL-4 enhances IFN-'y 
synthesis early in the response to PHA (245) and that it synergises with IL-12 to induce 
a cytotoxic T lymphocyte response (132), suggesting that IL-4 does not always play an 
anti-inflammatory role. 
IL-4 and other Th2 cytokines may play a protective role in parasitic infections by 
downregulating the inflammatory response and generating an Ab-mediated response. 
However, the results of different studies are mixed. Studies comparing control mice with 
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IL-4 knockout mice infected with P. c. chabaudi demonstrated either that there was no 
difference in parasitemia (341) or that infection was more severe in IL-4 knockout mice 
but that they were still able resolve infection (346). These studies indicate that 
immunity may not depend solely on IL-4 and that other anti-inflammatory cytokines may 
be involved, although IL-4 may be needed to set the cytokine environment. 
IL-4 receptor levels were higher in Gambian children who had symptomatic 
P. falciparum infections than in children with asymptomatic infections, indicating that 
IL-4 may play a pathogenic role in malaria infection or that there is little immune 
activation of any sort in asymptomatic children (154). However, clinically immune 
individuals had higher ratios of IL-4/IFN-y producing cells in response to a 
leucoagglutinin than naïve individuals (82), and IL-4 was not detected in cultures of 
PBMCs from naive individuals stimulated with P. falciparum Ag (75). 
1.5.4.2 IL-10 
IL-10, produced by Th2 cells (in mice) and Mø, has primarily anti-inflammatory 
functions(134, 135, 166, 263, 356). Although in certain circumstances it can synergise 
with pro-inflammatory cytokines to activate Thi CD4+ cells (228) and to induce lFN-y 
production from NK cells (46, 312). IL-10 is characterised by its ability to downregulate 
IL-I, IL-12, TNF-a and IFN-'y production, thereby preventing the immunopathogenic 
consequences of excessive inflammation (66, 144, 261). 
In murine malaria infections, the role of IL-10 is unclear. IL-10 KO mice infected 
with P. c. chabaudi AS showed higher levels of parasitemia and increased mortality 
compared with wildtype mice (206), but similar mice infected with P. chabaudi adami 
demonstrated no increased susceptibility (341). Exogenous IL-10 reduced cerebral 
malaria in mice susceptible to P. bcrghei infection (180), but mice with lethal P. yoelii 
infections had high levels of circulating IL-10 (176). 
In human malaria, high levels of circulating IL-1 0 correlate with disease severity 




The role of TGF-P in infectious diseases is complicated in that at low 
concentrations it is pro-inflammatory, and at high concentrations it is anti-inflammatory. 
Although, TGF-13 is mainly produced by Mø (12, 348), it is also produced by almost any 
cell that is put into culture (1, 52). Th3, or regulatory T, cells which have specific 
immunosuppressive functions produce TGF-p (171, 220, 338, 361). TGF-P is secreted 
in a latent form which must be activated by proteases and is neutralised by binding 
proteins released by both activated and inactivated Mø (12). TGF-3 immunomodulates 
the differentiation of B and T cells; it can stimulate or inhibit growth and differentiation of 
the same cells depending on its concentration (251, 252, 348). TGF-13 also helps 
mediate the shift towards the Th2 phenotype both directly and by modulating IL-10 
(214, 215). TGF-13 has been shown to down-regulate the activation of cytotoxic T cells 
(132), NK cells (22, 141), and Mø production of inflammatory cytokines (33, 141) and 
NO (76, 343). However, TGF-P can also augment NK cell activity when it is given orally 
but not intravenously (149), indicating its dual role in immunomodulation. 
TGF-3 is often associated with pathology in parasitic infections because it down-
regulates inflammatory cytokines. The inhibition of IL-12-induced lFN-y by TGF-3 
abrogated resistance to T. gondii infection (141). TGF-f3 made naturally resistant mice 
susceptible to infection with Leishmania major (16) and T. cruzi (314). However, Omer 
et al. found that treatment of lethal P. berghei with TGF-p prolonged survival time (252). 
Additionally, Wenisch et al. measured TGF-13 levels in patients with acute P. falciparum 
malaria and found that serum levels were lower than in uninfected controls (355). 
1.6 Conclusions: the immune response during malaria infection 
Adults living in highly endemic areas do not become clinically ill with malaria (i.e. 
they are classified as clinically immune), whereas individuals who have been infected 
but who are not clinically immune ('semi-immune' or exposed) and individuals who 
have never been infected (naïve) will become sick if infected with malaria. Hence, 
there must be a difference in the immune response to malaria between these groups of 
individuals. 
During P. falciparum infection, it was originally thought that there is an initial Mø-
dependent inflammatory response. When Mø come into contact with malaria Ag, 
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TN F-cL is released and mediates fever. Other inflammatory cytokines, such as IL-1, 
IL-6, and IL-12, are also produced to upregulate the inflammation (figure 1.2). Although 
low levels of inflammatory cytokines help mediate parasite clearance in the early stages 
of infection, excessive levels have been associated with malaria pathogenesis (i.e. 
cerebral malaria, hepatosplen omega ly, anaemia, hypoglycaemia). 
However, this scenario, or a totally innate response to malaria infection, does 
not explain why young infants do not become clinically ill during primary infection, as 
would be expected if the initial innate immune response alone caused excessive 
pathology. Recent studies have demonstrated that PBMCs from naïve individuals do 
not produce as much TNF-a and IL-12 in response to malaria Ag as in response to 
LPS, a bacterial pyrogen (308). TN F-a alone was not sufficient to neutralise the 
infectivity of gametocytes in P. vivax infections, demonstrating that inactivation was 
also dependent on other factors (358). Indeed levels of TNF-a induced directly by 
malaria parasites are very low and may be insufficient to cause a major febrile illness. 
Thus, there must be other factors in addition to parasite toxins which causes pathology 
in young children living in endemic areas and in naïve individuals. 
PBMCs from naïve (malaria-unexposed) adults proliferate in response to 
malaria Ag, suggesting that I cells may play an important role in the early response to 
malaria. Carter et aL showed that activation of monocytes against P. vivax infection 
was dependent upon IL-2 and granulocyte-macrophage-colony stimulating factor (GM-
CS F), cytokines produced predominantly by T cells (49). CD4+ a3+ cells may respond 
quickly to malaria infection in adults who have a large population of primed cross-
reactive T cells or in children who have previously been exposed to malaria and thus 
have a primed T cell response. These cells then proliferate and produce IFN-y and 
IL-2. y6+ cells bind malaria Ag, and in the presence of IL-12, secrete IFN-y. IFN-y from 
both CD4+ a+ and yö+ cells stimulate macrophages to produce inflammatory 
cytokines as mentioned above (figure 1.3). Thus, it has been hypothesised that, in 
naive individuals, the inflammatory response may be upregulated and continually 
exacerbated by cross reactive memory T cells producing Thl-like cytokines. 
Because, immune individuals are constantly exposed to malaria, they are able 
to mount an Ag-specific immune response to the invading pathogen. In naives, semi-
immunes and immunes, there is probably an initial inflammatory response, with Mø 
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and NK cells being activated. But in immune individuals, this inflammatory response is 
probably quickly downregulated and memory T cells activate a Th2-like, Ab-mediated 
response (figure 1.4). 
If there truly are different responses in terms of T cell subsets and cytokine 
responses between immune individuals and naïve individuals, these factors might 
explain the differences between the immune responses which cause illness and those 
which confer protection. In summary, a plausible hypothesis for the development of 
clinical immunity to malaria is that: (i) proinflammatory responses, mediated by primed 
populations of a+  and y6+ T cells, cause a febrile illness in non-immunes, but that 
(ii) these inflammatory responses are downregulated in clinically immune individuals 
and (iii) replaced with anti-parasitic mechanisms which may include the production of 
highly effective anti-malarial antibodies. If these hypotheses prove correct, then there 
are important implications both for the treatment of clinical malaria and for the 
development of malaria vaccines 
1.7 Aims and outline of the thesis 
This scenario for the development of clinical immunity to malaria is, for the 
moment, entirely hypothetical. I aim to determine whether there are differences in 
cellular responses between naïve, semi-immune and immune individuals at an in vitro 
level. I hope that if my hypothesis prove correct, I can make some broader 
conclusions about what might happen in vivo. Specifically, the aims of the project are 
to test the following hypotheses: 
that the development of clinical immunity is associated with the downregulation of 
pro-inflammatory cytokines. 
that immune responses of each group (naïve, semi-immune and clinically immune) 
are controlled by different mononuclear cells. 
The specific objectives of this project are: 
a) to develop sensitive and specific methods for detection of pro-inflammatory human 
cytokines, especially for IL-12 which has been difficult to quantify in the past. 
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to investigate the cellular source of IFN-y production from malaria-activated human 
cells and to determine how IFN-y production is regulated by other cytokines, 
especially IL-12. 
To compare lymphoproliferative and cytokine responses to malaria antigens in 
individuals with differing levels of anti-malarial immunity, in order to obtain 








CYCLES IN LIVER 
Figure 1.1: Life cycle of Plasmodium falciparum (taken from source (3)). 
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Figure 1.2: The innate immune response to malaria. It is hypothesised that when 
Mø come into contact with malaria Ag, IL-12 is produced to upregulate IFN-y 
production by NK cells. IFN-y acts synergistically with malaria antigens to upregulate 










Figure 1.3: Primed individuals (naives and semi-immunes). It is hypothesised that 
CD4+ a134-  cells interact with Ag presenting cells (APC) to proliferate and produce IFN-'y 
and IL-2. 'y+ cells bind malaria Ag in the presence of IL-2, and secrete IFN-y. IFN-y 
from both CD4+ a3+ and yö+ cells stimulates macrophages to produce increased 












Figure 1.4: Clinically immune individuals. It is hypothesised that the inflammatory 
response is downregulated by the production of anti-inflammatory cytokines and 





Chapter 2. Materials and methods 
2.1 Subjects and serology 
2. 1.1 Study populations 
A total of twenty-two malaria-naïve individuals living in Edinburgh, Scotland, UK 
were recruited for the various purposes of this study (table 2.1a). Most of the 
individuals had not travelled to a malaria-endemic country within the two years before 
blood samples were collected, and none of them have been infected with malaria. 
Twenty donors were recruited from Dodowa, a small village about 40 miles 
inland from Accra, the capital city of Ghana (table 2.1b). Malaria transmission is highly 
endemic in this area (20 infective bites/year) with over 40% prevalence of parasitaemia 
and with the highest intensity of infection found in children under 5 years of age (5). 
Most of the adults do not develop clinical symptoms when infected with malaria. These 
individuals were designated malaria-immune individuals. 
Twenty-one individuals were recruited from the greater Accra area (table 2.1 c). 
Malaria transmission has been reported to be much lower in this area (29), and many 
adults have clinical symptoms when infected with malaria. This group was designated 
malaria-exposed, but not clinically immune. 
Five additional naïve individuals were used as controls when the studies were 
carried out in Ghana. All of the individuals were taking anti-malarial prophylactics and 
were not infected with malaria at the time of blood collection (table 2.1d). 
A questionnaire was completed for each donor, providing information on previous 
exposure to malaria and use of anti-malarial drugs. Tests for malaria parasitemia and 
Ab responses to malaria Ag were also done on most individuals (protocols described in 
sections 2.1.2 and 2.1.3). The questionnaire and serology data are presented in tables 
2.1a-d and summarised in table 2.2. 
2.1.2 Parasite detection 
Thick and thin blood films from African donors were stained with Giemsa (BDH; 
Dorset, UK) and examined for the presence of malaria parasites. Donors were 
considered negative if no parasites were detected after 500 white blood cells had been 
counted. 
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In order to detect low levels of parasites, parasite DNA was detected by a 
polymerase chain reaction (PCR) method based on the multicopy 71-18/6 gene 
sequence (205). DNA was extracted from a small sample of blood by a method 
described by Foley et al. Briefly, 20 tl of whole blood were mixed with 500 pi of ice cold 
sodium phosphate, pH 8 (Sigma; Poole, UK) and centrifuged for 10 minutes at 
maximum speed in a picofuge. After the supernatant was discarded, the procedure 
was repeated twice more. The pellet was boiled with 50 j.il of water for 10 minutes and 
then centrifuged for 10 minutes. The pellet was discarded and the supernatant used for 
PCR (103). 
PCR conditions were optimised by Dr. Gillian Wagner in our laboratory (347). 
The primers were donated from Professor Allan Saul (Queensland Institute for Medical 
Research; Brisbane, Australia), and the sequences were 5'-
ACATTATCATAATGAC(T)CCAGAACT-3' and 5'-GTTTCCAATAATTCTTTTTCTATC-
3'. One microliter of extracted DNA was amplified in a 20 tl reaction mixture of 1X 
reaction buffer (500 mM KCI, 100 mM Tris-HCI (pH 9 at 25°C), 1% triton-x 100; 
Promega; Southampton), 0.5 U of Taq DNA polymerase (Promega), 4 mM MgCl2 
(Sigma), 75mM of each nucleotide (dATP, dCTP, dGTP, and dTTP; Boehringer-
Mannheim; East Sussex, UK), and I OOnM of each primer. The reaction was carried out 
for 35 cycles (94°C for 30 seconds, 55.8°C for 60 seconds and 72°C for 30 seconds) on 
a Hybaid thermocycler (Ashford, UK). PCR fragments were separated on ethidium 
bromide (EtBr; 0.5 .ig/ml; Sigma)-stained, 2% agarose (Boehringer-Mannheim) gels run 
in 0.5X Tris-borate-EDTA (TBE) buffer, and visualised under ultraviolet light. Details of 
buffers and solutions are given in section in 4.2.3. 
2.1.3 Detection of antibodies to malaria antigen 
Plasma samples from all exposed and immune and most naïve donors were 
tested for anti-malarial antibodies by ELISA. Immulon IV microtitre plates (Dynex, 
Billingshurst, UK) were coated with an optimal concentration of soluble malaria Ag 
(described in section 2.2) diluted in Na2CO3/NaHCO3 buffer (15mM Na2CO3, NaHCO3, 
0.02% NaN3; all from BDH) and incubated overnight at 4°C. The plates were washed 3 
times in phosphate-buffered saline (PBS) containing 0.05% polyoxyethylene sorbitan 
monolaurate (Tween 20; Sigma). Plates were blocked for 3 hours at room temperature 
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(RT) with PBS containing 0.05% Tween 20 and 1% non-fat milk powder (blocking 
buffer) and washed as before. Plasma samples, diluted 1:1000 in blocking buffer, were 
added to duplicate wells, and incubated for 3 hours at RI. After another wash, 100 tl of 
rabbit anti-human lgG-horse radish peroxidase (Dako, High Wycombe, UK) were added 
to each well at a 1:1000 final dilution. The plates were incubated for 3 hours at RI, 
washed, and bound Ab was finally detected with an o-phenylenediamine (OPD; 100 
j.d/well for 10 minutes; Sigma) solution. The reaction was stopped with 2 M H2SO4 
(BDH) and, optical density (OD) was measured at 492nm. Samples were designated 
positive for anti-malarial Ab if the OD was greater than the mean plus 2 standard 
deviations (SD) of the OD values of 22 control European plasma samples. Ab levels are 
expressed as a % of the value obtained for a pool of hyperimmune plasma from African 
adults tested on the same plate. 
22 In vitro culturing of P falciparum asexual stages 
2.2.1 Parasite culture medium 
Incomplete parasite culture medium 
RPMI-1 640 medium (Gibco Life Technologies; Paisley, UK) 
25 mM hepes buffer (Sigma) 
0.15 % NaHCO3 (ICN; Basingstoke, UK) 
5 tg/ml hypoxanthine (Sigma) 
Complete parasite culture medium 
incomplete parasite culture medium 
10% heat-inactivated human 0+ serum (Scottish Blood Transfusion Service; 
Edinburgh, UK) 
2.2.2 Maintenance of P. falciparum cultures 
Human 0+ red blood cells (RBCs; Scottish Blood Transfusion Service) were 
infected with the 3D7 clone of P. falciparum parasite isolate NF54 (351) and cultured 
according to standard protocol (48). Briefly, parasites were continuously cultured at 2-
4% hematocrit in complete parasite culture medium at 37°C in a humid, 5% CO2-95% 
air atmosphere. Medium was changed daily and cultures were examined by Giemsa-
stained thin blood smears. Cultures were grown to 6% parasitaemia and either used for 
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antigen preparation or passaged by diluting to 0.8% parasitaemia with fresh uninfected 
RBCs. 
It has been previously reported that Mycoplasma spp can survive in long term 
P. falciparum cultures (292, 339) and that Mycoplasma spp have also been detected in 
certain malaria strains kept in Edinburgh (31). As mycoplasma are potent inducers of 
cytokines (292), cultures were routinely screened for mycoplasma using a commercial 
PCR kit (BioWhittaker; Wokingham, UK) and were confirmed to be free of 
contamination. 
2.2.3 P. falciparum crude antigen preparation 
Mature schizonts were separated from the rest of the culture on a 60% percoll 
gradient (Amersham-Pharmacia; Buckinghamshire, UK), washed twice in incomplete 
parasite culture medium, and resuspended at 108  schizonts/mI. Parasites were lysed 
by three freeze-thaw cycles in liquid nitrogen. The whole extract (PfSE) was used for 
cell culture experiments. The supernatant portion of the extract was used for serology 
(see section 2.1.3). 
Optimal concentrations of PfSE were determined by titration in a lymphocyte 
proliferation assay (see section 2.5). Different batches of PfSE were standardised by 
using dilutions giving equivalent radioactive thymidine incorporation readings. A freeze-
thaw preparation of uninfected RBC5 (uRBC, 108/ml) was used as a negative control for 
PfSE. All preparations were aliquoted and stored at —80°C until required. 
2.3 Other stimuli used in cell culture experiments 
The following reagents were used to demonstrate the different kinetics of cellular 
immune responses and to compare these responses to the kinetics of the response to 
P. falciparum antigens. 
2 [tg/ml of PHA (Sigma) was used as a I cell mitogen and as a positive control for 
normal cellular proliferation. 
10 ig/ml of LPS (Sigma) plus 10 ng/mI recombinant IFN-y JCS; Botolph Claydon, 
UK) were used as a positive control for IL-12 production. 
2 p.g/ml of SEB (Sigma) was used as a superantigen and as a positive control for 
normal cellular proliferation. 
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100 U/mI of PPD (Evans Medical Ltd.; Horsham, UK) was used as a classical I cell 
Ag. 
Culture medium alone (CM) was used as a negative control for the stimuli. 
5 jg/ml of neutralising anti-interleukin-12 (alL-12; R&D Systems; Abingdon, UK) was 
used to neutralise interleukin-12 (IL-12) produced by cell cultures. 
5 tg/ml of goat lgG (R&D Systems) was used as a negative control for alL-12. 
2.4 In vitro cell cultures 
2.4.1 Cell culture medium 
Incomplete cell culture medium 
RPMI-1640 medium 
25 mM hepes buffer 
0.15% NaHCO3 
0.4 mM L-glutamine 
100 U/mI penicillin (Sigma) 
0.1 mg/ml streptomycin (Sigma) 
Complete cell culture medium 
incomplete cell culture medium 
10% heat-inactivated human 0+ serum 
2.4.2 Separation of PBMCs 
Venous blood was collected into heparinised tubes (1 U/mI of blood; Sigma) and 
diluted 2-fold with incomplete cell culture medium. Ten ml of diluted blood were layered 
onto 4 ml Lymphoprep® (Nycomed; Birmingham, UK) and centrifuged for 10 minutes at 
400 g. PBMCs were collected from the interface, washed twice in incomplete cell 
culture medium, and resuspended at 106  cells/ml in complete cell culture medium for 
cell culture experiments. 
2.5 Lymphocyte proliferation assays 
2.5.1 Assay set-up 
Cultures were set up in triplicate in round-bottomed 96-well microtitre plates 
(MacKay and Lynn; Edinburgh, UK). PBMCs were distributed at 105 cells/well in a total 
culture volume of 200 tI with their corresponding stimuli and appropriate controls. All 
cell cultures were incubated at 37°C in a humid, 5% CO2-95% air atmosphere for up to 
9 days. Eighteen hours before harvest, cultures were pulsed with 1 pCi/well of 
radioactive [methyl-3H] thymidine (Amersham-Pharmacia). Cultures were harvested in 
one of two ways. In the UK, cultures were harvested onto filter mats (EG&G Wallac; 
Milton Keynes, UK) using a Tomtec 96 Mach II harvester (EG&G Wallac). Scintillation 
fluid was melted onto the filter mats (Meltilex A; EG&G Wallac), and [methyl-3H] 
thymidine incorporation was assayed by a 1450 Microbeta Trilux liquid scintillation and 
luminescence counter (EG&G Wallac). In Ghana, cultures were harvested onto glass 
fibre filters (Canberra-Packard; Pangbourne, UK) using a Filtermate 196 Cell Harvester 
(Packard). [methyl-3H] thymidine incorporation was assayed by a Matrix 96 direct beta 
counter (Packard). 
2.5.2 Data analysis 
The geometric mean counts per minute (cpm) for triplicate wells were calculated 
and expressed as mean cpm. The stimulation index (SI) was calculated as the 
geometric mean cpm of cells stimulated with antigen/mitogen divided by the geometric 
mean cpm of cells stimulated with the corresponding control. 
2.6 Measuring cytokines by enzyme-linked immunosorbent assay (ELISA) 
2.6.1 Solutions used in ELISA 
1. Coating buffer- PBS, pH 7.4 
1 L sterile distilled water 
Blocking buffer (samples/controls, detection antibody, and enzyme diluted in this 
solution) 
PBS, pH 7.4 
4% bovine serum albumin (BSA; Sigma) 
Wash solution 
0.05% Tween 20 
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Substrate 
10 mg OPD 
6 ml 0.1 M citric acid (Sigma) 
6.4 ml: 0.2 M Na2HPO4 (Sigma) 
12.5 ml distilled water 
20 tl H202 
Stop solution 
2 M H2SO4 
2.6.2 Cell cultures 
PBMCs were distributed at 106  /well  in flat-bottomed 24-well plates or in triplicate 
at 105  /well  in round-bottomed 96-well microtitre plates in a total of 1 ml and 200 tl 
respectively. Cultures were incubated for up to 8 days with their corresponding 
antigens, mitogens, or antibodies. Depending on the assay, 300-900 p1 of culture 
supernatant were harvested at various timepoints and stored at -70°C until tested for 
cytokine levels. 
2.6.3 Basic protocol for the sandwich ELISA 
IFN-y, IL-12 p70, IL-12 p40, and IL-10 were measured using the indirect, 
sandwich ELISA. Immulon 4, 96-well, flat-bottom microtitre plates were coated with 
100 .il/well of mouse anti-human cytokine monoclonal Ab and incubated at RT 
overnight (for the complete list of Ab concentrations, refer to chapter 3). Plates were 
washed 4 times with wash solution, blocked with 200 p1/well blocking buffer for 1 hour at 
37°C, and then washed 3 more times. Fifty microliters per well of recombinant cytokine 
standard (20,000 to 1 pg/mI) or culture supernatant were added to duplicate wells and 
incubated at RT for 2-3 hours. After 4 washes, 50 p1/well of biotinylated mouse anti-
human cytokine monoclonal Ab were added and incubated for 1 hour at RT. After the 
plates were washed 6 more times, 100 p1/well of avidin-labelled horseradish peroxidase 
(HRP; Sigma) was added at 0.5 pg or 1 pg/ml solution for thirty minutes at RT. After a 
final 8 washes, plates were developed using OPD and H202 as substrate. After 15 
minutes, the reaction was stopped with 25 p1/well of 2 M H2SO4,  and absorbance was 
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read at 492 nm using an automated ELISA plate reader (Titretek Multiscan II; Life 
Sciences International; Basingstoke, UK) 
2.6.4 Data analysis 
Concentrations of cytokines were calculated from the standard curve given by 
the reference standard. Linear regression analysis was done and the best fit curve 
formula was used to calculate cytokine concentrations. The lowest level of detection 
(LLD) was determined as two standard deviations above the mean of the negative 
control (culture medium alone). 
2.7 IL-12 p40 detection by reverse transcriptase polymerase chain reaction (RT-
PCR) 
2.7.1 Cell cultures 
PBMCs were distributed at 106/well in a total of 1 ml of complete culture medium 
in flat-bottomed 24-well plates and cultured for up to 8 days with various stimuli. 
PBMCs were harvested, at various timepoints, into 15 ml conical tubes and washed 
twice with incomplete cell culture medium. Adherent cells in all cell cultures were 
detached from the wells with trypsin-EDTA (3.3X; Sigma) at 37°C for 15 minutes, 
inactivated with complete cell culture medium, and added to non-adherent cell 
suspensions. Cells were pelleted for immediate RNA extraction or stored at -70°C for 
future RNA extraction. 
2.7.2 Basic protocol for qualitative RT-PCR 
RNA was isolated using either a commercial RNA extraction kit or an assay 
based on guanidinium extraction (see Chapter 4 for complete details of the RT-PCR 
assay). RNA was extracted, resuspended in 50 pi of RNAse-free water and then treated 
with DNAse before using it for first strand synthesis. Complementary DNA (cDNA) was 
reverse transcribed from RNA with oligo-(dT) primer. Synthesis was run at 42°C for 
50 minutes and then stopped by raising the temperature to 70°C for 15 minutes. 
IL-12 p40 primers were synthesised by Oswel (Southampton, UK) based on 
published sequences. The sequences for IL-12 p40 and -actin (a constitutively 
expressed gene used as a positive control) are described in table 4.1. One microliter of 
cDNA was amplified in a 10 p1 reaction mixture of IX buffer, 0.5 U Taq DNA 
polymerase, 2 mM MgCl2, 200 pM dNTP mix, and 1pM each cytokine primer. The 
reaction was carried out for 35 cycles (94°C for 1 minute, 60°C for 1 minute and 72°C 
for 1 minute) on Hybaid thermocycler. PCR fragments were separated on EtBr-
stained, 1.5% agarose gels run in 05X TBE buffer and visualised under ultraviolet light. 
Fidelity of the amplified PCR product was confirmed to be -actin or IL-12 p40 by 
using a commercial sequencing kit and by then comparing sequences to the 
GEN-EMBL database. 
2.8 Cell phenotyping by flow cytometry 
2.8.1 Cell cultures 
PBMCs were distributed at lx or 2x106/well in a total of 1 or 2 ml culture medium 
respectively in flat-bottomed 24-well plates. Each culture had a total of 2 or 4x106 cells 
(except for immune individuals where there were a limited number of PBMCs and cell 
numbers were as low as 3.5x106/10 ml whole blood). After cells were cultured for 3 or 7 
days, PBMCs were harvested into 15 ml conical tubes and washed twice with PBS 
supplemented with 0.1% NaN3 and 0.1% BSA (FACs PBS) and resuspended in FACs 
PBS at 2x106/ml. 
2.8.2 Monoclonal antibody staining 
Cells were stained on days 0, 3 and 7 for analysis of surface markers by 3 colour 
flow cytometric analysis. Cells were equally distributed into round-bottomed 96-well 
microtitre plates. Each well contained 20 p1 of each of 3 different antibodies. Cells were 
incubated at 4°C for 40 minutes. Cells were washed twice and then transferred to 5 ml 
round-bottomed tubes in 300 p1 of FACs PBS for analysis. One cell aliquot was taken 
for an unstained sample control, and another cell aliquot was used for determining cell 
viability by trypan blue (Sigma) exclusion and absolute cell counts by haemocytometry. 
All antibodies were directly conjugated to fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), or tricolour (TRI). Anti-CD20, anti-TcR af3 and anti-TcR y  (all from 
TCS; Botoiph Claydon, UK) were all FITC-labelled. Anti-CD45RA, anti-CD45RO, anti-
CD4, and anti-CD8 were either FITC- or PE-labelled (all from TCS). Anti-CD56 was 
PE-labelled and anti-CD3 was TRI-labelled (both from TCS). All antibodies were used 
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at a final concentration of 0.2 .tg per staining combination with the exception of anti-
CD8 which was used at 0.05 ig per staining combination. Up to 9 different staining 
combinations were done, depending on the number of cells available, in order to 
identify different cell subsets. For the different sets of staining combinations and which 
cells they identify, refer to section 7.2. 
2.8.3 Data analysis 
Cell phenotyping was performed by flow cytometry (FACscan; Becton-Dickinson; 
London, UK). Ten thousand to 20,000 events were acquired per sample. Red blood 
cells and dead cells were gated out, and single stains were used to set the 
compensation for the fluorescence. Resting cells and lymphoblasts were gated 
separately, detected by forward scattered light (FSC) versus side scattered light (SSC), 
and analysed for the different staining combinations. Cell quest software package 
(Becton-Dickinson) was used for data analysis. Percentages and absolute numbers of 
cell subsets were calculated. 
2.9 Detection of IFN-'y by intracellular cytokine staining (ICS) 
2.9.1 Solutions used in ICS 
Staining buffer 
PBS 








0.3% saponin (BDI-l) 
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2.9.2 Cell cultures 
PBMCs were distributed at 2x106/well in flat-bottomed 24-well plates in a total of 
2 ml. A total of 6x106 cells (i.e. 3 wells) were used for each stimulus and all cultures 
were incubated for 7 days. Eighteen hours before harvest, 3 g of Brefeldin A (Sigma) 
was added per I ml of culture in order to stop Golgi transport of intracellular lFN-y. 
PBMC5 were then harvested into 15 ml conical tubes, washed twice with PBS and 
resuspended in staining buffer at 1061m1. 
2.9.3 ICS protocol 
Cells were first stained for surface markers as detailed in section 2.8.2. After one 
wash with PBS, cells were resuspended in 300 jil fixation buffer and incubated at RT in 
the dark for 15 minutes. Cells were washed again and then resuspended in 300 p.1 
permeabilisation buffer which contained 1-2 p.g of either FITC labelled anti-IFN-y (TCS) 
or PE-labelled anti-IFN-y (Becton-Dickinson). Cells were incubated at 4°C in the dark 
for 30 minutes. Cells were washed once in permeabilisation buffer and resuspended in 
0.5 ml of PBS for flow cytometry analysis as described in section 2.8.3. 
210 Statistical analysis 
All statistical analysis was performed with Microsoft excel (Seattle, Washington, 
USA) or Minitab 12 (Microsoft) software packages. Data was tested for normal 
distribution by the Ryan-Joiner normality test. Differences between groups were 
assessed by Student's t test on normal or log-transformed data. Differences in 
response to different treatments within groups, were assessed by paired t tests 
comparing treated and control cells from the same donors. The non-parametric Mann 
Whitney U test was used for severely skewed (non-normal even after log 
transformation) data, although McGuinness et al. demonstrated that normal parametric 
tests are still quite robust on highly skewed data (223). Chi-squared (X2  )analysiswas 
performed to compare responders versus non-responders. All correlations were done 
with the Pearson correlation test. For complete descriptions of these tests, refer to 
Kirkwood (1990) (174). 
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Table 21a: Summary of questionnaire data from naïve individuals living in Edinburgh, UK. 
ID # Sex Age Blood 	Travel When Where Malaria Antimalarials Type Crude Ag Ab 
Ni F 	39 Sep-97 N N/A N/A N N/A N/A ND NO 
N2 F 24 Sep-97 Y Aug-96 Zimbabwe N Y Larium - 0.05 
N3 M 	36 Nov-97 N N/A N/A N N/A N/A - 0.05 
N4 M 21 Nov-97 N N/A N/A N N/A N/A NO NO 
N5 M 	38 Nov-97 N N/A N/A N N/A N/A ND ND 
N6 M 25 Jul-98 	Y Jul-97 Indonesia N Y Larium NO ND 
N7 F 	26 Jul-98 N N/A N/A N N/A N/A ND ND 
N8 M 35 Jul-98 	N N/A N/A N N/A N/A - 0.04 
N9 M 	20 Jul-98 N N/A N/A N N/A N/A ND NO 
N10 F 31 Jul-98 	N N/A N/A N N/A N/A NO NO 
Nil F 	22 Jul-98 N N/A N/A N N/A N/A - 0.04 
N12 M 41 Oct-98 Y Dec-97 Ivory Coast N Y Chioroquine/Palludrine - 0.04 
N13 M 	27 Oct-98 	N N/A N/A N N/A N/A ND ND 
N14 F 31 Oct-98 N N/A N/A N N/A N/A - 0.06 
N15 M 	24 Oct-98 N N/A N/A N N/A N/A - 0.05 
N16 F 33 Nov-98 Y Jan-98 Kenya N Y Chloroquine/Palludrine - 0.08 
N17 F 	30 Nov-98 N N/A N/A N N/A N/A - 0.05 
N18 M 34 Nov-98 Y Apr-98 Kenya N N N/A - 0.07 
N19 M 	29 Nov-98 N N/A N/A N N/A N/A - 0.05 
N20 M 24 Feb-99 N N/A N/A N N/A N/A ND NO 
N21 F 	21 Jun-99 N N/A N/A N N/A N/A NO ND 
N22 M 24 Jun-99 	N N/A N/A N N/A N/A ND ND 
Sex- Male (M) or female (F). 
Blood- Date when blood sample was taken for the study. 
Travel- Have you traveled in a malaria endemic country within the 2 years prior to your blood being taken? 
When- When did you travel? 
Where- Where did you travel? 
Malaria- Did you contract malaria? 
Antimal- Were you taking antimalarials? 
Type- What kind of antimalarials were you taking? 
Crude Ag- Positive (+) or negative (-) Ab response to crude malaria Ag measured by ELISA. 
Ab- OD value given as a ratio of average OD value of Brefet sera, a highly immune sera. 
N/A- Not applicable. 
ND- Not done. 
Table 2.1b: Summary of questionnaire data from exposed individuals living in Accra, Ghana. 
ID # Sex Age Travel Mal/yr Last At Confm Severity Treat Antimal 	Film PCR Crude Ag Ab 
El M 37 Y N 96 N Mi Y N 	- - 	+ 0.27 
E2 M 28 N Y Jan-98 N Mi Y N - - + 0.31 
E3 M 40 Y N Jun-96 Y Mi Y N 	- - 	- 0.23 
E4 F 34 Y Y ? Y Mi ? N - - + 0.47 
E5 F 25 N Y 96 Y Ma Y N 	- - 	+ 0.26 
E6 M 26 N V Oct-97 N Mi Y N - - + 0.26 
E7 M 28 N N 96 N Mi Y N 	- - 	+ 0.35 
E8 M 26 N Y Dec-97 Y Ma Y N - - - 0.17 
E9 M 31 N Y Dec-97 Y Ma Y N 	- - 	+ 0.86 
ElO M 50 N ? Mar-94 N Ma Y N - - + 0.85 
Eli M 46 V V Jan-98 N Mi V N 	- - 	- 0.13 
E12 M 46 Y V Mar-98 Y Mi V N - - + 0.54 
E14 M 60 N Y Jan-98 Y Mi Y N 	- - 	+ 0.73 
E15 M 48 Y N Oct-97 Y Ma Y Y. - - + 0.60 
E16 M 29 N Y Dec-97 Y Mi Y Y* 	- - 	+ 0.43 
E17 F 21 N N Feb-96 Y Mi - - + 0.26 
E18 M 38 N N Jun-96 Y Mi Y (* 	- - 	+ 1.01 
E19 M 41 Y N Sep-93 Y Ma Y N - + - 0.20 
E20 M 52 N V 97 N Mi V Y. 	- - 	+ 0.35 
E21 M 28 N V Sep-97 Y Mi - - - 0.20 
E22 M 29 N ? Jun-97 ? Ma Y N 	- - 	- 0.24 
Sex- Male (M) or female (F) 
Travel- Have you traveled within the 2 years prior to your blood being taken? 
Mal/yr- Do you get malaria yearly? 
Last At- When was your last attack? 
Confm-Was it confirmed by blood film? 
Severity- How severe was the illness? Major (Ma) or minor (Mi). Time off work was considered a major illness. 
Treat- Were you treated for this last episode of malaria? 
Antimal- Do you use antimalarials regularly? *They  really mean no, because the date they gave when 
they last used antimalarials was when they had malaria. 
Film- Malaria status confirmed by blood film at the time of bleed. 
PCR- Malaria status confirmed by PCR at the time of bleed. 
Crude Ag- Positive (+) or negative (-) Ab response to crude malaria Ag measured by ELISA. 
Ab- OD value given as a ratio of average OD value of Brefet sera, a highly immune sera. 
Table 2.1c: Summary of questionnaire data from immune individuals living in Dodowa, Ghana. 
ID # Sex Age Travel Mal/yr Last At Confm Severity Treat Antimal Film 	PCR Crude Ag Ab 
Ii M 45 N Y Jun-98 N Mi Y N - + + 1.27 
12 F 46 N Y Oct-98 N Mi Y N - 	- + 0.93 
13 F 30 N Y Nov-98 N Mi Y N + - + 0.65 
14 F 30 N Y Jul-98 N Mi Y N - 	- + 1.16 
15 F 33 N Y Jan-99 N Mi Y N + - + 1.14 
16 F 40 N Y Oct-98 N Mi Y N - 	- + 0.46 
17 F 34 N Y Jul-98 Y Ma Y N - - + 0.88 
8 F 33 N Y Feb-99 N Ma Y N - 	+ + 0.45 
19 F 31 N Y Jan-99 N Mi Y N - + + 0.29 
110 M 30 N Y Feb-99 N Ma Y N - 	- + 0.42 
Ill M 38 N Y Oct-98 N Mi Y N - + + 0.97 
112 M 32 N Y Sep-98 N Ma Y NI - 	- + 0.93 
113 F 34 N Y Nov-98 N Mi Y N - - + 0.74 
114 F 47 N Y Jan-99 N Mi Y N - 	+ + 1.29 
115 M 38 N Y Feb-99 N Ma Y Y - - + 0.94 
116 F 30 N Y Feb-99 N Mi Y N - 	+ + 1.43 
117 M 31 N N Sep-98 N Mi Y N - - + 1.44 
118 M 30 N Y Dec-98 N Ma Y N - 	- + 0.60 
119 M 30 N Y Jan-99 N Mi Y N - - + 1.07 
120 F 44 N Y Feb-99 N Mi Y N - 	- + 0.24 
Sex- Male (M) or female (F) 
Travel- Have you traveled within the 2 years prior to your blood being taken? 
MaI,'yr- Do you get malaria yearly? 
Last At- When was your last attack? 
Confm-Was it confirmed by blood film? 
Severity- How severe was the illness? Major (Ma) or minor (Mi). Time off work was considered a major illness. 
Treat- Were you treated for this last episode of malaria? 
Antimal- Do you use antimalarials regularly? 
Film- Malaria status confirmed by blood film at the time of bleed. 
PCR- Malaria status confirmed by PCR at the time of bleed. 
Crude Ag- Positive (+) or negative (-) Ab response to crude malaria Ag measured by ELISA. 
Ab- OD value given as a ratio of average OD value of Brefet sera, a highly immune sera. 
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Table 2.1d: Summary of questionnaire data from naive individuals used as controls when studies were carried out in 
Ghana.* 
ID # Sex Age Blood Travel When Where Malaria Antimalarials Type Crude Ag Ab 
Cl F 41 Mar-98 Y Mar-98 Ghana N Y Chloroquine/Palludrine ND ND 
C2 F 39 Mar-98 Y Mar-98 Ghana N Y Chioroquine/Palludrine ND ND 
C3 F 25 Mar-98 Y Mar-98 Ghana N Y Chioroquine/Palludrine ND ND 
C4 M 39 Mar-98 V Mar-98 Ghana N V Larium ND ND 
C5 F 25 Mar-99 V Mar-98 Ghana N V ChloroquinelPalludrine - 0.06 
Sex- Male (M) or female (F). 
Blood- Date when blood sample was taken for the study. 
Travel- Have you traveled in a malaria endemic country within the 2 years prior to your blood being taken? 
When- When did you travel? 
Where- Where did you travel? 
Malaria- Did you contract malaria? 
Antimal- Were you taking antimalarials? 
Type- What kind of antimalarials were you taking? 
Crude Ag- Positive (+) or negative (-) Ab response to crude malaria Ag measured by ELISA. 
Ab- OD value given as a ratio of average 00 value of Brefet sera, a highly immune sera. 
ND- Not done. 
*All of the control naïve individuals were confirmed negative for malaria infection by blood smear and PCR. 
Table 2.2: Summary details of all blood donors. 
Naive (UK) Exposed (Accra) Immune (Dodowa) 
N 22 21 20 
Age range (years) 20-41 21-60 30-47 
Blood film + 0(0%) 0(0%) 2(10%) 
PCR + 0(0%) 1 (5%) 6(30%) 
Antibody + 0/11 (0%) 15/21(71%) 20(100%) 
Mean Ab*  (SEM) 0.05 (0.004) 0.41 (0.06) 0.87 (0.08) 
Ab Range 0.04-0.08 0.13 -1.01 0.24-1.44 
Confirmed malaria# 0/22(0%) 13/21(62%) 1/20 (5%) 
*OD values are expressed as a ratio of average OD value of Brefet sera, 
a highly immune sera. 
Confirmed clinical malaria in the past 5 years. 
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Chapter 3: Optimisation of enzyme-linked immunosorbent assay 
(ELISA) for measuring cytokine concentrations in cell culture 
supernatants 
3.1 Introduction 
The introduction of [LISA in 1971 by Engvall and Perlmann was a significant 
technical advance in the measurement of protein molecules (87-89). Although there 
were other methods already available for measuring and detecting antibodies and 
antigens such as radioactive immunoassays, none surpassed ELISA in its ease and 
simplicity. Overall, ELISA is much simpler, faster, requires less special equipment and 
its reagents are stable over a longer period of time than other protein detection assays. 
Engvall and Perlmann initially used [LISA for the detection and quantification of 
immunoglobulin. The scope of the assay has since then become much broader, and it 
now has numerous uses in clinical diagnostics and in analytical research. ELISAs are 
used not only for measuring Ab levels, but also for detecting and quantifying antigens of 
infectious agents (68, 167), and more importantly for the purpose of this thesis, for 
measuring proteins such as cytokines. 
3.1.1 The sandwich ELISA 
The primary type of ELISA which is used to measure cytokine levels is the 
sandwich [LISA. In the sandwich ELISA (41, 170, 244, 270, 344), bound Ab first 
captures the cytokine and is then detected (hence, "sandwiched" between two 
antibodies) by another Ab recognising a different epitope (figure 3.1). Although the 
method is quick and relatively simple, care needs to be taken in the conditions. 
3.2 Principles of assay optimisation 
3.2.1 Choice of solid phase 
There are a number of solid phase supports which are used, and these are 
divided into two general groups, high capacity and low capacity (how much protein they 
can bind) (167-169, 342). Although high capacity materials can bind much higher levels 
of protein and still be specific with crude coating material (170), the majority of 
researchers use low capacity materials which give low levels of nonspecific binding. 
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Polystyrene plates versus latex beads or tubes is the low capacity material of choice, 
because a large number of samples can be tested quickly. But care still must be taken 
with microtitre plates because there can be batch to batch variation and because the 
outer wells do not always bind protein as well as the inner plates (169, 342). 
3.2.2 Coating 
Incubation time, temperature, and buffer pH must all be optimised for the best 
sensitivity and specificity in each step of the assay. In particular, adsorption of coating 
Ab is said to increase with an increase in incubation time and temperature until a 
plateau is reached (342). But prolonged times at higher temperatures can also lead to 
a loss in function of the coated material (169). For some coating antibodies, the pH of 
the buffer can influence coating efficiency (167, 257), while for others it makes very little 
difference (169). Plates are typically coated overnight at 4°C with PBS pH 7.2-7.6 as 
the coating buffer. 
The type and quality of coating and detecting antibodies are also important 
aspects of how sensitive and specific the assay can be (185, 313). It is important to 
have highly purified antibodies whether they are monoclonal or polyclonal, although 
monoclonals are usually used, because they have a reproducible affinity for a given 
epitope. 
The method of coating, either direct or indirect, also makes a difference in 
binding efficiency (167, 168). The direct method, of passive adsorption of Ab onto the 
plate, is by far the most common method. But it has been shown that there can be a 
significant loss in function because of desorption when the Ab is not bound tightly 
enough and because of conformational changes of the Ab once bound (42, 342). 
Concentration of all reagents is the most important aspect of each step in the 
ELISA. If the concentration of the coating Ab is too high, antibodies will tend to bind to 
each other, while if the concentration is too low, there can be nonspecific binding of 
detector Ab to the plate (168, 257). The concentration of each substance can be 
determined by titration for each type of experiment. 
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3.2.3 Sample conditions 
There is specific binding of test samples to the capture Ab as well as nonspecific 
binding to the plate or Ab (169, 342). Blocking proteins, such as BSA or skimmed milk, 
are often added to reduce background noise from nonspecific binding. These proteins 
bind to vacant protein-binding sites on the plate. There are a maximum number of 
sample molecules that can specifically bind to the capture Ab. There tend to be weak 
affinity interactions between sample and Ab when concentrations are too high (168). 
Reducing sample volume helps increase binding efficiency. 
3.2.4 Detector antibody 
Again choice of buffer, temperature, incubation time and most of all, 
concentration (preferably used in slight excess) need to be standardised for the 
detecting Ab as for the coating Ab and sample. The specificity of the detector Ab is 
crucial and cross-reactions need to be minimised (167, 168). 
Enzyme conjugation is also an important consideration. Detector antibodies are 
often directly labelled with enzyme, making the assay one step simpler. However, use 
of a second Ab or an avidin-biotin system allows this reagent to be used in many 
different assays (167, 168, 270). Biotinylated antibodies can bind to avidin-linked 
enzymes specifically with high affinity which gives the assay a higher sensitivity (185, 
270). 
3.2.5 Choice of enzyme and substrate 
High turnover rate, low cost, reproducible quality, stability and absence of natural 
enzymes in test samples are all factors which need to be considered. Colourimetric 
methods are used more often over flourimetric methods because of product stability 
and quick, inexpensive equipment for measuring colour (257, 270). Horseradish 
peroxidase, beta-galactosidase, and alkaline phosphatase are the three main enzymes 
used for colourimetric methods. It has been shown that horseradish peroxidase has 
much higher activity and is less expensive, although chromogens are thought to be 
carcinogenic and need to be handled with care (269, 342, 345). 
3.2.6 Data analysis 
There is no set way of presenting ELISA data. It is often satisfactory just to 
define a cut-off value for positive samples (129, 167, 257). But even when looking for a 
simple positive or negative result in qualitative analysis, it is still necessary to optimise 
the assay and run proper controls. 
As in this report, quantitative analysis needs to be done when comparing the 
amount of specific protein between different samples. This analysis is often done by 
reading from a standard curve. Three factors must be considered when using 
reference standards. First, standards must have the highest purity and stability so that 
reproducible results can be obtained each time the assay is run (126, 257). It is also 
advisable that standards are diluted in the same diluent as test samples (257). Second, 
the shape of the reference curve is also important. Because ELISA have a narrow 
range (the upper limit is 2-2.5 for optical density readings), it is better to have a very 
steep curve over fewer log dilutions than to have a shallow curve over a larger range of 
dilutions (167, 168). Finally, a lower limit of detection needs to be established for each 
assay. Typically the lower limit is defined as some formulation of the background value. 
3.2.7 Conclusions 
In conclusion, ELISA is a very useful tool to measure proteins quantitatively. 
Because of the widespread use of this assay, many companies have now developed 
high quality antibodies, enzymes, etc. for use in ELISA as well as complete ELISA kits. 
But even though materials have improved, it can be seen from the discussion above 
that care must still be taken when optimising the conditions of a particular assay. All of 
the materials for cytokine detection in this report were from companies which had 
previously developed, standardised, and purified them themselves. Regardless, assay 
parameters still had to be optimised for maximum specificity and sensitivity for each 
cytokine. 
3.3 Optimisation of ELISA for measuring cytokine responses to P. falciparum 
antigen in vitro 
Monoclonal antibodies to IFN-'y, IL-12 p70, IL-12 p40 and IL-10 were coated onto 
the solid phase (microtitre plates), and plates were incubated with cell culture 
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supernatants. Bound cytokine was "sandwiched" by a biotinylated monoclonal Ab and 
detected by avidin-linked HRP and OPD/H202. Each step was optimised for the best 
sensitivity and specificity to cytokine. The complete protocol and concentrations of 
reagents for each cytokine measured are found in tables 3.1 and 3.2 
3.3.1 Solid phase 
Immulon 4, 96-well, polystyrene plates were chosen for their ability to bind high 
levels of protein (Ab). They are specially designed for Ab adsorption and reproducibility 
between assays. Outer wells were never used, and plates were never stacked higher 
than 6 plates. 
3.3.2 Reagent concentrations 
3.3.2.1 Coating and detector antibodies 
Coating and detector monoclonal antibodies had been highly purified by Ab 
affinity purification. Optimal concentrations of coating and detector antibodies were 
determined by checkerboard titration (168, 170, 345). Five dilutions of recombinant 
human cytokines were used to test varying concentrations of both antibodies (10, 5, 1, 
0.5, and 0.1 ng/ml for IFN-y, IL-12 p70 and IL-10 and 10, 1, 0.1, 0.01 and 0.001 ng/ml 
for IL-12 p40). Three of four dilutions (10, 5, 2, and 1 jig/ml for IFN-y, IL-12 p70 and IL-
10 and 4, 2 and 1 jig/ml for IL-12 p40) of the coating monoclonal Ab were tested with 
3 dilutions (1, 0.25, and 0.05 jig/ml for IFN-'y, IL-12 p70 and IL-10 and 0.3, 0.15 and 
0.075 jig/ml for IL-12 p40) of the detector monoclonal Ab. The concentrations which 
gave the widest range of OD readings (steepest standard curve) were 2 jig/ml of 
coating Ab for IFN-y, IL-12 p70 and IL-10 and 4 jig/ml for IL-12 used with 0.05 jig/ml of 
detector Ab for IFN-y and IL-l0, 0.25 jig/ml for IL-12 p70 and 0.3 jig/ml for IL-12 p40 
(table 3.2 and figures 3.2-3.3). 
3.3.2.2 Standard and sample volume 
Fifty and 100 jil volumes of recombinant human cytokine standards were tested 
in order to determine if there was a difference in the amount of sample which could be 
bound. There was little difference between the OD readings, thus 50 j.tI was chosen for 
economy of reagents (figure 3.4). 
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3.3.2.3 Enzyme and substrate detection system 
HRP was chosen because it could be used with more than one biotinylated 
detecting Ab. It was also chosen because avidin-HRP with substrate OPD is one of the 
most sensitive, rapid and least expensive systems to use. Two or three dilutions of 
HRP were tested: 2.5, 1 and 0.5 pg/ml. The optimal concentrations were 0.5 p.g/ml for 
lEN-? and IL-12 p70 and 1 jg/ml for IL-10 and IL-12 p40 (figure 3.5). 
.3.3 Miscellaneous protocol changes 
All of the following optimisation steps were done to identify the lowest level of 
detection of cytokine and to reduce background without compromising the assay (Not 
all of the assays were performed on the lL-12 p40 ELISA as this assay was optimised 
after the other cytokine ELISAs. Many of these protocol changes were already 
assumed to be optimal). 
3.3.3.1 Blocking step 
A blocking step was done for 1 hour at 37°C instead of the recommended 1 hour 
at room temperature (figure 3.6). 
3.3.3.2 Dilution medium 
Four percent bovine serum albumin (BSA) was compared to 1% skimmed milk 
as blocking buffer and diluent for detecting Ab and HRP. Four percent BSA was used, 
because 1% skimmed milk gave lower OD readings over the entire range for IFN-y and 
IL-12 p70 (figure 3.7). 
3.3.4 Data analysis 
Plates were read at 492 nm with an automated spectrophotometer. Each 
sample and standard was tested in duplicate and the arithmetic mean was taken. 
Concentrations of cytokine were calculated from the standard curve. Linear regression 
analysis was done and the best fit curve formula was used to calculate cytokine 
concentrations (figure 3.8). The LLD was determined as 2 SDs above the mean of the 
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negative control (culture medium alone or PBS). Representative data for cytokine 
production from PHA- or LPS-stimulated PBMCs are shown in figure 3.9. 
3.4 ELISA: the best way to measure cytokines? 
The study of cytokines is a rapidly growing field with new knowledge being 
accumulated almost daily. Measuring cytokine levels will undoubtedly become a 
standard requirement in clinical diagnosis. It is important to have tools which accurately 
portray the cytokine profile. The choice of assay depends on the amounts of cytokine 
produced. ELISAs can measure pg/mi amounts of cytokine. But if concentrations are 
much lower (e.g. IL-4 (75)), then PCR-based methods may be needed. 
In this study, IFN-y levels in test samples could be reliably measured by ELISA. 
However, levels of IL-12 p40 and IL-iD were almost always close to the LLD, and 
results were thus more difficult to interpret (see Chapter 6). RT-PCR methods were 
evaluated for IL-12 (see Chapter 4), but this method was also far from ideal. In some 
cases, neutralisation assays may be the most appropriate method of demonstrating 
cytokine production (e.g. (xL-12 Ab, see Chapter 6). Thus, methods other than ELISA 
should also be used in conjunction to measure cytokines. It has been found that some 
cytokines are only detectable by RT-PCR and not by ELISA and that significant 
decreases in cytokine production can be detected with ICS but not with ELISA (92, 
357). 
Because measuring cytokines by ELISA is the simplest method, there are two 
main factors which must be considered when using ELISAs. First, it must be noted that 
there are a number of naturally occurring molecules that inhibit cytokine detection and 
therefore skew results. It has been shown by a number of researchers that molecules 
such as alp ha-2-macroglobulin, soluble receptors, and autoantibodies bind to cytokines, 
although most commercial companies have taken this factor into consideration (4, 58, 
60, 124, 322, 359). Second, and more importantly, there is a lot of variation between 
commercial standards. Three separate studies demonstrated that there was a huge 
difference in standard and sample values between commercial kits (68, 203, 255). No 
two kits gave the same values. These studies emphasise the need to produce 
international standards for cytokine assays, especially if comparisons need to be 
revalidated between laboratories. Until then, standards need to be carefully evaluated 
before they are used, and internal consistency must be ensured by using the same 




















onto the solid phase) 
4 	 Solid phase 
Table 3.1: Complete protocol for all cytokine ELISAs (for the list of all reagents, refer to 
section 2.6.1). 
Add 100 ltI/weII of capture Ab at the appropriate dilution in coating buffer. 
Incubate plates overnight at RI. 
Wash plates 4 times with 300 1.11/well of wash solution. 
Add 200 p.1/well of blocking buffer. 
Incubate plates for 1 hour at 37°C. 
Wash plates 3 times with 300 p.1/well of wash solution. 
Add 50 1.11/well of standard or culture supernatant. 
Incubate plates for 3 hours at RI. 
Wash plates 4 times with 300 p.1/well of wash solution. 
Add 50 p.1/well of biotinylated detecting Ab at the appropriate dilution in blocking buffer.* 
Incubate plates for 1 hour at RI. 
Wash plates 6 times with 300 p.1/well of wash solution. 
Add 100 p.1/well of avidin-labeled horseradish peroxidase at the appropriate dilution in blocking buffer. 
Incubate plates for 30 minutes at RI. 
Wash plates 8 times with 300 p.1/well of wash solution. 
Add 100 p.1/well of OPD substrate. 
Incubate plates for 15 minutes at RT. 
Add 25 p.1/well of stop solution. 
Read absorbance at 492 nm. 
*Detecting Ab for IL-12 p40 was added at 100 p.1/well. 
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Table 3.2: Reagent concentrations used for each cytokine ELISA (all reagents are from 
TCS unless otherwise indicated).* 
IFN1' 	IL-12 p70!  IL-12  p40# 	IL-10  
Coating Ab 	2 2 	 4 	 2 
Detecting Ab 0.05 	0.25 0.3 0.05 
HRP 	 0.5 0.5 	 1 	 1 
*All values are given in jig/ml. 
'Recombinant IL-12 p70 standard from PeproTech EC Ltd (London, UK) 




Figure 3.2: Standard curves for a) IFN-'y, b) IL-12 p70, c) IL-10, and d) IL-12 p40 comparing varying concentrations of 
coating Ab with optimal concentrations of detecting Ab for each cytokine. 10 (•), 5 (U), 2 (A) and 1 (+) fig/ml for IFN-y, 
IL-12 p70 and IL-b. 4 (•), 2 (U) and 1(A) p.g/ml for IL-12 p40. 
Log of cytokine concentration (ngiml) 
Figure 3.3: Standard curves for a) IFN-'y, b) IL-12 p70, C) IL-10, and d) IL-12 p40 comparing varying concentrations of 
detecting Ab with optimal concentrations of coating Ab for each cytokine. 1 (•), 0.25 (N), 0.05 (A) tg/mI for IFN-y, IL-12 
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Figure 3.4: Standard curves for a) IFN-y, b) IL-12 p70, c) IL-10, and d) IL-12 p40 comparing 50 (•) versus 100 () p.1 of 
standard. 
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Figure 3.5: Standard curves for a) IFN-y, b) IL-12 p70, c) IL-10, and d) IL-12 p40 comparing 2.5 (•), 1 (•) and 0.5 
(A) jig/ml of HRP. 
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Figure 3.6: Standard curves for a) IFN-'y, b) IL-12 p70 and c) IL-lO comparing 37°C (•) 
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Figure 37: Standard curves for a) IFN-y, b) IL-12 p70 and c) IL-10 comparing 4% BSA 
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Figure 38: Given (•) versus predicted (N) concentrations of a) IFN-'y, b) IL-12 p70, c) IL-b, and d) IL-12 p40. Linear 
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Figure 3.9: Representative production of a) IFN-y and b) IL-10 from PHA-stimulated blasts and c) IL-12 p70 and d) IL-12 







Chapter 4: Optimisation of reverse transcriptase poymerase chain 
reaction (RT-PCR) for IL-12 messenger RNA (mRNA) detection 
4.1 Introduction 
RT-PCR, a variation of PCR, is one of the most useful tools for studying gene 
regulation and expression. In short, messenger RNA is reverse transcribed to its 
complementary DNA by a reverse transcriptase. Specific DNA sequences are 
subsequently amplified by primer extension in PCR. 
There are a number of molecular techniques, such as in situ hybridisation and Northern 
blot, which have been developed for measuring gene expression. But of these, RT-
PCR is the most versatile. RT-PCR requires much less RNA, is less time consuming 
and more sensitive than the other assays. 
RT-PCR has often been used to study cytokine expression during immune 
responses (30, 38, 111, 156, 204, 226, 241, 317). Although RT-PCR does not measure 
secreted cytokine and cytokine transcripts are often difficult to quantify, it is not always 
possible to use standard assays such as ELISA. Analysing cytokine mRNA levels is 
appropriate when there are too few cells (38), when a number of cytokines need to be 
measured at one time (317) and when measuring cytokines which rapidly get used up, 
have a short half-life or are produced at very low levels. 
4.1.1 Principles of assay optimisation 
4.1.1. 1 RNA isolation 
Choosing total RNA or poly (A)+ RNA isolation method depends on the 
downstream application. Although poly (A)+ RNA isolation highly enriches for mRNA, 
total RNA extraction methods (often based on guanidinium thiocyanate) may be 
preferred if there is a high throughput of samples (200, 273). 
The most important aspect of RNA extraction is keeping an RNAse-free 
environment in order to prevent RNA degradation. Extraction of RNA should be done 
as quickly as possible, because RNAses contained in secretory vesicles are released 
when cell surfaces are disrupted (150). Using sterile disposable plasticware, handling 
samples with gloves, and diethyl pyrocarbonate (DEPC)-treating glassware are just 
some of the measures which should be followed when working with RNA (200, 273). 
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4.1.1.2 First strand synthesis 
The choice of reverse transcriptase and cDNA primer are the 2 main aspects of 
first strand synthesis. The most commonly used reverse transcriptases are derived 
from Avian myeloblastosis virus and Moloney murine leukemia virus (202, 274). 
Random, oligo-(dT) and specific priming are the 3 ways to prime cDNA. Random 
priming is beneficial for detecting rare mRNA transcripts but is not often used (202). 
Oligo-(dT) is often the method of choice, because more than one transcript can be 
detected (65). 
A one step-one tube system which speeds up RT-PCR and reduces risk of 
contamination has been developed (274). However multiple transcripts cannot be 
measured, and it has been reported that reverse transcriptase can inhibit Taq DNA 
polymerase (81). 
4.1.1.3 PCR assay parameters 
Primers are the single most important aspect which determines the success of 
PCR amplification. There is no one best way to design primers, but most range from 
15-30 bp in length with 40-60% G-C content (272). Primers with complementary 
3' ends, significant secondary structure, runs of 3 or more G's and C's at 3'ends, and 
significantly different melting temperatures should be avoided (148, 272, 296). 
Concentration and pH are important parameters for the PCR master mix. 
Concentrations of MgCl2, dNTP and primers which are too high reduce the specificity of 
the reaction (148, 172, 272, 296, 329). However, molar excess of reagents compared 
to template drives the reaction (172). Buffer pH must not be too high as it decreases 
the fidelity of the Taq or too low as it damages DNA (80). 
The choice of DNA polymerase is also important. As errors in sequencing occur, 
using T4 or T7 DNA polymerases which have proof-reading ability is beneficial. 
Because these polymerases are not stable at high temperatures, Taq DNA polymerase 
is more often used, (80). As non-specific priming occurs even when the reaction mix is 
sitting at RT, it is also recommended to use a 'hot-start' polymerase which is only 
activated at denaturing temperatures (7). 
Finally cycling parameters need to be optimised. High annealing temperatures 
increase the specificity of the reaction (148, 172, 272, 296, 329). Annealing 
W. 
temperatures ranging between 55-60°C is usually recommended. Amplification 
reactions should proceed for, at most, 40 cycles. The reaction reaches a plateau phase 
where the efficiency is decreased and nonspecific priming occurs when the number of 
cycles is too high (172, 297). 
4.1.2 Quantitative methods of RT-PCR 
PCR products are normally separated on EtBr-stained agarose gels and 
visualised under ultraviolet light, although fluorescent labeled probes are often used 
because they afford greater sensitivity (10). These methods are only qualitative, but in 
some cases, such as when cytokines are up-regulated, a quantitative assay is 
necessary. 
Non-competitive methods have been used for a variety of purposes (30, 140, 
201, 226) and are divided into 2 basic categories: titration and kinetic. Although non-
competitive RT-PCR is fairly easy to optimise and can use external controls, it does not 
control for variations in tube-to-tube amplification efficiency and can only tell how much 
product there is relative to other samples. 
Competitive methods where internal controls are co-amplified with DNA targets 
are more often used. Endogenous RNA such as J3-actin can be used (178, 241) as an 
internal control, but exogenous RNA is more often used as a competitor molecule. A 
number of studies use synthetic RNA competitors which are amplified by the same 
primers but differ in length with the target sequence (36, 111, 204, 327, 352, 353). 
However, it is not known whether the amplification efficiency of the standard is equal to 
the target. Other studies avoid this complication by using a competitor molecule having 
an almost identical sequence except for a single point mutation of the target sequence 
(19, 131, 162). Although these methods are better for absolute quantitation than 
assays using external or endogenous RNA controls, developing synthetic controls is 
relatively time-consuming. 
4.2 Optimisation of RT-PCR for measuring IL-12 p40 responses to P. falciparum 
antigen in vitro 
The complete RT-PCR assay is summarised in section 2.7. 
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4.2.1 Total RNA isolation 
All RNA preparations were done using a commercial RNA extraction kit (RNeasy 
mini kit with Qiashredder; Qiagen; Crawley, UK) or with RNAz0I B (Biogenesis; Poole, 
UK). Both methods worked equally well for preparing total RNA for RT-PCR assays 
(figure 4.1). Total RNA extraction methods were chosen over poly(A)+ RNA methods 
primarily because of the cost, the relative ease of the assay and the large number of 
samples to be processed. Briefly, 106  cells were pelleted, lysed and homogenised with 
1 ml of RNAzol B containing guanidinium isothiocyanate. One hundred microliters of 
chloroform (Sigma) were added to the cell suspension, shaken for 15 seconds, and 
incubated at 4°C for 5 minutes. The suspension was centrifuged for 15 minutes at 
12,000 g at 4°C to extract the RNA into the aqueous phase. The soluble RNA was then 
transferred to a fresh tube and isopropanol (Sigma) was added at a 1:1 volume and 
incubated at 4°C for 15 minutes. RNA was precipitated by centrifuging for 15 minutes 
at 12,000 g at 4°C. The pellet was washed in 75% ethanol (Hayman Limited; Essex, 
UK), centrifuged for 8 minutes at 7,500 g at 4°C, and resuspended in 50 p1 of RNAse-
free water. The amount of RNA in the sample was not quantified with a 
spectrophotometer at this time, because there was very little starting material. RNA 
sample-to-sample variation was controlled for by visually equalising (under ultraviolet 
light) the housekeeping transcript, 13-actin. 
In order to remove any contaminating genomic DNA, RNAse-free DNAse 
(Boehringer-Mannheim) was added in excess of 1 U/tg RNA and then incubated at 
37°C for 30 minutes, 75°C for 5 minutes. Samples were either used immediately for 
first strand synthesis or stored in 100% ethanol at —70°C until required. 
4.2.2 First strand synthesis 
cDNA was reverse transcribed from 11 p1 (or less) RNA in a final volume of 20 p1 
with 1 p1 (0.5 pjg) oligo (dT)1218 primer (Gibco Life Technologies) as the primer. Oligo-
(dT)1218 primer was chosen because more than one transcript was being measured. 
Total reaction solution also included the following: 
2 p1 0.1 M dithiothreitol (DTT; Gibco Life Technologies), 
4 p1 5X first strand buffer (250 mM Iris pH8.3, 375 mM KCI, 15 mM MgCl2; Gibco Life 
Technologies) 
ce 
1 p1(10 mM) dNTP mix 
1 p1(200 U) superscript II reverse transcriptase (RT; Gibco Life Technologies). 
Synthesis was run at 42 °C for 50 minutes and then stopped by raising the temperature 
to 70°C for 15 minutes. 
4.2.3 PCR 
4.2.3.1 PCR controls 
The following controls were run for each PCR assay: 
3-actin, a constitutively expressed gene, was used as a positive control to show 
evidence of RNA in every sample, to control for variability between samples and to 
confirm the reverse transcription and PCR reactions. 
Plasmids containing both 13-actin and IL-12 p40 sequences were used as positive 
controls in order to make sure the PCR reaction worked (see section 4.2.4). 
A sample containing no RNA was used as a negative control for contamination in the 
RT-PCR reagents. 
An RNA sample with no AT step was used for a negative control for genomic DNA 
contamination. 
4.2.3.2 Primers 
Oligonucleotide sequences for IL-12 p40 primers were sourced from published 
sequences (364) and 13-actin primers were designed from the GEN-EMBL database. 
Primers were designed to sit on each side of at least one intron in order to distinguish 
between genomic and cDNA fragments, except for IL-12 p40 primers for which the 
genomic DNA had not been sequenced. IL-12 p40 primers were tested with human 
genomic DNA (Boehringer-Mannheim), and no 374 bp band was detected, although a 
band >2000 bp was detected (data not shown). 13-actin and IL-12 p40 primers were also 
designed to work at the same efficiency (same melting point and equivalent numbers of 
base pairs with 55% GC content) in order to use them in semi-quantitative analysis (see 
section 4.2.5). Sequence information is shown in table 4.1. 
4.2.3.3 PCR assay parameters 
Concentrations of MgCl2  and Taq were optimised (figures 4.2-4.3). Promega 
Taq DNA polymerase and its corresponding buffer (see section 2.1 .2 for details) were 
chosen for thermostability and cost. Variations in these parameters did not affect 3-
actin transcripts but were important in optimising conditions for IL-12 p40 transcripts. 
With low concentrations of MgCl2 and high concentrations of Taq, no IL-12 p40 
transcripts were detected. Variations in primer and dNTP concentrations did not affect 
PCR reactions for either transcript (data not shown). Equal concentrations of dATP, 
dCTP, dGTP, and dTTP were used. The optimal PCR mix thus contained the following: 
1 tl cDNA 
1 il (1pM) each cytokine primer (Oswel, Southampton, UK), 
0.8 tl (2 mM) MgCl2 
0.2 .tl (200 M) dNTP mix 
1 il lox buffer 
0.1 p1(0.5 U) Taq DNA polymerase 
Volume made up to 10 tl with sterile distilled water. 
PCR amplification was performed for 35 cycles for 3-actin and 35 or 40 cycles for 
IL-12 p40, because of the relative rarity of IL-12 p40 starting material. Cycle numbers 
were not increased to more than 40 cycles, because there was greater risk of 
nonspecific priming. Annealing temperature was also optimised. At lower 
temperatures, there was a lot of nonspecific binding for IL-12 (figure 4.4). The 
temperatures used for PCR were: denature 94°C for 1 minute, primer annealing 60°C 
for 1 minute, extension 72°C for 1 minute. Assay-to-assay variation was minimal as the 
same Hybaid thermocycler was used for each assay (figure 4.5). 
4.2.3.4 Analysis 
PCR products were analysed by gel electrophoresis. PCR fragments were 
separated on EtBr-stained, 1.5% agarose gels run in 0.5)( TBE buffer (5.4 g trizma 
base, 2.75 g boric acid, both from Sigma; 2 ml 0.5 M EDTA pH 8, Boehringer-
Mannheim, in 1 L distilled water). Forty percent of each sample was run in 6X loading 
buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, both from Sigma; 15% ficoll 
type 400, Amersham-Pharmacia) with 100 base pair DNA molecular weight marker (3 p1 
of 125 mg/ml solution; Boehringer-Mannheim) to determine size of PCR products. PCR 
products were visualised under ultraviolet light and analysed with Multi Analyst software 
package (Biorad, Hertfordshire, UK). 
4.2.4 Fidelity of PCR product by sequencing 
4.2.4.1 Solutions used in plasmid preparation 
LB broth pH7 
10 g sodium chloride (Sigma) 
10 g bacto-tryptone (Boehringer-Mannheim) 
5 g bacto-yeast extract (Boehringer-Mannheim) 
1 L deionised water 
LB ampicillin agar plates pH7 
LB broth 
20 g bacto-agar (Boehringer-Mannheim) 
50 mg ampicillin (Sigma) 
4.2.4.2 Preparation of plasmid control 
13-actin and IL-12 p40 DNA were purified from PCR products using a commercial 
purification kit (High Pure PCR Product Purification Kit; Boehringer-Mannheim). DNA 
was resuspended in 10 tl of water and 7 .tI of each suspension was used to clone DNA 
into plasmids using a commercial kit (pGEM®-T Easy Vector System; Promega). After 
the ligation reactions were run overnight, ligates were added to competent cells (XL1 - 
blue, a strain of Escherichia colt, Stratagene; Amsterdam, Netherlands) and incubated 
for 1 hour on ice. The cell suspensions were heat shocked for 45 seconds at 42°C, 
incubated on ice again for 15 minutes, and then added to 300 tl of LB broth to incubate 
at 37°C for at least 1 hour. Two hundred microliters of cell suspension were plated onto 
LB-Ampicillin plates containing 0.1 M isopropyl-B-D-thiogalactopyranoside (IPTG) and 
50 ng/ml 5-bromo-4-chloro-3-indolyl-B-D-galactopyranoside (X-GAL) (both from 
Boehringer-Mannheim). Plates were incubated at 37°C overnight and transformed 
colonies (white colonies) were selected either for -actin and IL-1 2 p40 PCR assays or 
for sequencing reactions to test the fidelity of amplified PCR products (see section 
4.2.4.3). 
Plasmids were purified with a commercial kit (Qiaprep Spin Miniprep Kit, 
Qiagen), and restriction digests were performed overnight at 37°C using 41 p1 of 
plasmid, 5 p1 of buffer 4 (50 mM potassium acetate, 20 mM Tris-acetate, 10 mM 
magnesium acetate, 1 mM DTT, pH7.9; New England Biolabs; Hitchin, UK) and 100 U 
of NDE1 or 200 U NSI1 restriction enzyme (both from New England Biolabs). The 
plasmid containing 13-actin was then treated with alkaline phosphatase (so that it would 
not religate onto itself) in a reaction containing 10 .tI plasmid, 2 jil buffer (50 mM Tris-
HCI pH 8; Amersham), 2 U shrimp alkaline phosphatase (Amersham), and 6 p1 of water. 
The reaction was run at 37°C for 30 minutes and then stopped by raising the 
temperature to 80°C for 10 minutes. Plasm ids containing 13-actin or IL-12 p40 were 
then ligated using the method described above. 
4.2.4.3 Sequencing /3-actin and IL- 12 p40 
Fidelity of the amplified PCR product was confirmed by using a commercial 
sequencing kit (ABI PRISMTM Dye Terminator Cycle Sequencing Ready Reaction Kit; 
Perkin Elmer-Applied Biosystems; Warrington, UK) using universal vector primers. 
After the purified plasmid was sequenced and run on a gel, the PCR product was 
purified by ethanol precipitation. Briefly, 2 tl of 3 M sodium acetate pH 5.5 (BDH), 50 p1 
100% ethanol and 20 pP of the reaction product were incubated at -20°C for 30 minutes 
and then centrifuged for 20 minutes at 12,000 g at 4°C. The DNA pellet was washed 
once in 70% ethanol and resuspended in 3 pP of loading buffer (5:1 ratio of deionised 
formamide, BDH to 25 mM EDTA pH 8 containing 50 mg/ml blue dextran, BDH). The 
reaction mixture was denatured at 90°C for 2 minutes and then run overnight on an 
automated sequencer (Perkin Elmer-Applied Biosystems). The sequences were 
analysed with ABI PRISMTM  377 Gene Scan Analysis software and confirmed to be 
actin or lL-12 p40 by comparing sequences to the GEN-EMBL database. 
4.2.5 Semi-quantitative RT-PCR optimisation 
IL-12 was originally measured by IL-12 p70 ELISA, but no significant IL-12 was 
detected from PfSE-stimulated PBMCs (see chapter 6). In order to determine amounts 
of IL-12 being produced, optimisation of a non-competitive, semi-quantitative RT-PCR 
was then begun. Relative levels of IL-12 p40 would be determined by co-amplification 
with 13-actin. A plasmid containing both 13-actin and IL-12 was developed to 
demonstrate that primers for these transcripts worked at equal efficiency (figure 4.6). 
However, subsequently semi-quantitative RT-PCR was discontinued, because 
qualitative RT-PCR assay turned out not to be as sensitive as the IL-12 p40 ELISA (see 
section 4.3). 
4.3 Results 
4.3.1 Study population and cell cultures 
Venous blood was taken from 13 naïve individuals, 20 exposed, but not clinically 
immune, individuals and 3 control individuals and processed for in vitro PBMC culture 
(study populations and method of cell separation are described in Chapter 2). PBMCs 
were distributed at 106/well in a total of 1 ml of complete culture medium in flat-
bottomed 24-well plates and cultured for 1, 2, 4, 6, and 8 days with uRBC or PfSE. 
PHA or LPS were used as positive control stimuli for cytokine production. Adherent and 
non-adherent PBMCs were harvested and pelleted for RNA extraction and subsequent 
RT-PCR as described in section 4.2. 
4.3.2 RT-PCR does not show high levels of IL-12 transcripts 
Figure 4.7 shows representative gels for the complete assay of 1 exposed donor, 
El 0. All positive and negative control PCRs worked for donor El 0. 13-actin PCR5 were 
all positive except for PBMCs stimulated with uRBC on day 6. However, there were no 
IL-12 transcripts detected even for the LPS-stimulated cells. PfSE-stimulated IL-12 p40 
transcripts with f3-actin controls for cells of all individuals are shown in figures 4.8-9 
(control individuals not shown). Positive plasmid and negative (no DNA) controls 
worked consistently for all individuals. RNA was demonstrated for almost all samples 
by 3-actin transcripts, and very few samples had genomic DNA contamination. The 
PCR reaction sometimes primed up 3-actin genomic DNA transcripts, but even in those 
samples, cDNA transcripts were dominant (complete details for each individual are 
given in Appendix 1, tables Al. 1 -Al .3). 
For both naïve and exposed individuals, PfSE-stimulated lL-12 p40 was detected 
more often on day 1 than any other day. On day 1, 38% and 20% had positive 
responses in naïve and exposed populations (5/13 and 4/20 positive responders 
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respectively; table 4.2). However, overall naïve individuals had more positive IL-12 
responses to PfSE than exposed (77%, 10/13 and 30%, 6/20 respectively). uRBC also 
stimulated IL-12 p40 production almost as much as PfSE in cells from naïve donors and 
equally as much in PBMCs from exposed donors on day 1. Although uRBC has been 
shown to non-specifically stimulate PBMCs (see Chapter 7), it is surprising that almost 
equal numbers of exposed individuals produced IL-12 p40 to uRBC and PfSE (naïve 
individuals had higher cumulative responses to PfSE by day 6). Conversely, IL-12 p40 
was not detected in all of the positive (LPS/PHA) controls (91 %, 10/11 and 35%, 7/20 
cumulative responses in naïve and exposed donors respectively). Also, more naïve 
donors produced IL-12 p40 to PfSE in comparison to exposed donors (table 4.2). This 
result was surprising in light of the fact that exposed individuals produced more IFN--y in 
response to PfSE than naïve individuals and that a significant proportion of that IFN-y 
was IL-12 dependent (see Chapter 6). 
Because the data seemed unusual and because there was not enough IL-1 2 p40 
transcript produced to quantify, an IL-12 p40 ELISA was used to confirm the RT-PCR 
results (analysis of IL-12 p40 ELISA results is found in Chapter 6). IL-12 p40 protein 
was measured on day 2 and compared with cumulative transcript responses to uRBC or 
PfSE (tables 4.3-4.4). IL-12 p40 protein levels were considered positive if they were 
above the LLD (171pg/ml). IL-12 p40 ELISA was more sensitive than RT-PCR for both 
groups overall (table 4.5). ELISA detected significantly more IL-12 p40 responders to 
uRBC and PfSE in the exposed group (Chi-squared, df=i, X2 23O2 p<0.001 for uRBC 
and X2 1238 p<0.001 for PfSE). All the individuals who had positive IL-12 responses 
detected by RT-PCR were also positive by ELISA, except for donors N16 and N2 (in 
response to uRBC and PfSE respectively). Although different numbers of responders 
were detected by each assay, ELISA confirmed RT-PCR analysis in that there were 
almost an equivalent number of responders to uRBC and PfSE. 
4.4 Discussion: Is RT-PCR the best way to measure IL-12? 
4.4.1 Justification for using RT-PCR 
IL-1 2 is an important cytokine in the inflammatory response to P. falciparum. It 
was demonstrated that IFN--y production from PfSE-stimulated PBMCs of naïve, 
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exposed and immune individuals was downregulated when IL-12 was neutralised (see 
Chapter 6). I therefore wanted to directly measure IL-12 responses in the system. 
IL-12 p70 ELISA was first used, but most samples tested had PfSE-stimulated 
IL-12 p70 levels below LLD (see Chapter 6). Although there is a standard bioassay for 
IL-12 p70 (109) that has been used to detect bioactive IL-12 (184), this assay was not 
chosen for a number of reasons. First, bioassays may not accurately reflect how much 
IL-12 is in the system, because IL-12 p40 homodimer can antagonise IL-12 p70 
bioactivity (124, 133, 359). Second, bioassays are fairly complex to standardise, and 
results may be variable. Heufler etal. reported variable readouts with IL-12 p70 
bioassay (133). Because it was difficult to measure detectable protein levels of IL-12 
and because such small amounts of IL-12 are needed for bioactivity, RT-PCR was 
chosen for its sensitivity in detecting minuscule amounts of transcript. 
4.4.2 Why was RT-PCR not as sensitive as ELISA? 
It was demonstrated that ELISA was actually more sensitive in detecting IL-1 2 
p40 than RT-PCR. There are a number of reasons which could possibly explain why 
RT-PCR might not have been as sensitive. First, there may have been problems with 
the optimisation of the assay itself. It is recommended to increase the number of cycles 
for rare transcripts. In this case, IL-12 PCR amplification was already increased to 40 
cycles, the upper limit of cycle number without increasing chances of mispriming. 
Alternatively, template could have been degraded or impure. It has been shown that 
impurities such as haemoglobin and heparin (both of which can be found in this assay 
system) can inhibit the efficiency of PCR amplification (207). However, after separating 
PBMCs from whole blood, levels of heparin or haemoglobin should have been much 
lower than the concentrations which would effect PCR. Any number of variables could 
also have effected efficiency and sensitivity such as missing or poor quality reagents, 
suboptimal reaction conditions, inconsistent cycling, etc. All these variables were 
accounted for as stated in the results section, and for the most part, there was little 
assay-to-assay variation. Technical problems with the assay therefore seem to be an 
unlikely explanation. 
It has been established that PfSE-stimulated PBMCs produce IL-12. Thus, the 
most likely reasons that IL-12 p40 could not be detected are because there was either 
too little transcript or transcript production was too transient. The timepoints chosen 
may have been too late to detect IL-12 p40. Phagocytic cells show increased 
accumulation of IL-i2 p40 transcripts 2-4 hours after being stimulated with LPS but 
subsequently decrease again after a few hours (212). Whole PBMCs may also not be 
the best population to detect IL-12 p40. It may have been better to separate out the 
possible IL-1 2 producing cells (macrophages or dendritic cells) in order to concentrate 
the specific RNA being measured. 
There is no one assay that best measures IL-12. A number of studies have 
demonstrated that cytokines are detectable by one assay but not another (92, 357). In 
particular, Meyer zum Buschnfelde et al. demonstrated that changes in IL-1 2 levels 
from Trypanosoma cruzi-stimulated spleen cells could be detected by in situ 
hybridisation but not by semi-quantitative RT-PCR (231). Measuring mRNA may not be 
the best method for determining the relative importance of IL-12 in a system. There 
may be post-transcriptional factors such as inhibiting translation and protein 
degradation which regulate bioactive IL-1 2. For example, it has been demonstrated 
that TGF-j3 down-regulates TNF-a not through inhibiting transcription but through 
suppressing translation (34). Thus, depending on the aim of the study, a combination 
of different assays should be used to detect IL-12 expression. 
However, the overall conclusion of both ELISA and RT-PCR methods is that 
parasite (PfSE-uRBC)-induced IL-12 cannot be consistently detected by either method, 
and the only clear demonstration of IL-12 activity was the assays when IL-12 was 
neutralised (see Chapter 6). 
Table 4.1: Description of primers used for RT-PCR. 
mRNA 	Strand 	 Sequence 	 mRNA Location!  Fragment Size 
f3-actin Sense* CATGGGTCAGAAGGATTCCT 	179 	 299 
	
Antisense* AGAGGCGTACAGGGATAGCA 457 
IL-12 Sense* GACCAGAGCAGTGAAGGTCTT 	199 	 374 
Antisense* CTCCTTGTTGTCCCCTCTGA 552 
* Sequences are read from 5' to 3'. 
Numbers indicate where the primer sequence begins. 
Figure 4.1: Comparison of -actin (299 bp) and IL-12 (374 bp) PCR products using 
different RNA extraction methods. 
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Figure 4.2: Comparison of 13-actin (299 bp) and IL-12 (374 bp) PCR products using 
different of MgCl2 concentrations in the PCR master mix (1.5 mM MgCl2 for lanes 2 and 
3, 2 mM MgCl2 for lanes 4 and 5). 
500 bp—),  
Lane 1= bp markers 
Lane 2= f3-actin 
Lane 3= IL-12 p40 
Lane 4= 13-actin 
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Figure 4.3: Comparison of 3-actin (299 bp) and IL-12 (374 bp) PCR products using 
different concentrations of Taq DNA polymerase concentrations in the PCR master mix 
(0.5 U Taq for lanes 2 and 3, 1 U Taq for lanes 4 and 5). 
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Figure 4.4: Comparison of IL-12 (374 bp) PCR products using different annealing 
temperatures during PCR. 
Lane 1= bp markers 






Figure 4.5: Two-fold serial dilutions of 13-actin (299 bp) and IL-12 (374 bp) plasmids for 
6 different PCR assays demonstrating little assay-to-assay variation. 
13-actin 	IL-12 
Figure 4.6: Plasmid containing both f3-actin (299 bp) and IL-12 p40 (374 bp) transcripts, 
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Lane Sample Primer Sample Primer Sample 	Primer Sample Primer Sample 	Primer 
1 no ANA -actin - uABC2 IL-12 - LPS4 -actin + uR8C6/no FIT IL-12 	- LPS8/no RT 	3-actin 	- 
2 IL-12 - uABC4 IL-12 - LPS6 	3-actin + uRBC8/no AT IL-12 - LPS1/no AT IL-12 - 
3 no cDNA -actin - uRBC6 IL-12 - LPS8 -actin + PISE1/no AT fI-actin 	- LPS2/no AT 	IL-12 	- 
4 IL-12 - uABC8 IL-12 - LPS1 	IL-12 - PISE2/no AT -actin - LPS4/no AT IL-12 - 
S Plasmid -actin + PISE1 (1-actin + LPS2 IL-12 PISE4/no AT -actin 	- LPS6/no AT 	IL-12 	- 
6 IL-12 ± PISE2 -actin + LPS4 	IL-12 - PISE6/no AT it-actin - LPS8/no AT IL-12 - 
7 LPS -actin + PISE4 -actin + LPS6 IL-12 - PISE8/no AT -actin 	- 
8 IL-12 - PISE6 -actin + LPS8 	IL-12 - PISE1/no AT IL-12 - 
9 LPS/no AT -actin - PISE8 -actin + uABC1/noAT 	-actin - PISE2/no AT IL-12 	- 
10 IL-12 - PfSE1 IL-12 - uRBC2/no.AT -actin - PISE4/no AT lL-12 - 
11 uABC1 1-actin + PISE2 IL-12 - uABC4/no AT 	0 -actin - PISEG/no AT IL-12 	- 
12 uRBC2 3 -actin + PISE4 IL-12 - uABC6/no AT 3-actin - PISE8/no AT IL-12 - 
13 uABC4 3 -actin + PISE6 IL-12 - uABC8/no AT 	3-actin - LPS1/no AT 3 -actin 	- 
14 uABC6 3 -actin - PISE8 IL-12 - uRBC1/noAT IL-12 - LPS2/no FIT 3-actin - 
15 uABC8 3 -actin + LPS1 3 -actin + uABC2/no.AT 	IL-12 - LPS4/no AT 3 -actin 	- 
16 uRBC1 IL-12 - LPS2 3 -actin + uABC4/no AT IL-12 - LPS6/no AT 3 -actin - 
-oample inojces wnicn sumun ano oay. 
aLPS blasts from another donor. 
'no AT indicates that there was no reverse transcription done (negative control for DNA contamination. 
= band of correct size detected 
no band/ no band of correct size detected 
92 
Figure 4.8a: -actin and IL-12 transcripts from PfSE-stimulated PBMCs for naïve 
individuals. 
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Figure 4.8b: f3-actin and IL-12 transcripts from PfSE-stimulated PBMCs for exposed 
individuals. 
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Table 4.2: Summary of the number of individuals who had detectable IL-12 p40 
transcripts in response to uRBC, PfSE and LPS (or PHA for naives) in a) naïve (n=13, 
n=1 1 for LPS/PHA) and b) exposed (n=20) study populations. 
a) Naives 
Stimulus 
Day RBC PfSE LPS/PHA 
1 4 (31%) 5(38%) 6(55%) 
2 5(38%) 6 (46%) 8 (73%) 
4 6(46%) 10(77%) 8(73%) 
6 6(46%) 10(77%) 10(91%) 
b) Exposed 
Stimulus 
Day RBC PfSE LPS 
1 4(20%) 4(20%) 7(35%) 
2 4(20%) 4(20%) 7(35%) 
4 4(20%) 6(30%) 7(35%) 
6 4(20%) 6(30%) 7(35%) 
8 4(20%) 6(30%) 7(35%) 
Table 4.3: Comparison between RT-PCR and ELISA in measuring IL-12 p40 for each 
naïve individual. IL-12 p40 protein was measured on day 2 and compared with 
cumulative transcript responses to a) uRBC and b) PfSE (IL-.12 p40 protein levels were 
considered positive if they were above the LLD =171 pg/mI). 
a) uRBC  
Donor RT-PCR ELISA 
N2 - - 
N3 - + 
N4 + + 
N5 - + 
N12 + + 
N13 + + 
N14 - + 
N15 - - 
N16 + - 
N17 + + 
N18 - + 
N19 - + 
Sum 5 9 
% 42% 75% 
Ratio 5/12 9/12 
b) PfSE 
Donor RT-PCR ELISA 
N2 + - 
N3 - + 
N4 + + 
N5 - + 
N12 + + 
N13 + + 
N14 + + 
N15 + + 
N16 - + 
N17 + + 
N18 + + 
N19 + + 
Sum 9 11 
75% 92% 
Ratio 9/12 11/12 
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Table 4.4: Comparison between RT-PCR and ELISA in measuring IL-1 2 p40 for each 
exposed individual. IL-12 p40 protein was measured on day 2 and compared with 
cumulative transcript responses to a) uRBC and b) PfSE (IL-12 p40 protein levels were 




Donor RT-PCR ELISA 
	
Donor RT-PCR ELISA 
El 	- 	+ 
E2 - + 
E3 	- 	+ 
E5 - + 
E6 	 + 
E7 - 	+ 
E8 	- + 
E9 + 	+ 
ElO 	- + 
Ell + 	+ 
E12 	+ + 
E14 - 	+ 
E15 	- + 
E16 - 	+ 
E17 	- + 
E18 + 	+ 
E19 	- + 
E20 - 	- 
E21 	- + 
E22 - 	+ 
Sum 	4 19 	 Sum 	6 	17 
% 20% 95% % 30% 85% 
Ratio 	4/20 	19/20 	 Ratio 	6/20 	17/20 
Table 4.5: Comparison of RT-PCR and ELISA methods in detecting IL-12 p40 
responses to uRBC and PfSE in a) naïve (n=12) and b) exposed (n=20) study 
populations. Number (%) of responders detected by each method. 
a) Naives 	 b) Exposed 
Ratios 	 Ratios 
RT-PCR ELISA 	 RT-PCR ELISA 
RBC 	5 (42%) 9 (75%) RBC 	4 (20%) 19 (95%) 
PfSE 9 (75%) 11(92%) 	PfSE 6 (30%) 17 (85%) 
El - + 
E2 - + 
E3 - + 
E5 - + 
E6 - + 
E7 - - 
E8 + + 
E9 + + 
ElO - + 
Ell - + 
E12 + + 
E14 - + 
E15 - + 
E16 - + 
E17 - - 
E18 + + 
E19 - + 
E20 - - 
E21 + + 
E22 + + 
Ell 
Chapter 5: Naïve, exposed and immune individuals have 
lymphoproliferative responses to P. falciparum antigen in vitro 
5.1 Introduction 
Both T and B cell responses play important roles in protection to malaria. The 
primary focus used to be on humoral responses, because it was found that malaria-
specific Ab could be induced during an immune response. It was originally thought that 
these responses were protective and thus they pointed the way towards vaccine 
therapy. It was then realised that although these Ab-mediated responses were 
sometimes protective, they did not give complete sterilising immunity. For example, 
Hoffman et al. demonstrated that individuals who had high levels of Ab to sporozoites 
could still become infected with malaria (139). 
Because T cells regulate both cell-mediated and Ab-dependent immune 
responses, there has been a major focus on elucidating T cell mechanisms in immunity 
to malaria. Understanding more about the role of T cell responses is fundamental to an 
understanding of protective immunity. A number of studies have focused on the need 
for vaccines to stimulate specific T cells which will clonally expand and either directly or 
indirectly destroy the invading organism (77, 324). 
5.1.1 T cell responses in malaria-exposed individuals 
Individuals who live in endemic areas are continuously exposed to malaria. 
When cultured in vitro, their cells respond vigorously to malaria Ag (114, 284, 336, 
366). Some of these responses are still found long after initial exposure, indicating that 
there is long-lasting memory to malaria (73) 
However, there have also been studies which show that malaria-exposed 
individuals have low or absent proliferative responses in vitro to malaria Ag, particularly 
during acute infection (284). Luty et al. found that individuals living in Gabon who had 
higher levels of parasitemia had lower proliferative responses (211). Ho et al. were also 
unable to demonstrate proliferative responses to malaria Ag in vitro from cells of 
splenectomised patients with acute malaria (136). It was demonstrated that there is an 
absence of circulating malaria-specific T cells in the periphery during acute infection, 
because activated cells upregulate LFA-1 and most likely sequester in the spleen or 
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liver during infection (146). It was also suggested that malaria Ag themselves could be 
immunosuppressive. Riley et al. demonstrated that P. falciparum extracts suppressed 
proliferative responses to Ag and mitogen in vitro, suggesting that not just malaria Ag-
specific responses are suppressed (285). 
5.1.2 T cell responses in unsensitised individuals 
Studies done in the late 1970s-early 1980s demonstrated that PBMCs, primarily 
T cells, from individuals who have never been exposed to malaria as well as cells from 
exposed individuals proliferate in response to P. falciparum extracts (14, 20, 62, 63, 97, 
105, 114, 115, 119, 290, 366, 370). Because cells from naive individuals were also 
able to respond, it was thought at the time that P. falciparum extracts were mitogenic 
(119). However, more recent studies showed that T cell responses to malaria Ag were 
MHC-dependent, meaning that malaria parasites could be activating via a 
superantigen- or Ag-mediated mechanism (see section 1 .3)(20, 62, 63, 114, 115, 290, 
370). 
The general consensus is that P. falciparum extracts are acting as conventional 
Ag. A number of studies demonstrated that T cell responses to P. falciparum are not 
only MHC-dependent but are MHC-restricted (97, 114, 290). It is generally agreed that 
PBMCs from naive individuals respond because their cells have been primed previously 
by other environmental Ag which share similar antigenic epitopes. Some studies have 
demonstrated that there is a rapid in vitro expansion of P. falciparum-specific CD4+ c43+ 
CD45RO+ memory T cells in individuals who have had no prior exposure to malaria 
(62, 63, 75). Clones generated from these memory T were able to proliferate in 
response to a number of common environmental Ag such as Streptococcus pyogenes, 
Alternaria, Aspergillus and Epidermophyton (62, 63). 
5.1.3 Is lymphoproliferation an indicator of immunity? 
Since both sensitised and unsensitised individuals both respond to malaria in 
vitro, proliferative responses may not be indicative of whether immune responses lead 
to pathogenesis or protection. However, the results of T cell activation may be different 
between naïve and exposed populations. T cell responses in individuals who are 
immune are Ag-specific, activating only a specific subset of cells. In contrast, cells from 
Ell 
naïve individuals may be responding to a number of antigenic epitopes, primed by 
cross-environmental Ag, resulting in a large proliferation of T cells. 
Lymphoproliferative responses to malaria Ag have mainly been studied in naïve 
and acutely infected individuals. Less is known about the differences in cell mediated 
immunity between clinically immune and naïve individuals (284). Here I present a study 
in which the proliferative responses to crude malaria Ag of cells from naïve, exposed 
and malaria-immune individuals were analysed and compared. 
5.2 Materials and methods 
5.2.1 Study population and cell culture 
Ten to 30 ml of venous blood was taken from 19 naïve individuals, 20 exposed 
individuals and 20 immune individuals, and PBMCs were isolated for in vitro cell 
cultures (see section 2.1.1 for description of study populations and section 2.4 for 
method of cell separation). Samples from 4 additional naïve individuals were used as 
controls when setting up cultures in Ghana. Cultures were set up in triplicate in round-
bottomed 96-well microtitre plates. PBMCs were distributed at 105  cells/well in a total 
culture volume of 200 tl and were cultured for 2, 3, 5, 7 and 9 days with uRBC or PfSE. 
PHA (2 jig/ml) was used as a positive control for proliferation (concentrations of stimuli 
are give in sections 2.2.3 and 2.3). 
Prior exposure and use of anti-malarial drugs was determined by a questionnaire 
completed by each donor. An aliquot of plasma was removed for anti-malarial Ab 
measurements, and parasite detection for all African donors was determined by 
Giemsa-stained blood films and PCR. Details of the serology and PCR methods are 
given in sections 2.1.3 and 2.1.2 respectively. 
5.2.2 Lymphocyte proliferation assay 
Eighteen to 20 hours before cells were harvested, 100 jil of supernatant were removed 
from each well and reserved for cytokine analysis. Cultures were then pulsed with 1 
jiCi radioactive [methyl-3H] thymidine in 100 jil of fresh culture medium per well. Cells 
were harvested onto filter mats and dried overnight. Filter mats were either read 
directly on a dry beta counter, or scintillation fluid was added and read with a 
scintillation counter. [methyl-3H] thymidine incorporation was assayed for 1 minute in 
counts per minute (see section 2.5 for a complete description of materials used for 
proliferation assays). 
5.2.3 Data analysis 
The geometric mean cpm for triplicate wells was calculated and expressed as 
mean cpm. The SI for each sample was calculated as the mean cpm for PfSE or PHA 
cultures divided by the mean cpm for uRBC cultures. SI values > 2.5 were considered 
positive (27). 
Comparisons within each group for uRBC versus PfSE were assessed by paired 
t test on log transformed mean cpm. Because the beta counters used in Ghana and in 
the UK measured emissions in linear and logarithmic fashion respectively, it was not 
possible to directly compare cpm values counted in different places. Therefore, 
differences between groups were assessed by student's t test on log transformed SI. 
Chi-squared analysis was performed to compare responders versus non-responders 
(i.e. SI ~! 2.5). Correlations between proliferation and Ab responses were assessed with 
Pearson correlation test. 
5.3 Results 
5.3.1 Study populations 
The three groups of donors were clearly distinguishable on the basis of their 
clinical history, malaria infection rates and serological responses to soluble malaria 
antigens (see tables 2.1 a-c and 2.2, Chapter 2). The naive donors had no previous 
history of malaria infection and antibody levels were within the normal range defined by 
non-immune sera. The majority of the exposed, but non-immune donors reported a 
clinical malaria infection (confirmed by microscopy and treated with anti-malarial drugs) 
within the last five years. Only one of the donors had a subclinical malaria infection at 
the time of blood sampling. Several donors had anti-malarial antibody levels below the 
cut-off level defined by non-immune sera and the mean antibody titre was only 41 % of 
the hyperimmune control serum. In contrast, in the clinically immune group, only one 
donor reported a confirmed clinical malaria attack in the past five years, 8 donors were 
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subclinically infected at the time of sampling (two detected by blood film, and 6 by 
PCR), all donors were seropositive and mean antibody titers were 87% of the 
hyperimmune control. 
5.3.2 Study populations' responses to PfSE 
Proliferative responses were measured after 3, 5, 7, and 9 days for naïve 
individuals, after 2, 3, 5, 7, and 9 days for exposed individuals and after 3, 5 and 7 days 
for immune individuals (a limited amount of blood was allowed to be taken for immune 
donors). Figure 5.1 shows the proliferative responses to PfSE for each individual over 
the timecourse of the assay, and table 5.1 shows the geometric mean cpm and 95% 
confidence intervals of proliferative responses to uRBC and PfSE (complete details for 
each individual are given in Appendix 2, tables A2.1-4). Cells from all donors 
proliferated strongly to PHA, showing that cells were viable (data not shown, see 
Appendix 2, tables A2.1-4). In all 3 groups proliferative responses to PfSE increased 
over time although responses started to decrease slightly by day 9. There were 
significant differences between proliferation to uRBC and to PfSE on all days for each 
of the groups (paired t ~! 3.99, p <0.001, df = 18 for naives, paired t ~! 7.48, p < 0.001, 
df ~!18 for exposed, paired t ~! 6.36, p < 0.001, df ~! 11 for immunes). 
Because 8/20 immune donors were subclinically infected at the time of blood 
sampling, maximum proliferative responses between non-infected and infected 
individuals were compared. Although proliferation to PfSE was higher in non-infected 
individuals (geometric mean = 2053 and geometric mean = 892 for infected individuals), 
the difference was not significant (student t = 1.22, p>0.05, df=26). 
5.3.3 Differences in proliferative responses between groups 
Proliferative responses were compared on days 3, 5 and 7. In all 3 groups, the 
geometric mean SI for PfSE/uRBC increased steadily with time (figure 5.2), but there 
was no significant difference between the groups in either the mean SI (SI ~: 2.5, paired 
t 	1.62, p > 0.05, df ~! 29) or in the proportion of responders. For example, at day 7, 
cells from 19/19 naive, 19/19 exposed and 18/20 immune donors gave positive 
responses to PfSE. The only noticeable difference between the groups was that 
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responses appeared slightly earlier in the exposed group than in the other two groups 
(table 5.2). Thus, cells from 13/19 donors gave an SI ~! 2.5 at day 3 compared to 6/19 
naives and 8/20 immunes, but the difference was not significant (x2 = 4.46, p > 0.05, 
df = 2). 
5.3.4 Correlation between proliferative and antibody responses 
Anti-malarial Ab responses were significantly correlated with maximum 
proliferative responses in exposed individuals (figure 5.3, r2 = 0.43, p = 0.002). 
However, there was no correlation found between proliferation and Ab responses for 
naïve or immune individuals (r2 = 0. 12, p >0.05 for naIves and r2 = 0. 17, p >0.05 for 
immunes). 
Discussion 
5.4.1 Study populations 
Subjects were allocated to naive, exposed or immune groups according to their 
place of residence and before any laboratory analyses (parasite detection, serology or 
cellular assays) were performed. Parasite detection and serology confirmed our 
allocation of individuals to appropriate groups, with the possible exception of one 
person in the exposed group (who had a low density, asymptomatic infection at the time 
of sampling and might therefore be regarded as clinically immune) and one person in 
the immune group (who reported a clinical attack of malaria 9 months previously and 
might therefore be considered exposed but non-immune). However, to avoid selection 
bias, neither of these subjects was reallocated to alternative groups. 
5.4.2 Lymphoproliferation and immunity to P. falciparum. 
PBMCs from naïve, exposed and immune individuals responded vigorously to 
PfSE in vitro. However, there was no significant difference in proliferative responses 
between any of the groups. Thus, lymphoproliferative responses are not associated 
with clinical immunity in this study. These results have been confirmed by other studies 
(283). 
It might be expected that immune and exposed individuals would have higher 
proliferative responses, because their immune systems have already been primed 
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specifically to P. falciparum, and malaria specific clones will have been expanded. 
Thus there should be a higher precursor frequency of malaria reactive cells. Some 
studies have demonstrated that sensitised individuals do show higher responses to P. 
falciparum Ag (14, 366). However, proliferative responses depend on a number of 
factors, such as the type of Ag. A crude schizont extract was used as an Ag in this 
study, but other studies have used different preparations of malaria Ag which result in 
differences of cellular subset expansion (354) and in differences in proliferative 
responses between individuals of varying degrees of immunity (284). Riley et al. 1988 
showed that PBMCs from naïve individuals did not respond in vitro to soluble malaria 
antigens whereas those from immune individuals did (284). Further, Ballet et al. 1981 
demonstrated that proliferative responses depended upon the concentration of Ag put 
into culture. A higher concentration of P. falciparum added to lymphocyte cultures 
resulted in similar proliferative responses for naïve and exposed individuals, whereas a 
lower concentration resulted in lower proliferation for naïve, but not exposed, individuals 
(14). Cross-reactive Ag may only be present in relatively low concentrations. Thus, a 
lot of Ag may be needed to stimulate cells from naïve donors. 
However, naive individuals also have strong proliferative responses, most likely 
resulting from being previously sensitised by cross-environmental antigens. Goodier et 
al. found much higher proliferative responses to malaria Ag in non-exposed versus 
exposed individuals (115). In previous studies on a group of immune individuals from 
the Gambia (Dick et al., unpublished data), no significant difference was found in the 
group mean SI when comparing these immune individuals to naives. Although there 
were more low responders in the immune group, their stimulation indices were in a 
similar range as naïve individuals. 
5.4.3 What do lymphoproliferative responses indicate? 
The selection of peripheral blood as the source of leucocytes is dictated by 
practical constraints but has been validated in many previous studies: although malaria-
reactive T cells tend to disappear from the peripheral circulation during an acute 
infection (probably migrating to the spleen and liver) they are released back into the 
periphery upon resolution of the infection (146). Although some of the immune 
individuals had subclinical malaria infection at the time of blood sampling, their PBMCs 
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still responded vigorously to PfSE, indicating that these individuals still have malaria 
reactive lymphocytes in their peripheral circulation. It is thus realistic to assume that, in 
healthy individuals, the peripheral T cell population is representative of the total malaria-
reactive T cell pool. 
However, lymphocyte proliferation assays do not indicate cell function or cell 
phenotype. It could be hypothesised that although there is no difference in whole 
PBMC proliferative responses, there may be a difference in which subsets of cells are 
being activated (see Chapter 7) and what cytokines are being produced (see Chapter 
6). There was a significant correlation between anti-malarial Ab and maximum 
lymphoproliferative responses in exposed individuals. Although there was no significant 
correlation found between Ab responses and lymphoproliferation in immune individuals, 
both responses were high, indicating that cells proliferating in these individuals may be 
Th2 cells providing help to generate an Ab-mediated response. 
In conclusion, lymphoproliferation is not an indicator of clinical immunity. 
However, the strong lymphoproliferative responses in all 3 study populations 
demonstrate that all groups have populations of primed T cells able to recognise 
malaria Ag. However, the clear differences in clinical status between the groups 
indicate that there may be differences in the cellular subsets of responding cells and 
their cytokine production profile, which explain differences in susceptibility to clinical 
malaria. 
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Figure 5.1: Geometric mean cpm values to PfSE of PBMCs for each individual over a 9 
day timecourse for a) naïve b) exposes and C) immune study populations (7 day 
timecourse for immune individuals). Ranges of cpm for uRBC-stimulated cultures for all 
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Table 5.1: Geometric mean cpm and 95% Cl to PfSE in PBMCs from a) naïve 
b) exposed and c) immune individuals for each day. 
a) 
uRBC-stimulated PfSE-stimulated 
Day Mean cpm Cl Mean cpm CI t p n 
3 238 136,416 572 332,984 3.99 <0.001 19 
5 308 163,581 2306 1280, 4155 8.86 <0.001 19 
7 663 408, 1077 10863 7486, 15763 16.03 <0.001 19 
9 909 485, 1704 8366 4102, 17059 7.15 <0.001 19 
b) 
uRBC-stimulated ME-stimulated 
Day Mean cpm Cl Mean cpm Cl t p n* 
2 30 24,39 53 41,68 7.48 <0.001 20 
3 61 46,79 218 146,325 10.62 <0.001 20 
5 153 111,211 1377 880.2153 18.56 <0.001 19 
7 275 191,397 3842 2635, 5602 15.94 <0.001 19 
9 457 288,727 3062 1534,4596 11.39 <0.001 16 
C) 
u RBC-stimu lated ME-stimulated 
Day Mean cpm 	Cl Mean cpm 	Cl t 	p n 
3 36 25,51 104 76, 147 6.36 <0.001 18 
5 60 	32,111 477 	215, 1060 6.50 	<0.001 12 
7 107 67, 171 2007 924, 4363 8.30 <0.001 20 
* there were insufficient cells from some individuals to set a full set of cultures. 
cpm- counts per minute. 
Cl- confidence interval. 
t- t value for the significance level. 
p- p value. 
n- number of samples/individuals on given day. 
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Figure 5.2: Lymphoproliferative responses to PfSE of PBMCs from naïve (•), exposed 
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Table 5.2: Number of positive responders to PfSE in naïve, exposed and immune 
donors (positive responder determined as SI (PfSE/uRBC) ~! 2.5). 
Day 	Naives 	Exposed 	Immunes 
3 6/19(32%) 13/19(65%) 8/18(44%) 
5 	18/19(96%) 	19/19 (100%) 	11/12(92%) 
7 19/19(100%) 19/19 (100%) 18/20(90%) 
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Figure 5.3: Correlation of antimalarial Ab responses with maximum geometric mean 
cpm for a) naïve (n-i 1) b) exposed (n = 20) and c) immune individuals (n = 20). 
a) 
70000 
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Chapter 6: Downregulation of IL-12-dependent and IL-12-independent 
IFN--y production is associated with acquisition of clinical immunity to 
P. falciparum malarial  
6.1 Introduction 
Individuals living in malaria endemic areas eventually develop clinical immunity 
to Plasmodium falciparum, meaning, that there is an absence of clinical symptoms (i.e. 
fever, malaise) even in the presence of parasites in the bloodstream. Pro-inflammatory 
cytokines aid in parasite killing (98, 216, 310), but clinical symptoms of malaria infection 
are also a result of an excessive inflammatory response (67, 181, 293). However, it is 
not clear whether clinical immunity develops as a result of anti-parasitic mechanisms or 
whether anti-toxic immunity (downregulating an excessive inflammatory response) is 
also involved. 
6.1.1 The role of inflammatory cytokines in malaria infection 
Studies in mice demonstrate that IFN-y is essential in clearing primary malaria 
infections (70, 93). Early IFN-y production from NK cells and T cells has been shown to 
mediate resistance to P. c. chabaudi (236) and P. yoelii infections (9) respectively. 
IL-12 induced IFN-y production mediates resistance via NO (151, 309, 320) and 
oxygen intermediates (i.e. H202) (310) which may be involved in parasite killing (286, 
310). However, IFN--y also plays a role in the acute symptoms of infection, such as 
fever, anorexia and weight loss, through induction of TNF-a and other endogenous 
pyrogens. Over-production of IL-1 2, IEN-y or TNF-cz predisposes to severe pathology 
(152, 181, 350, 368) and is associated with cerebral malaria (67, 293, 367). 
In humans, elevated serum IFN-y levels were found in convalescent individuals 
during parasite clearance (363) and in individuals who did not present with malaria 
(versus those who did)(74), suggesting a beneficial role in ihibiting parasite replication. 
Similarly, plasma TNF-c and nitrogen oxide levels are associated with rapid resolution 
of fever and parasite clearance (182, 183). However, elevated serum levels of 
inflammatory cytokines are also associated with severe P. falciparum malaria (15, 118, 
193, 238). Additionally, IFN-i responses to certain malaria antigens correlate with 
'See Appendix 5, manuscript submitted for publication. 
109 
predisposition to clinical symptoms (283). Taken together, these observations suggest 
that inflammatory cytokines are involved both in the pathogenesis and in the immunity 
to malaria infection. 
Previous studies show that PBMCs from malaria immune individuals produce 
very little IFN-i in response to crude malaria Ag (53, 284). In contrast, cells from 
individuals who have never been exposed to malaria, produce significant amounts of 
IFN-,yto schizont extracts or live malaria parasites (75, 354), suggesting that cross-
reactive memory T cells, primed by other common environmental organisms, are 
responding (62). 
6.1.2 The role of anti-inflammatory cytokines in malaria infection 
Work in mouse malaria models suggests that an early inflammatory (Thi) 
response reduces parasitemia (96, 330), but a switch to a Th2 response, with 
development of malaria-specific antibodies and production of IL-4, is required for 
clearance of infection (196, 197). Adding exogenous anti-inflammatory cytokines, such 
as IL-1 0 and TGF-, reduced mortality in mice against P. berghei infection (180, 252). 
Non-lethal infections of P. yoelii and P. bergheiin resistant strains of mice are 
correlated with higher circulating levels of TGF-3 in serum and increased IL-10 mRNA 
transcripts in the spleen (180, 252). It is thought that these cytokines decrease Mo and 
NK cell production of inflammatory cytokines, IL-12, IFN-y and TNF-ct (206, 346). 
In humans, decreased circulating levels of TGF-P were found in individuals with 
acute P. falciparum infection and TGF-P levels were inversely correlated with serum 
levels of TNF-a (355). Malaria-immune individuals had higher ratios of IL-4/IFN-y-
producing cells which were correlated with elevated serum levels of malaria-specific IgE 
(82). Ho et al. demonstrated that IL-1 0 decreased malaria-induced pro-inflammatory 
cytokine production (134). However, higher levels of serum IL-lU were found in 
individuals who had severe P. falciparum infection versus individuals with 
uncomplicated infection (15, 135, 154, 263, 356), suggesting that there is a critical 
balance in timing and concentration of cytokine production that determines clinical 
immunity to malaria. 
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6.1.3 Hypothesis 
I hypothesise that there is an association between in vitro levels of PfSE-
stimulated IFN-y production and the risk of clinical malaria. In order to test this 
hypothesis, I have compared IFN-y levels of PfSE-stimulated PBMCs from naive, 
exposed (but not clinically immune) and immune donors. I have also measured PfSE-
stimulated IL-12 and IL-10 levels and examined the effect of neutralising cdL-12 on IFN-
'y production, in order to determine how IFN-y production is regulated. 
6.2 Materials and methods 
6.2.1 Study population and cell culture 
Ten to 30 ml of venous blood were taken from 19 naïve individuals, 20 exposed 
individuals and 20 immune individuals and processed for in vitro PBMC cultures (see 
section 2.1.1 for description of study populations and section 2.4 for method of cell 
separation). Blood from 4 additional naïve individuals was used as controls when 
setting up cultures in Ghana. PBMCs were distributed at 10 6  /well  in flat-bottomed 
24-well plates or in triplicate at 1 0"/well in round-bottomed 96-well microtitre plates in a 
total culture volume of 1 ml and 200 tl respectively. 
Cells were cultured for 1, 2, 4, 6 and 8 days with uRBC or PfSE. PPD (only for 
immunes) and PHA were used as positive controls for IFN-y production. PHA and LIPS 
plus recombinant IFN-y were used as positive controls for IL-12 production. In order to 
determine the relationship between IL-12 and IFN-y, neutralising (AL-12 or a control 
isotype-matched goat lgG were also added to cultures (concentrations of reagents are 
given in sections 2.2.3 and 2.3). Three hundred to 900 p1 of culture supernatant were 
harvested at various timepoints and stored at -70°C until tested for cytokine levels. 
Lymphocyte proliferation assays were also performed for the above cultures (see 
sections 2.5 and 5.2.2). IL-12 p40 production by PBMCs stimulated with uRBC, PfSE, 
PHA or LIPS was also assessed by RT-PCR (see Chapter 4). 
6.2.2 Cytokine assays 
IFN-y, IL-12 p70, IL-12 p40, and IL-10 were measured in cell culture 
supernatants by 2-site capture ELISA. Immulon 4, 96-well, flat-bottom microtitre plates 
were coated with an optimal concentration of coating Ab (see Chapter 3, table 3.2 for 
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reagent concentrations and buffer/wash solutions) and incubated at RT overnight. 
Plates were washed, blocked with blocking buffer for 1 hour at 37°C, and then washed 
again (see Chapter 3, table 3.1 for basic ELISA protocol). Standards or culture 
supernatant were added to duplicate wells and incubated at RT for 2-3 hours. After 
plates were washed, an optimal concentration of biotinylated capture Ab was added 
and incubated for 1 hour at RT. Plates were washed, avidin-labelled horseradish 
peroxidase was added for thirty minutes at RT, plates were washed a final time, and 
were developed using OPD and H202 as chromogen/substrate. The reaction was 
stopped with 2 M H2SO4 after 15 minutes, and absorbance was read at 492 Tim. 
6.2.3 Data analysis 
Cytokine concentrations were calculated from best fit curve formula based on 
linear regression analysis. The LLD for each assay was as follows: IFN-y 
44-96 pg/mI, IL-12 p70 107 pg/mI, IL-12 p40 171 pg/mI, and IL-10 47 pg/mI. 
Comparisons within each group for uRBC versus PfSE were assessed by paired 
t test on log transformed cytokine concentrations. Differences between groups for IFN-y 
and IL-12 p40 (PfSE-uRBC) concentrations were assessed by non-parametric Mann 
Whitney U test. Student's t test on log transformed data was used to compare IL-1 0 
values. Chi-squared analysis was performed to compare the proportion of responders 
versus non-responders. Responders were defined as the following: for IFN-y, twice as 
much IFN-y from PfSE-stimulated cultures as from uRBC-stimulated cultures; for IL-12 
p40, IL-12 p40 from PfSE-stimulated cultures minus IL-12 p40 from uRBC-stimulated 
cultures ~! 20 pg/mI; for IL-1 0, IL-1 0 from PfSE-stimulated cultures> IL-1 0 from uRBC-
stimulated cultures and > LLD. Correlations between lymphoproliferative responses 
and each cytokine response were assessed by the Pearson correlation test. 
63 Results 
6.3.1 IFN-y production 
6.3.1.1 PBMCs from all groups of donors produce significant levels of /FN-y 
IFN-yin cell supernatants was measured after 1, 2, 4, 6 and 8 days for naïve and 
exposed individuals and after 2, 4, and 6 days for immune individuals (only a limited 
amount of blood was available for immune individuals). Table 6.1 shows the geometric 
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mean and Cl for IFN-y responses to uRBC and PfSE (complete details for each donor 
are given in Appendix 3, tables A3.1-A3.4). Cells from all donors produced IFN-y in 
response to PHA (maximum values were 12493 pg/mI for naives, 10701 pg/mI for 
exposed individuals and 10952 pg/mI for immune individuals). PBMCs from naïve 
individuals produced moderate amounts of IFN-y, which steadily increased over time 
and peaked by day 6 (224 pg/mI). IFN--y levels in PfSE cultures were significantly higher 
than in uRBC cultures on days 4, 6 and 8 (paired t ~! 3.6, p < 0.002, df ~! 12 on all days). 
PfSE-stimulated PBMCs from exposed individuals produced significantly higher levels 
of IFN-y than uRBC controls on all days and peaked at 1069 pg/mI on day 8 (paired t ~! 
2.43, p < 0.03, df ~! 17 on all days). In contrast, PBMCs from immune donors produced 
much lower levels of IFN-y in response to PfSE (maximum IFN--y level on day 6, 
91 pg/mI), although mean IFN-y levels were significantly higher than in uRBC-stimulated 
cultures on days 4 and 6 (paired t > 2.75, p ::~ 0.02, df ~L 12). 
6.3.1.2 Immune donors produce minimal amounts of IFN-y 
Median IFN--y levels (PfSE-uRBC) were compared between groups on days 2, 4 
and 6 (figure 6.1). PFSE-stimulated PBMCs from exposed individuals produced 
significantly higher amounts of IFN-y than naïve donors on days 4 and 6 (Mann-Whitney 
U, W = 253, p 0.001, df ~! 35). Immune donors had significantly lower median IFN--y 
levels than in the naive group on days 4 and 6 (Mann-Whitney U, W ~! 384, p :~ 0.008, 
df ~!30) and in the exposed group on days 2, 4 and day 6 (Mann-Whitney U, W ~! 230, p 
:~ 0.003, df ~! 30). 
However, not all PBMCs from naïve donors produced IFN-y. Additionally, 
PBMCs from a number of immune donors did produce IFN-y, although IFN-y levels 
were not as high as for exposed individuals. The number of IFN-y responders (PfSE ~ 
2XuRBC IFN-yon any day) was highest for exposed donors (19/20, 95%), intermediate 
for naïve donors (14/19, 74%) and lowest for immune donors (5/20, 25 %)(table 6.2). 
6.3.1.3 Correlation between proliferative and IFN-yresponses 
In vitro IFN-7 production for each group was compared with the kinetic 
timecourse of proliferative responses on the same day. The kinetics of median IFN-y 
responses are similar to changes in mean SI up to day 7, in all 3 groups (figure 6.2, 
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values are given in Appendix 2, table A3.5). By day 9, proliferative responses were 
decreasing while IFN-y responses were increasing for naïve individuals (figure 5.4a). 
There were also significant positive correlations between individual proliferative and 
1FN-i responses for donors in all 3 groups (figure 6.3, r2 = 0.13, p = <0.001 for naives, 
r2 = 0.33 p <0.001 for exposed and r2 = 0.57, p <0.001 for immunes). However, when 
responses from all 3 groups were combined, there was no significant correlation 
between proliferative and IFN-y responses (r2 = 0.01, p > 0.05), because the IFN-y 
responses were low in immune individuals and high in exposed individuals. Naïve and 
exposed individuals were more likely to have positive proliferative and IFN-y responses 
to PfSE (14/19 and 19/20 respectively), but most immune individuals had negative 
1FN-y responses although they had strong proliferative responses (13/20). 
6.3.2 IL-12 production 
6.3.2.1 IL-12 levels in culture supernatants 
IL-12 was initially measured by IL-12 p70 ELISA. PBMCs from 3 naïve donors 
were stimulated with varying concentrations of PfSE (3.1X105 parasites/ml to 3.9X104 
parasites/ml), and cell culture supernatants were collected at various timepoints (4 to 
115 hours). IL-12 p70 levels were below LLD for almost all of the timepoints collected 
(see Appendix 3, table A3.6). 
Because it was thought that the IL-12 p70 ELISA was not sensitive enough, 
IL-12 p40 transcripts were measured by RT-PCR and free IL-12 p40 was measured by 
IL-1 2 p40 ELISA. IL-1 2 p40 was measured on days 1, 2, 4, 6 and 8 of PfSE-stimulated 
cultures for naïve and exposed individuals and on days 2, 4 and 6 for immune 
individuals (only ELISA detection for immunes). Detection of IL-12 p40 transcripts was 
not consistent (see Chapter 4). For the IL-12 p40 ELISA, IL-12 levels were highest on 
day 2, therefore only day 2 data is shown (table 6.3, see Appendix 3, table A3.7 for 
complete data on each individual). 
Overall, levels of PfSE-specific IL-12 in supernatants were very low. There was 
no significant difference between uRBC and PfSE stimulated cultures in all 3 groups 
(paired t :~ 1.93, p > 0.05, df ~!1 7). PBMCs from exposed donors produced up to 530 
pg/mi IL-12 (PfSE-uRBC), but levels varied widely between individuals. Median IL-12 
levels were not significantly different between the groups (figure 6.4, Mann Whitney U 
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W ~! 289, p > 0.05, df ~! 36). When individuals are categorised as responders or non-
responders (PfSE-uRBC IL-12 ~! 20 pg/mI and > LLD), 11% (2/18) of naïve donors 45% 
(9/20) of exposed donors and 35% (7/20) of immune donors were responders 
responded, but the difference was not significant (2 = 5.31, p > 0.05, df =2). 
6.3.2.2 Relationship between IL-12 and IFN-y production. 
Although IL-12 p40 levels in supernatants were low, significant amounts of IL-12 
p40 were detected in culture supernatants from some donors. Thus, the kinetic 
relationship between IL-12 and IFN-y production was compared in individual donors. 
IL-12 production normally peaked at day 1 or 2 before there was an increase of IFN-y 
production (figure 6.5). However, there was no overall correlation between IL-12 levels 
and IFN-y production for any of the groups (data not shown). Thus in order to determine 
whether there was a causal relationship between IL-12 production and IFN-
-yproduction, neutralising alL-12 or control lgG was added to PfSE-stimulated or 
uRBC-stimulated cell cultures and IFN-y levels were measured. 
Although alL-12 or control lgG had some effect on lymphoproliferative responses 
(mean SI), most differences were not significant, and cdL-12 did not consistently 
decrease or increase mean SI as compared to control lgG (Appendix 3, table A3.8, 
complete details of each individual is found in tables A3.9-12). However alL-12 reduced 
IFN--y production in all 3 groups (figure 6.6, see Appendix 3, tables A3.1-4 for details of 
each donor). 
PBMCs from naïve donors had significantly reduced IFN-y levels when (xi L-12 
was added to cultures on days 2, 4, and 6 (figure 6.6a, paired t ~: 2.29, p !~ 0.04, df = 13 
on all days). By day 8, IFN-y levels began to increase slightly in alL-i 2/PfSE-stimulated 
cultures, but still remained close to background levels, indicating that lFN-' production 
from naive cells is largely IL-12 dependent. Cells from exposed donors also had 
significantly reduced PfSE-stimulated IFN-y levels in the presence of alL-12 on days 2, 
4, 6 and 8 (figure 6.6b, paired t ~ 2.81, p :!~ 0.01, df =19). However, alL-i 2 did not 
completely inhibit IFN--y production and by day 6, IFN-y levels were still significantly 
higher than in control lgG/uRBC-stimulated cultures (t ~! 5.2, p <0.001, df = 16) or in 
PfSE-stimulated cultures of naive cells (t ~! 4.56, p <0.001, df = 32), indicating that 
there is IL-12-dependent and IL-12-independent IFN-y production from cells of exposed 
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donors. Although PfSE-stimulated PBMCs from immune donors produced very little 
IFN-y, alL-12 still significantly reduced IFN-y levels to background levels by day 6 (figure 
6.6c, paired t = 2.18, df =19, P = 0.042). 
6.3.3 Production of IL-10 in PfSE-stimulated cell cultures 
IL-1 0 levels were measured in cell supernatants in order to determine whether 
differences in IL-1 0 production might explain the differences in IFN-y responses 
between groups. IL-1 0 was measured on days 1, 2, 4, 6 and 8 for naïve and exposed 
individuals and on days 2, 4, and 6 for immune individuals. 
Overall, PfSE-specific IL-1 0 levels were extremely low in all cultures on all days (table 
6.4). IL-lU production was significantly different between uRBC-stimulated and PfSE-
stimulated cultures for naïve donors on day 1 (table 6.4a, paired t = 2.66, p > 0.02, 
df =11) and for exposed donors on days 4 and 8 (table 6.4b, paired t ~! 2.68, p < 0.02, 
df ~! 15), but levels were still quite low. Almost none of the immune donors had 
detectable levels of IL-1 0 (table 6.4c, see Appendix 3, tables A3.13-16 for complete 
details of each donor). There was also no significant difference between groups in 
PfSE-specific IL-10 (PfSE-uRBC) levels on all days measured (figure 6.7, Mann 
Whitney U W ~! 282, p > 0.05, df ~! 28). When individuals were classified as either 
responders or non-responders for IL-1 0 production (PfSE > uRBC and > LLD on any 
day), 16/20 (80%) of exposed donors, 14/18 (78%) of naïve donors and 2/20 (10%) of 
immune donors were considered responders, (x2 = 25.21, p < 0.001, df =2). All groups 
had similar number of responders when looking at IL-1 0 responses to PHA (18/18 
(100%) naives, 19/20 (95%) exposed, 19/20 (95%) immunes). IL-1 0 production was 
correlated with neither lL-12 p40 nor IFN--y responses (data not shown). 
6.4 Discussion 
The data presented here clearly show that there is an association between the 
acquisition of clinical immunity to P. falciparum infection and in vitro downregulation of 
the pro-inflammatory cytokine, IFN-y. PBMCs from naïve individuals (who are at high 
risk of severe malaria if infected) and exposed individuals (who still get sick when 
infected) produce significant amounts of IFN-yto PfSE. In contrast, cells from malaria- 
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immune individuals produce minimal amounts of IFN-y when stimulated with malaria 
Ag. IFN-y production was mainly IL-12-dependent, as shown by decreased IFN--y levels 
when neutralising cdL-12 was added to cultures. However, malaria-specific IFN-y 
production was not completely neutralised in cultures from exposed individuals 
indicating that there may have been another source of IFN-y which was IL-12-
independent. There was very little malaria-specific IL-lU produced from cells of all 
donors, suggesting that this cytokine does not play a major role in regulating IFN-y 
production in vitro. 
6.4.1 The role of IFN-'yin malaria infection 
Complete sterilising immunity to malaria rarely, if ever, develops in humans. 
Rather, there is a state of premunition, where individuals are able to sustain low 
parasite densities in the absence of clinical symptoms. It is not entirely clear how 
parasitemia is limited but studies indicate that the release of pro-inflammatory cytokines 
and Ab-dependent cell-mediated inhibition are involved (37). 
However, high levels of circulating pro-inflammatory cytokines are also 
associated with severe malaria infection (15, 238, 356). Thus, it is not known whether 
clinical immunity develops as a result of anti-parasitic mechanisms of if the down-
regulation of inflammatory cytokines is also involved. 
On the basis of observations from in vitro cultures it was originally thought that 
malaria antigens directly stimulated the release of TNF-a, IL-1 and IL-6 from Mø to 
induce the clinical symptoms (i.e. fever) associated with the inflammatory response 
(117, 305). But this hypothesis has recently come into question, because it was found 
that mycoplasma is a strong inducer of TNF-a and can infect long-term malaria cultures 
(292). This stimulatory mechanism also cannot explain why young infants do not have 
clinical symptoms upon primary malaria infection (6, 40, 108, 213, 347). 
It is now beleived that IFN-y may be needed to induce the high levels of 
TNF-a and other inflammatory cytokines which mediate the clinical symptoms of severe 
malaria infection. Scragg et al. have demonstrated that malaria Ag does not induce 
similar levels of TNF-(x and IL-12 as LPS-stimulated PBMCs from naïve individuals in 
vitro (308). Scragg et al. also showed that malaria Ag stimulated significant early 
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IFN--y production, which is in agreement with the results of this study. Excessive IFN-y 
production may explain why naïve individuals or children living in malaria endemic 
areas (who are primed by either cross-reactive environmental antigens or constant 
exposure to malaria parasites) are more susceptible to severe malaria than infants 
(279). In this study, it was demonstrated that cells from clinically immune individuals 
produced significantly lower levels of IFN-yto PfSE compared to naïve and semi-
immune individuals. These results are in agreement with two other studies in clinically 
immune Africans (53, 284). Taken together, these results suggest that the 
down regulation of IFN-y may therefore be a critical factor in mediating clinical immunity 
to malaria. 
6.4.2 The role of IL-12 in malaria infection 
Significant levels of malaria-specific IL-12 were not detected in cell culture supernatants 
from naïve, exposed or immune individuals by ELISA or RT-PCR (see Chapter 4 
results). Although cells from one individual produced as much as 530 pg/mI of IL-12, 
IL-12 production varied between individuals and was not significantly different between 
the study populations. However, studies with neutralising ocIL-12 demonstrate that 
IL-12 is produced following PfSE-stimulation, even though the IL-12 may not reach 
detectable concentrations. The lack of detectable IL-12 could be explained by the fact 
that minuscule amounts of IL-12 are needed to be biologically active (reasons are 
discussed in section 4.4), and these very small amounts of IL-12 may bind to IL-1 2R 
and are taken out of solution. Additionally, other inflammatory cytokines such as IL-15 
and IL-18 (discussed further in Chapter 8) may be upregulated by IL-12, having potent 
effects (249, 323, 325). 
It has been demonstrated in this study that IFN-y responses are in part regulated 
by IL-12. PBMCs from naïve individuals produced moderate amounts of IFN-y which 
were decreased by the addition of neutralising antibodies to IL-12, suggesting that IFN-i 
production is strongly IL-12 dependent. It may be that the primary source of IFN-y in 
these individuals is NK cells as a number of studies have demonstrated that NK cell 
production of IFN-yto parasitic infections is IL-12 dependent (300, 301, 335). However, 
alL-12 only partially blocked IFN-y production in some naïve individuals suggesting that 
even in these individuals some IFN--y production is IL-12 independent. Exposed 
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individuals still had significantly higher of IFN-y in cultures with cdL-1 2 than PfSE-
stimulated cultures of naïve individuals. These results suggest that there might possibly 
be multiple sources of IFN-y, only one of which is IL-12-dependent. IL-12-independent 
IFN-y production in parasitic infections has been shown in other studies (300). In 
studies by Scragg et al. and studies done in our lab, T cells have been found to be one 
of the sources of early IFN-y production to malaria Ag in naïve individuals (308)(see 
Chapter 7). Taken together, these results support the idea that malaria-reactive T cells 
(primed by other cross-environmental antigens) are involved in the pro-inflammatory 
response during malaria infection. 
6.4.3 Downreciulation of the inflammatory response- a role for IL-b? 
The minimal amount of IFN--y produced from cells of immune individuals is not 
due to T cell anergy; PBMCs from immune individuals proliferated just as strongly to 
PfSE as cells from naïve and exposed individuals (see Chapter 5). The mechanism by 
which IFN-y levels (or the effects of IFN-y production) are downregulated is not clear. 
Cells from all individuals produced very little malaria-specific IL-10 and the differences 
between groups were not significant. The fact that malaria Ag does not induce IL-1 0 
has been confirmed by another recent study (308). Although, IL-10 has been shown to 
modulate cytokine production to malaria Ag in vitro (134), plasma levels of IL-1 0 are 
elevated in severe P. falciparum infection (15, 135, 154, 263, 356). Additionally IL-lU 
has been found to stimulate NK cell and T cell IFN-y production (46, 312). The 
additional role of IL-1 0 as a pro-inflammatory cytokine may in part explain why there 
were significantly more IL-1 0 responders in the naïve and exposed study populations 
than in the immune study group. IL-1 0 thus may not play a major anti-inflammatory 
role. Further studies need to be done in order to determine whether there are any other 
cytokines which may downregulate the inflammatory response. A possible cytokine 
would be TGF-, as there is known to be an inverse correlation between circulating 
TGF-3 levels and severity of malaria infection in mice (252). The potential role of 
TGF-13 is discussed in Chapter 8. 
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Table 6.1: Geometric mean IFN--y (pg/mi) and 95% Cl of PfSE-stimulated and uRBC-
stimulated PBMCs from a) naIve, b) exposed and c) immune individuals for each day. 
a) 
uRBC-stimulated PfSE-stimulated 
Day Mean IFN-y Cl Mean IFN-y CI t p n 
1 61 69,54 71 85,59 1.81 0.09 13 
2 67 74,61 92 119,70 2.54 0.02 19 
4 71 79,63 145 231,92 3.66 0.002 19 
6 70 76,63 224 371,136 5.09 <0.001 19 
8 67 73,61 171 247,119 5.20 <0.001 18 
b) 
uRBC-stimulated ME-stimulated 
Day Mean IFN-y CI Mean IFN-y Cl t p n 
1 46 51,41 52 61,45 2.43 0.03 20 
2 48 54,43 89 134,60 3.46 0.003 20 
4 56 68,45 605 1168, 313 8.46 <0.001 19 
6 79 121,52 946 1785, 502 9.01 <0.001 18 
8 83 113,60 1069 1953,585 9.41 <0.001 19 
C) 
uRBC-stimulated PfSE-stimulated 
Day Mean IFN-y Cl Mean IFN-y CI t p n 
2 57 57.0, 58.0 68 52.9, 87.3 1.42 >0.05 18 
4 57 56.7, 57.8 70 59.8, 81.7 2.79 0.02 13 
6 58 56.7, 58.6 91 64.3, 127.5 2.75 0.01 20 
*there  were insufficient cells from some individuals to set up a full set of experiments. 
Cl- confidence interval. 
t- t value for the significance level. 
p- p value. 
n- number of samples/individuals on given day. 
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Figure 6.1: Median PfSE-specific (PfSE-uRBC) 1FN-y (pg/mi) production by PBMCs 
from naïve (U), exposed (A) and immune (•) donors. Ranges of IFN-'y on all days are 
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Table 6.2: Number (percentage) of individuals who had positive IEN-y responses (PfSE 
~! 2XuRBC 1FN-7) on days 2, 4, 6 and total number of responders (positive on any day). 
Days Naives Exposed Immunes 
2 3/19 (16%) 5/20(25%) 1/18(6%) 2.69 >0.05 
4 5/19(26%) 16/19(84%) 1/13(8%) 21.91 <0.001 
6 11/19(58%) 17/18(94%) 5/20(25%) 18.74 <0.001 
Any day 14/19(74%) 19/20(95%) 5/20(25%) 22.43 <0.001 
x2- chi-squared value. 
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Figure 6.2: Kinetic timecourses of lymphoproliferative (•) and IFN-y (A) responses to 
PfSE of PBMCs from a) naïve (n=19), b) exposed (n=20) and c) immune (n=20) 
individuals (median (PfSE-uRBC) for IFN-'y (pg/mi) and geometric mean SI 
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Figure 6.3: Lymph proliferation (Sl=PfSE/uRBC) is positively correlated with median 
IFN-y production (PfSE-uRBC in pg/mI) for a) naIve, b) exposed and C) immune 
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Table 6.3: Geometric mean IL-12 p40 (pg/mI) and 95% Cl of PfSE-stimulated and 
uRBC-stimulated PBMCs from naïve, exposed and immune individuals for day 2. 
uRBC-stimulated 	PfSE-stimulated 
Group Mean IL-12 p40 Cl Mean IL-12 p40 Cl t 	p n 
Naives 198 176,223 199 177,224 0.21 >0.05 18* 
Exposed 263 204,339 279 209,373 1.93 	>0.05 20 
lmmunes 216 180,259 217 194,244 0.06 >0.05 20 
* not enough cell culture supernatant was available for I donor. 
Cl- confidence interval. 
t- t value for the significance level. 
p- p value. 
n- number of samples/individuals on given day. 
Figure 6.4: PfSE-specific (PfSE-uRBC) IL-12 p40 (pg/mI) production by PBMCs from 
naïve, exposed and immune donors on day 2. Ranges of IL-12 p40 are -20-28 pg/mI 
for naives (n=18), -32-530 pg/mi for exposed (n=20) and -545-73 pg/mI for immunes 
(n=20) (median values denoted). Two extreme values (530 pg/mI and —545 pg/mI) are 
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Figure 6.5: Kinetic timecourse of 1L-12 p40 (•, PfSE in pg/mi) and 1FN-7 (A, PfSE-
uRBC in pg/mi) responses to PfSE from naïve donor N4 (a) and exposed donor E9 (b). 
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Figure 6.6: Geometric mean IFN-y (pg/mi) and 95% CI of control lgG/PfSE-stimulated 
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Table 6.4: Geometric mean IL-10 (pg/mi) and 95% CI of PfSE-stimulated and uRBC-
stimulated PBMCs from a) naive, b) exposed and c) immune individuals for each day. 
a) 
uRBC-stimulated PfSE-stimulated 
Day Mean IL-10 CI Mean IL-10 CI t p fl 
1 50 42,59 56 45,69 2.66 0.022 12 
2 62 48,78 62 50,78 0.49 >0.05 17 
4 60 48,75 61 51,73 0.48 >0.05 18 
6 58 48,71 61 5073 0.71 >0.05 17 
8 56 48,65 59 50,70 1.18 >0.05 18 
b) 
uRBC-stimulated 	PfSE-stimulated 
Day Mean IL-10 Cl Mean IL-10 Cl t p n 
1 68 56,81 67 57,78 0.59 >0.05 20 
2 66 54,79 67 57,80 0.37 >0.05 19 
4 58 52,65 63 56,71 2.68 0.016 17 
6 56 49,63 58 51,65 0.58 >0.05 17 
8 53 47,59 63 53,76 3.39 0.004 16 
C) 
u RBC-stimulated PfSE-stimulated 
Day Mean IL-10 	Cl Mean IL-10 	CI t p 	n 
2 42 	41,43 43 	42,45 N/A' N/A" 18 
4 41 40,42 43 42,44 N/A N/A 	13 
6 41 	41,42 43 	42,44 N/A N/A 20 
* not enough cell culture supernatant was available from some donors. 
not applicable because mean IL-10 concentrations were below LLD. 
Cl- confidence interval. 
t- t value for the significance level. 
p- p value. 
n- number of samples/individuals on given day. 
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Figure 6.7: PfSE-specific (PfSE-uRBC) IL-lO (pg/mi) production by PBMCs from a) 
naIve, b) exposed and C) immune donors. Ranges of IL-10 on all days compared (i.e. 
days 2, 4 and 6) are -44 to 30 pg/rnl for naives, -132 to 66 pg/rnl for exposed and -0.95 
to 4.8 pg/mi for immunes (median values denoted). One extreme values (-132 pg/mi on 
day 2 for an exposed individual) is omitted from the plot. Numbers of individuals are 
given in table 6.4. 
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Chapter 7: Flow cytometric analysis of activated specific lymphocyte 
subsets and production of IFN-y in response to P. falciparum 
7.1 Introduction 
There have been numerous studies which have tried to elucidate T cell 
responses to P falciparum infection. However, the results have not necessarily made 
the T cell immune mechanism any clearer. The controversy lies in the fact that various 
studies show that different cell subsets are preferentially expanded in response to 
P. falciparum Ag. A number of studies in unsensitised individuals show that CD4+ c43+ 
memory cells are stimulated by P. falciparum Ag in vitro (62, 63, 75, 290), although 
other studies have demonstrated that y+  cells are the principal cell type to respond 
(20, 115). These results may be due to the fact that different Ag preparations were 
used (see discussion, section 7.4.2) 
In vivo, during acute infections the number of CD4+ c3+ cells, as well as the 
numbers of CD8+ and NK cells in peripheral blood are significantly reduced (295, 363), 
and the percentage and number of 'y+ cells are increased (137, 242, 260, 295). As 
different cells have different activation requirements, and mediate different effector 
mechanism, there is a need to determine which cell populations are involved in the 
response. 
In studies of both mouse and human malaria, it has been shown that CD4+, 
CD8+, y+ and NK cells are potent producers of IFN-y (75, 116, 236, 264, 363). IFN-y 
is beneficial in malaria infection, because it is able to inhibit parasite growth (98, 216) 
and mediate production of other inflammatory cytokines (113). But because there is 
cellular expansion of cells responding to multiple epitopes in naïve individuals in 
response to malaria Ag, it is believed that the excessive inflammation caused by these 
cells may contribute to pathology during infection. Although these cells are important 
players in cell mediated immunity, whether or not they are beneficial depends on the 
timing, location and strength of the response. 
The cell subsets which expand in response to malaria Ag in vitro have been 
isolated from individuals who have never been exposed to malaria or in individuals 
acutely infected with P. falciparum. Less is known about the differences in cellular 
responses between naïve individuals and healthy individuals living in malaria endemic 
129 
areas. Flow cytometry analysis combined with intracellular cytokine staining (ICS) are 
powerful tools that show which cells are being activated (i.e. blasting) and which cells 
are producing cytokines. Here I present a study, which uses these experimental 
assays, comparing phenotypes of activated cells responding to P. falciparum Ag in vitro 
from naïve, exposed and clinically immune individuals. I also present preliminary data 
on cellular function by examining which cell subsets produce IFN-'y in response to 
malaria Ag. 
7.2 Materials and Methods 
7.2.1 Study population and cell culture 
Ten to 30 ml of venous blood was taken from 13 naïve individuals, 19 exposed 
individuals and 18 immune subjects and processed for in vitro culture (see section 2.1.1 
for description of study populations and section 24 for method of cell separation). 
Blood samples from 3 additional naïve individuals were used as controls when setting 
up cultures in Ghana. PBMCs from 3 naïve donors were used for ICS, and cells from 
the rest of the donors were used for cell surface staining and analysis by flow 
cytometry. Cells were plated at 106  -2xl  06/well in flat-bottomed 24-well plates in a total 
of 1 or 2 ml complete culture medium. For control or mitogen/antigen culture, 2-4x1 06 
cells were available for cell surface staining (except for immune individuals where a 
limited number of cells, usually <106,  was available); see Appendix 4, tables A4.1-4 for 
cell counts. Six xl 06  cells were used for ICS. 
For cell surface staining, cells were cultured for 7 days with PfSE, PHA (i.e. 
positive mitogen control) or PPD (i.e. classical recall T cell Ag). Culture medium alone 
and uRBC were used as negative controls (concentrations of stimuli are given in 
sections 2.2.3 and 2.3). Because of the limited amount of blood taken, cells from 
immune donors were stimulated only with uRBC or PfSE. Additionally, PBMCs from 
naïve and immune donors were cultured for 3 days with uRBC or PfSE. For ICS, cells 
were cultured for 7 days with uRBC or PfSE. Culture medium alone was used as a 
negative control, and SEB was used as a positive control for intracellular IFN--y staining. 
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7.2.2 Cell surface staining 
After 0, 3 or 7 days, PBMCs were harvested into 15 ml conical tubes and 
washed twice with PBS supplemented with 0.1% NaN3 and 0.1% BSA (FACs PBS). 
Cells were prepared for 3-colour flow cytometry by resuspending in FACs PBS at 
2x1 06/ml and distributed equally into round-bottomed 96-well microtitre plates (i.e. up to 
2x105/well). Twenty microliters of diluted antibody were added to each well and PBMCs 
were incubated at 4 °C for 40 minutes (see tables 7.1 and 7.2 for staining combinations 
and cell subsets identified by each stain, Ab concentrations are detailed in section 
2.8.2). Cells were washed twice and resuspended in 300 jil of FACs PBS for 
phenotypic analysis. 
7.2.3 Intracellular cytokine staining 
The ICS procedure is based on the original protocol developed by Jung et al. 
(161). Eighteen hours before cells were harvested, 3 ig/ml of Brefeldin A was added to 
cultures for protein transport inhibition, in order to increase the IFN-y signal. PBMCs 
were harvested, washed twice with PBS and resuspended at a final concentration of 
106/ml in PBS supplemented with 1% fetal calf's serum and 0.1% NaN3 (staining buffer, 
buffers are detailed in section 2.9.1). Cells were surface stained as described in 
section 7.2.2, and then washed once with PBS. PBMCs were fixed for 15 minutes at 
RT in the dark, washed and then stained with FITC- or PE-labelled anti-IFN-y and 
permeabilised for 30 minutes at 4 °C in the dark. Cells were washed a final time and 
then resuspended in 0.5 ml PBS for FACS analysis. Complete details of the ICS 
protocol are given in section 2.9, and staining combinations are given in table 7.3. 
7.2.4 Data analysis 
Cell phenotyping was done by flow cytometry and analysed by Cell Quest 
software package (see section 2.8.3). RBCs, dead cells and apoptosing cells were 
gated out and 10,000 to 20,000 events were acquired for each staining combination. 
Resting cells (Ri) and lymphoblasts (R2) were gated separately, detected by FSC 
versus SSC, and analysed for the different staining combinations. Gating was based 
on unstained controls and samples single-stained with FITC-, PE- or TRI-conjugated 
antibodies. One cell aliquot was used to determine cell viability by trypan blue 
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exclusion and absolute cell numbers harvested from each stimulated or unstimulated 
culture. Percentages and absolute numbers of cell subsets were calculated excluding 
dead cells. Comparisons within each group were assessed by paired t test and 
between groups by student's t test on arithmetic mean percentages and on log 
transformed absolute cell counts. 
7.3 Results 
7.3.1 Phenotypic analysis of PBMCs cultured with PfSE; T cells and NK cells 
Cells were stained for CD3 (T cells), CD20 (B cells) and CD56 (NK cells) on days 
0, 3 (naïve and immune donors only) and 7, and percentages and absolute cell counts 
were compared between uRBC- and PfSE-stimulated cells for each group (tables 7.4-
7.7, day 0 data not given). Summary data of all subsets for each study population are 
given in Appendix 4, tables A4.5-4.10, and cell surface staining for PBMCs of each 
donor are given in Appendix 4, tables A4.11-4.18. There was no consistent difference 
in the numbers of cells retrieved or the total number of viable cells from uRBC- or PfSE-
stimulated cultures (data not shown). However, there were significant increases in the 
proportion and in the absolute numbers of blast cells (R2) in PfSE-stimulated cultures 
compared to uRBC-stimulated cultures of naïve (paired t ~! 2.44, p !~ 0.04, df = 9) and 
exposed (paired t ~! 7.53, p :!~ 0.001, df = 17), but not of immune (paired t !~ 1.98, 
p > 0.05, df = 17) donors for each day (tables 7.4-7.7). Representative dot plots for 
PfSE- and uRBC-stimulated PBMCs of naïve and exposed individuals are shown in 
figure 7.4b-c. Interestingly, naïve donors had a significantly higher proportion and 
number of Jymphoblasts on day 7 compared to both exposed (student's t ~! 3.38, 
p :!~ 0.002, df ~! 26) and immune individuals (student's t ~! 5.67, p !!~ 5.67, df ~ 26, figure 
7.1), possibly indicating greater activation of T and/or B cells in response to PfSE in 
naïve donors. 
For all study populations, blasting cells in PfSE cultures were predominantly T 
cells on day 3 (data not shown) and on day 7 (figure 7.2a). Exposed donors had a 
significantly lower proportion of T cells (mean = 57.5%) compared to naïve 
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(mean = 83.4%) and immune (mean = 73.7%) populations (student's t ~! 3.03, 
p 0.005, df ~! 26). However, there was a higher proportion of blasting B cells and NK 
cells in PfSE-stimulated cultures of exposed individuals which compensated for the 
smaller proportion of T cells (figure 7.2b-c). Naïve donors had a significantly higher 
absolute number of NK cells in PfSE cultures than in uRBC cultures on day 3 (table 
7.5a) and day 7 (table 7.7a, statistics are in the tables). For malaria-exposed donors, 
the number of NK cell blasts in PfSE-stimulated cultures were also significantly higher 
than in uRBC-stimulated cultures (table 7.7.b) and were significantly higher than for 
naïve donors on day 7 (student's t = 2.38, p = 0.03, df =25). It should be noted that 
exposed individuals also had a significantly higher proportion of NK cell blasts in uRBC 
cultures compared to naïve individuals (student's t = 5.37, p < 0.001 df = 25), indicating 
a non-specific activation of NK cells by uRBC in exposed individuals. In contrast, 
immune donors had very few malaria-specific NK cell blasts (tables 7.5c and 7.7c). The 
number of NK cell blasts were lower in immunes than in both naïve and exposed 
donors, although the difference between naïve and immune donors was not significant 
(student's t = 1.43, p = 0. 17, df =24). 
7.3.2 c3+ and y+ TcR usage 
Overall, TcR c3+ cells were the predominant lymphoblasts in naïve donors 
(tables 7.8a and 7.9a, 53% of total blasting PBMC5). The percentage and absolute 
numbers of TcR c43+ blast cells were significantly higher in PfSE-stimulated cultures 
than in uRBC-stimulated cultures (paired t ~! 9.95, p ::~ 0.001, df = 7). Although TcR c43+ 
cells were measured in cell cultures of exposed individuals, the staining did not work 
(data not shown). However, for both naïve and exposed populations, TcR -y+ cells 
were a small percentage of the total blasting cells (table 7.8, range 9-15% for naive, 2-
13% for exposed individuals). Although, TcR 'yö+ cells were such a small proportion of 
total blast cells, both naïve and exposed populations had significantly higher numbers 
of TcR y+ cells in PfSE cultures versus uRBC cultures (tables 7.8b and 7.9b, paired t ~ 
3.01, p :!~ 0.008, df ~! 9). Additionally, both the percentage and absolute number of TcR 
-y+ cells in PfSE-stimulated cultures was significantly higher in naïve than exposed 
donors (student's t ~! 4.69, p <0.001, df = 24). 
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7.3.3 CD45RA+ and CD45RO+ cells 
The absolute number and percentage of T cells which were CD45RO+ were 
consistently higher in PfSE cultures than uRBC cultures for all naïve and exposed 
donors (see Appendix 4, tables A4.1 1-A4.14, paired t ~! 4.77, p <0.001, df = 9). 
CD45RO+ T cells were higher in proportion and number than CD45RA+ T cells in 
PfSE-stimulated cultures for both for naïve and exposed individuals (tables 7.8 and 
7.9). An increase in CD45RO+ cells was matched by an apparent decrease in 
CD45RA+ cells and vice versa in uRBC and PfSE cultures. Although, the percentage 
of CD45RA+ T cells tended to be higher in uRBC-stimulated cultures than in PfSE-
stimulated cultures, there was no consistent difference in the absolute numbers of 
CD45RA+ T cells for the 2 stimuli (see Appendix 4, tables A4.12 and A4.14). The 
number of CD45RA+ and CD45RO+ T cells were significantly higher in PfSE-stimulated 
cultures of naïve individuals than of exposed individuals (student's t ~! 4.07, p <0.001, 
df = 26). 
7.3.4 CD4+/CD8+ ratios 
For both naïve and exposed populations, absolute numbers of CD4+ and CD8+ 
lymphoblasts were significantly higher in PfSE-stimulated cultures than in uRBC-
stimulated cultures (tables 7.8b and 7.9b). For naïve donors, the ratio of CD4+ICD8+ 
lymphoblasts in PfSE-stimulated cultures was approximately 40:1. In contrast, in 
exposed donors the CD4+ICD8+ ratio was approximately 1.7:1. This was due both to a 
fall in the percentage and number of CD4+ blasts and a rise in the percentage and 
number of CD8+ blasts in exposed donors (figure 7.3). 
7.3.5 lFN-y production to PfSE from NK, a+ and -y+ cells 
In order to determine the cellular source of IFN-y in PfSE-stimulated cultures, 
PBMCs from 3 naïve donors were stimulated with uRBC or PfSE, labelled with 
monoclonal antibodies (table 7.3) and analysed by flow cytometry (see Appendix 4, 
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tables A4.19-20 for details of each individual). The majority of IFN-y+ cells were in the 
blast population, and a higher proportion was found in PfSE-stimulated than uRBC-
stimulated cultures (figure 7.4, mean 4.7 ± 1.8% for PfSE, 1.6 ± 0.5% for uRBC). As 
can be seen from tables 7.5a and 7.5b, the major proportion of PfSE-stimulated cells in 
the lymphoblast population are T cells. TcR (43+ cells represent the dominant 
proportion of T cells, with 60-80% of these staining positive for IFN-y. There is a 
greater than 3-fold increase in the percentage of CD56+ IFN-y-staining cells and a 
greater than 2-fold increase in the percentage of TcR y+ lFN-y-staining cells in PfSE 
versus uRBC cultures. Eighty-five to 100% of CD56+ cells and TcR -yö-i- I cells 
produced IFN-y in the blast population. Hence, a mixture of cells produce IFN-y in 
response to PfSE. 
7.4 Discussion 
In order to determine if there are differences in cellular proliferation/activation 
during P. falciparum infection, the in vitro responses to PfSE of cells from malaria-
naïve, malaria-exposed and clinically immune individuals were compared. An attempt 
was also made to examine which of these cells produce IFN-y. It was not possible to 
examine differences in all cellular subsets, particularly in immune donors, however 
some initial conclusions can be made from this data. First, for naïve donors, PfSE-
stimulated cells were predominantly CD4+, TcR (43+, CD45RO+ I cells, but significant 
numbers of CD8+, CD56+ and TcR yö+ cells were also stimulated. TcR (43+ TcR y+ 
and NK cells all produced IFN-y in PfSE cultures of naïve individuals. Although, cells 
from naïve donors had much higher numbers of activated cells than exposed and 
immune donors, the phenotype of responding cells in exposed individuals is similar to 
that in naïve individuals (i.e. predominant CD4+, CD45RO+ T cells, TcR (43+ usage not 
known). However, exposed donors had much higher percentages of CD8+ T cell blasts 
and B lymphoblasts than naïve individuals. Finally, immune individuals had much lower 
numbers of activated cells, with no significant differences in cell subsets between 
uRBC- and PfSE stimulated cultures. 
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7.4.1 Immune response in naïve donors 
A number of studies have demonstrated that cells from individuals who have 
never been exposed to malaria can respond to malaria antigens in vitro (20, 62, 63, 75, 
115, 290, 370). It is generally agreed that the cellular response to malaria antigens is 
polyclonal (159) and is a result of cross-reactive responses of cells primed by other 
environmental antigens (62, 63, 97). However, it is not known whether this cross-
reactive response is beneficial or harmful. Naïve donors, who are at greater risk of 
severe clinical illness if infected with malaria, had higher absolute numbers of blasting 
cells than either exposed or immune donors. Numbers of CD3+, CD4+, CD20+, 
CD45RA+, CD45RO+, and TcR y+ lymphoblasts were higher in PfSE-stimulated 
cultures of naïve individuals than exposed individuals. However, it should be noted that 
in both exposed and immune populations, there was a non-specific response to uRBC, 
possibly indicating sensitisation to ABC antigens following repeated bouts of malaria. 
There are a number of explanations for the observed differences in cell numbers 
between these groups. First, there could have been variations in experimental set-up 
as samples of each group for flow cytometry were run at different times and locations. 
Lymphoblasts (R2) were identified on the basis of their FSC and SSC characteristics. 
Compensation parameters for FSC versus SSC were not identical for samples of 
immune donors versus naïve and exposed donors. As a result, red blood cells and 
dead cells were a slightly larger proportion of the total numbers of cells (data not 
shown). Second, a decrease in circulating malaria-reactive cells could be a result of 
sequestration in organs where cells are needed to fight off infection (146, 363), as 8/18 
immune donors were sub-clinically infected with malaria. However, neither of these 
reasons explains why exposed individuals had lower numbers of cells than naïve 
donors, as compensation parameters were identical to naïve donors and only 1 
individual was sub-clinically infected. The most likely reason is that malaria Ag 
polyclonally activates a larger proportion of cells in naïve individuals, and that this 
response is downregulated in exposed and immune individuals by acquired immune 
responses. The data indicate that immune responses in individuals living in malaria-
endemic areas are specific, as can be seen from studies which demonstrate that only 
cells from malaria-exposed individuals respond to purified malaria Ag, while both cells 
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from both naïve and exposed individuals respond to crude malaria Ag (284). Thus, 
higher numbers of PfSE-stimulated cells in naïve individuals may reflect an excessive 
activation of cross-reactive cells which may lead to pathogenic infection. In other 
words, the polyclonal, cross-reactive T cell response in naïve donors may be 
downregulated in exposed and immune donors to be replaced by malaria-specific T cell 
responses. 
7.4.2 c43+ and -+ T cells in malaria infection 
PfSE-stimulated T cells of naïve donors were predominantly TcR c43+ (>50%). 
Although c43 staining of cells from exposed individuals did not work due to a technical 
problem with the Ab, it could be concluded from the small proportion of TcR 18+ cells 
that the predominant cells from exposed individuals were also TcR c43+. This data is 
confirmed by previous work in our lab which demonstrated that PfSE-stimulated T 
lymphoblasts of clinically immune adult Gambians are predominantly uf3+ (Riley et al., 
unpublished data). 
These results are in agreement to a number of studies (63, 75) but seem to 
contradict others which state that there is a preferential expansion of -y+  T cells (20, 
112, 115). However, Waterfall etal. 1998 showed that using live rather than killed 
parasite, or adding exogenous IL-2, increased 'y+ T cells in culture (354). Additionally, 
a number of studies have demonstrated -yö+ cellular proliferation is dependent upon 
c43-i- cells, which are potent producers of IL-2 (84, 291, 319). 
Although cj3+ T cells are the major population of cells responding to malaria Ag, 
there was a significant expansion of yö+ T cells in PfSE-stimulated when compared with 
uRBC-stimulated cultures for both malaria-naïve and malaria-exposed adults. y+ T 
cells may interact with malaria Ag through an alternative pathway to a3+ T cells, as they 
are able to bind non-protein antigens (294). Elloso et al. showed that y+ T cells inhibit 
parasite replication by coming into direct contact with merozoites (85). However, naïve 
individuals had significantly higher numbers of malaria-specific y+ T cells than exposed 
individuals. Elevated circulating levels of y-- T cells have been found in individuals with 
acute P. falciparum infection (51, 137, 145). In contrast, there was no increase in yö+ T 
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cells found in children living in malaria-endemic areas regardless of severity of disease 
(145). Taken together, these results suggests that y6+ T cells may play a pathogenic 
role in malaria infection and may be downregulated during acquisition of clinical 
immunity. 
7.4.3 PfSE stimulates both CD45RA+ and CD45RO+ cells 
The majority of PfSE-responding cells in both naïve and exposed adults were 
CD45RO+, which is in agreement with other studies on cells of naïve individuals (75, 
159). These results may indicate that the majority of cells which are responding have 
been primed previously either by common environmental antigens or by malaria 
antigens. However CD45RA+ cells of both naïve and exposed individuals also 
responded to PfSE. These results, and other studies, indicate that naïve cells can also 
respond to malaria antigens (97). However, CD45RA+ and CD45RO+ expression does 
not necessarily indicate naïve versus memory cells. Rather, these cell surface markers 
may reflect inactivated versus activated cells. Hamann et al. 1996 demonstrated that 
cells which are CD45RO+ can revert back to CD45RA+ expression in the absence of 
constant antigenic stimulation (125). 
7.4.4 CD4+ and CD8+ T cells in malaria infection 
A number of studies have demonstrated that CD4+ T cells are the primary cells 
responding to PfSE in vitro in previously unexposed individuals (62, 63, 290, 370). 
PfSE-stimulated PBMCs of naïve individuals were also predominantly CD4+ in this 
study, and cell numbers responding were significantly higher than in exposed 
individuals. Interestingly, exposed individuals also showed activation of CD8+ cells that 
was not seen in naïve individuals. Expansion of CD8+ cells thus appears to be a 
malaria specific response. These results may indicate that CD4+ cells may help to 
exacerbate infection if in excess and that responses mediated by CD8+ cells may be 
beneficial in clearing infection. Studies in mice have shown that immunity to pre-
erythrocytic liver-stage malaria is dependent upon CD8+ T cells (78). No such studies 
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are reported for responses mediated by CD8+ cells in immunity to blood stage 
infections. 
7.4.5 Cellular function of NK, CD4+, CD8+, and yö+ cells in malaria infection 
Phenotypic analysis is important, but does not demonstrate the function of each 
subset. ICS was done on PfSE-stimulated and uRBC-stimulated PBMCs of 3 naïve 
individuals in order to determine which cells were producing IFN-y. TcR c43+ cells were 
the main producers of IFN-y, but significant proportions of TcR 'y+ and NK cells also 
produced IFN--yto PfSE. These data correlate well with previous studies which 
demonstrated that both CD4+ c43+ cells and 'y+ cells are potent producers of IFN--y 
during malaria infection (75, 116, 264). Although NK cell production of IFN-y has not 
been previously reported in human malaria infection, IFN-y production by NK cells is 
involved in resistance to murine P. c. chabaudiAS infection (236). 
Although further studies need to be done in order to determine if there are any 
differences between naïve, exposed and immune individuals as to which cells produce 
IFN-y, some tentative conclusions can be made based on these results and the results 
from Chapter 6. PfSE-stimulated cells of exposed individuals produced significantly 
higher levels of IFN-y than cells of naïve or immune individuals. A possible source of 
this IFN-y is CD8+ cells. Elevated circulating levels of CD8+, IFN-y+ cells were found in 
convalescent individuals during drug-induced clearance of P. falciparum infection (363). 
IFN-y could also be produced by NK cells in exposed individuals, as they had 
significantly higher proportions of NK cells than naive individuals. The hypothesis that 
NK cells are a major source of IFN-y in malaria infection is further supported by the fact 
that cells from immune individuals produced minimal amounts of IFN-y and that immune 
individuals had almost no PfSE-stimulated NK cells. Finally, because exposed 
individuals produce higher levels of IFN-y but have a lower risk of severe malaria than 
naïve individuals, there must be cells which produce anti-inflammatory cytokines which 
minimise the effects of IFN-y. Exposed and immune individuals had higher percentages 
of responding B cells and higher ratios of B lymphocytes to T lymphocytes than naïve 
individuals (table 7.6). B lymphocytes have been shown to provide signals to CD4+ 
cells to produce anti-inflammatory cytokines during P. c. chabaudi infection (196). 
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Taken together, these results suggest B cells may be involved in the anti-inflammatory 
response during malaria infection. Further studies are required to determine the cellular 
sources of downregulatory cytokines in P. falciparum infection (discussed further in 
Chapter 8). 
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Table 7.1: Ab staining combinations for cell surface markers used in flow cytometric 
analysis for a) naIve, b) exposed and c) immune individuals (concentrations of each Ab 
are given in section 2.8.2). 
 
FITC-labelled PE-labelled TRI-labelled 
CD20 CD56 CD3 
CD45RA CD45RO CD3 
TcR c3 CD4 CD3 
TcR yö CD8 CD3 
 
FITC-labelled PE-labelled TRI-labelled 
CD20 CD56 CD45RO 
CD45RO CD45RA CD3 
TcR c43 CD45RO CD3 
TcR yö CD45RO CD3 
CD4 CD45RO CD3 
CD8 CD45RO CD3 
V79 CD45RO CD3 
V1 CD45RO CD3 
C) 
FITC-labelled PE-labelled TRI-labelled 
CD20 CD56 CD3 
Table 7.2: Cellular subsets which are detected by the antibodies to the cell surface 
markers. 
Cell surface marker Cell Type 
CD20 B lymphocytes 
CD56 NK cells 
CD3 T lymphocytes 
CD4 Helper T lymphocytes 
CD8 Cytotoxic T lymphocytes 
CD45RA Naïve cells 
CD45RO Activated (memory) cells 
TcR c43 T cell receptor containing a and P chains 
TcR ,y6 T cell receptor containing y  and 6 chains 
V79 T cell receptor containing 'y9  chain 
V61 T cell receptor containing 61 chain 
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Table 7.3: Three-colour staining combinations used for ICS. 
FITC 	PE 	TRI 
IEN-y CD56 CD3 
TcR ap 	IFN-y 	CD3 
TcR y8 IFN-y CD3 
Table 7.4: Percentages of lymphoblasts (R2), and percentages of lymphoblasts that 
are T lymphocytes (CD3+), B lymphocytes (CD20+), or NK cells (CD56+) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naïve (n = 10) and b) 
immune (n = 16) donors for day 3 (arithmetic mean and SEM indicated). 
naIves 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM t p 
R2 1.49 0.09 1.91 0.15 2.44 0.04 
CD3+ 81.5 2.3 72.3 2.4 4.88 0.001 
CD20+ 2.7 0.6 3.6 0.8 1.29 >0.05 
CD56+ 0.2 0.2 2.2 0.6 3.59 0.006 
immunes 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM t p 
R2 1.92 0.30 2.33 0.43 1.98 >0.05 
CD3+ 70.6 2.3 70,7 2.6 0.06 >0.05 
CD20+ 19.9 1.5 10.0 1.5 0.52 >0.05 
CD56+ 3.6 0.7 2.7 0.6 0.96 >0.05 
SEM- Standard error of the mean. 
t- t value for the significance level. 
p- p value. 
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Table 7.5: Total numbers of lymphoblasts (R2), and total numbers of lymphoblasts that 
were T lymphocytes (CD3+), B lymphocytes (CD20+), or NK cells (CD56+) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naïve (n = 10) and b) 
immune (n = 16) donors for day 3 (geometric mean and 95% Cl indicated, cell count is 
per 106  cell plated out on day 0). 
nalves 
uRBC-stimulated PfSE-stimulated 
Cell Phenotype Mean 	Cl Mean 	Cl t p 
R2 8165 6820 	9776 12108 10151 	14443 5.00 0.001 
CD3+ 6634 	5398 8153 8643 	6963 10728 3.54 0.006 
CD20+ 183 111 	301 343 207 	566 3.36 0.008 
CD56+ 2 	1 9 95 	16 552 2.51 0.033 
immunes 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean Cl 	Mean 	Cl t p 
R2 4039 1897 8603 	3286 1541 	7009 0.87 >0.05 
CD3+ 2823 1263 	6308 2288 	1023 5118 0.87 >0.05 
CD20+ 331 105 1040 	169 38 	746 1.40 >0.05 
CD56+ 66 18 	241 37 	8 167 1.23 >0.05 
Cl- Confidence interval. 
t- t value for the significance level. 
p- p value 
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Table 7.6: Percentages of lymphoblasts (R2), and percentages of lymphoblasts that 
are T lymphocytes (CD3+), B lymphocytes (CD20+), or NK cells (CD56+) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naïve (n = 10), b) 




Cell Phenotype Mean SEM Mean SEM t p 
R2 0.4 0.1 8.0 1.0 7.53 <0.001 
CD3+ 62.8 5.1 83.4 2.8 4.93 0.001 
CD20+ 14.6 3.2 7.7 1.6 2.77 0.020 
*CD56+ 3.7 1.7 2.5 0.7 0.65 >0.05 
exposed 
uRBC-stimulated Pt SE-stimulated 
Cell Phenotype Mean SEM Mean SEM t p 
R2 3.3 0.4 4.6 0.5 3.90 0.001 
CD3+ 53.4 4.2 57.5 4.1 2.20 0.042 
CD20+ 10.1 1.6 13.7 1.9 2.45 0.030 
CD56+ 8.3 1.6 12.2 1.6 2.28 0.035 
immunes 
uRBC-stimulated Pt SE-stimulated 
Cell Phenotype Mean SEM Mean SEM t p 
R2 1.2 0.3 1.81.  0.4 1.43 >0.05 
CD3+ 68.6 3.9 73.7 2.7 1.55 >0.05 
CD20+ 10.3 1.8 9.6 1.8 0.53 >0.05 
*CD56+ 4.8 1.3 4.7 0.7 0.07 >005 
* 9  
n = 17 
SEM- Standard error of the mean. 
t- t value for the significance level. 
p- p value. 
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Table 77: Total numbers of lymphoblasts (R2), and total numbers of lymphoblasts that 
were T lymphocytes (CD3+), B lymphocytes (CD20+), or NK cells (CD56+) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naIve(n = 10), b) 
exposed (n = 18) and c) immune (n = 18) donors for day 7 (geometric mean and 95% 
Cl indicated, cell count is per 106  cell plated out on day 0). 
naives 
uRBC-stimulated PfSE-stimulated 
Cell Phenotype Mean Cl Mean Cl t p 




63892 11.12 <0.001 
CD3+ 880 326 2376 34131 20610 56522 11.30 <0.001 
CD20+ 121 513 	29 2597 4151 	1625 5.71 <0.001 
*CD56+  14 2 103 374 65 2156 3.58 0,007 
exposed 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean Cl Mean Cl t p 
R2 9928 6961 14160 14593 11279 	18881 2.91 0.010 
CD3+ 4850 3652 6441 7706 5825 10193 3.35 0.004 
CD20+ 800 500 1200 1700 1200 	2500 4.97 <0.001 
CD56+ 560 338 927 1464 1044 2054 4.00 0.001 
immunes 
uRBC-stimulated PfSE-stimulated 
Cell Phenotype Mean Cl 	Mean 	Cl t p 
R2 1787 929 	3439 	2712 1329 	5535 1.54 >0.05 
CD3+ 1189 587 2408 1977 	942 4151 1.61 >0.05 
CD20+ 93 28 	316 	128 36 	460 0.57 >0.05 
"CD56+ 54 24 	124 	108 	38 	306 1.55 >0.05 
n = 17 
Cl- Confidence interval. 
t- t value for the significance level. 
p- p value. 
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Figure 7.1: Comparison of total numbers of cells in the lymphoblast (R2) population of 
uRBC-stimulated (left hand columns) and PfSE-stimulated (right-hand columns) 
cultures between naïve, exposed and immune donors (geometric mean indicated). 
Numbers are expressed as number of blast cells harvested on day 7 per 106  cells 




















Figure 7.2: Comparison of percentages of the lymphoblast population (R2) which are 
a) I lymphocytes (CD3+), b) B lymphocytes (CD20+) and C) NK cells (CD56-i-) in uRBC-
stimulated (left hand columns) and PfSE-stimulated (right-hand columns) cultures 
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Table 7.8: Phenotype of I lymphoblasts (percentage of all lymphoblasts) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naïve and b) exposed 
donors for day 7 (arithmetic mean and SEM indicated). 
a) naives 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM n t p 
CD3+ CD45RA+ 35.1 7.1 16.5 1.0 10 2.60 0.029 
CD3+ CD45RO+ 18.6 6.5 72.0 3.5 10 7.89 <0.001 
CD3+ TcR(!3+ 26.0 5.1 52.8 4.7 8 6.69 <0.001 
CD3+TcR78+ 2.2 1.1 11.5 0.8 9 9.95 <0.001 
CD3+ CD4+ 31.8 4.3 79.4 2.6 10 11.43 <0.001 
CD3+ CD8+ 8.5 2.0 2.2 0.6 9 3.12 0.014 
b) exposed 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM n t p 
CD3+ CD45RA+ 28.2 2.7 19.5 2.4 18 5.01 <0.001 
CD3+CD45RO+ 31.6 3.3 42.9 3.4 18 5.10 <0.001 
CD3+TcR76+ 5.5 1.2 5.7 0.8 17 0.15 >0.05 
CD3+CD4+ 40.3 3.5 43.6 3.5 18 1.26 >0.05 
CD3+ CD8+ 26.1 2.9 25.6 3.1 18 0.14 >0.05 
*Some  individuals did not have enough cells for the full set of staining combinations. 
SEM- Standard error of the mean. 
n- number of samples/individuals on given day. 
t- t value for the significance level. 
p- p value. 
Table 7.9: Phenotype of T lymphoblasts (total numbers of all lymphoblasts) compared 
between uRBC-stimulated and PfSE-stimulated cultures for a) naïve and b) exposed 
donors for day 7 (geometric mean and 95% Cl indicated, cell count is per 106  cell plated 
out on day 0). 
a) naives 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean Cl Mean Cl n* t p 
CD3+ CD45RA+ 415 150 1148 6654 3978 	11131 10 8.43 <0.001 
CD3+ CD45RO+ 80 9 738 29271 17234 49714 10 6.65 <0.001 
CD3+TcRc43+ 356 96 1324 24522 13063 	46036 8 9.15 <0.001 
CD3+TcR7+ 5 1 25 4898 2876 8343 9 11.10 <0.001 
CD3+ CD4+ 420 139 1265 32472 19793 	53274 10 11.77 <0.001 
CD3+ CD8+ 80 13 508 773 436 1371 9 3.01 0.017 
b) exposed 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean Cl Mean Cl n t p 
CD3+ CD45RA+ 2507 3502 1794 2450 3243 	1851 18 0.21 >0.05 
CD3+ CD45RO+ 2787 3586 2167 5689 7759 4172 18 4.77 <0.001 
CD3+TcR76+ 421 660 268 712 1080 	470 17 3.01 0.008 
CD3+ CD4+ 3598 4831 2680 5748 7715 4282 18 2.97 0.009 
CD3+ CD8+ 2233 2994 1666 3285 4570 	2361 18 3.27 0.004 
*Some  individuals did not have enough cells for the full set of staining combinations. 
Cl- Confidence interval. 
n- Number of samples/individuals on given day. 
t- t value for the significance level. 
p- p value. 
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Figure 73: Comparison of CD4+ (a-b), CD8+ (c-d) and CD4+/CD8+ ratios (e-f) within 
the T lymphoblast population of uRBC-stimulated (left-hand columns) and of PfSE- 
stimulated (right-hand columns) cultures between naïve and exposed individuals on day 
7. Panels a, c and e compare percentages of cells (arithmetic mean indicated), and 
panels b, d and f compare total numbers of cells (geometric mean indicated, cell count 
is per 106  cell harvested). 
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Figure 7.4: Intracellular cytokine staining to determine the cellular source of IFN-y in 
PBMC from a malaria naïve donor cultured for 7 days with either SEB (panels a, d, g), 
PfSE (b, e, h) or uRBC (c, f, i). Lymphocytes were divided into resting cells (RI) 
(panels d-f) and lymphoblasts (R2) (panels g-i) on the basis of forward and side scatter 
(panels a to c) and stained for CD3 (vertical axis) and IFN-y (horizontal axis). 
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Table 7.10: Percentages (a) and absolute cells numbers (b) of total cells recovered 
which were lymphoblasts and the percentage of total number of lymphoblasts that were 
stained positive for IFN-y comparing uRBC-stimulated and PfSE-stimulated cultures in 
naïve individuals on day 7(arithmetic mean and SEM indicated, n = 3, cell count is per 
106 cell plated out on day 0). 
Percentages 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM 
R2 1.6 0.3 4.7 1.0 
CD56+ 5.2 3.7 18.6 5.0 
CD56+/IFN-7+ 5.2 4.0 18.1 5.4 
CD3+ 89.3 2.5 83.0 1.7 
CD3/IFN-7+ 56.0 4.0 56.6 7.4 
TcR (x3+ 76.8 2.6 65.5 6.9 
TcR u3+/lFN-y+ 57.6 2.3 51.3 9.2 
TcR y+ 8.6 1.9 19.6 3.4 
TcR y+/lFN-y+ 9.1 2.0 21.5 3.6 
Absolute numbers 
uRBC-stimulated ME-stimulated 
Cell Phenotype Mean SEM Mean SEM 
R2 12640 2085 37573 8170 
CD56+ 816 656 7036 2608 
CD56+/IFN-y-i- 826 703 6792 2707 
CD3+ 11197 1535 31425 7208 
CD3/IFN-y+ 6907 583 22439 6770 
TcR af3+ 9751 1750 25127 6567 
TcR c4-i-/lFN-y+ 7282 1233 20330 6444 
TcR 7+ 1129 372 7549 2267 
TcR y+/lFN-y+ 1186 377 8279 2446 
SEM- Standard error of the mean. 
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Chapter 8: Conclusions and future directions 
8.1 Summary of the study findings 
The specific aims of this study were to determine whether or not there were 
differences in cellular proliferation, cytokine production and cell subset expansion in 
response to P. falciparum Ag in vitro between malaria-naïve, malaria-exposed (semi-
immune) and clinically immune individuals, and if such differences were observed, to 
determine how these differences relate to the development of clinical immunity. These 
questions were answered by developing specific and sensitive methods for detecting 
IFN-y, IL-1 2 and IL-1 0, by determining the cellular source of IFN-y and its regulation and 
by comparing proliferative and cytokine responses between these groups. 
Two-site capture ELISAs were developed to detect IFN-y, lL-12 p70, lL-12 p40 
and IL-10. Sandwich ELISAs were specific for these human cytokines but were only 
sensitive enough to measure pg amounts of cytokine. Because IL-12 was not easily 
detected by ELISA, qualitative RT-PCR was also developed to measure IL-12 p40 
transcripts. Although IL-1 2 bioactivity was clearly demonstrated by IL-1 2 neutralisation 
assays, neither ELISA nor RT-PCR could consistently detect parasite-induced lL-12. 
Individuals were allocatedto naïve, exposed and immune populations before any 
immunological analyses were performed. Malaria-specific Ab measurements and 
parasite detection by blood smear or PCR confirmed the appropriate designation of 
individuals into each group (see table 2.2). Immunological responses were then 
measured by PfSE-stimulation of PBMCs in vitro. Peripheral blood was chosen as the 
source of lymphocytes because of practical constraints and also because peripheral 
blood is believed to represent the total malaria-reactive lymphocyte population in 
healthy individuals. 
Cells from all individuals responded vigorously to PfSE by lymphocyte 
proliferation, but there were no significant differences in geometric mean SI between 
any of the groups. Although malaria-specific Ab levels were high in immune individuals, 
Ab levels were only correlated with proliferative responses in exposed individuals. 
Further, IEN-y levels were correlated with proliferative responses in each group, 
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although when all individuals were grouped together, there was no correlation between 
these parameters. 
PBMCs from naïve individuals produced moderate levels of IFN-yin response to 
PfSE stimulation and production was, for the most part, IL-1 2-dependent. Additionally, 
c3+ I cells were the predominant cells which produced IFN-y, although significant 
proportions of y+ T cells and NK cells also produced IFN-y. Cells from exposed 
individuals produced significantly higher mean IFN-1 levels than PBMCs from naïve 
individuals, and IFN--y levels were only partially reduced by neutralising alL-12. In 
contrast, cells from immune individuals secreted marginal levels of IFN-y which were 
significantly lower than levels found in either naïve or exposed populations, and 
neutralising alL-12 reduced IFN-yto background levels. Low IFN-y responses in 
immune individuals were not due to anergy, as their cells proliferated in response to 
PfSE to the same extent as cells from naïve and exposed individuals. IL-1 0 was 
measured in order to determine if this cytokine was involved in the downregulation of 
the IFN-y response. Although the number of IL-1 0 producers was highest in exposed 
individuals, there were no significant differences in malaria-specific IL-10 levels 
between any of the study populations. 
Finally, in all individuals, cells which responded to PfSE were predominantly I 
cells, although there were significant proportions of activated NK cells in cell cultures of 
naïve and exposed individuals and higher proportions of activated B lymphocytes in cell 
cultures of exposed and immune populations than naïve individuals. Naïve individuals 
had significantly higher numbers of PfSE-stimulated cells than exposed and immune 
individuals. Parasite-stimulated cells from naïve individuals were predominantly CD4+ 
c43+ CD45RO+ cells, although y8+ and CD45RA+ T cells also responded to PfSE. In 
contrast, in exposed individuals, significantly higher numbers of CD8+ cells were 
activated than in naïve individuals. 
8.2 Practical constraints of measuring cellular immunity in humans 
Assays, such as measuring malaria-specific Ab levels, are able to directly 
monitor immune responses during an acute infection with malaria. Because invasive 
techniques are not practical or ethical in humans, mouse models are often used to 
determine immune responses in localised areas (i.e. liver or spleen). However, murine 
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models are, at best, only models and cannot be completely conclusive on how the 
human immune system responds to malaria infection. In vitro assays are also limited 
by the fact that simply removing and manipulating cells outside their natural 
environment may cause changes in how cells react, thus making comparisons between 
different studies difficult (282). Despite the limitations of in vitro assays, measuring 
peripheral blood responses was the only way in which to compare cellular immune 
responses in healthy individuals in this study. Although not all assays were performed 
at the same time with the same batch of malaria Ag, all of these differences were 
accounted for and there was little variation between assays. Thus, some initial 
conclusions can be made from these in vitro assays as to what happens during malaria 
infection in vivo. 
8.3 Clinical immunity: hypothesis revisited 
Severe clinical symptoms of malaria are associated with elevated levels of pro-
inflammatory cytokines such as TNF-cx (118, 154, 193). It was originally thought that 
parasite-derived endotoxins directly stimulate macrophages to produce TNF-a. 
However, the idea that this innate immune response is sufficient to mediate pathology 
cannot explain many of the epidemiological characteristics of malaria infections, 
including why young infants do not become ill when first infected with malaria (279). I 
have hypothesised that IFN-yis needed to stimulate excessive levels of pro-
inflammatory cytokines which cause pathology and that the acquisition of clinical 
immunity is dependent upon the downregulation of this inflammatory response. 
Although the innate immune response, mediated by Mo and NK cell production of pro-
inflammatory cytokines, may be important during malaria infection, it is likely that the 
inflammatory response is dependant upon an early T cell response primed by malaria 
Ag or other cross-reacting environmental antigens. To date, these hypotheses are 
confirmed by 3 studies which show that IFN--y levels are lower in malaria-immune adults 
than in unexposed individuals (53, 284) and that malaria Ag-stimulated TNF-a 
production is dependent upon CD3+ cells (308). 
The results from this study further confirm these hypotheses. Cells from naïve 
individuals proliferated vigorously in response to malaria Ag and secreted significant 
amounts of IFN-y. Upon PfSE stimulation, responding cells from naïve individuals 
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were predominantly CD3+ CD4+ c43+ CD45RO+ but NK, c43+ and y&- cells all 
produced IFN-'y. It was also found that naïve individuals had a significantly higher 
number of PfSE-stimulated lymphoblasts than exposed and immune individuals. Taken 
together, these results suggest that a polyclonal expansion of primed c4+ and y+ T 
cells stimulate excessive pro-inflammatory responses leading to a febrile illness in 
naïve individuals. Together with a+ and -y+ cells, NK cells also produce IFN-y which 
may stimulate macrophages to produce TNF-a, IL-1 and IL-6. In naïve individuals, 
there was no evidence of production of anti-inflammatory cytokines (such as IL-10) or 
of a Th2-like immune response which may ameliorate the pro-inflammatory response 
(196). It has been suggested that naïve individuals have primed CD4+ CD45RO+ 
cells, which are activated by cross-reactive memory responses to other environmental 
organisms (62, 63). If so, this would explain why foreign adults and young children 
living in endemic areas are more susceptible to severe malaria than young infants 
whose immune systems have never been previously primed to malaria. 
Exposed individuals, who are still susceptible to clinical malaria (but at lower risk 
of severe disease compared with naïve individuals), have significantly higher levels of 
IFN-7 in response to malaria Ag. Although the cellular source of IFN-y was not 
determined in exposed individuals, it could be that CD8+ cells are the primary 
producers of IFN-y, as this population was markedly expanded in exposed individuals. 
CD8+ cells in exposed individuals may be generating a malaria Ag-specific response 
while the polyclonal activation of CD4+ cells to numerous cross-reactive antigenic 
epitopes may be down regulated. Thus, the severity of infection does not only depend 
on inflammatory cytokine concentrations, but may also depend upon which cells are 
producing these cytokines and where they are being produced. Although IFN-i is 
beneficial in clearing primary malaria infections (93, 98), excessive levels can cause 
severe pathology (181, 350). Because exposed individuals are not necessarily at 
higher risk of severe malaria than naïve individuals, there may be mechanisms which 
ameliorate the downstream effects of higher levels of IFN-y. Although PfSE-stimulated 
PBMCs of exposed individuals did not produce significant levels of IL-1 0, exposed 
individuals had a much higher proportion of B cells than naïve individuals and a 
relatively high concentration of malaria-specific antibodies. This may be indicative of a 
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switch in the immune response away from a strong Thi profile towards a Thi/Th2 or 
Th2-dominated response. 
Finally, in clinically immune individuals, there is downregulation of inflammatory 
cytokines as evidenced by the fact that cells from immune individuals produced very 
low levels of IFN-y. Because ICS analysis was not performed for cells from immune 
individuals, the cellular source of IFN-'y is not known. However, it could be 
hypothesised that NK cells are the primary producers of IFN-y in immune individuals, 
because IFN-y was completely IL-12-dependent (144, 301) in immune individuals but 
not in naïve or exposed individuals. Low numbers of NK cells in the responding cell 
population in conjunction with marginal production of IFN-y in immune individuals give 
further support to this hypothesis. Thus, a plausible response to malaria infection in 
immune individuals is: (i) that there may be an immediate production of IFN-1 by NK 
cells which may be sufficient to induce IFN-y-dependent parasite killing, but that (ii) this 
initial innate immune response is quickly downregulated and production of Mø-derived 
TNF-a is inhibited by malaria-specific T cells which produce anti-inflammatory 
cytokines and provide help to B cells for malaria-specific Ab production. Again, there 
were no significant differences in IL-1 0 levels between any of the groups, suggesting 
that other anti-inflammatory cytokines, such as TGF-13, may be involved. 
In conclusion, the acquisition of clinical immunity to malaria seems to be due to 
a downregulation of the inflammatory response which is mediated both by the innate 
immune system and by previously primed T cells. However, clinical immunity is not 
completely a 'Thi-like' or 'Th-2' immune response. As in other parasitic infections, a 
combination of inflammatory and anti-inflammatory cytokines are needed to help 
reduce parasitemia and ultimately to develop clinical immunity (173, 298). Rather it is 
the timing, location, cellular source of cytokine production, as well as the balance in 
cytokine levels, which determine the outcome of malaria infection. 
The practical implications to consider from these results are how new therapies 
can be developed and what factors are important in vaccine development (see section 
8.3.1). Therapies which help to downregulate an excessive inflammatory response, 
and in a sense 'mimic' the immune response found in clinically immune individuals, 
would be beneficial in developing anti-toxic immunity. It is also important to understand 
when a therapy such as this can be used as results from this study seem to suggest 
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that an early moderate inflammatory response may be beneficial (i.e. IFN-y production 
from NK cells seems to persist in all 3 groups). However, this study has only begun to 
elucidate some of the mechanisms involved in the immune response to malaria 
infection. There are many questions which still remain to be answered. The following 
section describes some of the main ideas which need to be further investigated in order 
to gain a more thorough understanding of clinical immunity to malaria. 
8.4 Future studies 
8.4.1 Which component(s) of the malaria parasite activates the immune system? 
The exact parasite component or components which stimulate cells are still not 
known. In one study, the T cell activating component of malaria parasites was found to 
be distinct from the TNF-o inducing endotoxin-like Ag (75) used in other studies (305, 
328). Studies performed previously in our laboratory also demonstrated that live 
schizonts stimulate a higher percentage of 78+ cells to respond than does a crude Ag 
preparation of schizont extracts (354). Taken together, these results suggest that there 
are multiple components of the malaria parasite which stimulate different immune 
responses. 
More importantly, it is not known whether differences in immune responses 
between naïve and immune individuals are a result of cells responding to different 
antigenic components. Cells from malaria-exposed individuals proliferated vigorously in 
response to separated protein fractions of P. falciparum schizonts (114) and purified 
soluble malaria Ag (284) while cells from malaria-naïve individuals did not (114, 284). 
These results suggest that if soluble crude malaria Ag is affinity purified with antibodies 
from immune individuals, cross-reactive antigens are lost and malaria specific 
responses are maintained. CD4+ cells seem to respond to Ag expressed by schizonts 
and by many other environmental organisms. But data in this study from malaria-
exposed individuals seem to suggest that CD8+ cells may respond more specifically to 
malaria-specific Ag. These results have important implications in vaccine development, 
because different malaria antigens will stimulate different cellular subsets leading to 
production of cytokines which will either prevent or exacerbate severe malaria. The 
components which stimulate cells from immune individuals may be used to generate 
Ag-specific responses in a malaria vaccine. 
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8.4.2 Why was IL-12 not detected? 
8.4.2.1 IL-12 receptor expression 
There were no significant differences found in IL-12 levels in cell cultures of 
naïve, exposed and immune populations, and no obvious differences were found in IL-
12 mRNA transcription. However, IL-12 activity was demonstrated by assays in which 
IFN--y production was down-regulated in the presence of antibodies which neutralised 
IL-12. The question that remains to be answered is; why were differences in IL-12 
levels not detected? It could be that IL-12 production is very transient, and the 
timepoints when samples were collected were not representative of when IL-12 was 
actually being produced. Another reason may be that IL-12 is produced and is 
biologically active in such miniscule amounts that the assays were not sensitive enough 
to detect mRNA or protein levels. 
However, it could also be that the IL-12 levels measured were the true levels 
produced, but that there are other factors, such as IL-1 2R expression, which regulate 
IL-12 bioactivity. Ouyang et al. demonstrated that IL-12R P2 subunit expression is 
downregulated by IL-4 (323) and GATA-3, a transcription factor which augments IL-4 
and IL-5 production (254). Although PBMCs from all 3 groups generally produced 
equal amounts of IL-12, the cytokine milieu in immune individuals (i.e. Th2 cytokines) 
may help to downregulate IL-12R expression on NK or T cells. Reduced IL-i 2R 
expression could also explain why cells from immune individuals produce low levels of 
IFN-y, as most of their IFN-y production is dependent upon IL-1 2. Thus, even if there is 
lL-12 produced, absolute concentrations may not be important if other factors mediate 
IL-12R expression. 
8.4.2.2 Dendritic cells 
Again, there may have been differences in IL-12 production, but these 
differences may not have been detected because the wrong population of cells were 
examined. One possible population of cells that was not specifically examined is 
dendritic cells (DC). Because DC are such a small percentage of peripheral blood, the 
IL-12 signal may have been reduced by the presence of other cells which do not 
produce IL-12 (i.e. the assays were not sensitive enough). Purified mouse and human 
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DC are potent producers of IL-12 (50, 177) and were found to produce comparable 
amounts of IL-12 as PBMCs, spleen cells and macrophages on a cell to cell basis 
(133). IL-12 was primarily produced by DC, not Mo, in murine T. gondii infection (276). 
It was further demonstrated that DC were more effective transporters of Ag to T cell 
areas than Mo [Reis e Souza, 1997 #446], that they mediate Thi differentiation and 
production of IFN-y from Thi cells (133) and that anti-inflammatory cytokines 
downregulate IL-12 production by DC (177). These results could explain why T cells 
from naïve individuals produce IFN-y early on while there is no such response found in 
immune individuals. Although no such studies have been carried out in malaria 
infections, these results suggest that DC may be more important producers of IL-12 
than Mo during malaria infection. Further studies using purified PfSE-stimulated DC 
and Mø are needed to determine if this is the case. 
8.4.3 Factors which mediate cvtokine production other than IL-12 
Although IL-12 does play an important role in malaria infection as evidenced by 
the neutralisation assays with alL-12, there may be other factors which are important in 
determining whether the inflammatory response is excessive or downregulated. 
8.4.3.1 Co-stimulatory molecules 
Although MHC-T cell interaction stimulates cells to produce cytokines, it has 
been demonstrated that the additional binding of co-stimulatory ligands increases the 
production of cytokines such as IL-12 (50, 177), IFN-'y (143) and TGF-3 (52). 
CD40/CD40 ligand (CD40L) binding combined with IL-12 (259), and B7 interacting with 
CD28 receptors on NK cells (143), increase IFN-y concentrations. Although no work 
has been done in human malaria models on co-stimulatory molecules, these 
interactions could cause the increase in IFN-y levels found in cells from naïve and 
exposed individuals and not from immune individuals. 
Alternatively, it could also be that other co-stimulatory molecules are 
preferentially stimulated which increase concentrations of anti-inflammatory cytokines 
or downregulate inflammatory cytokines in immune individuals. Engagement of 137-2 
stimulates the production of IL-4 (104), and engagement of CTLA-4/CD28 induces 
TGF-13 and has been found to decrease proliferative responses and IFN-y production by 
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T cells (52). CD40/CD40L stimulates both Thi and Th2 cytokines (259, 271), but is 
absolutely needed for optimal production of Th2 cytokines (271). 
Additionally, co-stimulatory molecules are bi-directional in that they stimulate 
antigen presenting cells as well as T cells. Ligation of CD40 stimulates growth and 
differentiation of B cells, isotype switching and stimulates Mo production of IL-1 and 
TNF-cc(259). Thus an Ab-mediated or pro-inflammatory mediated response may 
depend on the type of antigen presenting cell. Further studies are required to 
determine if there are differences in co-stimulatory molecules and antigen presenting 
cells which present malaria antigens in naïve, exposed and immune populations. 
8.4.3.2 Other inflammatory cytokines: IL-15 and IL-18 
In this study, it has been demonstrated that IL-12 regulates IFN--y production. 
However, neutralising cdL-12 only partially decreased IFN-y levels in cells from exposed 
individuals and some naïve individuals, suggesting either that there are IL-1 2 
independent cellular sources of IFN-y or that other cytokines also mediate IFN-y 
production. Both IL-15 and IL-18 are produced by Mo and may play an important role 
in stimulating the inflammatory response during malaria infection. IL-15 is a potent 
stimulator of IFN-y from NK cells (160, 325) and y+ T cells (106). IL-15 is more 
important than IL-2 in localised stimulation of T cells (325) and has also been shown to 
increase the cytolytic function of CD8+ cells (160). It could be that the increase in the 
absolute numbers and proportions of CD8+ cells found in exposed individuals is 
mediated by IL-15 production and that the expansion of these CD8+ cells is indicative 
of a beneficial Ag-specific IFN-y-mediated response in localised areas where infection is 
present. 
IL-18 also stimulates IFN-y production from NK cells (179, 232, 249, 250). It is a 
more potent inducer of IFN-y than IL-12 and may be the cytokine which is stimulating 
IL-12 independent IFN--y from cells of some naïve and exposed individuals (249). IL-18 
can also synergise with IL-12 to enhance IFN-y levels (232). Although no studies have 
measured IL-15 and IL-18 levels in malaria models, it is possible that the insignificant 
differences detected in IL-12 production between cells of naïve, exposed and immune 
populations are real; levels of IL-12 produced are similar in all groups and that 
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differences in IL-15 or IL-18 may be more important than IL-12 in regulating IFN-i 
production by cells from naïve and exposed individuals. 
8.4.4 How is the inflammatory response downregulated? 
This project primarily focused on the role of inflammatory cytokines and only 
hypothesised on what role anti-inflammatory cytokines may play in malaria infection. 
This study has led to the suggestion that one of the mechanisms which is involved in 
the development of clinical immunity to malaria is the downregulation of inflammatory 
cytokines. IL-1 0 levels were low or undetectable in all cultures and no differences were 
observed between groups, suggesting that IL-1 0 does not play a major role in the 
downregulation of IFN-y. A prime candidate which can downregulate inflammatory 
responses that has not been examined in these individuals is TGF-13. TGF-13 levels are 
inversely correlated with the degree of severity in murine malaria (252) and lower 
circulating levels of TGF-3 have been found in individuals with acute P. falciparum 
malaria than in convalescent patients (355). TGF-J3 can either directly downregulate IL-
12 mediated IFN--yproduction by reducing IL-12R expression on T cells [Gorham, 1998 
#447] or downregulate the downstream effects of IFN-y without necessarily affecting 
IFN-y concentrations. In mice, TGF-P was found to decrease TNF-a concentrations 
without having any significant effect on IFN-y levels (252). If TGF-P is upregulated in 
exposed individuals this may explain why exposed individuals can produce significantly 
higher levels of IFN-i without necessarily being more susceptible to severe malaria than 
naïve individuals. 
TGF-13 is pro-inflammatory at low concentrations and anti-inflammatory at high 
concentrations (251). Thus, a balance in concentration, location and timing of TGF-J3 
production and activation will determine whether TGF-P is pathogenic or not. If low 
levels of TGF-13 can be stimulated early during acute P. falciparum infection, it could 
possibly aid parasite clearance by stimulating pro-inflammatory cytokines and 
upregulating FcyRlll on monocytes leading to the phagocytosis of infected RBCs (251). 
Later on in infection, high doses of TGF-P could down-regulate excessive inflammatory 
cytokines and thus prevent much of the immunopathology. 
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8.4.5 The cellular response in the exposed and immune individuals 
A more thorough examination needs to be carried out in immune individuals of 
which cellular subsets are expanded in response to PfSE. Although the proportions of 
T, B and NK cells were examined in cells from immune individuals, it is not known 
whether they also have a similar expansion of CD8+ cells as found in exposed 
individuals. If immune individuals do make a CD8+ response, it would imply that Ag-
specific T cell IFN-,y production is beneficial and that IFN-y production from polyclonally 
activated CD4+ cells (such as in naïve individuals) may be harmful. On the contrary, if 
immune individuals did not have a similar expansion of CD8+ cells, and as innate NK 
cell IFN-y responses seems to persist in all 3 groups, it may be that IFN-y production by 
T cells may exacerbate infection whereas IFN-.y production by NK cells is beneficial. 
Although it was determined that NK, c43 + and y+ cells produce IFN-y in naïve 
individuals, it is still unknown which cell populations produce IFN-y in exposed and 
immune individuals. In order to answer these questions, it is important to take time in 
choosing and developing the appropriate assay. Intracellular cytokine staining is a 
method which detects cytokine production at the single cell level. Although ICS cannot 
measure the exact concentrations of cytokines produced, it can determine the numbers 
and phenotype of cytokine producing cells. This approach may in fact be better than 
ELISA assays which can only measure the sum total of production, consumption and 
degradation of secreted cytokine, and thus may not represent the total amount of 
biologically active cytokine produced (47, 99, 357). This is a well recognised problem 
for measurement of cytokines which are quickly bound and internalised by cells such as 
IL-2 (1). Although RT-PCR is also used to measure cytokine concentrations, RNA 
transcripts do not necessarily correlate with the amount of protein synthesised (47, 99, 
357). A good example of this is TGF-13 where most cells constitutively express TGF-
transcripts, and its activity is modulated by post-translational processing of an inactive 
precursor molecule (348). However, ICS assays need to be carefully optimised for 
each cytokine measured. It has been found that different reagents, concentrations of 
reagents and incubation times (83, 246) need to be used depending on the cytokine 
measured as well as the type of cell being examined (83, 303). 
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8.4.6 Genetic regulation 
Although immune individuals generally had low IFN-y levels, cells from a number 
of immune individuals produced significant levels of IFN--y. Because there were no 
apparent sociological differences between any of the individuals, it could be that 
differing levels of IFN-y reflect different levels of immunity. Alternatively, it could be 
hypothesised that these individuals are all equally immune but that there are different 
strategies for attaining clinical immunity (i.e. decreasing IFN-y itself or its downstream 
effects). A last consideration is that there may also be genetic differences which control 
the immune response. 
A number of studies support the idea that differences in genetic regulation 
control immune responses. Differences were found in the susceptibility to P. yoeIii 
between different strains of mice (310). In humans, many polymorphisms have been 
described in cytokine genes which have been shown to affect cytokine levels and 
disease susceptibility. For example, high IL-1 0 production was correlated with certain 
haplotypes (90). Additionally, children who were homozygous for TNF2, an allele of the 
TN F-a gene promoter region, were more susceptible to cerebral malaria (224). 
Humans are not genetically identical, thus more work needs to be done in order to 
determine if there are heritable factors which cause each individual to respond 
differently to malaria infection. 
In conclusion, malaria is a complex disease which stimulates different 
immunological responses depending on levels of acquired immunity. There is likely to 
be a critical balance in the site and the timing of cytokine production and in the cellular 
sources of cytokines which determines if the immune response is beneficial or 
pathogenic. Although I have begun to elucidate some of the immune mechanisms 
involved in P. falciparum infection, not enough is known about how immune mediators 
function in malaria infections. If serious thought is to be given to malaria vaccine 
development, more studies need to be done on the critical immune mechanisms which 
mediate both protection and clinical immunity. 
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Appendix 1 
Table A1.1: Complete RT-PCR results for naïve study population. 
no RT= no reverse transcription. 
+ = band of correct size detected. 
- no band/ no band of correct size. 
ND= not done. 
Controls 
Blank 	-tin - 
IL-12 - 
Blank-cDNA 	3-tin  ND 
IL-12 ND 
Plasmid 	3,-actin ND 
IL-i2 ND 
Controls 
Blank 	ji-actin - 
IL-12 - 





Blank 	It-actin - 
IL-12 - 
Blank-cDNA 3-actin-  
IL-12 - 
Plasmid 	P-ad + 
IL-12 + 
Controls 
Blank 	fl-wt - 
IL-12 - 
Blank-cDNA 3-atm - 
IL-12 - 
Plasmid 	3-atm + 
IL-i2 + 
a) Ni 
Stimulus 	cDNA 	1 2 4 	6 	8 
ABCfl-actin + + + + + 
RBC-noRT 	-actin 	- + + 	+ 	- 
RBC 	IL-12 - + - - - 
RBC-noAT IL-12 
PtSE 	-tin 	+ + + 	+ 	+ 
PfSE-no F1T fl-actin - + + - - 
PISE 	IL-12 	+ + + 	+ 	- 
PISE-noAT 1-12 
Stimulus cDNA 1 2 4 6 8 
ABC 	fl-actin+ + + + + 
ABC-no AT fl-atm 
ABC 	IL-12 
RBC-no F-if IL-12 
PtSE 	3-atm 	+ + + + 
PtSE-no AT fl-atm - - - 	- - 
PfSE 	IL-12 
PtSE-noAT IL-12 
PHA 	3-actin + + + + + 
PRA-no AT 1-atm 	- - - + + 
PHA 	IL-12 + - - - - 
PRA-noFif IL-12 
N5 
Stimulus cDNA 1 2 4 6 8 
ABC 	fl-atm + + + + + 
RBC-noRT 3-atm 
ABC 	IL-12 
ABC-no AT IL-12 
ME 	fl-actin+ + + + + 
PfSE-no AT fl-actin  
PISE 	IL-12 
PfSE-noRT IL-12 	- - 	- + - 
PHA 	fl-actin+ + + + + 
PHA-no AT [-actin  
Pt-IA 	lL-12 
PHA-no Al IL-12 
g)N13 
Stimulus 	cDNA 	1 	2 
Day 
4 	6 
ABC 	fl-actin+ + + . 
RBC-noAT 	fl-actin - 	- + 	- 
ABC 	IL-12 	- - + - 
ABC-no AT IL-12 - 	- - 	- 
PISE 	3-actin+ + + + 
PtSE-no AT 3-atm 	- 	- - 	- 
PfSE 	IL-12 - - + - 
PISE-noFff 1-12 	- 	- - 	- 
LPS 	fl-actin + + + + 
LPS-noRT 	fl-actin - 	- - 	- 
LPS 	IL-12 	- + + + 
LPS-noRT 	IL-12 + 	- - 	- 
bl N2 
Stimulus 	cDNA 1 2 	4 	6 	8 
ABC 	fl-actin + + + + + 
ABC-noRT 	fl-actin + + 	- + 	- 
ABC 	IL-12 
ABC-no AT 	IL-12 
PtSE 	3-actin+ + 	+ 	+ 	+ 
PISE-no AT 	3-atm 





1 	2 	4 	6 	8 
ABC fl-actin+ + + + + 
ABC-no AT fl-actin  
ABC IL-12 + 	- 	- 	- 	- 
ABC-no AT IL-12 
F-tEE 1-atm + 	+ 	+ 	+ 	+ 
PfSE-no AT fl-actin  
PtSE IL-12 + 	- 	- 	- 	- 
PISE-no AT IL-12 
PHA fl-actin+ + 	+ 	+ 	+ 
PHA-no AT 1-actin 
PHA IL-12 + 	- 	- 	- 	- 
PHA-noRT IL-12 
i) N12 
Stimulus cDNA 1 	2 
Day 
4 6 
ABC fl-atm + + + + 
ABC-no AT fl-atm - 	- - - 
ABC lL-12 + - - - 
ABC-no AT IL-12 + 	- - - 
PfSE fl-actin+ + + + 
PfSE-no AT fl-atm - 	- - - 
PISE IL-12 - - + - 
PtSE-noAT JL-12 - 	- - - 
LPS 3-atm + + + + 
LPS-noRT fl-actin + 	- + - 
LPS IL-12 - - - + 




1 	2 	4 	6 
ABC fl-atm + + + + 
ABC-no AT fl-actin -  - 	- 	- 
ABC IL-12 - 	- - - 
RBC-noAT IL-12 - - 	- 	- 
PtSE fl-actin -  + + + 
F-tEE-no AT fl-actin -  - 	- 	- 
ABE IL-12 - 	+ - - 
PtSE-no AT IL-12 - - 	- 	- 
LPS fl-attn + + + + 
LPS-noRT fl-actin -  - 	- 	- 
LPS IL-12 + + - - 
LPS-noRT IL-12 - 	- 	- 	- 
Controls 
Bank 	fl-actmn - 
IL-12 - 
Blank-cDNA 	fi-actin ND 
IL-12 ND 
Plasmid 	fi-actin ND 
IL-12 ND 
Controls 
Blank 	[3-actin - 
IL-i2 - 
Bank-cDNA fl-actmn - 
IL-12 - 
Plasmid 	f3-actin + 
IL-12 + 
Controls 
Bank 	fl-actmn - 
IL-12 - 
Bank-cDNA fi-actin - 
IL-12 - 
Basnild 	fl-actmn + 
IL-12 + 
Controls 









Bank 	13-an 	- 
IL-12 - 
Bank-d4A 3-aim 	- 
IL-12 - 
Piid 3-aim + 
IL-12 + 
itro1s 
Blank 	3-an - 
IL-12 	- 
Blank-dNA P-actin - 
IL-12 	- 
RrTid 	3-an + 
IL-12 + 
SInUus cDNA 1 2 4 6 
FC 	13-actin + + + + 
FC-roRr 1 - n - 	- 	- 	- 
FeC 	IL-12 - - - - 
Fec-rio FTIF IL-12 	- 	- 	- 	- 
RISE 	-actin + + + + 
RISE-rio RI 13-actin - 	- 	- 	- 
PISE 	IL-12 - - + - 
PISE-noFff IL-12 	- 	- 	- 	- 
LIPS 	-actin + + + + 
LPS-noRr p-actin - - - - 
LIDS 	IL-12 + - - - 
LPS-noRI IL-12 - - - - 
Sdmuits 	cDNA 1 2 	4 	6 
FC 	3-actin + + + + 
FeC-no RI 	I3-actin - - 	- - 
FC 	IL-12 + - + 	- 
FeC-noRI IL-12 + + - - 
PISE 	13-aim + + 	. . 
RISE-no RT 3-aim - - - - 
PISE 	IL-12 - - 	- - 
ISE-noFr IL-12 + - - - 
LIDS 	13-an + + 	. + 
LPS-ncI 	fraimn - - - - 
LIDS 	IL-12 + - 	+ 	+ 
LPS-ncfTr 	IL-12 - - - + 




k)N17  1) N18 
Day  Controls Day  
Slimtus 	cDNA 1 	2 	4 	6 Blank 	p-actin 	- Stinilus 	cDNA 1 2 	4 	6 
FeC 	13-aim + + + + IL-12 - FUC 	13-aim + + + - 
FeC-no RI 13-aiiri - 	- - 	- Blank-cDNA 13-aim 	- FeC-no RI 13-aim - - 	- - 
FC 	IL-12 + + - - IL-12 - FeC 	IL-12 - - - - 
FeC-no FIr IL-12 - 	- - 	- PIrrid 	13-aim 	+ FeC-no RI 	IL-12 - - 	- - 
RISE 	13-aim + + + + IL-12 + RISE 	J3-aiin + + + 	+ 
RISE-no RT 13-aim - 	- - 	- PISE-rio Fr 	3-aim - - 	- - 
RISE 	IL-12 + + - - RISE 	IL-12 - - + 	- 
RISE-no FTr IL-12 - 	- + 	- PISE-rioRr IL-12 + - 	+ + 
LIDS 	13-aim + + + + LIDS 	3-aim F'L) + + 	+ 
I_PS-noIRI 	13-aim - 	- - 	- LPS-noRI 	f3-actin - - 	- - 
LIDS 	IL-12 + - - - LIDS 	IL-12 - + - - 
LPS-rioFff 	IL-12 - 	- - 	- LPS-noFI 	IL-12 - - 	- - 
M) N19 
Day Controls 
Slirntius 	cDNA 	1 	2 	4 	6 a,k 	f3-actin 	- 
FC 	f3-aiin + + + + L-12 - 
FEC-no RI 	3-aim 	- 	- - 	- Blank-cCNA 3-actin-  
FEC 	IL-12 - - - - IL-12 	- 
FEC-no RI IL-12 	- 	- - 	- Pnd 	f3-actin + 
PISE 	f3-aiin - + + + IL-12 	+ 
PISE-no RI 3-aim 	- 	- - 	- 
RISE 	IL-12 + - - - 
RISE-no RI IL-12 	- 	- - 	- 
LIPS 	13-aimrl . + . + 
LPS-noRI 	f3-actin 	- - 	- - 
LIDS 	IL-12 + - - - 
LPS-ncRIT 	IL-12 	- 	- - 	- 
Ccntrols 
Blank 	f3-actin - 
IL-12 	- 
aik-cct'IA f3-aimn - 
IL-12 	- 
Raid 	13-actin + 
IL-12 	+ 
204 
Table A1.2: Complete RT-PCR results for exposed study population. 
no RT= no reverse transcription. 
+ = band of correct size detected. 
- no band/ no band of correct size. 
ND= not done. 
a) El  b)E2  
Day Controls Day Controls 
Stimulus 	cDNA 1 	2 4 	6 8 Blank 	-actin Stimulus 	cDNA 1 	2 4 	6 8 	Blank 	3-actin 	- 
ABC 	13-tin + + + + + IL-12 ABC 	3-actin + + + + + IL-12 - 
RBC-no RI 	3-actin - 	- - 	- - Blank-cDNA 	3-actin ARC-no RI 3-actin - 	- - 	- - 	Blank-cONA 3-actin 	- 
ARC 	IL-12 IL-12 ARC 	IL-12 IL-12 - 
RBC-noRI IL-12 - 	- - 	- - Rasmai 	3-actin + RRC-'no 	IL-12 - 	- - 	- - 	Plasmid 	t-actin 	+ 
PfSE 	3-actin + + + + IL-12 + PfSE 	3-actin + + + + + IL-12 + 
PfSE-no RI 3-actin PfSE-no RI 13-actin 
F'ISE 	IL-12 PfSE 	IL-12 
PfSE-no RI IL-12 PfSE-no RI IL-12 
LPS 	3-actin + 	+ + 	+ + LPS 	3-actin + 	+ + 	+ + 
LPS-noRT 	3-actin LPS-noRT 	3-actin 
LPS 	IL-12 LPS 	IL-12 
LPS-noRT 	IL-12 LPS-noRT 	IL-12 
c)E3  d)E5  
Day Controls Day Controls 
Stimulus 	cDNA 1 	2 4 	6 8 Blank 	3-actin Stimulus 	cDNA 1 	2 4 	6 8 	Blank 	3-actin 	- 
RBC 	3-actin + + + IL-12 ABC 	3-actin + + + + + IL-12 - 
RBC-no RI 	3-actin - 	- - 	- - Blank-cDNA 	3-actin ABC-no RI 	3-actin - 	- - 	- - 	Blank-cDNA 3-actin 	- 
ABC 	IL-12 IL-12 ABC 	IL-12 IL-12 - 
RBC-noRI IL-12 - 	- - 	- - Plasmid 	3-actin + RBC-noRI IL-12 - 	- - 	- - 	Plasniid 	3-actin 	+ 
PfSE 	3-actin + + + + + IL-12 + PfSE 	3-actin + ND + + + IL-12 + 
PfSE-no RI 	3-actin PISE-no RI 	3-actin 
PfSE 	IL-12 PISE 	IL-12 
PISE-noRI IL-12 PfSE-no RI IL-12 
LPS 	3-actin + 	+ + 	+ + LPS 	3-actin + 	+ . 	+ + 
LPS-noRT 	3-actin LPS-noRT 	3-actin 
LPS 	IL-12 LPS 	IL-12 + 	- - - 
LPS-noRT 	IL-12 LPS-noRT 	IL-12 
e)E6  E7  
Day Controls Day Controls 
Stimulus 	cDNA 1 	2 4 	6 8 Blank 	3-actin Stimulus 	cDNA 1 	2 4 	6 8 	Blank 	3-actin 	- 
ABC 	3-actin + + + + + IL-12 ABC 	3-actin + + + ND + IL-12 - 
ABC-no RI 3-actin - 	- - 	- - Blank-cONA 3-actin ABC-no RI 	3-actin - 	- - 	ND - 	Blank-cDNA 3-actin 	- 
ABC 	IL-12 IL-12 ABC 	IL-12 - - - ND - IL-12 - 
ABC-no RI 	IL-12 - 	- - 	- - F'lasmid 	3-actin + ABC-no RI 	IL-12 - 	- - 	ND - 	Plasmid 	3-actin 	+ 
PfSE 	3-actin + + + + + IL-12 PfSE 	3-actin + + + + + IL-12 + 
PfSE-no RI 3-actin PISE-no RI 3-actin 
PfSE 	IL-12 PfSE 	L-12 
PISE-no RI IL-12 PISE-no RI IL-12 
LPS 	3-actin + 	+ + 	+ + LPS 	3-actin + 	+ + 	+ + 
LPS-noRT 	3-actin LPS-noRT 	3-actin 
LPS 	IL-12 LPS 	IL-12 
LPS-noRT 	IL-12 LPS-noAT 	IL-12 
g)E8  h)E9  
Day Controls Day Controls 
Stimulus 	cDNA 1 	2 4 	6 8 Blank 	3-actin Stimulus 	cDNA 1 	2 4 	6 8 	Blank 	3-actin 	- 
RBC 	3-actin + + + + IL-12 ARC 	3-actin + + + + + IL-12 - 
ABC-no RI 	3-actin  - 	- - 	- - Blank-cDNA 3-actin ABC-no RI 3-actin - 	- - 	- - 	Blank-cDNA 3-actin 	- 
ABC 	IL-12 IL-12 ABC 	IL-12 + + + - L-12 - 
ABC-no RI IL-12 - 	- - 	- - F'lasntd 	li-actin + ARC-no RI 	IL-12 - 	- - 	- - 	Plasmid 	3-actin 	+ 
PfSE 	3-actin + + + + + IL-12 + PISE 	3-attn + + - + + IL-12 + 
PfSE-no RI 3-actin ----- PfSE-no RI 	3-actin 
PfSE 	IL-12 + 	- - 	- ABE 	IL-12 + 	- - 	- - 
PfSE-noAI IL-12 - - - - - PISE-noRI IL-12 
LAB 	3-actin + 	+ + 	+ + LAB 	3-actin + 	- - 	- - 
LPS-noRT 	3-attn - - - - - LPS-nofff 	3-actin 
LPS 	IL-12 + 	- - 	- - LAB 	IL-12 + 	+ + 	+ - 
LPS-noRT 	IL-12 _____ LPS-noRT IL-12 
Table A1.2 (continued): 
flElO 
Sinidus cU1P 1 2 4 6 8 
F 	-in + + + 	+ 
FnoRT 13-ain - - - - - 
FB 	IL-12 
FoFW IL-12 
PfSE 	[3-ain + + + + + 
PfSE-ro FIT -n - - - - - 
PISE 	IL-12 
PfSE-roRr IL-12 
LPS 	-tin + + + + + 




Slinüus 	cW. 	1 2 	4 	6 8 
FBf3-actin + + + + + 
F-noHr 	f3-actin 	- - 	- - 	- 
FB 	IL-12 + + + - 
FBKFff IL-12 
PfSE 	3-aiin 	+ + 	+ + 	+ 
PISEmHr I3-an - - - - - 
PfSE 	IL-12 + 	+ 
PfSE-rtRf IL-12 
LPS 	f-ain 	+ + 	+ + 	+ 
LPS-ncftl 	3-actin - - - - - 
LFS 	IL-12 	+ + 	+ + 	+ 
LPS-rdRT 	IL-12 
m) E15 
Sfinxdus cU4A 1 2 4 6 8 
F8C 	fl-actin + + + + + 
FfoFff Il-aim 	- + - - + 
FOC 	IL-12 
F,noFff [-12 
PfSE 	3-aim + + + + + 
PfSBroRr [-actin - - - + - 
PfSE 	IL-12 
PfSE-roFff IL-12 





Sfinvulus ca4P 1 2 4 6 8 
FB 	I3-amn- -+++ 
FBnoR{ fl-actin  
FBC 	IL-12 
FBoFff IL-12 








j) Ell  
Qrdrds Day Controls 
a< 	Il-aim - Stimulus 	cA 1 2 	4 6 8 	Bark 	Il-aim - 
IL-12 - F13C 	0-actin + + + + + IL-12 - 
Hank-dA 13-aimn - FRoFff 3-aimn - - 	- - - 	Ba-k-ca' 	3-aim - 
IL-12 - FUC 	IL-12 + + - IL-12 - 
Hn1d 	13-aim + FBxRr IL-12 - - 	- - - 	Rid 	13-aim + 
IL-12 + PfSE 	13-aim + + + + + IL-12 + 
PtSEORr I3-aii  - - 	- - - 
PfSE 	IL-12 
PfSE-mFff IL-12 
LPS 	13-aim + + 	+ + 
LPS-ncfff 	3-aim 
IFS 	IL-12 + + 
LPS.-xRT 	IL-12 
I) E14  
cairds [y Controls 
Bank 	13-actin - Stimulus 	cU4A 1 2 	4 6 8 	Baic 	13-aim - 
IL-12 - FUC 	13-actin + + + + + [-12 - 
BaE-d'JA 3-aim - FBTh0RT 13-actin - - 	- - - 	--k-cCN 	[-actin - 
IL-12 - FB 	IL-12 IL-12 - 
Rn1d 	h -aim + FB-roRT IL-12 - - 	- - - 	Riid 	13-aim - 
IL-12 - PfSE 	13-aim + + + + + IL-12 + 
PfSE-mHT 13-aimn - - 	- - - 
PfSE 	[-12 
PfSE-roEff IL-12 





Controls pay   Controls_________________ 
Baik 	13-aim + StindLs 	cWA 1 2 	4 6 8 	Baic 	13-aim - 
IL-12 - Fe 	13-aim + + + + + IL-12 - 
Bank-dA [3-actin - FioFff 13-aim------Baic-dYk 13-actin- 
IL-12 - RBC 	IL-12 IL-12 - 
Ran-id 	[3-aim + F-noFff 	[-12 - - 	- - - 	Ranid 	13-almn + 




LIDS 	13-atm + + 	+ND+ 
LPS-rdff 	13-aim - - - ND - 
IFS 	IL-12 - - 	- ND - 
LPS-fW 	IL-12 - - - ND - 
p) E18  
cairds Day Qilrds 
Bank 	13-aimn - StinIiLs 	cU1A 1 2 	4 6 8 	Baic 	13-aim - 
IL-12 - F 	3-aim + + + + + L-12 - 
Baic-dA 13-aimn - FBRT 13-am + + 	Baic-d(k 13-atm - 
IL-12 - FBC 	IL-12 + - - [-12 - 
Ranid 	13-aimn - FThoRT IL-12 - - 	- - - 	Ranid 	13-aim + 
IL-12 + PfSE 	13-aim + + + + + IL-12 + 
PfSE-noRf 13-aim + - 
PfSE 	IL-12 + - 
PfSEnFff IL-12 
LPS 	13-almn + + 	+ + + 
LPS-rRr 	13-aimn + + + - 
LPS 	IL-12 + - 
LPS-rdff 	IL-12 
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Sthnli.s cU4A 1 2 4 6 8 








LPS 	1-in + + + + + 




Bank 	3-in - 
IL-12 	- 
Bank-ccNA 13- n 
IL-12 
RnId -n + 
L-12 + 
Sliniius ca4A 1 2 4 6 8 




PfSE 	-n + + + + + 
PfSE-no RI -ain 
PfSE 	IL-12 
PtSE-noRI IL-12 
LPS 	f3-in + + + + + 








Plasrid 	-fin + 
IL-12 + 
s)E21  t) E22  
Day Cc*lrols pay ODttrs 
SUmdus 	ct1JA 1 	2 	4 	6 	8 Bank 	13-tin Sfimdus 	cI4A 	1 	2 	4 	6 	8 Bank 	3-Win 	- 
FB 	I3-Win + + + + + IL-12 FB 	13-Win + + + + + IL-12 - 
FB-no RI 	-in Bank-dN 	3-an F&-no RI f3-Win 	- - 	- 	- 	- Bank-cCNA 13-in 
FDC 	IL-12 IL-12 FBC 	IL-12 - - - - - IL-12 
F-no RI 	IL-12 Rasid 	13-±in 	+ FL)no RI 	IL-12 	- 	- 	- 	- 	- Raaiid 	3-Win 	+ 
PfSE 	13-aiin + 	+ 	+ 	+ 	+ IL-12 + PfSE 	13-Win + + + + + IL-12 + 
PfSE-fo RI 3-atin PfSE-no FR 	-in 
RISE 	IL-12 + 	- 	- 	- RISE 	IL-12 	- 	- 	+ 	- 
RISE-no RI IL-12 RISE-no RI IL-12 
LPS 	f3-Win + 	+ 	+ 	+ 	+ LPS 	P-atin 	+ 	+ 	+ 	+ 	+ 
LPS-ncFT 	f3-Win - LPS-ncRI 	[3-Win 
LPS 	IL-12 + 	- 	+ LPS 	IL-12 	+ 	- 	- 	- 	- 
LPS-ndRT 	IL-12 LPS-ncfff 	IL-12 
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Day Cortrds 
S&i,Jus 	cI'1A 	1 	2 	4 	6 	8 Bank 	f3-&n 	- 
F6C 	 + + + + + IL-12 - 
F8GioRr 	-ain 	- - 	- 	- 	-aik-cct'A 3-an 	- 
F43C 	IL-12 IL-12 - 
F43GnoRT IL-12 	- 	- 	- 	- 	- Rnd 	-ain 	+ 
PfSE 	Padin + + + + + IL-12 + 
PISE-noRl [3-Win 	- - 	- 	- 	- 
PfSE 	IL-12 
PISE-noRT IL-12 
[PS 	I3-anND+ 	+ 	+ 	+ 
LPS-nofff 	I3-actin ND - 
LPS 	IL-12 	ND 	 - 
LFS-rtfff 	[-12 ND - 
itnIs 
StinUus c14A 1 	2 	4 6 	8 
F4BC 3-adinND+ + + -4- 
F3GnoRr I3-an ND 	- - - 	+ 
FIBC [-12 ND - - - - 
F3C-noRt IL-12 ND 	- - - 	- 
PfSE 3-an ND+ + + + 
PtSE-noRT f3-actin ND 	- - - 	- 
PISE IL-12 ND - - - - 
PfSEnoRT IL-12 ND 	- - - 	- 
LPS -nND+ + + + 
[PS-ncRt 13-actin ND + 	- - 	- 
[PS IL-12 ND - - - - 
LPS-noRV IL-12 ND 	- - - 	- 
Bank 	13,Win - 
[-12 - 
a'kdNA 3-n - 
[-12 - 
Rd 3-aim + 
[-12 + 
Table A1.3: Complete RT-PCR results for control individuals. 
no RT= no reverse transcription. 
+ = band of correct size detected. 
- = no band/ no band of correct size. 
ND= not done. 
MM 	 b) 
04 
Day ntrcs 
Sinius 	cl'1A 	1 2 	4 	6 	8 Bank 	J3-atin 	- 
FBC 	-Win + 	+ + + + IL-12 - 
F8C-no AT 	-n - - 	- 	- 	- Bk-dNA f-aiin 	- 
FC 	[-12 I[-12 - 
F8C-noFff 	IL-12 	-----P1nid J3-Win 	+ 




[PS 	IE'-adinND+ 	+ 	+ 	- 
LPS-rRT 	-adin ND - 
LPS 	I[-12 	ND 	 - 
LPS-noJff 	I[-12 ND - 
Appendix 2 
Table A2.1: Complete lymphoproliferative results for PBMCs of naïve individuals by 
day. Data is given in geometric mean cpm (left-hand tables), and SI (PfSE = 
PfSE/uRBC, PHA = PHNuRBC, right-hand tables)(ND= not done). 
a) Day 1 
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 398 331 547 Ni 1 1 
N2 303 174 470 N2 1 2 
N3 667 600 794 N3 1 1 
N4 908 830 1055 N4 1 1 
N5 600 489 1606 N5 1 3 
b) Day 2 
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 431 794 72158 Ni 2 167 
N2 221 491 71656 N2 2 324 
N3 730 1048 38149 N3 1 52 
N4 1102 1101 59626 N4 1 54 
N5 359 466 32188 N5 1 90 
c) Day 3 
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 89 2282 41677 Ni 26 467 
N2 86 2519 31224 N2 29 365 
N3 1093 1606 72535 N3 1 66 
N4 925 1274 92917 N4 1 100 
N5 479 1934 91055 N5 4 190 
N6 794 911 40866 N6 1 51 
N7 576 642 55953 N7 1 97 
N8 488 1252 38725 N8 3 79 
N9 515 853 41170 N9 2 80 
N10 498 717 57674 N10 1 116 
Nil 561 740 47383 Nil 1 85 
N12 406 805 58313 N12 2 144 
N13 246 375 16725 N13 2 68 
N14 144 187 24496 N14 1 170 
N15 233 318 18379 N15 1 79 
N16 47 lii 14449 N16 2 310 
N17 39 50 19073 N17 1 485 
N18 85 394 19200 N18 5 226 
N19 22 84 27230 N19 4 1221 
d) Day 4 
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 414 5592 93653 Ni 14 226 
N2 164 7249 104946 N2 44 639 
N3 1226 3083 96277 N3 3 79 
N4 930 2388 96082 N4 3 103 
N5 648 3061 72597 N5 5 112 
'I. 
Table A2.1 (continued): 
e) Day 5 
Donor RBC PISE PHA Donor PfSE PHA 
Ni 554 11151 ND Ni 20 ND 
N2 372 21461 90289 N2 58 242 
N3 1347 3881 107932 N3 3 80 
N4 731 2170 58922 N4 3 81 
N5 712 4508 53713 N5 6 75 
N6 988 2473 26546 N6 3 27 
N7 738 3071 18139 N7 4 25 
N8 1005 4388 34026 N8 4 34 
N9 685 4516 33719 N9 7 49 
N10 745 2758 21438 N10 4 29 
Nil 668 4052 41493 Nil 6 62 
N12 616 11322 17051 N12 18 28 
N13 543 1346 10303 N13 2 19 
N14 108 324 33284 N14 3 308 
N15 48 477 10410 N15 10 219 
N16 62 317 4427 N16 5 72 
N17 28 361 10603 N17 13 379 
N18 36 2036 7414 N18 56 203 
N19 50 940 6505 N19 19 131 
f) Day 6  
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 2183 27706 30434 Ni 13 14 
N2 632 58520 49461 N2 93 78 
N3 1296 4980 47210 N3 4 36 
N4 1086 1627 16739 N4 1 15 
N5 1119 14313 27989 N5 13 25 
g) Day 7  
Donor RBC PfSE PHA Donor PISE PHA 
Ni 2077 36539 11494 Ni 18 6 
N2 797 49436 18652 N2 62 23 
N3 3081 14536 21516 N3 5 7 
N4 1279 13961 11928 N4 ii 9 
N5 1489 22477 13941 N5 15 9 
N6 1888 10924 6813 N6 6 4 
N7 941 7339 3363 N7 8 4 
N8 1316 11270 7821 N8 9 6 
N9 1117 12160 7818 N9 ii 7 
N10 1415 14039 6258 N10 10 4 
Nil 1012 23123 11285 Nil 23 ii 
N12 749 8925 1338 N12 12 2 
N13 186 1897 1927 N13 10 10 
N14 254 4846 14967 N14 19 59 
N15 141 4513 6542 N15 32 46 
N16 142 11348 1984 N16 80 14 
N17 244 6863 10794 N17 28 44 
N18 146 4566 2708 N18 31 19 
N19 437 12457 2900 N19 28 7 
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Table A2.1 (continued): 
h) Day 9  
Donor RBC PfSE PHA Donor PfSE PHA 
Ni 1610 17154 1916 Ni ii 1 
N2 536 26635 3439 N2 50 6 
N3 3077 13394 10386 N3 4 3 
N4 1678 15273 7033 N4 9 4 
N5 1864 10862 4162 N5 6 2 
N6 5567 9197 11343 N6 2 2 
N7 1563 45663 5012 N7 29 3 
N8 2308 55774 8834 N8 24 4 
N9 1889 18343 4114 N9 10 2 
N10 5309 23834 7007 N10 4 1 
Nil 3165 44769 10712 Nil 14 3 
N12 406 159 166 N12 0 0 
N13 474 566 458 N13 1 1 
N14 322 3989 4368 N14 12 14 
N15 475 4420 3490 N15 9 7 
N16 35 3619 683 N16 105 20 
N17 125 5779 3571 N17 46 29 
N18 574 3027 1672 N18 5 3 
N19 421 7212 1835 N19 17 4 
Table A2.2: Complete lymphoproliferative results for PBMCs of exposed individuals by 
day. Data is given in geometric mean cpm (left-hand tables), and SI (PfSE = 
PfSE/uRBC, PHA = PHAIuRBC, right-hand tables)(ND= not done). 
a) Day 2  
Donor R B C PfSE PHA Donor PfSE PHA 
El 19 25 ND El 1 ND 
E2 19 27 2017 E2 1 105 
E3 15 32 ND E3 2 ND 
E5 38 57 1146 E5 2 30 
E6 28 26 578 E6 1 21 
E7 29 66 4204 E7 2 145 
E8 15 45 2908 E8 3 198 
E9 81 164 2318 E9 2 29 
ElO 48 86 3104 ElO 2 64 
Eli 99 115 4225 Eli 1 43 
E12 24 60 2888 E12 3 121 
E14 61 76 6062 E14 1 100 
E15 26 64 4636 E15 2 179 
E16 39 58 4620 E16 1 118 
E 1 7 23 35 1 91 5 E 1 7 2 83 
E18 29 68 3888 E18 2 133 
E 1 9 28 65 1714 E 1 9 2 61 
E20 41 74 4854 E20 2 119 
E 2 1 21 21 841 E 2 1 1 41 
E22 22 43 2258 E22 2 102 
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Table A2.2 (continued): 
b) Day 3  
Donor RBC PfSE PHA Donor PfSE PHA 
El 24 42 ND El 2 ND 
E2 21 30 8982 E2 1 429 
E3 28 118 ND E3 4 ND 
E5 42 150 6291 E5 4 151 
E6 36 83 5115 E6 2 142 
E7 67 337 9750 E7 5 145 
E8 53 134 6424 E8 3 122 
E9 80 789 4303 E9 10 54 
ElO 147 646 12508 ElO 4 85 
Eli 77 345 13695 Eli 4 177 
E12 37 306 13851 E12 8 375 
E14 94 294 14932 E14 3 159 
E15 54 335 14660 E15 6 273 
E16 184 417 13682 E16 2 74 
E17 61 122 12801 E17 2 209 
E18 76 456 7372 E18 6 97 
E19 76 307 10797 E19 4 142 
E20 66 417 7982 E20 6 122 
E21 81 171 6457 E21 2 79 
E22 104 257 10723 E22 2 103 
c) Day 5  
Donor RBC PfSE PHA Donor PfSE PHA 
El 66 311 2712 El 5 41 
E2 40 130 4000 E2 3 100 
E3 109 633 2146 E3 6 20 
ES 119 912 5279 E5 8 44 
E6 109 679 5184 E6 6 48 
E7 346 2892 4471 E7 8 13 
E8 49 469 4797 E8 10 99 
E9 269 5382 4421 E9 20 16 
ElO 328 3397 2576 ElO 10 8 
Ell 226 1578 10180 Ell 7 45 
E12 140 1756 13139 E12 13 94 
E14 110 1576 11121 E14 14 101 
E15 103 1850 10342 E15 18 100 
E16 272 1394 4100 E16 5 15 
E17 115 1368 3911 E17 12 34 
E18 344 5873 8380 E18 17 24 
E19 239 2439 9150 E19 10 38 
E20 276 4284 5952 E20 16 22 
E21 ND 1332 5089 E21 ND ND 
E22 235 1209 2280 E22 5 10 
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Table A2.2 (continued): 
d) Day 7 
Donor RBC PfSE PHA Donor PfSE PHA 
El 151 1373 1010 El 9 7 
E2 54 345 637 E2 6 12 
E3 336 1851 909 E3 6 3 
E5 281 5127 714 E5 18 3 
E6 169 3273 942 E6 19 6 
E7 532 5770 966 E7 ii 2 
E8 59 1296 1618 E8 22 28 
E9 245 9809 2112 E9 40 9 
ElO 310 6207 845 ElO 20 3 
Eli 397 3335 2395 Eli 8 6 
E12 309 5305 2769 E12 17 9 
E14 139 6677 1456 E14 48 10 
E15 202 5584 1169 E15 28 6 
E16 652 4317 1037 E16 7 2 
E17 851 2622 1218 E17 3 1 
E18 440 9115 2345 E18 21 5 
E19 ND 7654 1110 E19 ND ND 
E20 809 6552 1379 E20 8 2 
E21 290 5609 1558 E21 19 5 
E22 374 3828 430 E22 10 1 
e) Day 9  
Donor RBC PfSE PHA Donor PfSE PHA 
El 315 1399 851 El 4 3 
E2 126 652 308 E2 5 2 
E3 341 1524 691 E3 4 2 
ES 973 6291 263 ES 6 0 
E6 679 4177 178 E6 6 0 
E7 1495 6780 381 E7 5 0 
E8 152 1683 1080 E8 ii 7 
E9 442 5368 600 E9 12 1 
Ell 1660 2737 747 Eli 2 0 
E12 792 4298 447 E12 5 1 
E14 251 6313 493 E14 25 2 
E15 480 6313 553 E15 13 1 
E18 1038 5361 509 E18 5 0 
E19 263 4098 580 E19 16 2 
E20 943 3152 577 E20 3 1 
E21 100 822 985 E21 8 10 
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Table A2.3: Complete lymphoproliferative results for PBMCs of immune individuals by 
day. Data is given in geometric mean cpm (left-hand tables), and SI (PfSE = 
PfSE/uRBC, PHA = PHA/CM (CM data not shown), right-hand tables)(ND= not done). 
a) Day 3 
Donor RBC PfSE PHA Donor PfSE PHA 
Ii 22 36 4609 Ii 2 355 
12 36 186 11576 12 5 252 
13 12 52 8447 13 4 881 
14 24 60 7031 14 2 347 
15 31 95 13871 15 3 420 
16 37 73 14961 16 2 405 
17 216 345 557 17 2 2 
18 32 71 24152 18 2 629 
19 58 91 34928 19 2 2071 
110 55 112 33922 110 2 428 
Ill 20 49 8528 Ill 2 966 
112 22 53 3842 112 2 186 
113 71 214 8618 113 3 93 
114 72 274 37243 114 4 458 
115 37 165 29109 115 4 821 
116 80 80 3986 116 1 48 
117 12 335 12624 117 27 633 
118 17 85 33959 118 5 1595 
b) Day 5 
Donor RBC PfSE PHA 
	
Donor PfSE PHA 
Ii 10 33 320 Ii 3 34 
12 59 670 2849 12 11 89 
13 48 368 15839 13 8 1014 
14 26 703 6003 14 28 224 
15 65 2081 41494 15 32 688 
17 67 1150 15133 17 17 270 
18 ND 338 39717 18 ND 39717 
Ill 27 155 25756 Ill 6 3021 
113 214 2738 8000 113 13 25 
114 328 1087 46856 114 3 340 
115 36 1046 34082 115 29 1376 
116 70 53 2723 116 1 75 
118 149 557 33125 118 4 354 
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Table A2.3 (continued): 
c) Day 7  
Donor RBC PfSE PHA Donor PfSE PHA 
Ii 16 92 2031 Ii 6 348 
12 117 11763 13733 12 100 112 
13 146 1413 20 13 10 0 
14 60 7186 31 14 120 1 
15 90 4896 18651 15 54 95 
16 99 294 13533 16 3 135 
17 206 7319 13819 17 36 82 
18 188 1977 9968 18 11 78 
19 481 1153 11974 19 2 18 
110 100 2493 15755 110 25 419 
Ill 92 439 15420 Iii 5 238 
112 143 547 12738 112 4 170 
113 1151 7712 5150 113 7 38 
114 442 7816 9893 114 18 47 
115 47 6358 17436 115 134 1378 
116 42 51 3251 116 1 127 
117 61 14005 11138 117 229 364 
118 99 1584 2557 118 16 16 
119 79 17095 7379 119 217 111 
120 23 952 3316 120 42 155 
Table A2.4: Complete lymphoproliferative results for PBMCs of naive individuals used 
as controls in Ghana by day. Data is given in geometric mean cpm (left-hand tables), 
and SI (PfSE = PfSE/uRBC, PHA = PHNuRBC, right-hand tables)(ND= not done). 
Day 2  
Donor ABC PfSE PHA Donor PfSE PHA 
C2 404 438 2873 02 1 7 
C4 24 58 4499 C4 2 191 
Day 3  
Donor ABC PfSE PHA Donor PfSE PHA 
C2 160 164 3967 C2 1 25 
C3 28 60 3882 C3 2 139 
C4 32 114 8257 C4 4 256 
C5 104 397 13252 05 4 129 
Day 5  
Donor ABC PfSE PHA Donor PfSE PHA 
02 73 196 2825 02 3 39 
C3 42 361 2741 03 9 65 
C4 135 935 7393 C4 7 55 
215 
Table A2.4 (continued): 
Day 7 
Donor RBC PfSE PHA 
C2 91 239 1142 
C3 65 986 1570 
C4 80 1310 3012 
C5 38 5561 3203 
Day 9 
Donor RBC PfSE PHA 
C2 207 1436 863 
C3 98 2186 487 
C4 187 1753 1265 
Donor PfSE PHA 
C2 3 13 
C3 15 24 
C4 16 38 
C5 146 17 
Donor PfSE PHA 
C2 7 4 
C3 22 5 
C4 9 7 
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Table A2.5: Kinetic timecourses of lymphoproliferative and IFN--y responses to PfSE of 
PBMCs from a) naIve, b) exposed and c) immune individuals (median (PfSE-uRBC) 
and range for IFN-y and geometric mean SI (PfSE/uRBC) and 95% Cl for 
lymphoproliferation. 
a) 
Proliferation data IFN-y data 
Day Stats SI Day Stats IFN-y (pg/rn I) 
3 Mean 2.4 2 Mean 6 
CI 1.5, 2.8 Range o, 382 
n 19 n 19 
5 Mean 7.5 4 Mean 32 
CI 4.6, 	12.1 Range 5, 1221 
n 19 n 19 
7 Mean 16.4 6 Mean 64 
CI 11.4, 23.7 Range 4,2216 
n 19 n 19 
9 Mean 9.2 8 Mean 76 
CI 4.8, 17.7 Range -0.5, 1072 
n 19 n 18 
Proliferation data 1FN-y data 
Day Stats Si Day Stats IFN-y (pg/rn I) 
2 Mean 1.7 1 Mean 2 
CI 1.5,2.0 Range -3,63 
n 20 fl 20 
3 Mean 3.6 2 Mean 19 
CI 2.8, 4.6 Range -2, 1517 
n 20 n 20 
5 Mean 9.0 4 Mean 504 
CI 7.0, 	11.5 Range 84382 
fl 19 n 20 
7 Mean 13.5 6 Mean 1089 
CI 4.0, 16.7 Range 13, 4985 
n 19 n 20 
9 Mean 6.7 8 Mean 1049 
CI 4.7, 9.6 Range -4, 5974 
fl 16.0 n 19 
C) 
Proliferation data IFN-y data 
Day 	Stats SI Day Stats IFN-y (pg/mi) 
3 Mean 2.9 2 Mean 2 
CI 2.0, 4.2 Range -2,442 
n 18 n 18 
5 	Mean 8.2 4 Mean 7 
CI 4.0, 16.7 Range 0.2, 82 
n 12 n 13 
7 	Mean 18.8 6 Mean 8 
CI 9.0, 39.2 Range -4, 705 
n 20 n 20 
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PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
Ni 40 ND ND 
N2 93 ND ND 
N3 1 ND -1 
N4 8 ND 5 
N5 5 ND 0 
N12 0 ND ND 
N13 0 ND ND 
N14 0 ND ND 
N15 1 ND ND 
N16 -1 ND ND 
N17 1 ND ND 
N18 ii ND ND 
N19 0 ND ND 
PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
Ni 78 ND ND 
N2 382 ND ND 
N3 25 ND 5 
N4 ii ND 1 
N5 16 ND 1 
N6 9 2 1 
N7 2 6 0 
N8 41 22 2 
N9 3 12 3 
NiO 7 -1 4 
Nil 6 -10 4 
N12 1 0 -i 
N13 3 1 1 
N14 0 -i -i 
N15 2 1 0 
Ni6 3 1 0 
Ni7 0 7 3 
N18 213 204 210 
Ni9 2 -i 0 
PfSE+ PfSE+ 
Donor PISE IgG cdL-12 
Ni ND ND ND 
N2 536 ND ND 
N3 57 ND 7 
N4 40 ND 5 
N5 46 ND 3 
Appendix 3 
Table A3.1: Complete IFN--y (pg/mi) results for PBMCs of naïve individuals by day. 
Data is given in arithmetic mean (left-hand tables) and malaria-specific responses 
(PfSE-uRBC, right-hand tables)(ND = not done). 
a) Day 1 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG uIL-12 PfSE IgG aIL-12 PHA IgG aIL-12 
Ni 54 ND ND 94 ND ND 525 ND ND 
N2 50 ND ND 144 ND ND 478 ND ND 
N3 72 ND 77 73 ND 76 84 ND 86 
N4 74 ND 82 82 ND 87 965 ND 540 
N5 73 ND 78 79 ND 78 164 ND 199 
N12 72 ND ND 73 ND ND ND ND ND 
N13 72 ND ND 72 ND ND ND ND ND 
N14 72 ND ND 72 ND ND ND ND ND 
N15 72 ND ND 74 ND ND ND ND ND 
N16 49 ND ND 48 ND ND ND ND ND 
N17 47 ND ND 49 ND ND ND ND ND 
N18 49 ND ND 60 ND ND ND ND ND 
N19 47 ND ND 47 ND ND ND ND - ND 
b) Day 2 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG cxIL-12 PfSE IgG (AL-12 PHA IgG (AL-12 
Ni 55 ND ND 133 ND ND 5494 ND ND 
N2 79 ND ND 461 ND ND 6122 ND ND 
N3 75 ND 77 100 ND 82 11897 ND 1678 
N4 74 ND 83 85 ND 84 12493 ND 1155 
N5 73 ND 78 89 ND 79 3379 ND 861 
N6 80 84 78 89 86 79 9309 10221 4412 
N7 81 94 82 83 99 82 5548 6655 913 
N8 73 80 78 114 102 81 7255 9978 2731 
N9 75 80 74 78 92 77 601 90 143 
NiO 77 88 77 83 86 81 3428 590 549 
Nil 75 89 77 81 79 80 8979 7545 5043 
N12 72 71 73 73 71 71 221 611 210 
N13 72 74 71 75 74 72 198 756 150 
N14 72 73 73 72 72 72 120 292 115 
N15 73 71 72 75 72 72 151 297 156 
N16 47 47 49 50 48 49 3148 1929 914 
N17 48 45 48 48 53 51 3750 1715 163 
N18 52 50 48 265 254 258 4397 6317 525 
N19 47 48 47 49 47 47 2610 1781 462 
c) Day 3 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA-i- 
Donor ABC IgG ML-12 PfSE IgG (AL-12 PHA IgG (AL-12 
Ni ND ND ND 5992 ND ND 377 ND ND 
N2 122 ND ND 658 ND ND 3422 ND ND 
N3 73 ND 76 130 ND 83 11163 ND 2030 
N4 74 ND 79 114 ND 85 8902 ND 1711 
N5 73 ND 77 119 ND 80 5965 ND 3035 
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Table A3.1 (continued): 
d) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG (AL-12 PfSE IgG aIL-12 PHA IgG aIL12 
Ni 117 ND ND 1319 ND ND 7611 ND ND 
N2 90 ND ND 1311 ND ND 3764 ND ND 
N3 73 ND 77 298 ND 88 10574 ND 2228 
N4 77 ND 81 125 ND 90 9651 ND 1487 
N5 73 ND 76 270 ND 83 5358 ND 2797 
N6 79 87 78 124 99 83 9662 10419 5443 
N7 79 97 80 92 106 83 6803 9124 976 
NB 74 87 78 140 150 100 9968 10191 4315 
N9 74 78 78 86 99 95 4158 586 518 
N10 76 90 76 109 116 101 6575 1000 775 
Nil 78 86 76 84 120 81 8276 6104 2801 
N12 72 73 71 106 75 74 641 1782 309 
N13 71 74 72 80 77 72 553 533 128 
N14 75 72 72 80 79 77 1090 4993 243 
N15 73 72 71 83 84 77 486 1502 312 
N16 48 47 47 64 52 49 5074 6247 376 
N17 48 46 47 53 59 49 2323 3890 337 
N18 50 53 49 480 727 233 5963 6890 1623 
N19 47 46 47 61 55 52 1223 872 353 
e) Day 5 
PISE+ PfSE+ 
Donor PfSE IgG aIL-12 
Ni 1202 ND ND 
N2 1221 ND ND 
N3 225 ND ii 
N4 48 ND 9 
N5 197 ND 7 
N6 45 12 5 
N7 13 9 4 
N8 66 63 22 
N9 12 21 17 
NiO 32 26 25 
Nil 6 34 5 
Ni2 35 3 2 
Ni3 9 3 1 
Ni4 6 7 5 
N15 10 ii 6 
N16 16 5 2 
N17 5 13 2 
N18 429 675 185 
Ni9 14 9 6 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor ABC IgG (xIL-12 PfSE IgG txIL-12 PHA IgG cdL-12 Donor PfSE IgG cdL-12 
Ni ND ND ND 1923 ND ND ND ND ND Ni ND ND ND 
N2 104 ND ND 669 ND ND 1794 ND ND N2 565 ND ND 
N3 72 ND 77 349 ND 98 9045 ND 1309 N3 277 ND 22 
N4 73 ND 81 194 ND 90 6165 ND 983 N4 121 ND 9 
N5 72 ND 76 492 ND 86 2521 ND 1004 N5 420 ND 9 
f) Day 6 
PfSE+ PfSE+ 
Donor PfSE IgG cdL-12 
Ni 2216 ND ND 
N2 962 ND ND 
N3 325 ND 38 
N4 226 ND 30 
N5 294 ND 21 
N6 128 17 7 
N7 58 60 10 
N8 122 66 15 
N9 16 47 20 
NiO 692 502 86 
Nil 29 -54 35 
Ni2 27 3 8 
Ni3 3 16 2 
N14 51 36 42 
Ni5 51 8 5 
N16 57 17 13 
N17 17 56 10 
N18 1136 765 99 
N19 64 144 37 
RBC+ RBC+ PfSE+ PfSE+ PHAi- PHA+ 
Donor RBC IgG cxIL-12 PfSE IgG (xIL-12 PHA IgG clL-12 
Ni 80 ND ND 2297 ND ND ND ND ND 
N2 96 ND ND 1058 ND ND 3721 ND ND 
N3 72 ND 78 397 ND 116 9795 ND 1302 
N4 75 ND 79 302 ND 109 7912 ND 541 
N5 72 ND 77 366 ND 98 2545 ND 1184 
N6 83 112 77 211 129 84 10945 10662 5940 
N7 79 97 81 137 157 91 6159 7561 563 
N8 75 102 77 196 168 92 8128 8925 4438 
N9 74 81 77 90 127 98 4350 386 434 
NiO 76 86 75 768 588 160 4533 1904 364 
Nil 75 146 75 104 93 110 8055 5893 2656 
N12 74 72 71 101 75 79 261 3329 202 
N13 71 71 72 75 87 73 171 425 135 
N14 73 72 73 124 108 115 610 1510 150 
N15 74 73 71 125 80 76 345 1172 227 
N16 48 45 48 105 62 60 5136 5805 231 
N17 48 46 46 65 102 56 663 1553 165 
N18 49 52 48 1185 817 147 5174 5770 834 
N19 51 45 48 114 190 85 3610 3833 211 
g) Day 7 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor ABC IgG cdL-12 PfSE IgG cxIL-12 PHA IgG cIL-12 Donor PfSE IgG ctIL-12 
Ni 60 ND ND 2626 ND ND 4471 ND ND Ni 2566 ND ND 
N2 49 ND ND 2453 ND ND 2148 ND ND N2 2404 ND ND 
N3 74 ND 77 345 ND 98 9161 ND 819 N3 272 ND 22 
N4 75 ND 79 408 ND 139 7206 ND 611 N4 332 ND 60 
N5 74 ND 76 221 ND 116 2195 ND 1854 N5 146 ND 41 
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Table A3.1 (continued): 
h) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG uIL-12 PfSE IgG aIL-12 PHA IgG (AL-12 
NI 74 ND ND ND ND ND 6561 ND ND 
N2 61 ND ND 1134 ND ND 3721 ND ND 
N3 74 ND 76 408 ND 83 12466 ND 1144 
N4 74 ND 81 145 ND 145 8523 ND 1023 
N5 73 ND 77 244 ND 102 3640 ND 1783 
N6 77 100 79 119 lii 84 11497 8590 3910 
N7 78 127 78 206 181 115 5799 7508 1035 
N8 75 118 77 193 141 109 10079 9470 1773 
N9 75 95 74 105 154 99 3122 387 287 
N10 75 81 76 320 427 117 849 123 219 
Nil 76 105 74 158 138 119 8293 3122 1251 
N12 72 71 71 71 71 71 72 74 72 
N13 71 71 73 72 71 71 75 75 72 
N14 73 73 72 116 107 151 551 3524 199 
N15 74 73 71 96 83 81 209 1162 244 
N16 47 46 48 108 50 60 4275 4171 371 
N17 47 46 46 86 67 66 1958 4187 191 
N18 51 57 47 502 689 451 6324 4583 345 
N19 49 46 48 146 83 134 1271 4957 199 
PfSE+ PfSE+ 
Donor PfSE IgG cxIL-12 
Ni ND ND ND 
N2 1072 ND ND 
N3 334 ND 7 
N4 71 ND 64 
N5 171 ND 26 
N6 41 10 4 
N7 128 53 36 
N8 118 23 32 
N9 30 59 25 
N10 245 346 41 
Nil 82 33 45 
N12 0 0 0 
N13 0 0 -1 
N14 43 33 79 
N15 22 11 10 
N16 61 4 12 
N17 39 21 20 
N18 451 632 404 
N19 96 36 87 
Table A3.2: Complete IFN-y (pg/mi) results for PBMCs of exposed individuals by day. 
Data is given in arithmetic mean (left-hand tables) and malaria-specific responses 
(PfSE-uRBC, right-hand tables)(ND = not done). 
a) Day 1 
RBC+ RBC+ PfSE+ PfSE+ P1-IA-i- PHA+ 
Donor RBC IgG cdL-12 PfSE IgG (AL-12 PHA IgG (AL-12 
El 51 48 56 49 48 52 ND 93 70 
E2 49 48 59 52 48 51 85 123 92 
E3 53 53 51 52 54 50 ND 240 123 
E5 48 49 52 49 48 51 69 67 61 
E6 70 49 67 121 51 54 195 385 276 
E7 48 47 51 48 47 43 51 60 53 
E8 53 52 53 55 55 53 380 300 145 
E9 37 46 46 101 138 131 626 868 531 
EiO 50 50 55 56 51 57 68 80 71 
Eli 36 35 39 37 39 41 837 735 328 
E12 36 35 40 43 41 39 494 992 508 
E14 32 31 37 38 37 40 54 69 54 
E15 34 35 37 37 39 40 166 164 85 
E16 65 65 59 66 67 72 205 281 236 
E17 47 48 54 47 47 53 68 87 82 
E18 34 37 41 37 40 39 48 73 50 
E19 59 56 59 59 57 52 497 506 220 
E20 37 75 46 46 43 47 52 72 55 
E21 50 58 56 65 65 64 335 337 317 
E22 50 48 52 47 50 52 95 71 102 
PfSE+ PfSE+ 
Donor PfSE IgG cxIL-12 
El -3 0 -4 
E2 3 0 -8 
E3 -1 1 -i 
ES 1 -i -i 
E6 Si 3 -12 
E7 0 1 -8 
E8 2 4 0 
E9 63 92 86 
ElO 6 1 2 
Eli 1 4 2 
E12 7 6 0 
E14 6 5 3 
ElS 3 4 3 
E16 0 2 13 
E17 1 0 -1 
E18 4 3 -2 
E19 0 1 -7 
E20 9 -32 2 
E21 15 7 9 
E22 -3 2 -1 
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PfSE+ PfSE+ 
Donor PfSE IgG cxIL-12 
El -2 1 6 
E2 -1 5 -1 
E3 17 31 45 
E5 -1 3 -1 
E6 25 34 10 
E7 10 -10 -16 
E8 41 158 8 
E9 1517 788 210 
ElO 265 99 16 
Ell 11 8 1 
E12 16 13 6 
E14 19 11 5 
E15 19 16 6 
E16 120 129 31 
E17 1 -4 5 
E18 38 76 14 
E19 105 58 4 
E20 40 15 -8 
E21 64 57 18 
E22 12 32 4 
PfSE+ PfSE+ 
Donor PfSE IgG aIL-12 
El 39 59 2 
E2 8 11 3 
E3 804 582 19 
E5 259 92 54 
E6 496 246 31 
E7 132 140 28 
E8 596 794 94 
E9 4382 2598 246 
ElO 3091 2461 792 
Ell 23 22 4 
E12 253 89 25 
E14 246 590 43 
E15 353 180 40 
E16 1137 1852 251 
E17 1925 324 23 
E18 1143 761 139 
E19 3894 2156 297 
E20 3788 1113 508 
E21 ND 3699 588 
E22 504 446 80 
Table A3.2 (continued): 
b) Day  
- BC+ RBC PfSE+ PfSE+ PHA+ PHA+ 
Donor RRC IgG cdL-12 PfSE IgG (AL-12 PHA IgG (AL-12 
El 57 50 51 55 51 57 ND ND 273 
E2 48 51 55 46 56 54 380 379 141 
E3 53 52 51 70 82 96 ND 800 152 
E5 50 48 51 49 51 51 274 683 95 
E6 52 58 59 77 92 69 1592 2269 1844 
E7 46 49 52 56 38 36 223 192 82 
E8 55 77 58 96 235 66 3134 5349 454 
E9 48 92 53 1564 880 263 2672 4768 2068 
ElO 63 76 63 327 175 78 899 475 248 
Eli 38 36 39 49 44 40 3035 5490 820 
E12 35 37 38 51 50 45 4781 4391 2773 
E14 32 35 36 51 45 41 694 1018 117 
E15 34 37 37 53 52 43 1925 3064 503 
E16 73 82 62 193 211 93 3076 4397 878 
E17 49 55 53 51 51 58 488 710 504 
E18 35 41 44 73 117 58 521 457 99 
E19 54 62 62 159 120 66 3543 3807 703 
E20 42 38 60 81 53 52 193 1032 89 
E21 77 62 71 141 119 89 1381 2062 672 
E22 53 64 53 65 96 58 2703 3730 603 
c) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG (AL-12 PfSE IgG cxIL-12 PHA IgG (AL-12 
El 58 57 54 97 116 56 889 773 95 
E2 48 47 50 55 58 53 5055 2253 267 
E3 54 68 50 858 650 69 2625 3226 221 
E5 47 48 52 306 140 106 1689 1553 137 
E6 69 86 57 566 332 88 5034 3752 2191 
E7 50 58 53 182 198 81 310 226 126 
E8 53 58 55 649 852 149 5848 6799 429 
E9 62 146 63 4444 2744 309 6917 4415 2210 
ElO 177 351 70 3268 2813 863 1883 1144 223 
Ell 43 39 40 65 61 44 6303 3240 1687 
E12 36 38 38 288 127 62 4625 7227 1481 
E14 32 34 36 277 624 80 1078 4159 153 
E15 35 37 39 387 217 79 3101 2651 624 
E16 133 147 86 1270 2000 337 9117 10315 2124 
E17 54 147 65 1979 471 87 1588 2914 603 
E18 37 41 39 1180 802 178 2084 2647 91 
E19 68 476 54 3961 2632 351 8997 7688 1512 
E20 52 47 53 3840 1160 560 818 729 174 
E21 ND 321 67 3287 4020 655 5200 5308 1262 
E22 67 78 64 571 524 144 4733 5555 746 
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PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
El 70 1 420 
E2 13 46 9 
E3 970 -1 2422 
ES 723 553 77 
E6 599 813 95 
E7 1354 202 24 
E8 1144 1163 37 
E9 4985 2596 454 
ElO 3270 3404 1435 
Eli 46 27 20 
E12 379 660 76 
E14 1992 2379 295 
E15 1034 1185 142 
E16 2511 2846 1573 
E17 1228 429 506 
E18 963 1641 284 
E19 ND ND ND 
E20 ND 4009 799 
E21 4301 ND 916 
E22 1461 1522 665 
PfSE+ PfSE+ 
Donor PfSE IgG aIL-12 
El 69 13 129 
E2 46 20 6 
E3 1064 -132 2046 
ES 973 1151 413 
E6 837 580 260 
E7 1134 91 81 
E8 3115 1426 51 
E9 3146 3372 834 
ElO 3979 2958 1553 
Eli -4 108 4 
E12 857 369 61 
E14 2529 3356 695 
E15 655 576 290 
E16 ND ND 1679 
E17 1049 814 836 
E18 407 513 195 
E19 5974 6835 92 
E20 851 1608 1887 
E21 4750 4371 72 
E22 1786 2058 200 
Table A3.2 (continued): 
d) Day 6 
RBC+ RBC+ PfSE+ PfSE+ PHA-i- PHA+ 
Donor RBC IgG (AL-12 PfSE IgG aIL-12 PHA IgG uIL-12 
El 49 57 46 120 58 466 2321 519 70 
E2 52 49 51 65 95 60 4827 4888 212 
E3 131 135 53 1100 134 2475 3905 3520 145 
E5 48 49 51 770 602 129 460 1613 90 
E6 96 111 56 695 924 151 5604 4874 1464 
E7 57 93 56 1411 295 80 519 403 67 
E8 54 55 64 1198 1218 101 4601 6364 377 
E9 51 123 54 5035 2718 508 5062 7806 1106 
ElO 405 557 88 3675 3961 1524 3113 3081 236 
Eli 41 89 37 87 116 58 4807 6430 1346 
E12 62 55 39 441 715 115 5511 5353 1678 
E14 32 34 36 2024 2412 331 2972 1370 110 
E15 35 38 36 1070 1223 179 3101 3565 482 
E16 776 797 143 3287 3643 1716 10702 7882 1407 
E17 146 236 93 1375 665 599 1512 3063 465 
E18 42 51 37 1005 1692 321 3322 2428 75 
E19 ND ND ND 8521 5269 650 8189 8984 551 
E20 ND 46 41 1844 4055 840 692 2365 173 
E21 142 ND 75 4443 7929 990 5124 4775 841 
E22 81 225 56 1542 1747 721 4308 3881 745 
e) Day 8 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA-i- 
Donor RBC IgG aIL-12 PfSE IgG aIL-12 PHA IgG cxIL-12 
El 54 51 49 123 64 178 609 219 63 
E2 49 56 49 95 77 56 3923 5089 140 
E3 100 240 57 1163 108 2103 3838 2799 203 
E5 67 57 51 1040 1208 464 1169 2015 102 
E6 181 162 58 1018 742 318 4917 5806 1828 
E7 54 73 57 1188 165 137 1717 425 82 
E8 56 58 52 3171 1484 103 4654 4776 467 
E9 98 169 66 3244 3541 900 7481 6353 1443 
ElO 405 295 85 4384 3253 1637 2303 1383 163 
Eli 101 58 42 96 166 46 5921 5247 1301 
E12 57 74 42 913 442 103 3485 7392 1869 
E14 32 47 37 2561 3403 732 1721 1558 127 
E15 37 75 37 692 651 328 3764 1602 468 
E16 ND ND 245 3031 3036 1925 7270 7553 1667 
E17 207 218 83 1257 1032 919 2306 1528 315 
E18 50 54 42 457 568 237 1650 3358 61 
E19 192 141 54 6166 6977 145 5814 5953 520 
E20 72 84 63 923 1692 1950 1887 1133 151 
E21 74 104 59 4824 4476 131 4214 8274 839 
E22 97 296 56 1883 2354 256 1621 5629 555 
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Table A3.3: Complete IFN-y (pg/mi) results for PBMCs of immune individuals by day. 
Data is given in arithmetic mean (left-hand tables) and malaria-specific responses 
(PfSE-uRBC, right-hand tables)(ND = not done). 
a) Day  
RBC+ RBC+ PfSE+ PfSE+ 
Donor CM RBC IgG aIL-12 PfSE IgG cilL-12 PHA PPD 
Il 59 58 57 60 58 57 56 92 179-- 
12 60 56 61 57 73 67 56 1174 974 
13 56 59 59 56 60 60 56 606 193 
14 56 57 57 57 60 59 59 160 57 
15 56 59 56 58 60 59 57 268 211 
6 58 58 57 56 57 58 56 196 62 
17 59 56 58 56 61 61 56 593 2864 
18 58 58 61 54 56 57 56 1378 103 
19 56 57 56 54 55 55 56 1699 177 
110 57 60 59 55 57 62 56 425 115 
Ill 57 56 56 56 58 57 57 1211 73 
112 57 58 57 58 61 64 57 881 1055 
13 58 58 61 57 64 60 58 189 113 
114 56 57 58 57 66 63 59 5506 85 
115 57 59 58 58 65 68 66 2380 119 
116 57 56 56 57 56 56 59 60 58 
117 63 58 66 67 500 290 104 3933 503 
118 57 57 59 55 63 60 56 8433 296 
b) Day 4 
RBC+ RBC+ PfSE+ PfSE+ 
Donor CM ABC IgG cdL12 PfSE IgG (AL-12 PHA PPD 
Ii 59 58 58 59 59 59 63 61 2073- 
12 57 57 72 57 139 157 64 2482 4275 
13 55 57 58 55 60 59 56 543 1823 
14 57 58 56 58 69 64 63 169 57 
15 56 58 56 56 87 76 65 1746 4248 
17 57 57 62 56 64 72 58 639 3555 
18 57 57 58 54 58 58 54 2991 338 
Ill 57 56 57 57 56 57 57 4580 170 
113 57 59 62 58 66 63 59 219 467 
114 56 57 58 60 91 79 73 10953 98 
115 57 57 58 57 74 79 62 4002 211 
116 56 55 56 56 56 55 57 59 57 
118 57 57 61 56 61 60 56 5236 280 
PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
Ii 1 0 -4 
12 17 6 -1 
13 1 1 0 
14 3 2 1 
5 1 3 -1 
16 0 0 -1 
17 5 2 0 
18 -2 -4 1 
19 -1 -1 2 
110 -2 3 1 
Ill 2 0 1 
112 3 7 -2 
113 6 -1 1 
114 8 4 2 
115 6 10 8 
116 0 0 2 
117 442 224 38 
118 6 1 2 
PfSE+ PISE+ 
Donor PfSE IgG alL-12 
Ii 0 1 4 
12 82 85 7 
13 3 1 1 
14 12 9 5 
15 29 19 9 
17 7 10 2 
18 1 1 0 
Ill 0 0 0 
13 7 2 1 
114 33 21 13 
115 17 21 5 
16 0 -1 I 
118 4 -2 0 
223 
Table A33 (continued): 
c) Day 6 
RBC+ RBC+ PfSE+ PfSE+ 
Donor CM RBC IgG uIL-12 PfSE IgG uIL-12 PHA PPD 
Ii 58 57 58 58 59 59 57 74 1971 
12 56 58 60 68 116 107 63 2903 3652 
13 57 55 57 57 59 61 59 1699 3920 
14 56 58 56 58 69 67 62 155 72 
5 64 56 58 56 99 69 57 1124 3622 
6 58 59 59 57 58 56 55 332 74 
7 55 56 66 56 64 58 58 561 2763 
18 57 60 56 55 58 55 56 2185 405 
9 62 57 57 54 57 58 55 1206 405 
110 57 57 58 55 64 59 58 1646 1765 
Ill 58 56 57 55 59 58 57 5738 89 
112 59 63 57 58 59 61 57 1314 5621 
113 56 63 63 58 88 72 74 409 460 
114 56 58 59 57 151 116 94 3426 292 
115 57 58 57 56 131 112 62 3022 1152 
116 56 56 56 56 56 55 59 61 57 
117 64 56 88 58 528 424 104 3837 14627 
118 57 57 59 56 70 62 59 7445 372 
119 57 58 87 69 763 1143 136 7694 7561 
120 57 57 61 63 66 60 59 131 484 
PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
Ii 2 2 -1 
12 59 47 -6 
3 5 5 2 
14 11 11 4 
5 43 11 1 
16 -1 -3 -1 
17 8 -7 2 
18 -1 0 1 
9 0 1 1 
110 7 1 3 
Ill 3 1 2 
112 -4 3 -1 
113 26 9 15 
14 93 57 37 
115 74 55 6 
116 0 0 3 
117 471 336 46 
118 13 3 3 
119 705 1056 67 
120 9 -1 -4 
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Table A3.4: Complete IFN-y (pg/mi) results for PBMCs of naive individuals used as 
controls in Ghana by day. Data is given in arithmetic mean (left-hand tables) and 
malaria-specific responses (PfSE-uRBC, right-hand tables)(ND = not done). 
a) Day 1 
RBC+ RBC+ PfSE+ PfSE+ PHA-i- PHAi- PfSE+ PfSE+ 
Donor ABC IgG aIL-12 PfSE IgG aIL-12 PHA IgG aIL-12 Donor PfSE IgG cdL-12 
C2 65 80 70 119 69 59 214 1040 202 C2 54 -11 -10 
C4 53 50 52 52 52 53 200 170 122 C4 -2 3 1 
b) Day 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor ABC IgG cxIL-12 PfSE IgG aIL-12 PHA IgG cdL-12 Donor PfSE IgG (AL-12 
C2 63 71 53 70 89 78 507 4085 300 C2 7 17 24 
C3 57 51 57 51 51 62 92 303 140 C3 -5 1 5 
C4 57 54 60 53 57 54 1086 2348 464 C4 -5 3 -6 
C5 58 58 56 69 65 63 94 ND ND CS 11 8 7 
c) Day 
RBC+ RBC+ PfSE+ PfSE+ PHAi- PHA+ PfSE+ PfSE+ 
Donor ABC IgG (AL-12 PfSE IgG ctIL-12 PHA IgG cdL-12 Donor PfSE IgG(AL-12 
C2 60 70 61 187 69 70 1126 4314 281 C2 126 0 8 
C3 51 50 53 76 68 58 88 898 169 C3 24 18 4 
C4 52 49 59 168 135 79 5967 4954 1137 C4 116 86 20 
d) Day 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHAT7  PfSE+ PfSE+ 
Donor ABC IgG (AL-12 PfSE IgG (AL-12 PHA IgG (AL-12 Donor PfSE IgG cxIL-12 
C2 81 68 74 229 513 70 1539 4061 231 C2 147 445 -4 
C3 61 55 52 72 120 63 133 884 189 C3 11 65 11 
C4 50 50 47 381 131 74 2314 5877 982 C4 331 81 26 
C5 60 56 57 111 103 73 121 ND ND C5 51 47 17 
e) Day 8 ____ 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor RBC IgG (AL-12 PfSE IgG uIL-12 PHA IgG aIL-12 Donor PfSE IgG uIL-12 
C2 97 86 65 416 1233 77 872 3198 137 C2 320 1147 12 
C3 48 62 52 124 78 68 113 284 212 C3 75 17 16 
C4 51 52 47 508 151 80 2550 5263 817 C4 457 99 33 
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Table A3.5: Kinetic timecourses of lymphoproliferative and 1FN-y responses to PfSE of 
PBMCs from a) naIve, b) exposed and c) immune individuals (median (PfSE-uRBC) 
and range for 1FN-y (pg/mi) and geometric mean Si (PfSE/uRBC) and 95% Cl for 
lymphoproiiferation). 
a) 
Proliferation data IFN-y data 
Day 	Stats SI Day Stats IFN -y (pg/rn I) 
3 Mean 2.4 2 Mean 6 
CI 1.5, 2.8 Range 0,382 
n 19 fl 19 
5 	Mean 7.5 4 Mean 32 
CI 4.6, 	12.1 Range 5,1221 
fl 19 fl 19 
7 	Mean 16.4 6 Mean 64 
CI 11.4, 23.7 Range 4,2216 
fl 19 fl 19 
9 	Mean 9.2 8 Mean 76 
CI 4.8, 17.7 Range -0.5, 1072 
n 19 n 18 
II 
Proliferation data IFN-y data 
Day Stats SI Day Stats IFN-y (pglm I) 
2 Mean 1.7 1 Mean 2 
CI 1.5, 2.0 Range -3,63 
n 20 n 20 
3 Mean 3.6 2 Mean 19 
CI 2.8, 4.6 Range -2,1517 
fl 20 fl 20 
5 Mean 9.0 4 Mean 504 
CI 7.0, 	11.5 Range 84382 
fl 19 fl 20 
7 Mean 13.5 6 Mean 1089 
CI 4.0, 16.7 Range 13, 4985 
n 19 fl 20 
9 Mean 6.7 8 Mean 1049 
CI 4.7, 9.6 Range -4, 5974 
fl 16.0 fl 19 
C) 
Proliferation data IFN-y data 
Day 	Stats SI Day Stats IFN-y (pg/rn I) 
3 Mean 2.9 2 Mean 2 
CI 2.0, 4.2 Range -2, 442 
fl 18 n 18 
5 	Mean 8.2 4 Mean 7 
CI 4.0, 16.7 Range 0.2,82 
fl 12 n 13 
7 	Mean 18.8 6 Mean 8 
CI 9.0, 39.2 Range -4, 705 
fl 20 n 20 
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Table A3.6: IL-12 p70 (pg/mI) results for donors a) N3, b) N4 and c) N5 (- indicates that 
free IL-12 p70 in cell culture supernatants was below LLD = 107 pg/mI). 
N2 
PfSE PfSE PfSE PfSE LPS+ 
Hours RBC 1:320 1:640 1:1280 1:2560 IFN-y 
4 	- 	- 	- 	- 	- 	- 
20 - - - - - - 
28 	- 	- 	- 	- 	- 	- 
45 113 - - - - - 
51 	131 	- 	- 	- 	- 	- 
68 110 - - - - - 
76 	- 	- 	- 	- 	- 	107 
92 - - - - - - 
100 	- 	- 	- 	- 	- 	- 
115 - - - - - - 
N3 
PfSE 	PfSE 	PfSE 	PfSE LPS+ 
Hours 	RBC 1:320 1:640 1:1280 1:2560 IFN-y 
4 - - 	- 	- 	- 113 
20 	- - - - - 143 
28 - - 	- 	- 	- 155 
45 	- - - - 108 155 
51 - - 	- 	- 	107 142 
68 	- - - - - 139 
76 - - 	- 	- 	- 139 
92 	- - - - - 150 
100 - - 	- 	- 	114 141 
115 - - - 120 131 
N5 
PfSE 	PfSE 	PfSE 	PfSE LPS+ 
Hours 	RBC 1:320 1:640 1:1280 1:2560 IFN-y 
4 - - 	- 	- 	112 - 
20 	- - - - - 107 
28 - - 	- 	- 	- - 
45 	- - - - - 109 
51 - - 	- 	- 	- - 
68 	- - - - 109 - 
76 - - 	- 	- 	- - 
92 	- - - - - 108 
100 - - 	- 	- 	- - 
115 	- - - 107 - 100 
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Table A37: Complete IL-12 p40 (pg/mI) results for PBMCs of a) naïve, b) exposed, 
c) immune and d) control (naïve) individuals on day 2. Data is given in arithmetic mean 
(left-hand tables) and malaria-specific responses (PfSE-u RBC, right-hand tables). 
a) 
Donor RBC PfSE 
	
Donor PfSE 
N2 167 147 N2 -20 
N3 213 213 N3 0 
N4 378 364 N4 -14 
N5 204 199 N5 -5 
N6 320 305 N6 -15 
N7 153 156 N7 3 
N8 147 145 N8 -2 
N9 186 207 N9 21 
N10 224 232 N10 8 
Nil 184 212 Nil 28 
N12 199 195 N12 -4 
N13 214 225 N13 ii 
N14 211 223 N14 12 
N15 170 172 N15 2 
N16 161 173 N16 ii 
N17 175 163 N17 -12 
N18 193 177 N18 -16 
N19 176 176 N19 0 
b)  
Donor RBC PfSE Donor PfSE 
El 187 190 El 3 
E2 207 221 E2 14 
E3 210 219 E3 10 
E5 326 351 E5 25 
E6 372 388 E6 16 
E7 173 153 E7 -20 
E8 205 194 E8 -11 
E9 1124 1654 E9 530 
ElO 259 285 ElO 26 
Ell 562 592 Eli 30 
E12 776 870 E12 94 
E14 279 372 E14 93 
E15 202 223 E15 21 
E16 245 243 E16 -2 
E17 201 169 E17 -32 
E18 267 258 E18 -9 
E19 173 200 E19 26 
E20 138 132 E20 -5 
E21 173 230 E21 57 
E22 184 171 E22 -12 
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Table A3.7 (continued): 
C)  
Donor RBC PfSE Donor PfSE 
Ii 155 171 Ii 16 
12 173 200 12 26 
13 168 185 13 17 
14 184 183 14 -1 
15 351 340 15 -11 
16 806 261 16 -545 
17 203 199 17 -4 
18 183 148 18 -34 
19 249 322 19 73 
110 191 220 110 30 
Ill 189 198 Iii 8 
112 182 181 112 -2 
113 212 250 113 38 
114 384 379 114 -5 
115 192 193 115 1 
116 179 214 116 34 
117 185 193 117 8 
118 224 264 118 40 
119 187 200 119 14 
120 162 178 120 16 
d)  
Donor RBC PfSE Donor PfSE 
C2 138 127 02 -12 
C3 145 135 C3 -10 
C4 156 152 C4 -4 
C5 185 174 C5 -11 
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Table A3.8: Geometric mean SI and 95% Cl of control lgG/PfSE-stimulated and (XlL-
12/PfSE-stimulated PBMCs from a) naIve, b) exposed and c) immune individuals for 
each day. 
Day Mean CI Mean CI t p n 
3 1.7 1.2,2.3 1.9 1.4,2.6 1.15 >0.05 13 
5 3.3 1.7, 6.4 4.8 2.7, 8.7 1.70 >0.05 14 
7 6.8 3.3, 14.0 9.1 5.5, 15.2 1.49 >0.05 14 
9 3.4 1.6, 7.2 8.1 4.3, 15.5 3.61 0.003 14 
Day Mean CI Mean CI t p n 
2 1.4 1.2,1.7 1.4 1.1,1.7 0.46 >0.05 20 
3 3.0 2.4, 3.7 3.2 2.6, 4.0 0.75 >0.05 20 
5 6.5 4.9,8.5 7.0 5.2,9.4 0.93 >0.05 19 
7 10.1 7.2, 14.3 14.1 9.8, 20.3 2.79 0.013 18 
9 5.6 4.0,7.7 8.2 4.9, 13.5 3.11 0.007 16 
C 
E+cdL-12 
Day Mean CI Mean CI t 	p n 
3 1.8 1.3,2.7 2.0 1.2,3.5 0.45 >0.05 18 
5 2.1 0.6,7.5 2.7 1.0,7.4 0.92 	>0.05 11 
7 5.5 3.2,9.5 3.1 1.9,4.8 2.52 0.021 20 
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PfSE+ PfSE+ 
Donor PfSE IgG (ZIL-12 
Ni 26 ND ND 
N2 29 ND ND 
N3 1 ND 1 
N4 1 ND 1 
N5 4 ND 2 
N6 1 1 1 
N7 1 1 2 
N8 3 1 2 
N9 2 2 1 
NiO 1 1 
Nil 1 1 2 
N12 2 2 2 
N13 2 1 2 
Ni4 1 1 1 
N15 1 ND 1 
N16 2 2 2 
Ni7 1 3 2 
N18 5 5 6 
Ni9 4 3 4 
PfSE+ PfSE+ 
Donor PfSE IgG (AL-12 
Ni 14 ND ND 
N2 44 ND ND 
N3 3 ND 1 
N4 3 ND 1 
N5 5 ND 2 
Table A3.9: Complete lymphoproliferative results for PBMCs of naïve individuals by 
day. Data is given in geometric mean cpm (left-hand tables) and SI (PfSE/uRBC with 
and without control IgG or (AL-1 2, right-hand tables)(ND = not done). 
a) Day 1 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor ABC IgG uIL-12 PfSE IgG aIL-12 PHA (AL-12
Ni 
IgG aIL-12 Donor PfSE IgG 
398 ND ND 331 ND ND 547 ND ND Ni 1 ND ND 
N2 303 ND ND 174 ND ND 470 ND ND N2 1 ND ND 
N3 667 ND 684 600 ND 758 794 ND 560 N3 1 ND 1 
N4 908 ND 963 830 ND 593 1055 ND 1128 N4 1 ND 1 
N5 600 ND 1203 489 ND 562 1606 ND 1075 N5 1 ND 0 
b) Day 2 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
Donor ABC IgG (AL-12 PfSE IgG (AL-12 P1-IA IgG aIL-12 Donor PfSE IgG aIL-12 
Ni 431 ND ND 794 ND ND 72158 ND ND Ni 2 ND ND 
N2 221 ND ND 491 ND ND 71656 ND ND N2 2 ND ND 
N3 730 ND 886 1048 ND 1102 38149 ND 32675 N3 1 ND 1 
N4 1102 ND 1043 1101 ND 953 59626 ND 53680 N4 1 ND 1 
N5 359 ND 432 466 ND 480 32188 ND 25513 N5 1 ND 1 
c) Day 3 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG (AL-12 PfSE IgG (AL-12 PHA IgG aIL-12 
Ni 89 ND ND 2282 ND ND 41677 ND ND 
N2 86 ND ND 2519 ND ND 31224 ND ND 
N3 1093 ND 1028 1606 ND 1407 72535 ND 69616 
N4 925 ND 823 1274 ND 1150 92917 ND 86822 
N5 479 ND 497 1934 ND 787 91055 ND 65940 
N6 794 805 662 911 686 754 40866 44511 41080 
N7 576 723 500 642 830 751 55953 49490 48538 
N8 488 693 512 1252 1029 972 38725 41945 37843 
N9 515 526 390 853 1023 526 41170 7143 25362 
N10 498 448 509 717 577 677 57674 21148 35696 
Nil 561 449 419 740 381 893 47383 26981 33108 
N12 406 451 359 805 941 773 58313 57316 35041 
N13 246 255 221 375 313 438 16725 18019 17761 
N14 144 159 163 187 226 150 24496 34061 29497 
N15 233 ND 216 318 257 225 18379 22072 19902 
N16 47 74 46 lii 167 83 14449 15266 13088 
N17 39 34 24 50 87 51 19073 22533 18085 
N18 85 103 88 394 504 542 19200 16073 14727 
N19 22 28 19 84 79 69 27230 27256 29790 
d) Day 4 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG czIL-12 PfSE IgG aIL-12 PHA IgG ctIL-12 
Ni 414 ND ND 5592 ND ND 93653 ND ND 
N2 164 ND ND 7249 ND ND 104946 ND ND 
N3 1226 ND 1319 3083 ND 1757 96277 ND 90584 
N4 930 ND 1068 2388 ND 1409 96082 ND 77284 
N5 648 ND 655 3061 ND 983 72597 ND 72778 
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PfSE+ PfSE+ 
Donor PfSE IgG aIL-12 
Ni 20 ND ND 
N2 58 ND ND 
N3 3 ND 2 
N4 3 ND 2 
N5 6 ND 2 
N6 3 1 1 
N7 4 2 2 
N8 4 2 3 
N9 7 2 3 
NiO 4 2 4 
Nil 6 5 3 
N12 18 3 5 
N13 2 4 2 
N14 3 2 5 
N15 10 3 4 
N16 5 0 5 
N17 13 23 22 
N18 56 16 33 
N19 19 17 29 
PfSE+ PfSE+ 
Donor PfSE IgG cxIL-12 
Ni 13 ND ND 
N2 93 ND ND 
N3 4 ND 2 
N4 1 ND 3 
N5 13 ND 4 
PfSE+ PfSE+ 
Donor PfSE IgG aIL-12 
Ni 18 ND ND 
N2 62 ND ND 
N3 5 ND 2 
N4 ii ND 1 
N5 15 ND 3 
N6 6 1 2 
N7 8 3 5 
N8 9 1 5 
N9 11 6 5 
N10 10 12 ii 
Nil 23 3 17 
N12 12 1 2 
N13 10 19 37 
N14 19 13 11 
N15 32 5 8 
N16 80 14 22 
N17 28 39 15 
N18 31 11 13 
N19 28 48 23 
Table A3.9 (continued): 
e) Day 5 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG (xIL-12 PfSE IgG aIL-12 PHA IgG aIL-12 
Ni 554 ND ND 11151 ND ND ND ND ND 
N2 372 ND ND 21461 ND ND 90289 ND ND 
N3 1347 ND 1408 3881 ND 2272 107932 ND 78674 
N4 731 ND 602 2170 ND 1359 58922 ND 42786 
N5 712 ND 590 4508 ND 1465 53713 ND 53977 
N6 988 1525 1274 2473 1910 1796 26546 27437 19236 
N7 738 1307 791 3071 2524 1674 18139 21338 13714 
NB 1005 1689 1479 4388 4109 3912 34026 33695 28714 
N9 685 1703 1580 4516 3568 5082 33719 8905 19289 
N10 745 800 792 2758 1970 2803 21438 5041 13421 
Nil 668 829 795 4052 4542 2030 41493 13392 17508 
N12 616 1707 1164 11322 5100 5323 17051 28222 18198 
N13 543 513 481 1,346 2049 955 10303 11515 9816 
N14 108 105 67 324 231 313 33284 47017 32887 
N15 48 242 63 477 662 263 10410 17035 13003 
N16 62 205 60 317 59 270 4427 5789 2568 
N17 28 25 20 361 575 449 10603 10987 12144 
N18 36 120 60 2036 1910 2013 7414 6256 5363 
N19 50 50 38 940 832 1098 6505 5989 4938 
f) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG aIL-12 PfSE IgG cdL-12 PHA IgG (AL-12 
Ni 2183 ND ND 27706 ND ND 30434 ND ND 
N2 632 ND ND 58520 ND ND 49461 ND ND 
N3 1296 ND 1577 4980 ND 2802 47210 ND 25114 
N4 1086 ND 670 1627 ND 2146 16739 ND 9124 
N5 1119 ND 1167 14313 ND 4167 27989 ND 18189 
g) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PI-JA+ 
Donor RBC IgG aIL-12 PfSE IgG alL-12 PHA IgG aIL-12 
Ni 2077 ND ND 36539 ND ND 11494 ND ND 
N2 797 ND ND 49436 ND ND 18652 ND ND 
N3 3081 ND 3394 14536 ND 6275 21516 ND 18262 
N4 1279 ND 1479 13961 ND 1959 11928 ND 7066 
N5 1489 ND 1752 22477 ND 4800 13941 ND 9275 
N6 1888 4854 1327 10924 4307 2972 6813 8765 7505 
N7 941 2880 1366 7339 10077 6891 3363 3901 4828 
N8 1316 4720 1504 11270 6560 8092 7821 9749 9571 
N9 1117 2239 3006 12160 14009 14547 7818 3764 5375 
NiO 1415 1584 1236 14039 18811 13090 6258 1963 4402 
Nil 1012 3214 992 23123 10689 17276 11285 8496 6928 
N12 749 5917 5139 8925 7548 9111 1338 2581 2024 
N13 186 287 305 1897 5509 11321 1927 2540 3497 
N14 254 368 335 4846 4696 3738 14967 14184 16821 
N15 141 549 203 4513 2671 1554 6542 7258 7311 
N16 142 349 309 11348 4952 6656 1984 2551 2865 
N17 244 263 253 6863 10374 3737 10794 11068 10367 
N18 146 404 235 4566 4516 3036 2708 2114 4271 
N19 437 303 484 12457 14426 11122 2900 2313 4030 
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Table A3.9 (continued): 
h) Day 9 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG (AL-12 PfSE IgG cxIL-12 PHA IgG x[L-12 
Ni 1610 ND ND 17154 ND ND 1916 ND ND 
N2 536 ND ND 26635 ND ND 3439 ND ND 
N3 3077 ND 4390 13394 ND 3148 10386 ND 5949 
N4 1678 ND 2882 15273 ND 3537 7033 ND 3487 
N5 1864 ND 1632 10862 ND 6258 4162 ND 3738 
N6 5567 5065 5927 9197 8721 9370 11343 11337 10495 
N7 1563 17447 3996 45663 49521 55488 5012 3643 8796 
N8 2308 12137 7201 55774 27124 12394 8834 9491 7599 
N9 1889 6190 3748 18343 35022 31330 4114 4398 5459 
N10 5309 3938 3770 23834 31131 26190 7007 3265 5378 
Nil 3165 6979 2709 44769 23305 26760 10712 6104 5215 
N12 406 237 43 159 85 156 166 266 384 
N13 474 814 419 566 647 773 458 418 550 
N14 322 676 334 3989 7179 8589 4368 4560 5986 
N15 475 934 195 4420 3397 2817 3490 3980 3233 
N16 35 225 160 3619 531 3816 683 414 766 
N17 125 65 82 5779 3644 5962 3571 3348 4411 
N18 574 2584 372 3027 2552 1888 1672 1696 3625 
N19 421 618 1034 7212 8381 12248 1835 1154 1903 
PfSE+ PfSE+ 
Donor PfSE IgG aIL12 
Ni ii ND ND 
N2 50 ND ND 
N3 4 ND 1 
N4 9 ND 1 
N5 6 ND 4 
N6 2 2 2 
N7 29 3 14 
N8 24 2 2 
N9 10 6 8 
N10 4 8 7 
Nil 14 3 10 
N12 0 0 4 
N13 1 1 2 
N14 12 ii 26 
N15 9 4 14 
N16 105 2 24 
N17 46 56 73 
N18 5 1 5 
N19 17 14 12 
Table A3.10: Complete lymphoproliferative results for PBMCs of exposed individuals by 
day. Data is given in geometric mean cpm (left-hand tables) and SI (PfSE/uRBC with 
and without control IgG or alL-i 2, right-hand tables)(ND = not done). 
a) Day  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG (AL-12 PfSE IgG (AL-12 PHA IgG (AL-12 
El 19 20 14 25 18 19 ND 2174 2257 
E2 19 30 32 27 24 15 2017 2871 3759 
E3 15 26 20 32 34 37 ND 2180 2210 
E5 38 52 52 57 42 56 1146 1336 935 
E6 28 19 25 26 23 21 578 536 595 
E7 29 40 37 66 53 62 4204 3862 3679 
E8 15 19 32 45 24 18 2908 2908 2934 
E9 81 85 72 164 146 132 2318 2513 2618 
ElO 48 50 53 86 81 90 3104 3266 3063 
Eli 99 76 80 115 103 89 4225 4489 4103 
E12 24 26 28 60 82 103 2888 3282 3068 
E14 61 52 51 76 69 66 6062 5936 6325 
E15 26 23 35 64 55 42 4636 4949 4798 
E16 39 44 50 58 57 60 4620 4291 4256 
E17 23 25 31 35 37 29 1915 1387 1729 
E18 29 30 21 68 44 53 3888 3443 3225 
E19 28 31 43 65 59 109 1714 1470 1726 
E20 41 60 47 74 93 82 4854 4718 4541 
E21 21 22 23 21 34 43 841 762 758 
E22 22 22 27 43 39 36 2258 2423 2335 
PfSE+ PfSE+ 
Donor PfSE IgG xIL-12 
El 1 1 1 
E2 1 1 0 
E3 2 1 2 
ES 2 1 1 
E6 1 1 1 
E7 2 1 2 
E8 3 1 
E9 2 2 2 
ElO 2 2 2 
Eli 1 1 1 
E12 3 3 4 
E14 1 1 
E15 2 2 1 
E16 1 1 
E17 2 1 1 
E18 2 1 2 
E19 2 2 3 
E20 2 2 2 
E21 1 2 2 
E22 2 2 1 
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PfSE+ PfSE+ 
Donor PfSE IgG (AL-112 
El 2 2 2 
E2 1 3 1 
E3 4 2 6 
ES 4 3 3 
E6 2 3 2 
E7 5 3 5 
E8 3 2 2 
E9 10 9 6 
ElO 4 3 5 
Eli 4 3 3 
E12 8 3 6 
E14 3 4 3 
E15 6 7 6 
E16 2 2 3 
E17 2 1 2 
E18 6 4 5 
E19 4 3 4 
E20 6 5 4 
E21 2 3 3 
E22 2 2 2 
PfSE+ PISE+ 
Donor PfSE IgG (AL-12 
El 5 7 6 
E2 3 3 2 
E3 6 4 6 
E5 8 6 7 
E6 6 3 5 
E7 8 7 7 
E8 10 8 12 
E9 20 13 16 
ElO 10 6 3 
Ell 7 5 5 
E12 13 6 10 
E14 14 13 12 
E15 18 15 12 
E16 5 4 3 
E17 12 3 3 
E18 17 20 18 
E19 10 5 8 
E20 16 13 ii 
E21 ND 3 6 
E22 5 5 9 
Table A3.10 (continued): 
b) Day 3 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG (AL-12 PfSE IgG aIL-12 PHA IgG uIL-12 
El 24 26 24 42 53 51 ND 5903 5796 
E2 21 8 19 30 24 23 8982 9428 8118 
E3 28 52 25 118 105 141 ND 4659 3771 
E5 42 40 37 150 117 93 6291 6800 6126 
E6 36 42 38 83 107 93 5115 5340 5554 
E7 67 79 91 337 235 414 9750 7569 8615 
E8 53 52 52 134 123 112 6424 6919 6112 
E9 80 79 79 789 687 493 4303 4074 3851 
ElO 147 163 107 646 531 550 12508 12504 12960 
Eli 77 108 99 345 276 311 13695 12675 12835 
E12 37 73 42 306 253 248 13851 14484 13511 
E14 94 68 72 294 262 182 14932 15683 15130 
E15 54 52 49 335 349 307 14660 14043 13926 
E16 184 172 135 417 426 388 13682 13332 14104 
E17 61 114 79 122 110 179 12801 12310 12804 
E18 76 98 66 456 423 318 7372 6266 5817 
E19 76 108 90 307 316 323 10797 10305 10392 
E20 66 72 82 417 333 323 7982 7610 7787 
E21 81 59 62 171 169 157 6457 5732 6051 
E22 104 135 113 257 253 170 10723 9941 10703 
c) Day 5 
- RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor ABC IgG cdL-12 PfSE IgG uIL-12 PHA I9G (AL-112 
El 66 55 48 311 368 273 2712 2267 2276 
E2 40 36 42 130 96 91 4000 3804 3333 
E3 109 160 83 633 561 512 2146 1980 2178 
E5 119 137 113 912 868 742 5279 4746 4027 
E6 109 116 92 679 376 494 5184 4130 5366 
E7 346 368 315 2892 2610 2218 4471 1883 3551 
E8 49 71 45 469 533 530 4797 4574 6114 
E9 269 308 190 5382 3970 2985 4421 4038 1813 
ElO 328 429 875 3397 2575 2870 2576 2340 2644 
Ell 226 250 285 1578 1289 1294 10180 10453 13021 
E12 140 207 156 1756 1237 1604 13139 12077 11556 
E14 110 111 100 1576 1483 1163 11121 12403 11578 
E15 103 124 111 1850 1822 1315 10342 9660 11244 
E16 272 417 456 1394 1667 1349 4100 3776 2812 
E17 115 327 327 1368 1079 984 3911 4509 4135 
E18 344 216 228 5873 4350 4213 8380 7585 4594 
E19 239 362 262 2439 1774 2126 9150 8888 7802 
E20 276 259 316 4284 3248 3621 5952 4546 5974 
E21 ND 451 196 1332 1363 1275 5089 4168 4439 
E22 235 265 174 1209 1264 1649 2280 2412 1796 
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PfSE+ PfSE+ 
Donor PISE IgG (AL-12 
El 9 8 19 
E2 6 6 8 
E3 6 5 3 
E5 18 18 36 
E6 19 6 21 
E7 11 6 6 
E8 22 15 23 
E9 40 19 33 
ElO 20 10 7 
Ell 8 5 14 
E12 17 11 23 
E14 48 53 36 
E15 28 20 18 
E16 7 5 5 
E17 3 4 7 
E18 21 20 32 
E19 ND ND ND 
E20 8 17 14 
E21 19 ND 10 
E22 10 8 12 
PfSE+ PISE+ 
Donor PfSE IgG aIL-12 
El 4 3 8 
E2 5 3 5 
E3 4 4 2 
E5 6 10 14 
E6 6 8 12 
E7 5 4 4 
E8 ii 8 10 
E9 12 8 19 
Ell 2 2 2 
E12 5 4 7 
E14 25 10 18 
E15 13 7 10 
E18 5 5 6 
E19 16 12 44 
E20 3 2 2 
E21 8 13 33 
Table A310 (continued): 
d) Day 7 
RBC+ RBC+ PfSE+ PfSE+ PHA-i- PHA+ 
Donor RBC IgG aIL-12 PISE IgG (AL-12 PHA IgG uIL-12 
El 151 107 59 1373 850 1091 1010 1224 1387 
E2 54 60 52 345 378 409 637 610 483 
E3 336 385 328 1851 2005 1137 909 986 1425 
E5 281 223 168 5127 3950 6066 714 635 615 
E6 169 346 136 3273 2228 2839 942 887 726 
E7 532 922 826 5770 5730 4831 966 937 948 
E8 59 79 58 1296 1212 1371 1618 1751 1760 
E9 245 384 245 9809 7225 8055 2112 1520 563 
ElO 310 459 974 6207 4606 6688 845 627 1226 
Eli 397 607 233 3335 2861 3354 2395 2651 3065 
E12 309 351 221 5305 3993 5110 2769 2512 2699 
E14 139 120 141 6677 6337 5054 1456 1681 1762 
E15 202 360 244 5584 7079 4498 1169 1175 1129 
E16 652 975 863 4317 4397 4419 1037 1182 949 
E17 851 561 544 2622 2123 3792 1218 909 1226 
E18 440 392 300 9115 7794 9592 2345 1763 2170 
E19 ND ND ND 7654 7708 9046 1110 939 1745 
E20 809 393 492 6552 6636 6721 1379 1032 1559 
E21 290 ND 572 5609 5682 5723 1558 1366 1290 
E22 374 531 387 3828 3996 4821 430 494 336 
e) Day 9 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ 
Donor RBC IgG atL-12 PISE IgG aIL-12 PHA IgG uIL-12 
El 315 243 154 1399 824 1274 851 1283 1536 
E2 126 135 129 652 385 677 308 285 337 
E3 341 366 370 1524 1490 728 691 510 1072 
E5 973 429 626 6291 4314 8826 263 263 346 
E6 679 379 161 4177 3010 1938 178 139 520 
E7 1495 1201 1321 6780 5391 5121 381 270 350 
E8 152 164 177 1683 1352 1711 1080 805 1298 
E9 442 787 360 5368 6440 6666 600 647 276 
Eli 1660 1314 1183 2737 2524 2028 747 738 1381 
E12 792 880 655 4298 3725 4264 447 456 1123 
E14 251 586 292 6313 5704 5274 493 643 641 
E15 480 870 695 6313 6319 6929 553 514 522 
E18 1038 1029 877 5361 4836 5070 509 407 841 
E19 263 247 81 4098 2889 3547 580 599 1029 
E20 943 1391 1657 3152 2860 3738 577 275 524 
E21 100 100 64 822 1315 2112 985 828 2080 
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Table A3.1 1: Complete lymphoproliferative results for PBMCs of immune individuals by 
day. Data is given in geometric mean cpm (left-hand tables) and SI (PfSE/uRBC with 
and without control IgG or alL-i 2, right-hand tables)(ND = not done). 
a) Day 3 
RBC+ RBC+ PfSE+ PISE+ 
Donor CM ABC IgG aIL-12 RISE IgG (AL-12 PHA PPD 
Il 13 22 12 16 36 40 26 4609 23 
2 46 36 44 26 186 76 86 11576 266 
3 10 12 7 21 52 53 48 8447 292 
4 20 24 10 8 60 53 78 7031 43 
15 33 31 49 47 95 78 62 13871 803 
16 37 37 66 43 73 62 48 14961 110 
17 239 216 185 140 345 70 14 557 119 
8 38 32 13 17 71 25 243 24152 175 
19 17 58 44 12 91 40 95 34928 816 
110 79 55 130 57 112 117 128 33922 863 
Ill 9 20 11 12 49 48 27 8528 36 
112 21 22 50 35 53 64 44 3842 811 
13 93 71 61 104 214 143 81 8618 896 
14 81 72 97 100 274 203 228 37243 359 
15 35 37 43 46 165 142 140 29109 386 
16 83 80 84 66 80 85 58 3986 139 
17 20 12 27 91 335 35 230 12624 2601 
18 21 17 27 13 85 66 36 33959 690 
b) Day 5 
RBC+ RBC+ PISE+ PISE+ 
Donor CM ABC IgG cdL-12 RISE IgG aIL-12 PHA PPD 
Il 9 10 8 25 33 ND ND 320 4822 
12 32 59 381 194 670 11 23 2849 6800 
3 16 48 74 44 368 297 1102 15839 2571 
4 27 26 53 122 703 675 1227 6003 140 
5 60 65 161 158 2081 1693 1723 41494 7382 
7 56 67 308 241 1150 1639 1223 15133 5447 
8 1 ND 15 52 338 609 268 39717 2241 
Ill 9 27 33 34 155 199 102 25756 306 
113 322 214 612 634 2738 1427 728 8000 3360 
14 138 328 403 542 1087 199 976 46856 1342 
115 25 36 68 67 1046 971 413 34082 1758 
16 36 70 49 58 53 14 32 2723 50 
18 94 149 265 143 557 340 202 33125 1225 
PISE+ PISE+ 
Donor RISE IgG cdL-12 
Il 2 3 2 
2 5 2 3 
13 4 7 2 
14 2 6 9 
5 3 2 1 
16 2 1 1 
17 2 0 0 
18 2 2 15 
19 2 1 8 
110 2 1 2 
Ill 2 4 2 
112 2 1 1 
113 3 2 1 
114 4 2 2 
115 4 3 3 
116 1 1 1 
117 27 1 3 
118 5 2 3 
PISE+ PISE+ 
Donor RISE IgG MIL-12 
H 3 ND ND 
12 11 0 0 
13 8 4 25 
14 28 13 10 
15 32 11 11 
17 17 5 5 
18 ND 40 5 
Ill 6 6 3 
13 13 2 1 
114 3 0 2 
15 29 14 6 
116 1 0 1 
118 4 1 1 
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Table A3.11 (continued): 
C) Day  
RBC+ RBC+ PfSE+ PfSE+ 
Donor CM RBC IgG uIL12 PfSE IgG (AL-12 PHA PPD 
Ii 6 16 14 32 92 101 51 2031 29756 
12 123 117 803 1754 11763 14414 8908 13733 21059 
13 75 146 255 213 1413 1502 458 20 10255 
4 32 60 373 453 7186 5590 559 31 483 
15 197 90 321 166 4896 4332 1267 18651 35763 
16 100 99 311 102 294 417 153 13533 1067 
17 168 206 2768 979 7319 5922 5231 13819 18142 
8 129 188 770 181 1977 1486 940 9968 13377 
19 652 481 895 501 1153 967 394 11974 12153 
110 38 100 331 254 2493 2352 1030 15755 26201 
Ill 65 92 298 82 439 445 294 15420 1589 
112 75 143 67 190 547 778 480 12738 41973 
113 135 1151 2894 1888 7712 5832 4360 5150 19229 
14 211 442 468 309 7816 6185 8162 9893 6918 
115 13 47 56 132 6358 4328 895 17436 17943 
116 26 42 23 45 51 82 34 3251 74 
117 31 61 730 677 14005 6291 5511 11138 36573 
118 156 99 472 288 1584 822 436 2557 7376 
19 66 79 654 876 17095 13220 8276 7379 21411 
120 21 23 323 694 952 894 475 3316 4713 
PfSE+ PfSE+ 
Donor PISE IgG aIL-12 
Ii 6 7 2 
12 100 18 5 
13 10 6 2 
4 120 15 1 
15 54 14 8 
16 3 1 1 
17 36 2 5 
18 11 2 5 
19 2 1 1 
110 25 7 4 
Ill 5 1 4 
112 4 12 3 
113 7 2 2 
114 18 13 26 
115 134 78 7 
116 1 4 1 
17 229 9 8 
118 16 2 2 
19 217 20 9 
120 42 3 1 
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Table A3.12: Complete lymphoproliferative results for PBMCs of naïve individuals used 
as controls in Ghana by day. Data is given in geometric mean cpm (left-hand tables) 
and SI (PfSE/uRBC with and without control IgG or alL-12, right-hand tables)(ND = not 
done). 
a) Day 2 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
DAY ABC IgG czIL-12 PfSE IgG aIL-12 PHA IgG aIL-12 Donor PfSE IgG cxIL-12 
C2 404 403 415 438 408 381 2873 5435 5068 C2 1 1 1 
C4 24 10 30 58 56 50 4499 6539 7966 C4 2 5 2 
b) Day 3  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
DAY RBC IgG (x(L12 PfSE IgG aIL-12 PHA IgG cdL-12 Donor PfSE IgG uIL-12 
C2 160 157 122 164 167 164 3967 8331 7573 C2 1 1 1 
C3 28 25 24 60 75 54 3882 5485 5628 C3 2 3 2 
C4 32 38 32 114 149 139 8257 12579 12995 C4 4 4 4 
C5 104 25 77 397 214 267 13252 ND ND CS 4 9 3 
c) Day 5  
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
DAY ABC IgG IL-12 PfSE IgG aIL-12 PHA IgG cdL-12 Donor PfSE IgG aIL-12 
C2 73 60 45 196 120 199 2825 6683 3307 C2 3 2 4 
C3 42 39 35 361 306 333 2741 4871 5792 C3 9 8 9 
C4 135 90 76 935 633 646 7393 7541 8563 C4 7 7 8 
d) Day 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ PfSE+ 
DAY ABC IgG cxIL-12 PfSE IgG cxIL-12 PHA IgG (AL-12 Donor PfSE IgG (AL-12 
C2 91 86 53 239 502 284 1142 971 1650 C2 3 6 S 
C3 65 54 50 986 670 855 1570 1724 1689 C3 15 12 17 
C4 80 142 80 1310 894 908 3012 1671 1860 C4 16 6 11 
CS 38 175 49 5561 3545 3484 3203 ND ND C5 146 20 71 
e) Day 9 _____ 
RBC+ RBC+ PfSE+ PfSE+ PHA+ PHA+ PfSE+ P IS E+ 
DAY ABC IgG aIL-12 PfSE IgG czIL-12 PHA IgG cdL-12 Donor PfSE IgG(AL-12 
C2 207 163 114 1436 1385 733 863 437 598 C2 7 8 6 
C3 98 61 69 2186 1513 1777 487 1020 1242 C3 22 25 26 
C4 187 424 386 1753 1776 2197 1265 1184 2235 C4 9 4 6 
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Table A313: Complete IL-1 0 (pg/mi) results for PBMCs of naïve individuals by day. 
Data is given in arithmetic mean (left-hand tables) and Ag-specific responses (Ag-
uRBC, right-hand tables)(ND = not done). 
a) Day 1  
Donor RBC PfSE PHA Donor PfSE PHA 
N2 48 45 76 N2 -3 28 
N3 42 42 44 N3 0 2 
N4 55 50 61 N4 -5 6 
N5 41 42 45 N5 1 4 
N12 54 53 ND N12 -1 ND 
N13 108 145 ND N13 36 ND 
N14 45 50 ND N14 6 ND 
N15 44 48 ND N15 4 ND 
N16 46 62 ND N16 16 ND 
N17 40 46 ND N17 6 ND 
N18 48 64 ND N18 16 ND 
N19 50 66 ND N19 17 ND 
b) Day 2  
Donor RBC PfSE PHA Donor PfSE PHA 
N2 46 45 371 N2 -1 325 
N3 73 86 233 N3 12 160 
N4 86 69 297 N4 -17 211 
N5 46 54 142 N5 8 97 
N6 100 79 263 N6 -20 163 
N7 103 111 ND N7 7 ND 
N8 51 55 72 N8 4 21 
N9 233 209 540 N9 -24 306 
N10 46 44 91 N10 -2 45 
Nil 46 44 102 Nil -3 56 
N12 44 48 127 N12 4 83 
N13 86 100 160 N13 14 74 
N14 51 49 112 N14 -2 61 
N15 ND 49 63 N15 ND ND 
N16 44 49 158 N16 5 114 
N17 41 42 145 N17 0 104 
N18 42 49 136 N18 7 95 
N19 50 50 190 N19 -1 140 
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Table A3.13 (continued): 
c) Day 4  
Donor RBC PfSE PHA Donor PfSE PHA 
N2 43 50 284 N2 7 241 
N3 85 68 229 N3 -17 144 
N4 108 75 577 N4 -33 470 
N5 50 63 145 N5 13 96 
N6 88 70 510 N6 -18 423 
N7 106 93 302 N7 -13 196 
N8 50 58 127 N8 8 77 
N9 218 174 486 N9 -44 267 
N10 43 49 179 N10 6 136 
Nil 47 43 111 Nil -3 64 
N12 47 53 178 N12 6 131 
N13 65 90 152 N13 24 87 
N14 52 50 108 N14 -3 56 
N15 44 50 70 N15 5 25 
N16 44 49 120 N16 5 76 
N17 42 41 107 N17 -1 64 
N18 43 51 147 N18 8 104 
N19 42 52 164 N19 9 122 
d) Day 6  
Donor RBC PfSE PHA Donor PfSE PHA 
N2 46 67 193 N2 22 147 
N3 92 77 188 N3 -15 96 
N4 113 77 321 N4 -36 208 
N5 41 57 111 N5 16 70 
N6 88 69 346 N6 -19 257 
N7 74 100 202 N7 26 128 
N8 52 45 109 N8 -7 57 
N9 125 155 226 N9 30 101 
N10 46 48 123 N10 2 77 
Nil 47 43 108 Nil -4 61 
N12 46 49 130 N12 4 84 
N13 69 91 103 N13 22 34 
N14 52 48 97 N14 -4 45 
N15 46 47 68 N15 0 22 
N16 ND 47 107 N16 ND ND 
N17 41 41 83 N17 0 42 
N18 44 44 104 N18 0 60 
N19 43 48 153 N19 5 110 
Table A3.13 (continued): 
e) Day 8 
Donor RBC PfSE PHA Donor PfSE PHA 
N2 48 75 91 N2 27 43 
N3 80 103 110 N3 23 30 
N4 lii 69 218 N4 -43 107 
N5 43 54 89 N5 12 46 
N6 78 72 190 N6 -7 112 
N7 72 110 262 N7 39 190 
N8 49 46 116 N8 -3 67 
N9 94 107 107 N9 13 13 
N10 45 47 122 N10 1 76 
Nil 47 44 78 Nil -2 32 
N12 45 45 107 N12 0 62 
N13 64 74 95 N13 10 32 
N14 54 51 99 N14 -3 46 
N15 47 45 63 N15 -3 15 
N16 44 48 96 N16 4 52 
N17 43 43 89 N17 0 46 
N18 44 43 110 N18 0 66 
N19 44 48 147 N19 4 104 
Table A3.14: Complete IL-10 (pg/mi) results for PBMCs of exposed individuals by day. 
Data is given in arithmetic mean (left-hand tables and Ag-specific responses (Ag-uRBC, 
right-hand tables)(ND = not done). 
a) Day 1  
Donor RBC PfSE PHA Donor PfSE PHA 
El 42 45 ND El 3 ND 
E2 56 68 85 E2 12 29 
E3 51 55 ND E3 3 ND 
E5 108 106 163 E5 -2 55 
E6 150 132 85 E6 -19 -66 
E7 65 71 85 E7 6 19 
E8 48 48 46 E8 0 -2 
E9 44 44 54 E9 0 10 
ElO 72 70 138 ElO -2 66 
Eli 53 57 87 Eli 4 34 
E12 64 58 95 E12 -6 31 
E14 68 62 83 E14 -6 15 
E15 139 130 247 E15 -9 108 
E16 53 56 112 E16 3 58 
E17 112 75 191 E17 -36 79 
E18 44 48 55 E18 4 11 
E19 115 113 102 E19 -1 -13 
E20 64 62 75 E20 -2 11 
E21 50 53 56 E21 2 6 
E22 66 59 98 E22 -7 32 
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Table A3.14 (continued): 
b) Day 2 
Donor RBC PfSE PHA 
El 46 42 ND 
E2 58 64 134 
E3 53 54 ND 
E5 68 66 161 
E6 65 64 101 
E7 75 88 130 
E8 44 47 52 
E9 48 53 73 
ElO 78 90 256 
Eli 53 63 304 
E12 62 76 247 
E14 70 74 304 
E15 143 209 505 
E16 57 69 549 
E17 209 76 207 
E18 50 50 98 
E19 ND 70 125 
E20 69 76 120 
E21 45 45 65 
E22 73 66 196 
c) Day 4 
Donor RBC PfSE PHA 
El 44 43 64 
E2 59 69 138 
E3 51 54 66 
E5 72 61 158 
E6 71 68 80 
E7 69 86 150 
E8 42 47 60 
E9 47 50 80 
ElO 63 85 302 
Eli 47 49 438 
E12 58 60 320 
E14 48 56 255 
E15 92 96 400 
E16 67 75 1373 
E17 182 ND 120 
E18 52 51 129 
E19 ND 63 124 
E20 58 74 113 
E21 ND 47 77 
E22 73 72 407 
Donor PfSE PHA 
El -4 ND 
E2 6 76 
E3 1 ND 
ES -3 93 
E6 -1 37 
E7 13 54 
E8 3 8 
E9 5 25 
ElO 11 178 
Eli 10 251 
E12 14 185 
E14 4 234 
EiS 66 362 
E16 11 491 
E17 -132 -2 
E18 0 48 
E19 ND ND 
E20 8 52 
E21 1 21 
E22 -7 123 
Donor PfSE PHA 
El 0 20 
E2 10 79 
E3 3 15 
ES -10 87 
E6 -3 9 
E7 17 81 
E8 4 18 
E9 3 33 
ElO 22 239 
Eli 2 390 
E12 2 263 
E14 8 207 
E15 4 308 
E16 8 1306 
E17 ND -62 
E18 -1 77 
E19 ND ND 
E20 16 55 
E21 ND ND 
E22 -1 334 
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Table A3.14 (continued): 
d) Day 6  
Donor RBC PfSE PHA Donor PfSE PHA 
El 44 45 51 El 1 8 
E2 55 54 123 E2 0 68 
E3 50 52 70 E3 2 20 
E5 53 52 81 E5 -1 28 
E6 64 80 114 E6 16 50 
E7 ND ND 156 E7 ND ND 
E8 44 47 65 E8 2 21 
E9 43 48 87 E9 6 44 
ElO 60 73 174 ElO 13 114 
Eli 47 48 242 Eli 1 194 
E12 55 68 265 E12 13 211 
E14 49 60 304 E14 11 255 
E15 69 91 439 E15 22 370 
E16 63 77 988 E16 15 926 
E17 115 53 107 E17 -62 -8 
E18 55 48 120 E18 -8 65 
E19 ND 59 124 E19 ND ND 
E20 ND 66 121 E20 ND ND 
E21 44 43 69 E21 -1 25 
E22 69 67 287 E22 -2 218 
e) Day 8  
Donor RBC PfSE PHA Donor PfSE PHA 
El 45 43 56 El -2 11 
E2 51 47 138 E2 -4 87 
E3 ND ND 71 E3 ND ND 
E5 54 53 74 ES -1 20 
E6 53 66 87 E6 12 34 
E7 ND ND 153 E7 ND ND 
E8 43 42 61 E8 -1 18 
E9 42 49 72 E9 7 29 
ElO 57 65 152 ElO 7 95 
Ell 47 55 207 Ell 8 160 
E12 48 60 173 E12 12 125 
E14 47 76 229 E14 29 181 
E15 64 105 384 E15 41 320 
E16 ND ND 698 E16 ND ND 
E17 99 150 79 E17 52 -19 
E18 46 56 76 E18 10 30 
E19 ND 73 126 E19 ND ND 
E20 59 71 184 E20 12 125 
E21 44 78 80 E21 34 36 
E22 68 60 323 E22 -9 255 
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Table A3.15: Complete IL-10 (pg/mi) results for PBMCs of immune individuals by day. 
Data is given in arithmetic mean (left-hand tables) and Ag-specific responses (Ag-
uRBC, right-hand tables)(ND = not done). 
a) Day 2  
Donor RBC PfSE PHA Donor PfSE PHA 
Il 39 39 45 Ii 0 6 
12 40 42 52 12 2 11 
13 39 40 57 13 1 18 
14 41 42 50 14 1 9 
15 46 51 66 15 5 19 
16 41 42 51 16 2 10 
17 43 43 64 17 0 21 
18 43 42 60 18 -1 17 
19 46 51 160 19 5 114 
110 43 47 86 110 4 43 
Iii 40 42 65 Iii 2 25 
112 40 41 47 112 1 7 
113 40 43 53 113 3 13 
114 43 44 124 114 2 81 
115 41 41 71 115 0 30 
116 40 41 41 116 1 1 
117 40 41 66 117 1 26 
118 42 45 108 118 3 66 
b) Day 4  
Donor RBC PtSE PHA Donor PfSE PHA 
Ii 39 39 42 Ii 0 3 
12 41 43 51 12 1 10 
13 39 40 52 13 1 13 
14 42 43 46 14 1 4 
15 43 48 72 15 5 29 
17 42 44 66 17 2 24 
18 41 42 74 18 1 33 
Ill 41 43 81 Iii 2 40 
113 40 43 45 113 3 5 
114 41 43 91 114 2 50 
115 41 42 52 115 1 11 
116 40 42 40 116 2 0 
118 42 43 64 118 1 22 
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Table A3.15 (continued): 
c) Day 6  
Donor RBC PfSE PHA Donor PfSE PHA 
Ii 39 39 42 Ii 1 3 
12 41 46 51 12 5 10 
13 40 41 53 13 0 12 
14 41 44 46 14 4 5 
15 45 49 68 15 4 23 
16 40 42 52 16 2 12 
17 41 43 60 17 2 18 
18 40 42 63 18 2 23 
19 43 47 95 19 4 51 
110 43 45 108 110 2 65 
Iii 40 45 79 lii 4 39 
112 40 42 49 112 2 9 
113 41 42 46 113 2 5 
114 42 43 74 114 2 32 
115 40 41 52 115 1 12 
116 41 43 40 116 2 -1 
117 41 44 57 117 3 16 
118 42 44 81 118 2 39 
119 40 43 168 119 3 128 
120 41 43 99 120 2 58 
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Table A3.16: Complete IL-1 0 (pg/mi) results for PBMCs of naïve individuals used as 
controls in Ghana by day. Data is given in arithmetic mean (left-hand tables) and Ag- 
specific responses (Ag-uRBC, right-hand tables)(ND = not done). 
a) Day 1  
Donor RBC PfSE PHA Donor PfSE PHA 
C2 86 78 125 C2 -9 39 
C4 49 50 60 C4 1 11 
b) Day 2  
Donor RBC PfSE PHA Donor PfSE PHA 
02 81 103 146 02 22 65 
C3 56 66 72 C3 9 15 
C4 49 54 97 C4 5 48 
C5 46 54 96 C5 8 50 
c) Day 4  
Donor RBC PfSE PHA Donor PfSE PHA 
C2 84 127 112 C2 43 28 
03 74 87 94 C3 13 20 
C4 55 62 92 C4 7 38 
d) Day 6  
Donor RBC PfSE PHA Donor PtSE PHA 
02 80 178 108 C2 98 27 
03 65 72 67 C3 6 2 
C4 57 61 73 C4 4 17 
05 47 51 64 CS 4 18 
e) Day 8  
Donor RBC PfSE PHA Donor PfSE PHA 
02 81 136 127 C2 55 46 
03 70 61 88 C3 -10 18 
04 53 58 62 C4 5 8 
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Appendix 4 
Table A4.1: Total number of cells cultured and harvested for each naïve donor for 
phenotypic analysis (cells are indicated as 10). 
EiO Eäj3 L,7 
FM FM an FEC PM RA RD 
Wu Td OJtuaI Hrwetw OltuBi Hneskr Qi1u1 I* Qitual WYMkX QltuuJ HrAskx Qitual Hneskc Oltual Krieft  
NB 5) 20 105 2) 	103 a) 110 2) 	69 2) 90 2) 124 23 88 
NY 8) 23 138 2) 150 2) 102 23 105 23 138 2) 138 2) 52 
NB 5) 23 103 2) 	23 2) 11.3 2) 	83 23 173 2) 140 23 140 
N13 8) 2) 88 23 11.0 2) 47 2) 52 2) 102 2) 69 2) 47 
N14 5) 2) 140 2) 	198 29 88 2) 	160 23 171 23 124 2) 21 
MS 5) 2) 140 2) 138 2) 80 2) 11.6 23 146 2) 80 2) 96 
N17 8) 23 140 2) 	138 2) 77 2) 	44 2) 99 2) 127 23 102 
NiB 5) 2) 93 2) 105 2) 41 2) 36 2) 50 20 154 2) 69 
M9 3) 2) 85 2) 	133 2) 11.6 2) 	256 2) 157 2) ai9 2) 102 
N) 8) 2) 168 2) 145 2) 44 2) 102 20 72 2) 338 20 140 
Table A42: Total number of cells cultured and harvested for each exposed donor for 
phenotypic analysis (cells are indicated as 10). 
Day  Wy7 
cm FIBC PfSE fl-IA PA) 
Donor Total Cdtised Haivested Cdtired I-bwsted Ctued Wrvested Cdtiid Haivested Cdtued Haiwsted 
El 20 40 9.0 40 15.0 40 12.2 40 17.0 40 11.8 
E2 20 40 8.8 40 84 40 8.0 40 14.8 40 8.8 
E3 20 40 186 40 19.0 40 17.6 40 17.4 40 24.0 
E4 20 40 15.2 40 15.0 40 186 40 11.2 40 19.0 
ES 20 40 11.6 40 21.4 40 11.2 40 29.0 40 182 
ES 20 40 19.6 40 16.8 40 16.2 40 19.4 40 19.4 
E7 20 40 iao 40 13.8 40 13.6 40 14.4 40 9.0 
E8 20 40 14.2 40 ao 40 130 40 128 40 19.0 
E9 20 40 22.4 40 30.2 40 17.6 40 23.0 40 19.6 
ElO 20 40 10.4 40 7.2 40 12.0 40 ao 40 134 
Ell 20 40 12.8 40 11.8 40 120 40 80 40 142 
E12 20 40 10.0 40 7.4 40 13.6 40 86 40 20.6 
E14 20 40 14.2 40 17.4 40 15.0 40 15.2 40 82 
E15 20 40 19.4 40 88 40 11.2 40 134 40 23.4 
E16 20 40 24.2 40 282 40 180 40 44.4 40 24.8 
E17 20 40 17.2 40 13.0 40 14.6 40 220 40 15.2 
E18 20 40 14.8 40 16.2 40 17.0 40 11.0 40 10.4 
E19 2) 40 11.6 40 11.6 40 138 40 322 40 220 
E20 20 40 14.0 40 220 40 15.2 40 20.8 40 51.0 
E21 20 40 15.8 40 162 40 220 40 224 40 20.4 
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Table A4.3: Total number of cells cultured and harvested for each immune donor for 
phenotypic analysis (cells are indicated as 10). 
Day  Day Day 
RBC PfSE RBC PfSE 
Donor Total Cultured Harvested Cultured Harvested Cultured Harvested Cultured Harvested 
Il 4 10 3.2 10 1.7 10 3.8 10 1.7 
12 4 5 2.4 5 1.8 5 1.7 5 2.0 
13 4 25 14.7 25 1.7 25 2.7 25 4.5 
14 4 10 4.2 10 2.3 10 1.1 10 1.1 
15 4 50 24.2 50 20.0 50 15.6 50 9.8 
7 4 10 3.3 10 3.5 10 3.8 10 2.7 
8 4 5 3.8 5 2.3 5 0.8 5 1.8 
19 4 5 1.1 5 3.0 5 1.4 5 1.7 
Ill 4 5 3.0 5 1.2 5 2.3 5 1.4 
12 4 5 0.9 5 1.1 5 2.1 5 4.1 
113 4 25 3.2 25 4.1 25 5.4 25 6.3 
114 4 10 2.7 10 1.2 10 2.3 10 2.3 
115 4 25 4.7 25 6.5 25 2.3 25 2.0 
116 4 5 2.0 5 0.6 5 1.2 5 0.6 
117 4 5 0.3 5 0.6 5 1.2 5 1.2 
118 4 10 1.4 10 1.1 10 1.5 10 0.9 
119 4 5 ND 5 ND 5 1.7 5 3.2 
120 4 5 ND 5 ND 5 1.2 5 2.3 
Table A4.4: Total number of cells cultured and harvested for each naïve donor used as 
controls in Ghana for phenotypic analysis (cells are indicated as 105). 
EbyD 	 E,7 
Donor Td2d Oitiied l-wed Oitued I-ed Oitued t-ed Oitued I-Li'edOitued l-ed 
Cl 	20 	29 	10 	23 	a4 	29 	8 	20 	21.6 	a) 	6 
C2 2) 40 53 40 7.6 40 a5 40 15 40 55 
C4 	2) 	2) 	32 	40 	51 	40 	11 	40 	112 	40 	127 
WMI 
Table A45: Summary data for percentages of cellular subsets stained on 	a) day 
0, b) day 3 and c) day 7 for naïve individuals (arithmetic mean and SEM indicated). 
Resting cells (Ri) and lymphoblasts (R2) are indicated for each stimuli. 
a) 
RI R2 
% in gate 83.59 8.33 
1.17 0.62 
CD20 5.23 2.50 
0.56 0.43 
CD56 1.73 7.40 
0.29 1.52 
CD56/CD3 0.37 4.71 
0.08 1.06 
Total CD3 77.97 64.36 
2.44 2.88 
CD45RNCD3 51.26 31.99 
3.69 2.11 
CD45RO/CD3 55.12 62.70 
2.56 2.65 
TcRc3/CD3 67.07 21.81 
2.45 2.24 
TcRy/CD3 3.81 2.53 
0.84 0.48 
CD4ICD3 43.50 56.69 
3.67 2.61 
CD8/CD3 19.90 28.35 
2.15 2.32 
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Table A4.5 (continued): 
b) 
RBC 	 PFSE 
Ri R2 	Ri 	R2 
% in gate 86.80 1.49 82.61 1.91 
1.16 0.09 1.34 0.15 
CD20 1.02 2.73 0.85 3.56 
0.23 0.63 0.18 0.78 
CD56 0.22 0.20 0.47 2.20 
0.06 0.16 0.11 0.57 
CD56/CD3 0.08 0.08 0.14 0.24 
0.06 0.08 0.10 0.17 
CD3 81.82 81.54 80.61 72.34 
- 	- 2.01 2.28 1.97 2.45 
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Table A4.5 (continued): 
C) 
CM ABC PISE PHA PPD 
Ri R2 Al R2 Ri R2 Al R2 Ri R2 
% in gate 39.04 0.52 39.33 0.45 43.60 7.95 10.98 16.12 30.44 10.12 
2.42 0.11 2.65 0.09 2.49 1.02 1.20 0.78 4.30 2.71 
CD20 5.50 13.78 5.71 14.63 10.72 7.66 3.02 2.94 6.72 6.16 
1.11 4.42 1.00 3.17 2.10 1.61 0.60 0.77 1.45 1.50 
CD56 1.98 2.51 1.84 3.68 3.33 2.51 4.47 0.19 4.94 2.04 
0.65 1.15 0.67 1.72 0.75 0.74 0.49 0.05 0.70 0.51 
CD56/CD3 1.39 0.94 1.34 2.19 0.63 0.81 0.45 0.10 1.53 0.26 
0.64 0.54 0.67 1.56 0.22 0.52 0.07 0.03 0.63 0.09 
TotaICD3 83.78 55.29 83.92 62.80 79.11 83.44 82.26 93.76 84.03 83.38 
2.22 7.17 1.83 5.09 2.60 2.77 2.11 1.57 1.43 3.85 
CD45RAICD3 42.81 27.00 42.19 35.13 41.83 16.51 31.23 34.14 46.52 20.72 
2.69 3.54 3.95 7.13 3.16 1.05 2.91 2.49 3.22 2.70 
CD45RO/CD3 17.81 25.54 16.78 18.60 17.13 71.98 31.03 42.78 21.38 67.95 
3.52 6.59 3.18 6.45 2.82 3.52 3.53 5.30 2.97 7.08 
TcRc43/CD3 25.56 27.62 25.14 25.97 26.33 52.82 27.12 56.84 30.92 56.25 
3.86 2.95 4.03 5.11 4.50 4.65 3.94 4.61 4.17 6.00 
TcRy5/CD3 4.92 5.75 4.73 2.17 3.85 11.53 4.21 8.07 4.97 11.24 
0.90 2.45 1.26 1.13 0.67 0.77 0.63 1.13 0.99 2.03 
CD4ICD3 51.10 34.98 50.97 31.80 47.58 79.39 44.19 61.62 53.06 76.64 
3.25 4.01 3.45 4.32 3.22 2.61 3.85 4.54 2.31 5.63 
CD8/CD3 15.20 8.98 14.49 8.55 16.08 2.24 24.02 30.32 17.72 6.55 
2.98 2.42 2.94 2.00 3.33 0.56 4.07 4.07 3.31 2.18 
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Table A46: Summary data for total numbers of cells of cellular subsets stained on a) 
day 0, b) day 3 and c) day 7 for naïve individuals (arithmetic mean and SEM indicated, 
cells are per 106  cells plated on day 0). Resting cells (Ri) and lymphoblasts (112) are 




cells in gate 	835890 83290 
11671 	6247 
CD20 	 43691 	2016 
4786 280 
CD56 	 14464 	5901 
2362 1162 
CD56/CD3 	3083 	3770 
648 819 
Total CD3 	653704 	53726 
27286 4898 
CD45RAICD3 	431477 	26490 
35693 2374 
CD45RO/CD3 460364 52386 
21344 	4767 
TcRab/CD3 	562723 	17812 
26590 1898 
TcRgd/CD3 	31648 	2085 
6932 373 
CD4/CD3 	367044 	46881 
35011 3586 
CD8/CD3 	165440 	23755 
17349 2679 
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Table A4.6 (continued): 
b) 
RBC 	 PFSE 
Ri R2 	Ri 	R2 
cells in gate 501282 8413 534840 12461 
44938 726 43645 1054 
CD20 4737 225 4351 425 
1066 48 1311 94 
CD56 982 18 2501 274 
201 15 517 68 
CD56/CD3 310 7 703 32 
219 7 490 23 
CD3 413835 6909 429122 9031 
41866 720 39260 963 
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Table A4.6 (continued): 
C) 
CM RBC PfSE PHA PPD 
Ri R2 Al R2 Al R2 Ri R2 Ri R2 
cells in gate 162397 2227 208069 2554 269361 48125 80117 124188 136778 53519 
23119 642 52689 886 39035 8689 12840 21326 19391 17437 
CD20 9351 362 13739 312 31013 3163 2396 3585 11150 1714 
2687 133 5792 113 9218 658 537 1104 4520 370 
CD56 2526 109 3118 79 8496 796 3358 243 6129 1061 
444 58 1063 32 2199 138 469 93 832 337 
CD56/CD3 1513 30 1875 19 1725 145 366 118 1880 176 
455 18 838 10 752 79 111 38 993 73 
Total CD3 137251 1367 175481 1681 213098 41721 66439 116333 114512 48909 
20904 554 44109 615 30834 8324 11429 19479 15315 16965 
CD45RA/CD3 71254 607 101966 1086 118620 8042 24990 43489 67215 8869 
11188 261 33553 575 22530 1434 4681 8339 14276 2669 
CD45RO/CD3 29989 642 26291 472 42846 36706 23651 49971 26590 43974 
9421 255 5314 151 9135 7982 4406 8643 3766 15806 
TcRc4/CD3 44724 699 52743 846 74040 28065 20224 68290 40365 35890 
9112 224 12530 353 15697 6740 3376 9059 5269 12219 
TcR-y8/CD3 6964 94 8017 36 10350 6017 3363 10216 6493 7250 
1135 43 2196 16 2075 1256 684 2579 1315 2782 
CD4/CD3 87245 873 114422 1037 135161 39499 36368 76081 74129 47282 
15725 374 32010 477 24444 7850 7282 11938 11496 16865 
CD8/CD3 22945 210 25410 224 35915 1000 18500 38603 22632 1323 
4908.74 98.95 5343.13 62.31 5167.48 243.46 3463.00 9433.94 3976.45 314.05 
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Table A4.7: Summary data for percentages of cellular subsets stained on 	a) day 
o and b) day 7 for exposed individuals (arithmetic mean and SEM indicated). Resting 
cells (Al) and lymphoblasts (R2) are indicated for each stimuli. 
a) 
Ri R2 
% in gate 44.69 7.78 
3.91 2.08 
CD20 10.05 16.71 
1.23 2.64 
CD20/C045R0 0.07 0.46 
0.04 0.10 
CD56 0.86 3.15 
0.44 1.01 
CD56/CD45RO 0.44 1.11 
0.41 0.78 
Total CD3 58.21 52.52 
2.47 2.93 
CD45RA/CD3 31.44 24.13 
1.92 2.08 
CD45RO/CD3 20.49 30.90 
1.78 2.25 
TcRaIl/CD3 1.49 3.18 
0.42 0.70 
TcR4I/CD45RO 0.20 1.19 
0.05 0.20 
TcR/CD3 3.22 5.64 
0.62 0.70 
TcRy6/CD45RO 0.35 2.33 
0.05 0.38 
CD4/CD3 31.60 36.54 
2.67 2.70 
CD4/CD45RO 10.66 19.48 
1.32 2.15 
CD8ICD3 15.61 28.93 
1.68 1.69 
CD8/C045R0 1.92 4.79 
0.84 1.14 
TcR Vy9/CD3 3.62 4.68 
1.03 1.43 
TcR V79/CD45RO 0.26 1.25 
0.10 0.28 
TcR V81/CD3 2.77 3.95 
0.62 0.74 
TcR V61/CD45RO 0.04 0.79 
0.01 0.20 
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Table A4.7 (continued): 
b) 
CM ABC PfSE PHA PPD 
Ri R2 Ri R2 Al R2 Ri R2 Al R2 
% in gate 39.01 4.14 40.16 3.27 39.04 4.64 29.79 16.74 36.96 7.38 
1.70 0.92 2.10 0.42 1.74 0.47 1.19 1.76 1.67 1.09 
CD20 7.03 11.62 6.23 10.13 6.57 13.67 8.95 23.40 5.82 13.48 
1.23 1.69 0.92 1.61 0.83 1.94 1.46 3.34 0.83 1.63 
CD20/CD45RO 0.07 0.84 0.04 1.24 0.05 1.25 0.55 3.37 0.05 1.39 
0.01 0.16 0.01 0.29 0.01 0.22 0.44 1.72 0.02 0.25 
CD56 3.60 8.68 3.56 8.34 4.25 12.18 5.20 7.96 5.27 13.18 
0.86 1.52 0.97 1.57 0.89 1.57 2.15 3.64 1.15 1.47 
CD56/CD45RO 0.19 1.30 0.15 1.73 0.14 2.38 1.11 3.02 0.18 2.69 
0.05 0.38 0.04 0.55 0.04 0.71 0.97 2.02 0.05 0.59 
Total CD3 45.46 54.88 44.60 53.41 44.30 57.52 45.14 69.70 46.40 63.72 
4.00 5.05 4.11 4.22 3.91 4.13 4.74 3.69 3.94 3.82 
CD45RA/CD3 21.61 29.43 21.11 28.19 19.61 19.51 14.46 27.35 19.95 16.49 
2.39 3.23 2.46 2,69 2.31 2.42 2.14 2.74 2.15 2,19 
CD45RO/CD3 15.45 33.38 15.67 31.55 16.51 42.86 21.72 43.86 19.01 51.65 
1.70 3.78 1.76 3.26 1.70 3.43 2.33 2.55 2.05 3.86 
TcRc3/CD3 0.65 5.74 0.59 4.86 0.71 8.26 4.12 16.51 1.85 10.38 
0.23 1.20 0.21 1.37 0.25 1.54 1.59 3.07 0.87 2.20 
TcRcz3/CD45RO 0.28 4.80 0.24 2.81 0.35 7.43 1.44 9.77 0.90 9.29 
0.09 0.78 0.09 0.57 0.12 1.36 0.45 1.32 0.40 1.81 
TcR78/CD3 2.38 4.52 2.23 5.75 2.04 5.74 2.31 4.10 2.52 6.37 
0.46 0.65 0.49 1.15 0.51 0.77 0.63 1.15 0.54 1.17 
TcFt7/CD45RO 0.45 3.15 0.34 4.23 0.45 4.32 0.87 2.96 0.61 4.92 
0.10 0.39 0.06 1.08 0.09 0.61 0.37 1.13 0.17 1.07 
CD4/CD3 29.52 40.44 30.05 40.33 28.11 43.60 21.20 36.86 31.09 52.60 
2.49 3.48 2.80 3.46 2.92 3.49 2.35 2.99 2.80 3.53 
CD4/CD45RO 13.12 26.83 13.70 27.68 13.16 35.18 11.56 24.23 16.11 45.02 
1.56 2.87 1.71 3.04 1.40 3.16 1.51 2.40 1.93 3.75 
CD8/CD3 12.56 28.23 12.12 26.11 13.34 25.63 20.45 42.32 12.34 16.90 
1.53 3.21 1.59 2.93 1.52 3.08 3.45 4.52 1.39 1.57 
CD8/CD45RO 1.46 10.28 1.34 9.60 1.72 11.61 3.75 11.11 1.66 9.44 
0.26 1.77 0.25 1.37 0.30 1.41 1.01 1.53 0.44 1.00 
TcR Vy9/CD3 1.26 3.78 1.28 3.20 1.38 3.54 3.38 5.35 1.43 3.28 
0.21 0.42 0.21 0.39 0.32 0.82 2.11 3.09 0.29 0.86 
TcR Vy9/CD45RO 0.27 2.20 0.26 1.79 0.36 2.46 0.96 2.29 0.34 2.56 
0.05 0.35 0.06 0.29 0.09 0.72 0.41 0.91 . 	0.16 0.88 
TcR V1/CD3 1.46 2.29 1.46 2.25 1.55 3.62 1.90 3.78 1.91 4.90 
0,34 0.48 0.35 0.45 0.39 0.90 0.55 1.29 0.47 1.30 
TcR V51/CD45IRO 0.14 1.25 0.11 1.04 0.15 2.38 0.54 2.56 0.37 3.35 
0.07 0.31 0.04 0.24 0.06 0.92 0.38 1.46 0.21 1.20 
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Table A48: Summary data for total numbers of cells of cellular subsets stained on a) 
day 0 and b) day 7 for exposed individuals (arithmetic mean and SEM indicated, cells 
are per 106  cells plated on day 0). Resting cells (Ri) and lymphoblasts (R2) are 
indicated for each stimuli. 
a) 
RI R2 
cells in gate 446906 77839 
39128 20839 
CD20 45036 13135 
6505 4208 
CD20/CD45RO 280 264 
128 68 
CD56 3483 2128 
1542 647 
CD56/CD45RO 1544 549 
1386 361 
TotaICD3 263549 45614 
27631 15876 
CD45RA/CD3 142431 21700 
16436 8308 
CD45RO/CD3 90857 26431 
11629 8509 
TcRa)/CD3 6174 2994 
2003 1371 
TcRcx)3/CD45RO 823 958 
265 321 
TcRy6/CD3 15954 5202 
3886 1671 
TcRy8/CD45RO 1531 1935 
265 505 
CD4/CD3 138164 29161 
17507 9384 
CD4/CD45RO 45853 15307 
6867 4949 
CD8/CD3 71849 23729 
11433 6791 
CD8/CD45RO 9817 3732 
4803 1125 
TcRVy9/CD3 17619 4189 
5697 1643 
TcRVy9/CD45RO 1092 1087 
388 383 
IcR V61/CD3 13288 3231 
3446 1007 
IcR V61/CD45RO 208 450 
59 106 
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Table A4.8 (continued): 
b) 
CM ABC PfSE PHA PPD 
Ri A2 Al R2 Al R2 Ri R2 Ri R2 
cells in gate 147869 15471 154679 12405 141076 16327 130214 75555 166768 47546 
13869 3498 16344 1940 8751 1709 16365 16019 19176 13779 
CO20 10286 1746 9969 1243 9457 2371 10325 15865 9737 7254 
1936 396 1924 365 1472 597 1691 2765 1780 3272 
CD20/CD45RO 103 137 60 126 68 205 392 1738 90 529 
24 39 17 33 14 51 247 645 36 138 
CD56 5982 1671 5418 842 6422 1812 5133 4761 9275 5373 
1514 680 1230 174 1523 293 1301 1626 2523 1265 
CD56/CD45RO 342 197 246 164 195 326 745 1393 314 1164 
130 57 84 61 57 101 541 746 98 379 
Total CO3 71392 8275 71022 5578 65621 8724 63810 55813 84395 30950 
11263 2444 10121 656 8353 902 11639 12456 14497 8908 
CD45FtA/CD3 34295 4481 33933 3051 29273 2788 21396 21704 34405 5854 
5891 1454 5450 428 4544 307 5010 5131 5224 1489 
CD45RO/CD3 22916 5029 23164 3114 23434 6643 29904 36232 34062 26165 
3518 1478 2893 334 2522 786 5701 9675 6161 7557 
TcRa/CD3 1118 776 1224 612 1094 1471 8853 18812 5239 7639 
459 202 546 188 396 401 4859 9058 3518 5077 
TcRaI3/CD45RO 448 635 475 340 509 1347 2400 7792 2437 6488 
169 143 222 87 179 379 912 2070 1583 4021 
TclRy/CD3 3962 826 3798 608 3124 962 3294 3744 4209 2320 
1003 259 964 109 910 173 955 1540 1039 550 
TcR-y8/CD45RO 703 576 570 416 656 746 1086 2117 978 1668 
177 172 123 73 134 157 360 743 304 417 
CD4/CD3 45955 6067 46913 4181 41470 6606 29444 29105 57756 26592 
7104 1722 6629 512 5683 737 5568 6636 10770 7992 
CD4/CD45RO 19570 3989 20517 2852 18910 5442 14691 17601 30140 23260 
3156 1097 2862 367 2232 691 2378 3293 6751 6762 
CD8/CD3 20159 3976 20024 2597 19682 4039 29784 34937 22342 6472 
3814 1115 3519 321 2880 693 6864 9496 4030 1525 
CD8/CD45RO 2541 1346 2322 980 2562 1933 5881 9410 2827 3712 
628 247 570 144 504 335 1968 2936 684 807 
TcRVy9/CD3 1976 618 2055 420 2112 668 4799 4844 2229 1461 
454 181 376 87 501 220 3242 3018 456 644 
TcRVy9/CD45RO 423 362 476 284 535 518 1217 1725 478 1079 
99 105 143 90 122 208 501 667 166 461 
TcR V81/CD3 2440 372 2535 313 2413 732 2662 3257 3106 2025 
764 99 685 72 717 246 774 1506 788 603 
TcRV51/CD45RO 222 195 216 156 217 541 551 1726 540 1319 
103 48 98 48 85 266 289 807 259 440 
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Table A4.9: Summary data for percentages of cellular subsets stained on 	a) day 
0, b) day 3 and c) day 7 for immune individuals (arithmetic mean and SEM indicated). 
Resting cells (Ri) and lymphoblasts (R2) are indicated for each stimuli. 
 
Hi 	R2 
% in gate 46.39 2.70 
5.30 0.50 
CD20 4.35 15.83 
0.51 2.15 
CD56 2.91 7.43 
0.42 1.18 
CD56/CD3 1.22 1.49 
0.19 0.31 




Ri R2 Ri R2 
% in gate 38.78 1.92 37.63 2.33 
3.93 0.30 3.80 0.43 
CD20 2.62 10.93 2.19 10.03 
0.33 1.37 0.34 1.50 
C056 2.08 3.61 2.56 2.72 
0.25 0.66 0.35 0.61 
CD56/CD3 1.31 2.48 1.54 1.65 
0.18 0.58 0.29 0.53 
CD3 74.33 70.58 71.73 70.72 
3.33 2.28 3.78 2.61 
C) 
RBC PfSE 
Al R2 Ri R2 
% in gate 31.31 1.23 31.86 1.77 
3.96 0.33 3.74 0.35 
CD20 1.81 9.89 2.02 8.84 
0.22 1.83 0.31 1.75 
CD56 3.31 4.84 2.87 4.76 
1.12 1.25 0.68 0.65 
CD56/CD3 2.56 2.72 1.89 2.12 
1.02 0.78 0.59 0.39 
CD3 77.06 68.57 74.76 73.71 
3.70 3.87 4.08 2.74 
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Table A4.1 0: Summary data for total numbers of cells of cellular subsets stained on a) 
day 0, b) day 3 and c) day 7 for immune individuals (arithmetic mean and SEM 
indicated, cells are per 106  cells plated on day 0). Resting cells (Ri) and lymphoblasts 
(R2) are indicated for each stimuli. 
a 
R  R2 
cells in gate 463889 27011 
52985 4974 
CD20 19958 4033 
3194 849 
CD56 13488 2272 
2511 554 
CD56/CD3 5562 425 
1155 81 
CD3 352601 15345 
53228 3660 
R B C PfSE 
DONOR R  R2 RI R2 
cells in gate 139322 7927 101654 7244 
23846 1972 18080 1858 
CD20 4829 922 2852 827 
1289 215 758 227 
C D 5 6 3477 312 3126 307 
918 112 742 98 
CD56/CD3 2114 210 1791 186 
531 78 464 63 
CD3 111459 5984 77577 5519 
20369 1630 14513 1528 
C) 
RBC PfSE 
Hi R2 Ri R2 
cells in gate 81942 3397 103084 5067 
14158 1127 22471 1005 
CD20 1721 347 2207 470 
474 121 516 127 
C D 5 6 2467 86 2973 341 
818 18 814 94 
CD56/CD3 1953 51 1805 162 
723 11 528 45 
CD3 67206 2586 83216 3826 
13396 946 20749 761 
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Table A4.1 1: Complete data for percentages of cellular subsets for each naïve 
individual on a) day 0, b) day 3 and c) day 7. Resting cells (Ri) and lymphoblasts (R2) 
are indicated for each stimuli (ND = not done). 
a) 
% in gate 
DONOR Ri R2 
N3 82.8 8.5 
N7 88.6 6.6 
NB 84.3 7.1 
N13 77.9 12.7 
N14 86.0 8.2 
N16 85.2 7.1 
N17 84.4 7.9 
N18 77.5 10.5 
N19 87.4 6.2 
N20 81.8 8.4 
CD2O 
DONOR Ri R2 
N3 2.5 2.6 
N7 5.3 0.9 
N8 6.0 2.3 
N13 5.4 1.7 
N14 5.7 2.1 
N16 2.5 1.3 
N17 4.0 2.5 
N18 6.5 2.3 
N19 8.1 5.9 
N20 6.3 3.5 
CD56 
DONOR Ri R2 
N3 1.3 7.4 
N7 1.5 6.1 
N8 2.4 5.2 
N13 0.9 2.6 
N14 2.0 12.4 
N16 2.6 15.8 
N17 0.5 3.5 
N18 2.1 3.5 
N19 0.7 3.8 
N20 3.3 13.7 
C D56/C D 3 
DONOR Ri R2 
N3 0.4 6.9 
N7 0.5 4.5 
N8 0.2 2.6 
N13 0.1 1.7 
N14 0.4 8.0 
N16 0.4 10.0 
N17 0.1 2.7 
N18 0.4 1.1 
N19 0.2 1.1 
N20 0.9 8.6 
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Table A4.1la (continued): 
Total CD3 
DONOR RI R2 
N3 83.7 67.2 
N7 84.8 80.8 
N8 82.4 68.0 
N13 71.0 71.4 
N14 85.3 63.1 
N16 76.6 49.8 
N17 74.0 70.2 
N18 60.5 55.6 
N19 80.9 55.8 
N20 80.5 61.9 
CD45RA/CD3 
DONOR RI R2 
N3 44.1 33.9 
N7 60.4 44.2 
N8 40.2 41.4 
N13 40.3 31.7 
N14 68.1 25.4 
N16 58.2 24.6 
N17 45.4 25.0 
N18 36.1 33.6 
N19 66.9 31.1 
N20 52.9 29.3 
CD45RO/CD3 
DONOR RI R2 
N3 66.3 66.7 
N7 45.5 76.0 
N8 67.1 66.5 
N13 54.2 69.3 
N14 51.9 60.6 
N16 45.7 48.6 
N17 58.2 69.3 
N18 47.4 54.7 
N19 52.7 54.4 
N20 62.4 61.0 
TcR43/CD3 
DONOR RI R2 
N3 71.6 8.6 
N7 73.6 17.4 
N8 65.8 22.5 
N13 58.3 18.5 
N14 77.5 31.0 
N16 68.9 29.1 
NJ17 64.9 19.8 
N18 50.8 16.6 
N19 70.3 24.4 
N20 69.1 30.3 
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Table A4.1 1 a (continued): 
TcR/CD3 
DONOR Ri R2 
N3 1.7 1.0 
N7 2.6 1.9 
N8 10.2 6.0 
N13 6.3 1.8 
N14 2.3 3.8 
N16 2.2 1.5 
N17 4.0 1.8 
N18 2.0 2.8 
N19 2.4 1.3 
N20 4.4 3.5 
CD4ICD3 
DONOR RI R2 
N3 31.0 58.5 
N7 57.6 71.0 
N8 45.1 60.2 
N13 31.8 57.3 
N14 59.8 55.6 
N16 51.2 50.7 
N17 40.9 67.9 
N18 26.2 44.6 
N19 52.0 48.5 
N20 39.5 52.5 
CD8/CD3 
DONOR Ri R2 
N3 34.4 38.9 
N7 13.0 26.9 
N8 20.8 37.0 
N13 20.9 29.1 
N14 14.0 30.0 
N16 16.2 23.2 
N17 26.6 13.2 
N18 18.1 27.2 
N19 12.8 25.0 
N20 22.2 33.2 
263 
Table A4.11 b: 
b) 
% in gate 
RBC 	 PFSE 
DONOR Ri R2 Ri R2 
N3 80.2 1.1 78.9 2.9 
N7 92.9 1.3 88.5 1.2 
N8 87.3 1.6 85.2 2.0 
N13 85.9 1.7 84.5 1.7 
N14 89.4 2.0 85.9 2.0 
N16 88.4 1.4 85.1 1.5 
N17 86.6 1.6 76.3 2.3 
N18 81.8 1.7 77.5 2.0 
N19 89.1 1.1 85.2 1.7 
N20 86.7 1.4 79.0 1.7 
CD 20 
RBC PFSE 
DONOR Ri R2 Ri R2 
N3 0.4 1.8 0.6 2.5 
N7 0.6 0.6 0.6 2.3 
N8 1.3 2.3 0.9 2.5 
N13 0.8 2.1 0.7 2.8 
N14 1.8 1.7 1.7 3.5 
N16 0.4 3.0 0.1 1.6 
N17 2.4 7.6 1.8 8.9 
N18 1.0 4.4 0.6 3.5 
N19 0.2 2.4 0.3 1.0 
N20 1.4 1.5 1.1 7.0 
CD56 
RBC PFSE 
DONOR Ri R2 Ri R2 
N3 0.1 0.0 0.4 0.9 
N7 0.0 0.0 0.1 1.2 
N8 0.3 0.0 0.9 5.0 
N13 0.2 0.4 0.5 0.0 
N14 0.1 0.0 0.2 0.0 
N16 0.1 0.0 0.3 2.6 
N17 0.1 0.0 0.3 1.0 
NiB 0.7 0.0 1.2 3.5 
N19 0.2 1.6 0.4 3.9 
N20 0.2 0.0 0.4 3.7 
C D56/C D 3 
RBC PFSE 
DONOR Ri R2 Ri R2 
N3 0.1 0.0 0.2 0.0 
N7 0.0 0.0 0.0 0.0 
N8 0.0 0.0 0.0 0.8 
N13 0.0 0.0 0.0 0.0 
N14 0.0 0.0 0.0 0.0 
N16 0.0 0.0 0.0 0.0 
N17 0.0 0.0 0.1 0.0 
N18 0.7 0.0 1.0 1.6 
N19 0.0 0.8 0.0 0.0 
N20 0.0 0.0 0.0 0.0 
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Table A4.11b (continued): 
Total CD3 
RBC PFSE 
DONOR RI R2 Ri R2 
N3 87.3 79.7 87.2 72.6 
N7 88.9 86.2 85.9 80.1 
N8 86.8 90.8 84.4 79.0 
N13 71.5 70.0 71.8 67.9 
N14 84.2 91.0 83.8 80.7 
N16 80.5 75.2 79.1 74.2 
N17 78.5 73.9 73.4 54.0 
N18 71.1 79.8 71.2 72.8 
N19 83.8 81.7 85.3 71.6 
N20 85.6 87.3 84.0 70.6 
Table A4.11c: 
C) 
% in gate 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 RI R2 RI R2 Ri R2 
N3 26.40 0.53 26.12 0.63 29.06 10.24 7.20 13.62 21.00 10.74 
N7 38.60 0.08 43.02 0.24 47.60 7.20 7.16 19.62 52.18 2.36 
N8 52.84 1.26 47.80 0.88 40.32 12.56 9.78 13.70 21.70 7.28 
N13 35.64 0.19 32.34 0.20 45.40 3.28 17.38 13.04 27.06 9.24 
N14 46.94 0.44 48.28 0.58 55.88 7.28 17.80 17.34 28.80 3.86 
N16 37.52 0.20 41.40 0.20 46.48 9.14 9.32 19.28 20.28 22.56 
N17 43.74 0.70 46.74 0.66 51.28 5.28 10.72 13.96 26.56 15.32 
N18 30.28 0.82 31.20 0.05 39.32 6.08 11.18 17.34 34.94 0.76 
N19 38.90 0.60 45.86 0.74 45.80 5.48 8.04 15.44 56.14 3.52 
N20 39.50 0.36 30.53 0.31 34.82 13.00 11.22 17.82 15.76 25.54 
CD2O 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 RI R2 RI R2 
N3 2.05 1.45 1.85 5.75 2.44 3.78 2.61 2.23 1.21 2.42 
N7 4.01 8.33 5.24 20.00 6.43 2.99 3.77 1.13 5.36 8.23 
N8 3.09 13.33 2.83 10.00 9.89 5.36 5.58 2.59 5.76 2.67 
N13 6.23 0.00 9.10 21.43 14.75 7.78 4.70 8.59 9.02 9.14 
N14 10.28 35.29 9.06 11.43 17.25 8.57 1.90 2.51 8.74 9.50 
N16 0.75 0.00 0.63 6.67 1.25 2.74 0.47 0.84 1.92 0.61 
N17 6.98 39.02 5.77 31.25 8.28 17.49 0.58 1.24 4.88 2.87 
N18 5.11 5.56 6.92 27.27 11.53 9.31 3.20 1.53 5.23 8.33 
N19 11.93 18.18 9.87 12.50 22.99 14,77 5.70 5.77 17.57 15.60 
N20 4.60 16.67 5.79 0.00 12.37 3.80 1.70 2.94 7.53 2.24 
CD56 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
N3 1,68 4.35 1.38 10.35 1.25 1.33 2.14 0.13 3.30 2.23 
N7 0.76 ND 0.22 0.00 1.72 0.00 5.78 0.11 3.21 1.90 
NB 1.15 6.67 1.24 0.00 3.39 1.25 5.58 0.15 5.58 5.34 
N13 1.23 0.00 0.68 14.29 2.19 6.11 5.77 0.17 4.73 0.29 
N14 1.07 0.00 1.78 2.86 2.98 0.57 3.27 0.00 4.31 2.71 
N16 0.71 0.00 0.40 ND 7.40 1.47 5.84 0.31 7.39 0.61 
N17 2.87 2.44 1.30 3.12 2.24 4.56 4.64 0.46 5.26 3.21 
N18 7,57 0.00 7.66 0.00 7.79 6.47 5.94 0.24 9.23 0.00 
N19 1.18 9.10 1.85 2.50 1.12 2.53 2.19 0.00 1.35 2.75 
N20 1.60 0.00 1.89 0.00 3.24 0.79 3.56 0.36 5.06 1.32 
CD 56/CD 3 
CM ABC PFSE PHA PPD 
DONOR Ri R2 Al A2 Al R2 RI R2 RI R2 
N3 1.17 1.45 1.23 2.30 0.07 0.22 0.48 0.13 0.00 0.37 
N7 0.49 ND 0.09 0.00 0.33 0.00 0.75 0.11 1.02 0.63 
N8 0.00 0.00 0.04 0.00 0.09 0.00 0.21 0.00 0.00 0.27 
N13 0.66 0.00 0.34 14.29 0.82 1.67 0.43 0.00 1.51 0.00 
N14 0.31 0.00 0.26 0.00 0.32 0.00 0.21 0.00 0.44 0.00 
N16 0.38 0.00 0.23 ND 2.45 0.00 0.70 0.21 0.20 0.23 
N17 2.25 2.44 1.02 3.12 0.54 0.76 039 0.31 0.30 0.80 
N18 6.92 0.00 7.12 0.00 0.62 5.26 0.15 0.12 8.68 0.00 
N19 0.79 4.55 1.48 0.00 0.30 0.00 0.44 0.00 0.66 0.00 
N20 0.96 0.00 1.62 0.00 0.77 0.16 0.77 0.12 2.48 0.30 
Table A4.11c (continued): 
Total CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 RI R2 Ri R2 Ri R2 
N3 93.14 54.46 88.28 47.50 91.64 85.60 88.06 95.84 91.46 86.79 
N7 86.99 80.00 87.84 93.94 85.94 91.13 85.56 97.04 88.70 79.20 
N8 91.92 85.19 90.51 52.38 84.00 91.42 79.52 96.33 87.03 87.22 
N13 70.95 20.00 69.12 42.86 68.00 68.67 71.41 82.66 76.04 85.24 
N14 79.80 47.37 82.83 76.93 74.76 83.46 87.23 95.06 80.97 81.45 
N16 80.69 50.00 84.06 75.00 85.55 92.90 81.88 98.68 84.11 97.20 
N17 87.03 71.43 85.88 54.76 83.63 69.05 83,06 95.59 85.88 88.20 
N18 83.21 73.34 83.19 50.00 69.13 79.62 70.46 95.97 83.81 53.57 
N19 76.02 21.06 83.48 67.92 70.31 83.50 89.55 87.13 79.78 78.97 
N20 88.07 50.00 84.05 66.66 78.17 89.05 85.84 93.31 82.47 95.92 
CD45RA/C D3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 RI R2 RI R2 Ri R2 Ri R2 
N3 37.28 17.86 29.45 13.75 39.81 14.88 30.15 32.33 37.24 16.08 
N7 50.44 43.33 52.32 27.27 52.82 20.12 38.58 40.57 58.37 32.89 
N8 35,79 40.74 32.71 15.87 31.96 15.89 19.40 40.00 30.95 22.44 
N13 24.48 20.00 22.05 28.57 24.73 17.47 24.35 31.54 39.52 11.48 
N14 51.47 31.58 54.21 50.00 48.89 14.96 47.46 47.66 55.44 28.96 
N16 48.53 33.33 53.77 75.00 55.04 16.39 34.59 24.92 48.26 9.95 
N17 44.09 14.29 42.01 11.90 43.01 17.01 30.33 23.71 47.00 13.92 
N18 42.59 33.33 41.86 50.00 34.14 9.81 21.89 26.67 39.25 21.43 
N19 50.98 10.53 59.44 62.26 50.70 22.33 41.54 40.48 63.28 33.18 
N20 42.48 25.00 34.04 16.67 37.16 16.22 24.01 33.56 45.93 16.90 
CD45RO/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 RI R2 Ri R2 Ri R2 
N3 33.01 41.07 29.13 25.00 29.81 77.80 42.09 55.95 32.20 80.62 
N7 13.48 61.67 10.79 63.64 11.68 73.67 31.68 40.45 14.46 51.68 
N8 35.13 35.19 34.58 36.51 32.93 85.71 50.86 60.76 33.90 74.15 
N13 10.51 0.00 11.92 0.00 11.69 56.02 23.06 26.76 16.45 78.89 
N14 8.09 5.26 8.98 23.08 9.27 71.39 16.27 23.70 9.55 66.52 
N16 6.72 8.33 6.80 0.00 13.86 87.98 32.94 61.36 23.87 92.22 
N17 26.31 50.00 22.87 23.81 23.87 56.46 32.22 50.15 25.25 79.58 
N18 25.37 26.67 23.47 0.00 16.26 6.81 34.18 55.28 31.06 17.86 
N19 5.77 10.53 5.19 5.66 5.88 62.46 13.68 13.72 7.52 50.47 
N20 13.67 16.67 14.10 8.33 16.09 78.52 33,33 39.68 19.51 87.51 
TcRaf3IC D3 
CM RBC PFSE PHA PPD 
DONOR RI R2 Ri R2 Ri R2 Ri R2 Ri R2 
N3 42.54 35.04 41.22 31.06 47.06 66.25 46.80 72.71 52.36 70.54 
N7 40.02 36.73 40.65 33.33 38.55 67.45 27.45 69.38 30.39 45.96 
N8 30.12 31.37 36.24 16.22 38.16 68.11 15.07 60.04 41.43 70.47 
N13 6.12 ND 7.03 ND 9.69 39.51 9.91 28.81 15.50 45.66 
N14 25.59 25.00 22.10 24.00 20.16 54.02 33.94 61.69 29.90 57.00 
N16 30.96 33.33 30.68 50.00 42.50 73.82 42.45 72.61 46.00 82.98 
N17 28.78 23.40 29.43 3.85 27.25 38.38 31.76 63.61 38.02 71.34 
N18 26.20 25.00 18.98 14.29 11.38 37.20 13.93 46.72 21.68 22.86 
N19 18.49 11.11 19.54 35.00 17.08 42.75 31.41 52.25 16.67 33.33 
N20 6.76 ND 5.48 ND 11.51 40.70 18.48 40.62 17.23 62.33 
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Table A4.11c (continued): 
TcRy/CD3 
CM RBC PFSE PHA PPD 
DONOR RI R2 Ri R2 Ri R2 Ri R2 Ri R2 
N3 3.46 4.90 2.67 3.85 1.21 14.56 2.58 16.81 4.23 12.72 
N7 1.95 18.75 1.81 0.00 2.63 11.33 3.60 4.84 2.91 4.46 
N8 5.02 6.12 5.70 2.50 5.58 12.47 8.85 7.07 5.76 20.13 
N13 5.68 0.00 3.49 0.00 7.50 9.42 6.17 8.33 5.60 10.16 
N14 1.96 0.00 2.88 0.00 2.67 8.70 2.21 4.93 2.78 19.89 
N16 3.65 20.00 1.85 11.11 4.32 14.14 3.10 6.90 1.68 8.79 
N17 6.26 0.00 4.26 4.19 ND ND 4.19 6.20 2.49 10.17 
N18 11.89 7.69 15.46 0.00 2.61 10.61 2.83 7.46 11.90 0.00 
N19 3.97 0.00 4.35 0.00 2.55 8.85 4.10 6.90 3.97 9.34 
N20 5.32 0.00 4.80 0.00 5.55 13.72 4.51 11.30 8.34 16.76 
CD4/CD3 
CM 	 RBC 	 PFSE 	 PHA 	 PPD 
DONOR Ri R2 	Al R2 	RI R2 	Ri R2 	Ri R2 
N3 47.03 45.26 47.34 24.24 43.69 82.71 24.23 39.87 48.51 85.97 
N7 64.83 40.82 64.68 26.67 64.96 83.28 52.51 77.88 65,78 66.46 
N8 61.11 56.86 60.89 45.95 52.19 86.12 37.37 76.23 57.09 84.68 
N13 27.22 33.33 26.76 16.67 30.95 75.12 36.64 40.89 39.10 80.92 
N14 55.04 43.75 54.13 36.00 51.52 77.01 62.06 74.46 55.29 80.50 
N16 48.67 33.33 56.42 50.00 59.87 90.55 60.14 73.05 58.91 96.53 
N17 55.73 34.04 50.54 23.08 46.51 61.28 38.56 63.92 53.15 81.76 
N18 53.23 25.00 49.13 28.57 37.59 73.72 33.28 64.52 51.53 40.00 
N19 52.19 11.11 58.34 52.50 47.90 78.81 49.75 51.26 54.65 54.85 
N20 45.96 26.32 41.51 14.29 40.62 85.26 47.32 54.12 46.57 94.69 
CD8/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Al R2 Ri R2 
N3 35.20 14.69 33.31 13.46 38.83 5.22 57.47 57.71 39.03 7.46 
N7 15.68 18.75 15.39 16.67 12.28 0.65 18.88 21.01 17.42 13.39 
N8 16.00 14.29 13.58 12.50 14.52 1.46 18.58 18.65 15.87 3.57 
N13 9.90 0.00 6.66 0.00 7.18 1.45 19.23 36.64 13.89 1.22 
N14 7.61 0.00 6.35 11.11 5.99 2.56 16.63 18.03 11.20 7.53 
N16 11.52 20.00 17.24 11.11 17.86 1.64 20.53 29.25 14.76 0.70 
N17 3.79 0.00 2.52 1.57 ND ND 10.12 15.90 0.88 0.42 
N18 26.74 7.69 25.66 0.00 18.60 4.90 29.51 34.93 30.44 21.95 
N19 9.51 6.67 9.91 4.76 8.74 1.15 25.68 31.14 14.08 8.24 
N20 16.07 7.69 14.27 14.29 20.69 1.10 23.57 39.92 19.58 1.06 
'I: 
Table A4.12: Complete data for total numbers of cells (per 106  cells plated on day 0) of 
cellular subsets for each naïve individual on a) day 0, b) day 3 and c) day 7. Resting 
cells (Ri) and lymphoblasts (R2) are indicated for each stimuli (ND = not done). 
a) 
cells in gate 
DONOR Al R2 
N3 828200 85000 
N7 886300 65900 
N8 842800 70800 
N13 779200 127400 
N14 859800 82200 
N16 852000 70900 
N17 844000 78800 
N18 774800 105400 
N19 873900 62300 
N20 817900 84200 
CD2O 
DONOR Al R2 
N3 20539 2176 
N7 47240 606 
N8 50821 1607 
N13 42077 2217 
N14 48837 1726 
N16 21470 936 
N17 33422 1954 
N18 50362 2382 
N19 70699 3645 
N20 51446 2913 
CD56 
DONOR R  R2 
N3 11098 6316 
N7 13560 3994 
N8 20227 3667 
N13 6623 3274 
N14 16938 10176 
N16 22408 11216 
N17 4389 2734 
N18 16193 3710 
N19 6292 2367 
N20 26909 11552 
CD 56/CD 3 
DONOR Ri R2 
N3 3644 5823 
N7 4609 2952 
N8 1854 1834 
N13 1091 2217 
N14 3525 6543 
N16 3323 7062 
N17 506 2151 
N18 3099 1191 
N19 1573 692 
N20 7606 7233 
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Table A4.12a (continued): 
Total CD3 
DONOR Ri R2 
N3 693038 57078 
N7 751848 53241 
N8 694720 48137 
N13 553310 90925 
N14 732980 51868 
N16 652291 35287 
N17 624729 55278 
N18 469064 58581 
N19 706898 34732 
N20 658164 52128 
CD45RA/CD3 
DONOR RI R2 
N3 365071 28773 
N7 535148 29115 
N8 338468 29276 
N13 313862 40360 
N14 585868 20846 
N16 496120 17427 
N17 383429 19676 
N18 279315 35435 
N19 584901 19350 
N20 432587 24637 
C D45 A 0/C D3 
DONOR Ri R2 
N3 548683 56695 
N7 403089 50051 
N8 565350 47054 
N13 422015 88250 
N14 446580 49813 
N16 389279 34422 
N17 490955 54640 
N18 366868 57685 
N19 460371 33860 
N20 510451 51387 
TcRcf3/CD3 
DONOR Ri R2 
N3 592660 7285 
N7 651962 11493 
N8 554310 15937 
N13 454196 23505 
N14 666603 25507 
N16 586943 20618 
N17 547587 15587 
N18 393521 17507 
N19 614526 15214 
N20 56492425471 
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Table A4.12a (continued): 
Tc Ry/C D3 
DONOR Ri R2 
N3 13914 833 
N7 23132 1219 
N8 85713 4213 
N13 49168 2268 
N14 19603 3148 
N16 18914 1035 
N17 33844 1442 
N18 15573 2930 
N19 20711 835 
N20 35906 2930 
CD4/CD3 
DONOR Ri R2 
N3 257073 49742 
N7 510243 46815 
N8 379934 42607 
N13 247786 72987 
N14 513902 45720 
N16 436139 35932 
N17 345112 53497 
N18 202688 47051 
N19 454166 30228 
N20 323398 44230 
CD8ICD3 
DONOR Ri R2 
N3 2.851 0.330 
N7 1.149 0.177 
N8 1.749 0.262 
N13 1.629 0.370 
N14 1.199 0.246 
N16 1.379 0.164 
N17 2.248 0.104 
N18 1.402 0.286 
N19 1.120 0.156 




cells in gate 
ABC PFSE 
DONOR Al R2 Ri R2 
N3 421050 5828 406438 14987 
N7 640803 8625 587052 10557 
N8 449338 8292 524042 12546 
N13 377872 7612 464640 9130 
N14 625450 13790 850509 20196 
N16 618660 9870 587052 10557 
N17 402504 7626 400523 11970 
N18 347565 7225 515176 13500 
N19 748188 9324 617773 12470 
N20 381392 5940 395200 8700 
CD 20 
RBC 	 PFSE 
DONOR Ri R2 	Al R2 
N3 1516 102 2520 373 
N7 3588 54 704 167 
N8 5752 191 4769 316 
N13 3023 157 3113 257 
N14 11258 237 14714 701 
N16 2227 299 704 167 
N17 9660 580 7330 1067 
N18 3510 316 3297 478 
N19 1347 222 1977 122 
N20 5492 89 4387 605 
CD56 
ABC PFSE 
DONOR Al R2 Al R2 
N3 547 0 1666 139 
N7 192 0 1644 278 
N8 1528 0 4559 632 
N13 907 31 2184 0 
N14 876 0 1871 0 
N16 742 0 1644 278 
N17 564 0 1282 119 
N18 2468 0 6337 478 
N19 1197 147 2286 489 
N20 801 0 1541 325 
CD56ICD3 
RBC PFSE 
DONOR RI R2 RI R2 
N3 337 0 935 0 
N7 64 0 59 0 
N8 45 0 210 105 
N13 76 0 186 0 
N14 125 0 85 0 
N16 0 0 59 0 
N17 40 0 320 0 
N18 2259 0 5049 212 
N19 75 74 124 0 
N20 76 0 0 0 
272 
Table A4.12b (continued): 
Total CD3 
RBC 	 PFSE 
DONOR Ri R2 	Ri R2 
N3 367577 4642 354536 10879 
N7 569353 7431 464476 7834 
N8 389845 7529 442291 9910 
N13 270254 5325 333426 6197 
N14 526879 12542 712301 16296 
N16 497959 7417 464476 7834 
N17 316086 5636 294064 6459 
N18 246980 5763 366908 9832 
N19 626832 7621 526898 8925 




cells in gate 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Al R2 Ri R2 
N3 145200 2915 90114 2174 130770 46080 44640 84444 92400 47256 
N7 196860 408 225855 1260 328440 49680 49404 135378 135668 6136 
N8 298546 7119 198370 3652 348768 108644 68460 95900 151900 50960 
N13 83754 447 84084 520 231540 16728 59961 44988 63591 21714 
N14 206536 1936 386240 4640 477774 62244 110360 107508 174240 23353 
N16 150080 800 240120 1160 339304 66722 37280 77120 97344 108288 
N17 168399 2695 102828 1452 253836 26136 68072 88646 135456 78132 
N18 62074 1681 56160 90 98300 15200 86086 133518 120543 2622 
N19 225620 3480 587008 9472 359530 43018 104118 199948 286314 17952 
N20 86900 792 109908 1116 125352 46800 172788 274428 110320 178780 
CD2O 
CM RBC PFSE PHA PPD 
DONOR Al R2 Al R2 Ri R2 Al R2 Al R2 
N3 2977 42 1667 125 3191 1742 1165 1883 1118 1144 
N7 7894 34 11835 252 21119 1485 1863 1530 7272 505 
N8 9225 949 5614 365 34493 5823 3820 2484 8749 1361 
N13 5218 0 7652 111 34152 1301 2818 3864 5736 1985 
N14 21232 683 34993 530 82416 5334 2097 2698 15229 2219 
N16 1126 0 1513 77 4241 1828 175 648 1869 661 
N17 11754 1052 5933 454 21018 4571 395 1099 6610 2242 
N18 3172 93 3886 25 11334 1415 2755 2043 6304 218 
N19 26916 633 57938 1184 82656 6354 5935 11537 50305 2801 
N20 3997 132 6364 0 15506 1778 2937 8068 8307 4005 
CD56 
CM ABC PFSE PHA PPD 
DONOR Al R2 Ri A2 Al R2 Al R2 RI R2 
N3 2439 127 1244 225 1635 613 955 110 3049 1054 
N7 1496 ND 497 0 5649 0 2856 149 4355 117 
N8 3433 475 2460 0 11823 1358 3820 144 8476 2721 
N13 1030 0 572 74 5071 1022 3460 76 3008 63 
N14 2210 0 6875 133 14238 355 3609 0 7510 633 
N16 1066 0 960 ND 25108 981 2177 239 7194 661 
N17 4833 66 1337 45 5686 1192 3159 408 7125 2508 
N18 4699 0 4302 0 7658 983 5114 320 11126 0 
N19 2662 317 10860 237 4027 1088 2280 0 3865 494 
N20 1390 0 2077 0 4061 370 6151 988 5582 2360 
CD56ICD3 
CM RBC PFSE PHA PPD 
DONOR Al R2 Al A2 Al R2 Al R2 Ri R2 
N3 1699 42 1108 50 92 101 214 110 0 175 
N7 965 ND 203 0 1084 0 371 149 1384 39 
N8 0 0 79 0 314 0 144 0 0 138 
N13 553 0 286 74 1899 279 258 0 960 0 
N14 640 0 1004 0 1529 0 232 0 767 0 
N16 570 0 552 ND 8313 0 261 162 195 249 
N17 3789 66 1049 45 1371 199 265 275 406 625 
N18 4296 0 3999 0 609 800 129 160 10463 0 
N19 1782 158 8688 0 1079 0 458 0 1890 0 
N20 834 0 1781 0 965 75 1330 329 2736 536 
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Table A4.12c (continued): 
Total CD3 
CM RBC PFSE PHA PPD 
DONOR RI R2 Ri R2 Ri R2 Ri R2 RI R2 
N3 135239 1588 79553 1032 119838 39444 39310 80931 84509 41013 
N7 171249 326 198391 1184 282261 45273 42270 131371 120338 4860 
N8 274423 6065 179545 1913 292965 99322 54439 92380 132199 44447 
N13 59423 89 58119 223 157447 11487 42818 37187 48355 18509 
N14 164816 917 319923 3570 357184 51949 96267 102197 141082 19021 
N16 121100 400 201845 870 290275 61985 30525 76102 81876 105256 
N17 146558 1925 88309 795 212283 18047 56541 84737 116330 68912 
NiB 51652 1233 46720 45 67955 12102 60656 128137 101027 1405 
N19 171516 733 490034 6433 252786 35920 93238 174215 228421 14177 
N20 76533 396 92378 744 97988 41675 148321 256069 90981 171486 
CD45RA/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
N3 54131 521 26539 299 52060 6857 13459 27301 34410 7599 
N7 99296 177 118167 344 173482 9996 19060 54923 79189 2018 
N8 106850 2900 64887 580 111466 17264 13281 38360 47013 11435 
N13 20503 89 18541 149 57260 2922 14601 14189 25131 2493 
N14 106304 611 209381 2320 233584 9312 52377 51238 96599 6763 
N16 72834 267 129113 870 186753 10936 12895 19218 46978 10775 
N17 74247 385 43198 173 109175 4446 20646 21018 63664 10876 
NiB 26437 560 23509 45 33560 1491 18844 35609 47313 562 
N19 115021 366 348918 5897 182282 9606 43251 80939 181179 5956 
N20 36915 198 37413 186 46581 7591 41486 92098 50670 30214 
CD45RO/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Al R2 
N3 47931 1197 26250 543 38983 35850 18789 47246 29753 38098 
N7 26537 252 24370 802 38362 36599 15651 54760 19618 3171 
N8 104879 2505 68596 1333 114849 93119 34819 58269 51494 37787 
N13 8803 0 10023 0 27067 9371 13827 12039 10461 17130 
N14 16709 102 34684 1071 44290 44436 17956 25479 16640 15534 
N16 10085 67 16328 0 47028 58702 12280 47321 23236 99863 
N17 44306 1348 23517 346 60591 14756 21933 44456 34203 62177 
N18 15748 448 13181 0 15984 10611 29424 73809 37441 468 
N19 13018 366 30466 536 21140 26869 14243 27433 21531 9060 
N20 11879 132 15497 93 20169 36747 57590 108893 21523 156450 
TcRoI3/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
N3 61768 1021 37145 675 61540 30528 20892 61399 48381 33334 
N7 78783 150 91810 420 126614 33509 13561 93925 41230 2820 
N8 89922 2233 71889 592 133090 73997 10317 57578 62932 35912 
N13 5126 ND 5911 ND 22436 6609 5942 12961 9857 9915 
N14 52853 484 85359 1114 96319 33624 37456 66322 52098 13311 
N16 46465 267 73669 580 144204 49254 15825 55997 44778 89857 
N17 48465 631 30262 56 69170 10031 21620 56388 51500 55739 
N18 16263 420 10659 13 11187 5654 11992 62380 26134 599 
N19 41717 387 114701 3315 61408 18390 32703 104473 47729 5983 
N20 5874 ND 6023 ND 14428 19048 31931 111473 19008 111434 
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Table A4.12c (continued): 
TcftyS/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 RI R2 Ri R2 Ri R2 Ri R2 
N3 5024 143 2406 84 1582 6709 1152 14195 3909 6011 
N7 3839 77 4088 0 8638 5629 1779 6552 3948 274 
N8 14987 436 11307 91 19461 13548 6059 6780 8749 10258 
N13 4757 0 2935 0 17366 1576 3700 3748 3561 2206 
N14 4048 0 11124 0 12757 5415 2439 5300 4844 4645 
N16 5478 160 4442 129 14658 9434 1156 5321 1635 9519 
N17 10542 0 4380 61 ND ND 2852 5496 3373 7946 
N18 7381 129 8682 0 2566 1613 2436 9960 14345 0 
N19 8957 0 25535 0 9168 3807 4269 13796 11367 1677 
N20 4623 0 5276 0 6957 6421 7793 31010 9201 29964 
CD4/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 RI R2 RI R2 Ri R2 
N3 68288 1319 42660 527 57133 38113 10816 33668 44823 40626 
N7 127624 167 146083 336 213355 41374 25942 105432 89242 4078 
N8 182441 4048 120787 1678 182022 93564 25584 73105 86720 43153 
N13 22798 149 22501 87 71662 12566 21970 18396 24864 17571 
N14 113677 847 209072 1670 246149 47934 68489 80050 96337 18799 
N16 73044 267 135476 580 203141 60417 22420 56336 57345 104530 
N17 93849 917 51969 335 118059 16016 26249 56663 71995 63881 
N18 33042 420 27591 26 36951 11205 28649 86146 62116 1049 
N19 117751 387 342460 4973 172215 33902 51799 102493 156471 9847 
N20 39939 208 45623 159 50918 39902 81763 148520 51376 169287 
CD8/CD3 
CM RBC PFSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 RI R2 Ri R2 
N3 51110 428 30017 293 50778 2405 25655 48733 36064 3525 
N7 30868 77 34759 210 40332 323 9327 28443 23633 822 
N8 47767 1017 26939 457 50641 1586 12720 17885 24107 1819 
N13 8292 0 5600 0 16625 243 11531 16484 8833 265 
N14 15717 0 24526 516 28619 1593 18353 19384 19515 1758 
N16 17289 160 41397 129 60600 1094 7654 22558 14368 758 
N17 6382 0 2591 23 ND ND 6889 14095 1192 328 
N18 16599 129 14411 0 18284 745 25404 46638 36693 576 
N19 21456 232 58172 451 31423 495 26738 62264 40313 1479 
N20 13965 61 15684 159 25935 515 40726 109552 21601 1895 
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Table A4.13: Complete data for percentages of cellular subsets for each exposed 
individual on a) day 0 and b) day 7. Resting cells (Ri) and lymphoblasts (R2) are 
indicated for each stimuli (ND = not done). 
a) 
% in gate 
DONOR Ri R2 
El 35.64 38.91 
E2 9.08 10.23 
E3 34.27 4.62 
E4 26.61 2.03 
E5 27.65 1.54 
E6 52.96 5.28 
E7 55.60 7.50 
E8 47.75 6.38 
E9 38.94 11.42 
ElO 22.58 5.93 
Ell 43.83 19.10 
E12 46.73 3.19 
E14 48.54 1.79 
E15 70.88 4.78 
E16 65.77 4.80 
E17 64.64 5.25 
E18 62.15 5.07 
E20 50.81 2.29 
CD2O 
DONOR Al R2 
El 15.23 8.31 
E2 4.36 17.39 
E3 9.27 6.99 
E4 7.85 12.00 
E5 11.73 14.96 
E6 5.07 11.81 
E7 11.88 9.72 
E8 1.36 7.66 
E9 9.86 11.47 
ElO 11.50 12.50 
Eli 24.72 40.00 
E12 10.66 14.20 
E14 13.41 19.50 
E15 8.70 16.88 
E16 8.80 7.84 
E17 6.94 44.09 
E18 14.88 34.55 
E20 4.61 10.91 
CD 20/a D 45 A 0 
DONOR Ri R2 
El 0.17 0.30 
E2 0.00 0.18 
E3 0.68 0.97 
E4 0.00 0.00 
E5 0.00 0.39 
E6 0.00 0.00 
E7 0.07 0.47 
ES 0.07 0.35 
E9 0.00 0.34 
ElO 0.00 0.00 
Ell 0.03 0.00 
E12 0.00 0.97 
E14 0.02 0.83 
E15 0.07 0.18 
E16 0.03 0.17 
E17 0.02 1.08 
E18 0.02 0.91 
E20 0.04 1.21 
277 
Table A4.13a (continued): 
CD56 
DONOR Ri R2 
El 0.57 1.82 
E2 0.00 2.93 
E3 7.88 15.92 
E4 0.37 0.89 
E5 0.38 1.96 
E6 0.24 0.79 
E7 0.37 2.66 
E8 2.76 13.46 
E9 0.40 3.21 
ElO 0.38 2.81 
Eli 0.10 0.36 
E12 0.26 1.29 
E14 0.16 2.49 
E15 0.25 1.27 
E16 0.53 1.53 
E17 0.40 0.86 
E18 0.25 0.60 
E20 0.17 1.82 
CD 56/CD 45 A 0 
DONOR Ri R2 
El 0.04 0.12 
E2 0.00 0.00 
E3 7.32 14.37 
E4 0.04 0.00 
ES 0.00 0.39 
E6 0.00 0.00 
E7 0.02 0.31 
E8 0.22 1.16 
E9 0.00 0.17 
E10 0.00 0.31 
Eli 0.05 0.18 
E12 0.04 0.32 
E14 0.02 0.83 
E15 0.03 0.36 
E16 0.01 0.17 
E17 0.05 0.43 
E18 0.03 0.30 
E20 0.00 0.61 
Total CD3 
DONOR Ri R2 
El 74.04 76.98 
E2 49.39 64.16 
E3 64.71 59.14 
E4 62.86 52.80 
E5 53.17 66.76 
E6 61.80 61.39 
E7 64.86 59.20 
E8 63.51 40.42 
E9 47.10 64.09 
E10 55.90 59.94 
Eli 55.50 45.09 
E12 59.68 49.28 
E14 49.77 41.96 
E15 59.42 44.38 
E16 60.56 31.72 
E17 74.06 33.84 
E18 62.98 39.90 
E20 28.53 54.31 
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Table A4.13a (continued): 
CD45RA/CD3 
DONOR Ri R2 
El 45.06 39.85 
E2 25.38 19.47 
E3 26.98 18.28 
E4 34.16 24.80 
E5 33.35 33.82 
E6 42.99 34.74 
E7 36.20 25.61 
E8 36.29 18.09 
E9 25.15 37.11 
ElO 30.04 24.46 
Ell 29.15 22.37 
E12 15.77 13.33 
E14 32.09 21.77 
E15 28.39 17.95 
E16 35.60 13.00 
E17 45.28 12.69 
E18 23.90 19.95 
E20 20.22 37.07 
C D45 ROtC D3 
DONOR Ri R2 
El 26.88 40.82 
E2 19.64 44.25 
E3 31.88 40.32 
E4 22.84 30.40 
E5 14.96 35.29 
E6 13.95 32.90 
E7 22.10 31.40 
E8 19.91 19.40 
E9 15.90 39.20 
ElO 22.48 41.59 
Ell 19.55 26.78 
E12 35.68 40.58 
E14 11.68 19.56 
E15 27.21 34.12 
E16 15.37 15.64 
E17 17.28 16.07 
E18 27.10 28.43 
E20 4.47 19.40 
TcRaf3/CD3 
DONOR RI R2 
El 2.12 6.28 
E2 0.49 1.48 
E3 1.01 3.33 
E4 2.07 5.18 
ES 3.45 5.85 
E6 4.83 9.52 
E7 2.96 3.65 
E8 5.08 6.82 
E9 3.68 7.79 
ElO 0.68 0.28 
Ell 0.03 0.33 
E12 0.02 1.70 
E14 0.00 0.39 
E15 0.13 1.03 
E16 0.01 0.19 
E17 0.12 1.54 
E18 0.06 0.75 
E20 0.02 1.16 
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Table A4.13a (continued): 
Ic Rcx 3/C D45 A 0 
DONOR Ri R2 
El 0.32 1.36 
E2 0.18 0.49 
E3 0.39 2.22 
E4 0.08 1.59 
E5 0.16 1.46 
E6 0.77 2.67 
E7 0.43 0.66 
E8 0.25 1.04 
E9 0.62 3.18 
ElO 0.25 0.28 
Eli 0.00 0.67 
E12 0.00 1.42 
E14 0.00 0.39 
E15 0.09 0.77 
E16 0.00 0.19 
E17 0.02 1.32 
E18 0.00 0.57 
E20 0.02 1.16 
TcR78/CD3 
DONOR Ri R2 
El 3.39 7.60 
E2 0.86 7.32 
E3 0.92 3.46 
E4 2.57 2.45 
E5 1.86 2.94 
E6 3.90 11.75 
E7 2.45 7.17 
E8 4.82 7.47 
E9 2.90 8.19 
ElO 0.96 2.38 
Eli 7.01 7.38 
E12 3.07 4.88 
E14 1.22 1.11 
E15 1.78 3.19 
E16 1.92 2.63 
E17 4.33 5.74 
E18 11.69 5.83 
E20 2.27 10.07 
Ic R-y/C D45 R 0 
DONOR Ri R2 
El 0.85 1.75 
E2 0.31 4.88 
E3 0.37 1.57 
E4 0.24 1.05 
E5 0.15 1.47 
E6 0.51 5.97 
E7 0.37 2.12 
E8 0.35 0.96 
E9 0.15 4.71 
ElO 0.33 2.12 
Eli 0.46 2.62 
E12 0.86 3.08 
E14 0.11 0.00 
E15 0.37 2.03 
E16 0.19 0.75 
E17 0.42 2.98 
E18 0.13 0.45 
E20 0.04 3.36 
Table A413a (continued): 
CD4/CO3 
DONOR RI R2 
El 44.13 45.59 
E2 30.53 53.63 
E3 47.84 50.00 
E4 40.55 36.33 
E5 35.22 40.00 
E6 23.04 29.09 
E7 2.59 5.57 
ES 35.77 21.04 
E9 21.61 31.29 
ElO 35.56 42.66 
Eli 25.17 27.91 
E12 36.21 42.55 
E14 27.82 34,36 
E15 30.94 44.94 
E16 37.46 45.52 
E17 47.52 31.10 
E18 31.16 42.73 
E20 15.74 33.49 
C D4/C D45R 0 
DONOR Ri R2 
El 15.59 23.97 
E2 8.59 26.26 
E3 18.52 31.05 
E4 11.45 22.66 
E5 9.48 19.68 
E6 4.84 14.18 
E7 0.38 1.91 
E8 8.73 9.45 
E9 11.51 24.10 
ElO 15.17 26.57 
Eli 11.52 9.51 
E12 23.20 32.22 
E14 5.80 12.74 
E15 12.40 33.93 
E16 7.93 14.41 
E17 9.46 11.54 
E18 14.79 24.86 
E20 2.59 11.63 
CD8/CD3 
DONOR Al R2 
El 19.80 31.70 
E2 13.10 41.18 
E3 10.95 32.79 
E4 14.75 27.01 
E5 15.47 30.91 
E6 20.74 42.40 
E7 39.86 35.28 
E8 18.23 19.39 
E9 14.84 35.34 
ElO 13.06 28.79 
Eli 15.32 29.19 
E12 7.20 21.77 
E14 9.70 34.44 
E15 16.13 22.47 
E16 15.95 23.99 
E17 16.07 23.33 
E18 12.38 17.66 
E20 7.39 23.08 
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Table A4.13a (continued): 
CD 8/C D45R 0 
DONOR Ri R2 
El 1.17 3.59 
E2 1.35 4.41 
E3 0.36 4.37 
E4 0.80 5.84 
E5 0.49 2.69 
E6 1.26 6.01 
El 15.83 22.45 
E8 0.89 1.50 
E9 1.13 8.10 
ElO 1.61 6.44 
Eli 0.53 1.52 
E12 1.29 4.30 
E14 0.36 0.74 
E15 3.51 4.25 
E16 0.60 1.06 
E17 0.92 2.78 
E18 2.34 4.37 
E20 0.04 1.81 
TcR Vy9/CD3 
DONOR Ri R2 
El 3.02 6.56 
E2 0.90 0.91 
E3 8.93 13.94 
E4 2.04 2.69 
E5 0.93 3.46 
E6 2.09 4.35 
E7 18.52 25.53 
E8 2.38 2.13 
E9 2.11 4.65 
ElO 0.72 1.13 
Eli 5.50 2.97 
E12 3.57 2.97 
E14 0.76 0.77 
E15 0.87 1.05 
E16 1.37 1.83 
E17 4.71 6.03 
E18 6.40 2.13 
E20 0.36 1.14 
TcR V-y9/CD45RO 
DONOR Ri R2 
El 0.11 1.75 
E2 0.09 0.00 
E3 1.74 4.24 
E4 0.11 1.35 
E5 0.04 0.69 
E6 0.24 2.57 
E7 0.87 2.44 
E8 0.07 0.51 
E9 0.38 1.83 
ElO 0.24 0.75 
Eli 0.15 0.93 
E12 0.16 0.37 
E14 0.00 0.38 
E15 0.21 0.42 
E16 0.04 0.17 
E17 0.06 3.02 
E18 0.13 1.07 
E20 0.00 0.00 
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Table A4.13a (continued): 
IcR V81/CD3 
DONOR Ri R2 
El 2.46 3.39 
E2 0.78 0.68 
E3 0.12 2.08 
E4 2.23 1.46 
E5 2.66 6.93 
E6 5.19 5.56 
E7 1.88 4.55 
E8 7.72 8.11 
E9 3.47 6.82 
ElO 0.39 0.00 
Eli 6.84 7.34 
E12 0.49 1.06 
E14 0.72 1.12 
E15 0.54 1.24 
E16 1.18 1.55 
E17 1.62 2.70 
E18 8.68 5.59 
E20 2.96 10.86 
TcR V1/CD45RO 
DONOR Ri R2 
El 0.06 0.15 
E2 0.05 0.00 
E3 0.06 0.00 
E4 0.00 0.73 
E5 0.00 0.00 
E6 0.00 0.51 
E7 0.13 0.76 
E8 0.17 0.53 
E9 0.03 1.00 
ElO 0.00 0.00 
Eli 0.03 0.56 
E12 0.02 1.41 
E14 0.06 0.56 
E15 0.04 0.35 
E16 0.00 0.58 
E17 0.05 1.87 
E18 0.08 2.93 




% in gate 
CM RBC PfSE PHA PPD 
DONOR Ri R2 RI R2 Ri R2 Ri R2 Ri R2 
El 41.33 4.85 37.56 3.40 41.24 7.24 36.27 22.76 39.27 11.02 
E2 32.60 3.79 33.01 2.48 33.44 2.47 26.18 18.10 33.70 2.95 
E3 40.49 7.34 35.20 0.88 37.08 1.77 28.16 9.41 32.21 8.99 
E4 33.50 1.17 34.20 1.06 34.48 1.68 29.63 8.40 33.51 1.83 
E5 37.45 0.68 36.21 1.82 35.34 2.17 27.71 12.68 35.93 1.77 
E6 48.25 2.04 47.35 2.88 47.09 2.88 42.56 20.29 39.63 6.68 
E7 40.02 1.97 48.97 4.02 47.06 4.94 35.20 27.97 45.51 6.73 
E8 40.56 1780 54.97 5.43 51.08 5.78 32.88 27.18 44.20 11.63 
E9 32.38 2.78 32.46 2.02 32.39 4.29 23.95 4.69 31.10 3.68 
ElO 33.46 1.89 31.73 1.63 30.08 5.13 24.79 8.35 31.39 2.79 
Eli 35.25 5.46 34.01 7.06 35.23 7.68 22.85 24.23 32.58 14.30 
E12 31.94 3.73 31.48 3.84 33.41 4.91 26.14 17.38 31.11 10.49 
E14 27.43 0.47 31.68 1.87 33.45 3.38 31.68 10.24 31.40 4.08 
E15 47.84 2.00 48.24 1.60 42.41 6.00 27.65 18.11 39.46 9.67 
E16 39.39 4.81 42.56 4.50 43.14 5.32 29.22 28.81 38.94 6.01 
E17 56.42 3.52 60.03 3.98 56.34 3.50 35.18 18.77 58.88 4.40 
E18 37.16 6.20 35.08 6.44 32.20 6.84 25.97 9.16 34.63 7.10 
E20 46.71 3.93 48.22 4.02 37.18 7.55 30.13 14.72 31.90 18.63 
CD 20 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 10.65 13,44 10.99 11.44 9.35 11.63 13.21 26.69 6.49 9.64 
E2 3.27 10.00 1.77 4.39 3.97 16.39 4.95 21.82 4.01 11.26 
E3 3,53 10.37 2.89 10.17 3.21 10.06 5.16 23.48 2.38 9.22 
E4 5.26 11.85 3.58 11.32 3.24 14.05 5.36 19.45 3.16 13.33 
ES 4.78 8.93 5.07 5.82 5.55 9.68 6.05 15.44 6.01 13.49 
E6 3.69 10.57 3.13 7.40 3.94 10.49 4.15 11.43 3.81 6.61 
E7 9,49 5.29 8.89 4.99 10.48 8.42 8.16 18.51 7.90 8.81 
E8 6.58 8.96 7.47 13.51 6.87 13.60 5.41 17.14 4.79 8.24 
E9 5.03 13.64 3.85 8.20 4.31 14.20 0.00 0.22 2.74 11.08 
ElO 3.85 13.29 2.96 8.93 3.78 15.99 4.55 22.27 3.18 15.20 
Eli 16.99 31.83 15.35 29.03 10.31 22.93 15.21 25.39 14.65 17.41 
E12 4.99 12.32 4.35 14.23 4.38 20.52 23.13 67.45 3.24 6.08 
E14 2.91 0.81 2.31 5.47 3.77 15.42 7.52 18.63 3.07 8.26 
E15 7.48 20.45 6.86 16.04 5.30 9.61 7.29 27.95 3.20 7.06 
E16 4.46 6.10 4.57 2.82 4.43 4.14 4.37 15.23 7.72 29.05 
E17 5.83 9.83 7.66 7.08 12.63 5.09 9,51 15.95 12.19 24.30 
E18 5.04 1.72 6.87 0.91 7.86 4.28 18.10 30.05 9.91 17.87 
E20 22.79 19.70 13.61 20.62 14.83 39.53 18.93 44.06 6.38 25.70 
CD20/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Al R2 Ri R2 RI R2 Ri R2 RI R2 
El 0.11 1.98 0.00 4.11 0.08 1.94 0.06 2.68 0.06 1.98 
E2 0.00 1.33 0.06 0.88 0.06 2.46 0.17 3.19 0.03 0.87 
E3 0.03 1.22 0.02 4,24 0.00 1.18 0.00 3.20 0.03 2.94 
E4 0.03 1.32 0.03 0.94 0.06 0.83 0.00 1.51 0.03 1.43 
E5 0.03 0.89 0.00 1.94 0.03 1.94 0.12 2.50 0.00 2.38 
E6 0.00 0.81 0.02 1.23 0.04 0.00 0.09 0.51 0.00 0,27 
E7 0.05 0.79 0.15 0.83 0.07 0.86 0.31 3.21 0.02 1.36 
E8 0.04 0.90 0.00 1.08 0.00 1.87 0.05 1.40 0.02 0.86 
E9 0.03 0.00 0.06 0.00 0.06 1.45 0.00 0.00 0.00 0.81 
ElO 0.06 0.00 0.00 0.00 0.00 0.00 0.04 0.74 0.03 0.00 
Eli 0.08 0.60 0.09 1.07 0.12 3.60 0.03 1.04 0.00 0.95 
E12 0.12 0.70 0.03 1.50 0.04 1.78 8.07 32.23 0.03 0.40 
E14 0.03 0.00 0.00 0.68 0.00 0.42 0.03 1.58 0.00 1.14 
E15 0.04 2.27 0.00 1.60 0.02 1.01 0.07 3.15 0.00 0.51 
E16 0.09 1.38 0.02 0.00 0.07 0.17 0.00 0.11 0.24 3.73 
E17 0.12 0.58 0.04 0.39 0.09 0.85 0.28 0.55 0.05 2.23 
E18 0.24 0.31 0.08 0.13 0.11 0.27 0.27 1.69 0.24 2.75 
E20 0.16 0.00 0.06 1.72 0.00 1.83 0.33 1.44 0.09 0.34 
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Table A4.13b (continued): 
CD56 
CM RBC PfSE PHA PPD 
DONOR Al R2 RI R2 Hi R2 Ri R2 RI R2 
El 3.51 14.82 2.69 6.74 4.39 15.89 2.57 2.33 5.55 11.36 
E2 1.21 2.66 0.96 3.51 1.16 21.31 4.58 8.17 1.97 15.58 
E3 3.82 20.73 3.57 8.47 4.94 23.08 2.20 11.10 4.58 10.64 
E4 2.66 15.79 2.42 15.09 1.46 9.09 1.04 2.64 2.42 14.28 
E5 2.22 9.82 1.90 9.71 2.17 12.90 1.44 2.08 2.83 15.88 
E6 6.78 14.64 6.73 20.99 5.99 11.99 3.58 2.69 8.15 11.61 
E7 3.47 5.03 4.44 15.23 4.95 6.91 2.78 3.17 7.99 11.51 
E8 16.85 17.91 18.47 20.54 17.29 24.49 12.36 3.42 22.20 29.50 
E9 2,65 7.57 3.06 4.92 4.74 13.33 0.00 0.22 3.84 8.65 
ElO 2.25 6.29 1.92 3.58 3.49 9.30 1.10 1.98 2.96 6.37 
Eli 0.45 1.35 0.29 2.53 0.65 1.50 0.73 3.45 0.89 4.54 
E12 1.36 6.34 1.35 3.75 2.47 6.54 39.84 68.44 3.05 13.54 
E14 0.15 0.00 0.26 2.74 1.86 10.00 0.42 1.46 1.99 12.82 
E15 4.83 16.48 4.48 17.64 7.81 19.89 7.06 6.20 8.89 23.62 
E16 2.97 5.11 2.88 3.39 2.35 6.90 2.68 6.49 3.29 17.37 
E17 5.47 6.36 4.95 7.87 4.99 9.75 4.00 2.89 6.86 15.09 
E18 3.24 0.94 2.95 0.26 4.54 2.54 5.30 12.38 6.03 11.00 
E20 0.97 4.48 0.70 3.09 1.30 13.87 1.98 4.25 1.44 3.80 
CD56/CD45RO 
CM - 	ABC PISE PHA PPD 
DONOR Ri R2 RI R2 Al R2 Ri R2 Ri R2 
El 0.29 1.38 0.10 1.17 0.03 2.71 0.06 0.79 0.17 2.25 
E2 0.15 1.33 0.03 0.88 0.09 4.10 0.00 1.66 0.06 2.16 
E3 0.16 1.83 0.10 0.00 0.11 8.88 0.10 3.42 0.08 3.65 
E4 0.12 1.32 0.11 2.83 0.09 0.83 0.03 0.88 0.09 3.33 
E5 0.00 0.00 0.03 0.97 0.06 0.00 0.15 1.04 0.09 1.59 
E6 0.69 4.07 0.72 8.64 0.41 2.25 0.48 0.42 0.65 4.59 
E7 0.17 0.53 0.45 4.43 0.22 1.73 0.12 1.64 0.30 2.30 
E8 0.09 1.19 0.10 0.00 0.15 3.06 0.03 0.42 0.11 2.68 
E9 0.15 2.27 0.20 0.82 0.09 2.03 0.00 0.22 0.15 2.16 
ElO 0,12 0.00 0.07 1.79 0.03 0.29 0.00 0.25 0.00 0.49 
Eli 0.00 0.30 0.00 0.80 0.15 0.61 0.14 0.86 0.08 1.42 
E12 0.09 1.76 0.12 0.75 0.04 1.34 17.59 37.21 0.19 4.68 
E14 0.00 0.00 0.00 1.37 0.00 4.17 0.03 0.73 0.09 3.13 
E15 0.86 6.25 0.39 5.88 0.71 10.62 0.65 2.74 0.69 11.17 
E16 0.11 0.39 0.09 0.38 0.04 0.00 0.03 0.21 0.07 1.14 
E17 0.15 0.58 0.04 0.39 0.09 0.00 0.28 0.65 0.07 0.56 
E18 0.18 0.16 0.16 0.00 0.03 0.27 0.10 0.85 0.24 1.06 
E20 0.03 0.00 0.00 0.00 0.09 0.00 0.25 0.36 0.09 0.11 
Total CD3 
CM - ABC PfSE PHA PPD 
DONOR Al R2 Ri A2 Ri A2 Ri R2 RI R2 
El 68.02 62.00 62.62 55.44 60.70 59.85 65.02 71.12 67.51 70.44 
E2 25.39 59.00 22.85 56.46 19.19 45.06 31.99 77.86 26.26 57.90 
E3 38.22 73.30 32.99 57.95 34.05 60.62 25.45 63.33 45.54 81.14 
E4 37.69 65.25 36.42 63.70 34.71 66.24 33.31 75.25 37.22 63.83 
E5 44.84 80.74 40.35 63.00 43.36 65.36 44.24 85.31 38.34 77.56 
E6 61.82 77.88 62.38 78.72 59.82 75.00 70.46 90.83 62.73 85.31 
E7 63.40 48.24 66.07 62.02 63.82 61.08 69.67 81.80 64.26 67.52 
E8 68.53 68.95 65.00 60.00 65.75 65.09 71.28 80.04 62.34 65.57 
E9 22.14 50.49 22.08 51.00 24.73 60.47 10.53 66.11 23.54 69.01 
ElO 32.24 54.17 26.71 56.16 29.66 61.73 21.79 68.49 27.60 60.09 
Ell 35.84 49.33 37.49 47.30 34.15 68.00 38.29 50.92 42.55 60.22 
E12 36.56 57.98 37.32 63.91 31.75 61.27 41.02 65.65 43.00 73.29 
E14 28.10 42.35 21.74 41.73 31.84 63.09 32.73 71.87 27.43 65.19 
E15 72.44 78.45 71.70 70.83 67.21 75.81 63.31 69.12 67.55 74.27 
E16 46.78 14.66 52.97 17.43 52.04 27.53 49.98 73.71 45.13 31.13 
E17 68.59 73.44 68.47 72.17 68.11 74.46 75.66 85.16 66.86 64.32 
E18 30.36 10.18 32.97 11.30 27.04 8.83 20.68 22.33 24.25 18.07 
E20 37.39 21.51 42.63 32.34 49.48 35.84 47.09 55.72 63.13 62.05 
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Table A4.13b (continued): 
C D45RA/C D 3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Al R2 Ri R2 
El 33.80 29.56 30.69 28.47 28.14 13.43 24.41 32.75 28.48 11.17 
E2 11.95 26.62 10.08 29.93 8.71 13.58 4.94 22.08 11.93 17.54 
E3 18.04 40.91 14.65 27.84 14.42 21.56 6.93 29.36 16.78 9.93 
E4 21.28 32.09 19.11 24.84 17.77 22.29 14.93 35.43 19.73 18.72 
E5 26.43 54.81 22.40 34.00 25.47 37.07 23.21 42.89 21.13 42.44 
E6 35.55 48.72 39.73 54.61 35.73 40.96 39.66 60.42 33.17 17.51 
E7 32.53 34.50 32.75 38.97 29.96 22.72 20.69 26.10 31.06 18.81 
E8 34.24 40.99 34.43 37.36 29.60 24.97 15.84 22.12 31.39 14.35 
E9 11.53 25.49 10.41 28.51 11.26 18.88 5.12 29.86 10.42 14.62 
ElO 17.09 30.09 13.93 33.99 14.25 9.11 8.01 28.92 13.48 19.75 
Ell 15.01 26.48 18.00 25.16 8.77 17.31 15.89 25.62 19.30 16.79 
E12 6.37 12.18 8.92 19.54 3.85 15.19 7.99 11.60 7.34 5.26 
E14 17.36 29.41 13.57 23.62 19.30 13.73 11.76 27.20 15.50 13.27 
E15 35.03 36.77 34.12 29.43 29.15 18.27 11.62 23.61 26.97 10.50 
E16 23.94 9.54 27.17 9.91 25.57 14.21 12.82 27.31 25.99 18.05 
E17 30.35 37.67 30.07 39.39 29.84 36.78 23.58 24.49 30.78 34.47 
E18 6.69 2.96 7.14 5.01 5.46 3.15 5.54 9.77 4.46 8.96 
E20 11.80 11.00 12.83 16.85 15.66 7.96 7.41 12.85 11.19 4.66 
CD45RO/CD3 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Al R2 
El 29.86 37.62 28.90 35.89 28.54 49.10 34.43 44.86 34.69 62.06 
E2 10.37 41.73 9.49 29.93 7.39 30.25 18.31 54.91 10.93 43.86 
E3 14.13 53.41 12.12 37.50 13.77 47.50 13.62 44.74 23.57 77.53 
E4 11.73 44.39 12.25 50.32 11.82 52.23 14.44 46.68 13.04 50.64 
E5 12.53 41.48 11.85 35.00 13.58 39.51 15.90 51.52 12.46 47.80 
E6 17.09 46.47 16.71 40.78 16.32 46.69 19.31 30.10 23.66 74.51 
E7 18.95 22.04 22.43 30.68 24.13 44.69 34.32 57.18 24.76 55.75 
E8 19.85 38.72 17.32 28.79 18.39 40.12 30.33 46.33 18.47 49.52 
E9 7.39 30.39 8.42 26.10 9.75 46.61 3.58 39.81 10.64 57.31 
E10 10.00 32.87 8.25 31.53 10.67 51.48 8.39 32.81 8.93 38.24 
Eli 13.11 27.81 16.96 29.78 21.93 55.62 19.06 31.35 20.18 48.83 
E12 27.16 51.26 25.92 55.63 26.69 54.79 29.44 59.96 32.20 69.59 
E14 6.32 16.47 4.64 18.90 8.43 52.79 12.07 35.36 8.49 55.75 
E15 30.23 61.12 31.48 57.11 31.39 69.14 36.27 49.56 33.10 70.01 
E16 9.37 4.77 9.37 8.62 12.87 20.96 31.56 58.87 13.34 23.01 
E17 13.53 30.62 13.08 26.18 13.69 34.95 26.48 45.23 15.27 36.41 
E18 11.58 6.40 14.08 8.09 10.83 6.31 14.75 20.99 11.63 16.81 
E20 14.96 13.20 18.73 17.12 17.07 28.81 28.72 39.18 26.82 52.05 
TcR all/CD  3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Al R2 Ri R2 Al R2 Al R2 
El 1.51 12.82 0.81 10.58 0.48 7.92 1.20 9.75 0.31 7.22 
E2 0.38 7.29 0.15 2.46 0.03 1.91 0.55 10.42 0.27 1.85 
E3 0.21 7.14 0.39 8.33 0.16 6.39 0.55 12.92 3.10 19.79 
E4 0.23 6.98 0.24 5.45 0.36 16.91 1.62 15.41 0.44 11.30 
ES 0.12 11.25 0.09 6.38 0.17 7.11 4.12 33.03 1.25 11.63 
E6 0.07 4.52 0.18 3.48 0.05 3.17 5.99 29.62 0.73 13.96 
E7 0.05 0.79 0.05 0.00 0.07 2.33 0.79 10.59 0.05 2.81 
E8 0.06 1.35 0.04 0.50 0.15 2.61 0.99 5.28 0.05 1.09 
E9 0.09 0.42 0.06 1.57 0.09 8.72 0.07 6.83 0.13 4.92 
EiO 0.12 3.17 0.06 0.00 0.23 5.49 0.49 9.68 0.20 7.73 
Ell 0.11 5.48 0.17 3.05 1.11 9.92 0.40 6.85 0.89 6.91 
E12 0.32 4.10 0.67 5.77 0.34 5.44 0.34 9.61 0.26 3.23 
E14 0.00 2.06 0.00 1.14 0.06 3.85 0.15 2.88 0.16 5.84 
E15 0.02 3.00 0.07 1.85 0.05 5.43 0.43 5.36 0.05 1.01 
E16 1.59 4.83 1.65 4.84 2.07 13.16 26.94 52.22 3.84 17,25 
E17 2.46 21.07 1.25 25.00 1.83 18.60 11.57 32.03 1.95 17.23 
E18 0.79 1.91 1.35 2.20 1.43 3.75 8.18 20.54 3.95 13.73 
E20 3.54 5.19 3.41 4.93 4.05 25.89 9.81 24.23 15.75 39.28 
Table A413b (continued): 
TcRaIi/CD45RO 
CM - RBC PfSE PHA PPD 
DONOR Ri R2 Al R2 Ri R2 Ri R2 Ri R2 
El 0.80 9.05 0.43 8.06 0.31 6.22 0.89 7.24 0.23 6.46 
E2 0.16 6.25 0.06 2.46 0.00 1.91 0.38 8.55 0.12 1.85 
E3 0.11 6.55 0.21 6.55 0.00 6.39 0.39 10.51 1.62 19.58 
E4 0.09 6.98 0.06 4.46 0.18 16.91 0.52 11.65 0.18 11.74 
E5 0.06 10.00 0.03 4.26 0.09 6.60 1.79 23.45 0.51 8.14 
E6 0.02 3.62 0.02 3.04 0.05 2.82 0.84 9.72 0.48 13.30 
El 0.03 0.79 0.05 0.00 0.02 2.00 0.56 9.17 0.02 2.81 
E8 0.00 1.08 0.02 0.00 0.00 2.43 0.54 3.70 0.00 0.92 
E9 0.09 0.42 0.03 0.52 0.03 8.41 0.04 5.22 0.09 4.92 
ElO 0.06 3.17 0.03 0.00 0.17 5.49 0.19 5.95 0.03 6.28 
Eli 0.05 5.10 0.17 2.41 0.80 9.88 0.16 6.44 0.43 7.29 
E12 0.29 4.92 0.41 5.77 0.34 5.99 0.34 10.59 0.33 3.85 
E14 0.00 1.03 0.00 1.14 0.06 3.42 0.06 1.92 0.03 5.52 
E15 0.00 4.33 0.02 2.46 0.05 6.05 0.33 4.65 0.00 1.46 
E16 0.73 3.90 0.64 3.91 1.20 13.16 4.64 11.30 1.97 16.67 
E17 0.61 11.95 0.00 0.00 0.30 7.85 3.56 14.16 0.52 11.82 
E18 0.38 1.50 0.80 1.96 0.87 3.75 6.49 21.67 2.59 13.44 
E20 1.52 5.74 1.39 3.62 1.74 24.51 -- 4.20 10.00 7.08 31.17 
TcRyö/C D3 
CM RBC PfSE PHA PPD 
DONOR Al R2 Ri R2 RI R2 Ri R2 Al R2 
El 3.28 8.71 2.45 8.54 3.03 7.93 1.50 2.21 2.58 5.20 
E2 0.59 1.49 0.46 3.00 0.24 5.67 0.24 1.23 0.43 7.18 
E3 0.52 4.00 0.81 4.64 0.61 3.46 0.13 0.81 0.57 1.21 
E4 1.07 5.16 1.30 6.10 1.07 6.43 0.68 0.95 0.91 4.61 
E5 1.43 1.77 0.95 3.67 1.85 6.94 0.50 1.26 1.30 5.75 
E6 6.41 10.08 7,49 15.71 8.13 12.63 5,97 2.35 7.34 7.67 
E7 3.37 4.42 3.26 4,87 2.82 2.67 2.76 2.65 3.31 3.96 
E8 2.20 7.69 2.51 4.82 3.19 11.33 2.10 2.41 2.82 13.72 
E9 1.97 6.77 1.81 4.32 2.22 7.22 0.29 0.68 2.00 4.56 
ElO 0.18 1.11 0.06 1.99 0.10 2.44 0.19 2.04 0.38 3.35 
Eli 2.35 3.51 2.50 2.79 1.12 2.83 2.53 3.81 3.22 6.46 
E12 1.32 3.52 1.04 4.47 0.88 2.03 1.27 3.23 1.50 1.11 
E14 0.29 0.00 0.23 1.63 0.52 3.33 0.16 0.93 0.52 2.10 
E15 0,61 3.52 1.13 19.71 0.51 1.55 0.72 0.98 0.87 1.22 
E16 2.43 4.17 1.78 3.19 1.53 9.11 3.42 8.40 4.13 14.24 
E17 5.19 7.19 6.17 9.34 ND ND 4.45 7.81 6.57 17.49 
E18 6.35 2.23 5.27 2.59 6.12 4.93 10.47 16.29 6.50 12.52 
E20 3.26 6.02 0.98 2.14 0.67 7.14 4.20 15.78 0.47 2.36 
TcRy6/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Ri R2 Al R2 
El 0.98 5.71 0.67 4.69 0.81 4.34 0.56 1.46 0.81 3.26 
E2 0.08 0.75 0.06 2.00 0.06 4.96 0.07 1.04 0.00 6.63 
E3 0.26 3.43 0.29 3.97 0.21 2.60 0.07 0.35 0.24 1.21 
E4 0.18 4.52 0.18 4.88 0.24 6.43 0.16 0.81 0.12 3.69 
ES 0.06 1.77 0.06 2.75 0.06 3.47 0.07 0.59 0.06 3.45 
E6 0.21 3.23 0.92 10.00 0.90 8.07 0.64 0.52 0.59 3.31 
E7 0.59 3.54 0.38 3.33 0.38 2.00 0.60 1.91 0.43 2.90 
E8 0.50 4.90 0.25 2.63 0.57 7.81 0.40 1.13 0.42 9.06 
E9 0.26 4.17 0.12 2.16 0.24 4.64 0,04 0.00 0.42 2.13 
ElO 0.09 1.11 0.00 1.32 0.00 1.63 0.11 1.25 0.19 2.87 
Eli 0.31 1.83 0.38 1.47 0.54 1.49 0.33 1.97 0.84 4.05 
E12 0.45 3.52 0.37 4.12 0.85 1.82 0.58 3.46 0.61 1.11 
E14 0.00 0.00 0.00 1.63 0.15 2.96 0.06 0.72 0.13 2.10 
E15 0.25 3.27 0.53 20.67 0.26 0.42 0.37 0.93 0.61 0.71 
E16 1.12 4.55 0.50 3.19 0.35 8.43 1.15 3.78 2.29 15.63 
E17 0.25 2.74 0.34 3.81 ND ND 1.25 4.09 0.58 12.02 
E18 1.12 1.96 0.66 1.77 1.43 4.57 6.73 20.17 2.60 13.28 
E20 1.42 5.73 0.43 1.83 0.52 7.83 2.42 9.16 0.00 1.11 
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Table A4.13b (continued): 
CD4ICD3 
CM RBC PfSE PHA PPD 
DONOR RI R2 Al R2 Al R2 Ri R2 Al R2 
El 40.59 50.00 49.82 52.27 44.79 55.79 23.01 35.90 43.28 60.18 
E2 19.66 45.74 19.11 45.19 17.78 35.29 7.69 29.95 19.39 47.83 
E3 28.59 54.33 29.49 51.61 27.41 51.06 14.63 43.72 36.15 77.79 
E4 27.75 51.43 26.32 50.29 23.06 41.82 23.07 53.02 25.67 54.04 
ES 25.09 56.62 24.69 48.28 28.44 54.59 27.87 61.17 29.52 50.29 
E6 30.61 45.00 27.70 41.51 28.67 45.49 22.41 31.12 32.07 72.42 
E7 41.37 40.94 43.56 40.39 44.13 50.71 35.29 49.33 39.78 57.50 
E8 43.17 48.37 40.47 38.52 42.34 45.35 20.67 28.30 38.53 42.69 
E9 13.31 31.22 13.86 35.26 12.80 42.97 3.41 17.98 13.18 54.74 
ElO 20.05 30.20 18.40 39.16 21.58 58.76 9.07 27.08 15.42 42.23 
Eli 24.52 37.85 24.36 33.52 9.88 19.81 24.37 37.35 24.14 47.56 
E12 31.50 52.75 31.54 52.85 17.56 38.41 32.99 53.33 35.05 65.47 
E14 15.80 33.67 15.12 27.43 16.70 52.25 14.80 32.84 18.45 52.66 
E15 47.59 54.98 51.47 61.09 47.17 67.19 19.13 23.37 47.81 66.50 
E16 31.29 14.99 38.65 23.70 34.58 29.94 23.66 38.16 31.83 27.16 
E17 46.46 52.63 43.32 60.77 45.75 54.42 41.97 52.33 48.12 56.42 
E18 18.44 7.37 16.68 5.56 15.14 5.57 11.70 19.42 13.80 15.15 
E20 25.64 19.75 26.40 18.54 28.28 35.41 25.91 29.13 47.43 56.19 
CD4/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Al R2 Al R2 Ri R2 Al R2 Al R2 
El 21.64 36.92 28.06 43.56 26.58 51.99 14.25 22.66 28.16 57.83 
E2 7.61 27.13 7.61 24.04 7.38 28.57 4.77 20.82 7.12 35.40 
E3 9.76 37.98 9.93 32.26 11.15 44.26 8.89 32.26 16.80 71.93 
E4 9.53 38.57 8.38 38.73 8.57 32.12 8.73 28.02 9.22 47.66 
ES 8.31 25.00 9.67 21.55 10.60 34.78 10.86 31.19 12.36 33.14 
E6 9.97 33.46 8.92 28.30 11.22 36.10 7.77 12.63 15.09 65.11 
E7 18.98 23.94 19.79 26.52 21.29 36.71 20.09 33.43 22.01 48.76 
E8 15.11 29.63 14.27 20.42 16.10 30.18 9.16 16.70 15.24 36.12 
E9 6.17 18.99 6.99 23.12 6.68 35.54 0.88 8.26 7.45 46.61 
ElO 6.44 15.35 6.18 24.48 9.49 48.20 4.10 14.29 6.19 25.50 
Ell 15.54 29.31 16.18 25.76 7.61 17.41 16.25 32.03 17.28 44.73 
E12 25.40 45.80 25.02 49.85 15.91 36.21 26.93 51.19 28.48 64.90 
E14 4.12 22.45 3.39 15.93 7.12 47.40 8.45 25.80 8.26 47.85 
E15 25.87 48.42 26.73 56.27 24.36 65.36 11.83 17.57 27.08 64.49 
E16 7.48 6.45 12.62 16.82 12.06 25.69 8.92 18.48 11.19 23.07 
E17 16.81 24.34 15.89 31.56 14.59 27.56 18.26 32.57 18.09 36.31 
E18 11.80 5.36 10.81 4.66 9.89 5.45 9.75 19.75 8.79 14.29 
E20 15.64 13.75 16.15 14.33 16.33 29.73 18.26 18.57 31.17 46.62 
CD8ICD3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Al R2 Al R2 
El 22.57 35.35 21.21 29.60 19.74 20.08 1.32 1.51 18.81 12.12 
E2 6.70 21.11 4.73 15.93 4.32 18.18 15.53 62.39 4.60 16.05 
E3 5.76 19.13 4.37 27.27 5.26 15.30 6.69 28.33 4.92 7.25 
E4 10.55 40.62 8.30 33.73 8.57 37.70 11.30 36.94 9.62 27.07 
ES 11.70 46.09 9.16 39.82 12.08 35.95 14.00 32.78 12.21 30.72 
E6 27.75 51.04 26.21 43.32 26.21 45.25 44.23 71.47 24.83 20.55 
E7 17.83 24.88 18.76 26.71 17.27 19.27 31.56 47.78 16.84 15.18 
E8 18.45 33.89 18.00 32.28 19.30 25.17 49.55 66.95 17.38 16.43 
E9 6.94 33.97 7.73 18.52 7.92 17.30 6.21 57.58 8.36 15.65 
ElO 7.97 25.55 7.81 36.42 8.92 14.29 11.01 41.71 5.85 21.24 
Eli 9.33 26.89 9.31 21.98 22.39 59.40 9.95 20.49 11.74 17.55 
E12 5.80 21.11 5.11 20.87 11.91 34.63 5.58 17.71 5.21 5.85 
E14 5.06 17.86 5.33 20.56 5.06 16.49 16.01 47.85 6.01 11.99 
E15 17.68 52.67 18.13 52.40 14.72 25.17 39.89 58.08 15.59 16.57 
E16 12.08 7.83 13.80 9.95 13.39 16.16 27.37 54.24 13.75 20.80 
E17 17.85 30.41 20.00 26.12 18.17 30.33 35.47 48.75 19.41 25.80 
E18 8.48 5.60 6.61 3.60 7.46 5.00 13.92 18.59 11.47 13.97 
E20 13.54 14.13 13.52 10.82 17.50 25.63 28.50 48.57 15.48 9.33 
Table A4.13b (continued): 
CD8/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 RI R2 Ri R2 
El 2.34 16.28 1.69 10.20 2.06 11.94 0.75 0.90 1.74 7.63 
E2 0.27 5.00 0.55 7.08 0.28 5.45 2.53 15.18 0.30 6.17 
E3 0.32 6.09 0.18 8.52 0.24 4.10 0.58 8.33 0.27 4.39 
E4 1.19 12.50 0.66 14.20 0.76 14.75 1.34 9.12 0.87 14.41 
E5 0.70 13.04 0.56 7.96 0.80 15.03 1.13 8.46 0.67 9.04 
E6 3.75 23.96 2.35 16.61 3.10 22.62 4.36 7.41 2.33 12.40 
E7 1.11 5.91 0.78 7.05 1.07 8.12 2.90 10.51 1.01 6.90 
E8 1.07 5.97 1.12 6.93 0.74 8.33 3.29 7.50 0.89 8.25 
E9 0.21 10.53 0.54 5.29 0.44 5.57 0.26 7.58 0.53 7.71 
ElO 0.49 5.84 0.35 9.88 0.77 5.17 1.10 6.55 0.35 7.25 
Eli 0.98 6.03 0.49 6.61 3.94 16.36 0.51 6.02 0.90 8.82 
E12 1.09 9.68 1.18 8.74 2.63 11.04 1.44 11.23 1.29 3.75 
E14 0.10 2.38 0.07 7.48 0.09 6.45 0.61 5.98 0.20 6.94 
E15 2.71 31.28 2.68 28.37 2.70 14.55 3.98 10.89 3.06 12.09 
E16 2.45 5.57 2.73 8.14 2.84 13.64 6.56 16.19 4.16 18.61 
E17 2.75 14.86 3.44 13.20 3.33 20.33 13.93 26.58 2.63 15.69 
E18 3.01 4.31 3.07 2.98 3.31 4.74 8.52 18.59 7.68 14.71 
E20 1.79 5.87 1.76 3.51 1.78 20.85 13.62 22.90 0.97 5.18 
Tcfl Vy9/CD3 
CM ABC PfSE PHA PPD 
DONOR Al R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 2.34 7.31 2.66 5.83 5.36 9.77 38.60 56.37 2.31 2.45 
E2 0.85 2.31 0.34 0.00 0.35 2.06 0.25 0.61 0.42 0.50 
E3 0.63 4.15 0.64 1.74 0.62 1.40 0.29 0.47 0.49 0.68 
E4 0.64 5.93 0.83 3.29 0.85 4.03 0.75 1.64 0.66 0.83 
E5 0.74 0.90 0.63 6.03 0.69 2.76 0.32 0.33 0.69 3.27 
E6 1.89 1.97 1.47 3.24 2.35 2.17 1.32 0.81 1.82 1.98 
E7 1.78 3.54 1.80 2.36 2.02 1.61 1.30 1.00 2.05 0.66 
68 1.79 5.28 1.58 2.12 1.85 2.31 1.05 0.91 1.68 2.29 
E9 0.68 5.19 0.82 4.81 0.88 3.91 0.11 0.47 0.71 2.76 
610 0.06 2.34 0.25 3.79 0.17 0.45 0.11 0.47 0.30 1.63 
Eli 1.53 2.04 1.66 2.73 0.64 0.45 1.67 0.90 1.81 1.40 
E12 0.94 3.62 1.16 3.78 0.89 1.90 1.66 3.08 1.62 1.08 
614 0.29 5.26 0.16 1.92 0.25 1.91 0.47 0.67 0.42 2.62 
E15 0.57 3.24 0.78 1.72 0.58 0.63 0.54 0.45 0.59 0.65 
E16 0.64 2.09 1.08 4.81 0.76 3.88 1.29 4.05 1.47 10.38 
E17 3.42 6.16 3.06 5.40 3.41 8.43 2.71 4.45 3.64 7.14 
E18 2.42 2.31 2.92 1.66 2.53 2.94 7.20 11.96 4.85 13.83 
E20 1.39 4.41 1.15 2.34 0.60 13.16 1.28 7.70 0.27 4.93 
TcR V79/C045R0 
CM ABC PfSE PHA PPD 
DONOR Al R2 RI R2 Ri R2 Ri R2 Ri R2 
El 0.50 3.16 0.51 2.80 1.61 6.14 5.51 10.68 0.47 1.43 
E2 0.06 1.16 0.00 0.00 0.03 0.00 0.18 0.46 0.00 0.50 
E3 0.05 2.59 0.08 1.16 0.13 0.70 0.13 0.00 0.03 0.29 
E4 0.24 5.93 0.00 1.97 0.12 2.01 0.26 0.60 0.06 0.83 
E5 0.03 0.90 0.00 0.86 0.03 1.66 0.03 0.25 0.00 0.65 
E6 0.48 1.57 0.23 1.18 0.58 1.09 0.47 0.53 0.27 1.40 
67 0.34 1.36 0.19 1.42 0.22 1.25 0.47 0.74 0.17 0.40 
E8 0.10 2.94 0.04 1.06 0.21 0.43 0.26 0.40 0.07 1.46 
E9 0.06 1.89 0.21 2.67 0.47 2.51 0.07 0.24 0.06 0.92 
ElO 0.03 0.58 0.06 0.76 0.03 0.22 0.07 0.16 0.00 1.22 
Eli 0.08 0.14 0.29 1.50 0.24 0.27 0.14 0.39 0.23 0.61 
E12 0.39 1.97 0.18 2.77 0.50 1.61 0.38 2.61 0.29 0.97 
614 0.06 1.32 0.07 0.96 0.03 1.91 0.34 0.56 0.10 2.33 
E15 0.32 2.65 0.25 1.15 0.31 0.63 0.29 0.23 0.11 0.65 
E16 0.15 1.33 0.55 4.81 0.28 4.07 0.46 2.16 0.76 10.18 
E17 0.50 3.77 0.29 1.42 0.53 3.93 1.39 2.71 0.43 4.86 
E18 0.75 1.73 0.90 1.40 0.73 2.94 5.91 13.83 2.94 14.09 
E20 0.64 4.68 0.79 4.35 0.44 12.94 0.94 4.74 0.12 3.32 
PIZ 
Table A4.13b (continued): 
TcR V61/CD3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 RI R2 Ri R2 Ri R2 Ri R2 
El 1.36 4.32 1.32 4.74 1.50 2.65 1.48 1.98 1.61 3.77 
E2 0.23 1.06 0.38 2.29 0.20 1.40 0.27 1.65 0.23 0.40 
E3 0.03 0.56 0.00 0.64 0.00 0.33 0.03 0.13 0.03 0.10 
E4 1.05 2.92 0.98 2.60 0.95 0.64 0.88 1.57 0.91 4.57 
ES 1.70 0.90 1.39 1.06 1.55 1.84 1.04 0.54 2.23 2.63 
E6 5.93 7.05 6.22 8.55 6.83 8.14 5.51 2.08 6.88 7.60 
E7 1.62 0.48 1.86 1.51 1.78 1.41 2.22 1.63 2.17 2.22 
E8 2.10 2.55 2.14 1.65 2.82 6.27 3.29 2.13 3.65 16.51 
E9 1.35 1.42 1.77 2.48 2.45 5.75 0.37 2.87 2.07 2.18 
ElO 0.12 1.18 0.12 0.00 0.10 0.50 0.11 0.45 0.13 0.44 
Eli 2.03 4.80 1.75 3.10 1.98 3.89 1.67 6.05 2.67 6.36 
E12 0.33 1.03 0.34 0.59 0.25 0.58 0.36 1.30 0.38 0.86 
E14 0.06 0.00 0.13 1.25 0.12 1.29 0.30 0.50 0.10 0.37 
E15 0.28 0.29 0.45 1.62 0.36 1.36 0.86 0.97 0.41 0.42 
E16 0.85 1.83 0.98 2.48 0.86 6.68 2.82 8.67 2.45 14.63 
E17 2.01 5.15 2.14 1.33 1.68 3.79 1.85 4.24 1.76 6.43 
E18 3.39 1.33 3.30 1.62 3.27 3.07 9.51 23.27 6.08 16.23 
E20 1.76 4.30 1.08 2.90 1.12 15.53 1.70 8.00 0.56 2.39 
TcR V61/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 0.09 1.69 0.06 0.95 0.10 1.42 0.10 0.99 0.31 1.83 
E2 0.00 1.06 0.03 0.00 0.00 0.70 0.17 1.10 0.00 0.00 
E3 0.00 0.56 0.00 0.64 0.00 0.33 0.03 0.13 0.00 0.10 
E4 0.03 0.73 0.12 1.30 0.00 0.64 0.00 0.48 0.00 2.28 
ES 0.03 0.90 0.00 0.00 0.00 0.61 0.110 0.15 0.03 0.66 
E6 0.06 3,52 0.02 3.95 0.14 3.88 0.05 0.45 0.13 2.71 
E7 0.05 0.48 0.14 0.86 0.09 0.16 0.20 0.90 0.02 0.89 
ES 0.02 0.77 0.04 0.62 0.06 2.20 0.24 0.60 0.50 10.18 
E9 0.03 0.47 0.00 0.00 0.03 2.88 0.00 0.41 0.03 0.48 
ElO 0.03 0.00 0.00 0.00 0.07 0.50 0.00 0.00 0.00 0.00 
Eli 0.06 2.49 0.09 0.90 0.28 1.94 0.03 2.67 0.14 3.06 
E12 0.03 1.03 0.00 0.59 0.00 0.22 0.09 0.87 0.06 0.65 
E14 0.00 0.00 0.06 1.25 0.03 0.32 0.03 0.20 0.00 0.00 
E15 0.02 0.00 0.02 1.62 0.00 0.61 0.21 0.64 0.11 0.53 
E16 0.21 1.43 0.18 2.07 0.17 5.85 0.69 4.32 1.54 15.51 
E17 0.08 1.82 0.07 0.33 0.08 1.03 0.16 1.19 0.06 4.09 
E18 0.78 0.59 0.56 1.08 0.86 2.69 6.90 26.89 3.57 15.88 
E20 0.99 5.02 0.62 2.58 0.82 16.84 0.76 4.17 0.09 1.39 
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Table A4.14: Complete data for total numbers of cells (per 106  cells plated on day 0) of 
cellular subsets for each exposed individual on a) day 0 and b) day 7. Resting cells 
(Ri) and lymphoblasts (R2) are indicated for each stimuli (ND = not done). 
a) 
cells in aate 
DONOR Al R2 
El 	356400 389100 
E2 90800 102300 
E3 	342700 46200 
E4 266100 20300 
E5 	276500 15400 
E6 529600 52800 
E7 	556000 75000 
E8 477500 63800 
E9 	389400 114200 
ElO 225800 59300 
Eli 	438300 191000 
E12 467300 31900 
E14 	485400 17900 
E15 708800 47800 
E16 	657700 48000 
617 646400 52500 
E18 	621500 50700 
E20 508100 22900 
CD2O 
DONOR Ri R2 
El 54280 32334 
62 3959 17790 
E3 31768 3229 
E4 20889 2436 
E5 32433 2304 
E6 26851 6236 
E7 66053 7290 
E8 6494 4887 
E9 38395 13099 
EiO 25967 7413 
Eli 108348 76400 
E12 49814 4530 
E14 65092 3491 
E15 61666 8069 
E16 57878 3763 
617 44860 23147 
E18 92479 17517 
E20 23423 2498 
CD 20/a D 45 HO 
DONOR RI R2 
El 606 1167 
E2 0 184 
E3 2330 448 
E4 0 0 
E5 0 60 
E6 0 0 
67 389 353 
E8 334 223 
E9 0 388 
ElO 0 0 
611 131 0 
612 0 309 
E14 97 149 
615 496 86 
E16 197 82 
E17 129 567 
E18 124 461 
E20 203 277 
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Table A4.14a (continued): 
CD56 
DONOR Ri R2 
El 2031 7082 
E2 0 2997 
E3 27005 7355 
E4 985 181 
E5 1051 302 
ES 1271 417 
E7 2057 1995 
E8 13179 8587 
E9 1558 3666 
ElO 858 1666 
Eli 438 688 
E12 1215 412 
E14 777 446 
E15 1772 607 
E16 3486 734 
E17 2586 452 
E18 1554 304 
E20 864 417 
CD 56/CD 45 AG 
DONOR Ri R2 
El 143 467 
E2 0 0 
E3 25086 6639 
E4 106 0 
ES 0 60 
E6 0 0 
E7 Ill 233 
E8 1051 740 
E9 0 194 
ElO 0 184 
Eli 219 344 
E12 187 102 
E14 97 149 
E15 213 172 
E16 66 82 
E17 323 226 
E18 186 152 
E20 0 140 
Total CD3 
DONOR RI R2 
El 	263879 299529 
E2 44846 65636 
E3 	221761 27323 
E4 167270 10718 
ES 	147015 10281 
E6 327293 32414 
E7 	360622 44400 
E8 303260 25788 
E9 	183407 73191 
ElO 126222 35544 
Eli 	243257 86122 
E12 278885 15720 
E14 241584 7511 
E15 	421169 21214 
E16 398303 15226 
E17 	478724 17766 
E18 391421 20229 
E20 	144961 12437 
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Table A4.14a (continued): 
CD45RA/CD3 
DONOR Ri R2 
El 160594 155056 
E2 23045 19918 
E3 92460 8445 
E4 90900 5034 
E5 92213 5208 
E6 227675 18343 
E7 201272 19208 
E8 173285 11541 
E9 97934 42380 
ElO 67830 14505 
Eli 127764 42727 
E12 73693 4252 
E14 155765 3897 
E15 201228 8580 
E16 234141 6240 
E17 292690 6662 
E18 148539 10115 
E20 102738 8489 
CD45RO/CD3 
DONOR Ri R2 
El 95800 158831 
E2 17833 45268 
E3 109253 18628 
E4 60777 6171 
E5 41364 5435 
E6 73879 17371 
E7 122876 23550 
E8 95070 12377 
E9 61915 44766 
ElO 50760 24663 
Eli 85688 51150 
E12 166733 12945 
E14 56695 3501 
E15 192864 16309 
E16 101088 7507 
E17 111698 8437 
E18 168427 14414 
E20 22712 4443 
TcRaIl/C D3 
DONOR Ri R2 
El 7556 24435 
E2 445 1514 
E3 3461 1538 
E4 5508 1052 
ES 9539 901 
E6 25580 5027 
E7 16458 2738 
E8 24257 4351 
E9 14330 8896 
ElO 1535 166 
Eli 131 630 
E12 93 542 
E14 0 70 
E15 921 492 
E16 66 91 
E17 776 809 
E18 373 380 
E20 102 266 
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Table A4.14a (continued): 
TcRof3/CD45RO 
DONOR Ri R2 
El 1140 5292 
E2 163 501 
E3 1337 1026 
E4 213 323 
ES 442 225 
E6 4078 1410 
E7 2391 495 
E8 1194 664 
E9 2414 3632 
ElO 565 166 
Eli 0 1280 
E12 0 453 
E14 0 70 
E15 638 368 
E16 0 91 
E17 129 693 
E18 0 289 
E20 102 266 
TcR6/CD3 
DONOR Al R2 
El 12082 29572 
E2 781 7488 
E3 3153 1599 
E4 6839 497 
ES 5143 453 
E6 20654 6204 
E7 13622 5378 
E8 23016 4766 
E9 11293 9353 
ElO 2168 1411 
Ell 30725 14096 
E12 14346 1557 
E14 5922 199 
E15 12617 1525 
E16 12628 1262 
E17 27989 3014 
E18 72653 2956 
E20 11534 2306 
TcRyS/C 045 R 0 
DONOR Ri R2 
El 3029 6809 
E2 281 4992 
E3 1268 725 
E4 639 213 
E5 415 226 
E6 2701 3152 
E7 2057 1590 
E8 1671 612 
E9 584 5379 
ElO 745 1257 
Ell 2016 5004 
E12 4019 983 
E14 534 0 
E15 2623 970 
E16 1250 360 
E17 2715 1565 
E18 808 228 
E20 203 769 
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Table A4.14a (continued): 
CD4/CD3 
DONOR Ri R2 
El 	157279 177391 
E2 27721 54863 
E3 	163948 23100 
E4 107904 7375 
E5 	97383 6160 
E6 122020 15360 
E7 	14400 4178 
E8 170802 13424 
E9 	84149 35733 
ElO 80294 25297 
Eli 	110320 53308 
E12 169209 13573 
E14 135038 6150 
E15 	219303 21481 
E16 246374 21850 
E17 	307169 16328 
E18 193659 21664 
E20 79975 7669 
C D4/C D45 R 0 
DONOR Ri R2 
El 	55563 93267 
E2 7800 26864 
E3 	63468 14345 
E4 30468 4600 
E5 	26212 3031 
E6 25633 7487 
E7 	2113 1433 
E8 41686 6029 
E9 	44820 27522 
ElO 34254 15756 
Eli 	50492 18164 
E12 108414 10278 
E14 28153 2280 
E15 	87891 16219 
E16 52156 6917 
E17 61149 6059 
E18 	91920 12604 
E20 13160 2663 
CD8/CD3 
DONOR Al R2 
El 70567 123345 
E2 11895 42127 
E3 37526 15149 
E4 39250 5483 
E5 42775 4760 
E6 109839 22387 
E7 221622 26460 
E8 87048 12371 
E9 57787 40358 
ElO 29489 17072 
Ell 67148 55753 
E12 33646 6945 
E14 47084 6165 
E15 114329 10741 
E16 104903 11515 
E17 103876 12248 
E18 76942 8954 
E20 37549 5285 
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Table A4.14a (continued): 
C D8IC D45R 0 
DONOR RI R2 
El 4170 13969 
E2 1226 4511 
E3 1234 2019 
E4 2129 1186 
E5 1355 414 
E6 6673 3173 
E7 88015 16838 
E8 4250 957 
E9 4400 9250 
ElO 3635 3819 
Ell 2323 2903 
E12 6028 1372 
E14 1747 132 
E15 24879 2032 
E16 3946 509 
E17 5947 1460 
E18 14543 2216 
E20 203 414 
TcR V79/CD3 
DONOR RI R2 
El 10763 25525 
E2 817 931 
E3 30603 6440 
E4 5428 546 
E5 2571 533 
E6 11069 2297 
E7 102971 19148 
E8 11365 1359 
E9 8216 5310 
ElO 1626 670 
Ell 24107 5673 
E12 16683 947 
E14 3689 138 
E15 6167 502 
E16 9010 878 
E17 30445 3166 
E18 39776 1080 
E20 1829 261 
TcR Vy9/CD45RO 
DONOR Ri R2 
El 392 6809 
E2 82 0 
E3 5963 1959 
E4 293 274 
ES 111 106 
E6 1271 1357 
E7 4837 1830 
E8 334 325 
E9 1480 2090 
ElO 542 445 
Ell 657 1776 
E12 748 118 
E14 0 68 
E15 1488 201 
E16 263 82 
E17 388 1586 
E18 808 542 
E20 0 0 
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Table A4.14a (continued): 
TcR V81/CD3 
DONOR Ri R2 
El 8767 13190 
E2 708 696 
E3 411 961 
E4 5934 296 
E5 7355 1067 
E6 27486 2936 
E7 10453 3413 
E8 36863 5174 
E9 13512 7788 
E 1 881 0 
Ell 29980 14019 
E12 2290 338 
E14 3495 200 
E15 3828 593 
E16 7761 744 
E17 10472 1418 
E18 53946 2834 
E20 15040 2487 
TcR V81/CD45RO 
DONOR Ri R2 
El 214 584 
E2 45 0 
E3 206 0 
E4 0 148 
E5 0 0 
E6 0 269 
E7 723 570 
E8 812 338 
E9 117 1142 
E 1 0 0 
Eli 131 1070 
E12 93 450 
E14 291 100 
E15 284 167 
E16 0 278 
E17 323 982 
E18 497 1486 




cells in gate 
CM RBC PISE PHA PPD 
DONOR Al R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 92993 10913 140850 12750 125782 22082 154148 96730 115847 32509 
E2 71720 8338 69321 5208 66880 4940 96866 66970 74140 6490 
E3 188279 34131 167200 4180 163152 7788 122496 40934 193260 53940 
E4 127300 4446 128250 3975 160332 7812 82964 23520 159173 8693 
E5 108605 1972 193724 9737 98952 6076 200898 91930 163482 8054 
E6 236425 9996 198870 12096 190715 11664 206416 98407 192206 32398 
E7 120060 5910 168947 13869 160004 16796 126720 100692 102398 151425 
E8 143988 63190 109940 10860 166010 18785 105216 86976 209950 55243 
E9 181328 15568 245073 15251 142516 18876 137713 26968 152390 18032 
ElO 86996 4914 57114 2934 90240 15390 49580 16700 105157 9347 
Eli 112800 17472 100330 20827 105690 23040 45700 48460 115659 50765 
E12 79850 9325 58238 7104 147004 16694 56201 37367 160217 54024 
E14 97377 1669 137808 8135 125438 12675 120384 38912 64370 8364 
E15 232024 9700 106128 3520 118748 16800 92628 60669 230841 56570 
E16 238310 29101 300048 31725 194130 23940 324342 319791 241428 37262 
E17 242606 15136 195098 12935 205641 12775 193490 103235 223744 16720 
E18 137492 22940 142074 26082 136850 29070 71418 25190 90038 18460 
E20 163485 13755 265210 22110 141284 28690 156676 76544 407523 237533 
CD2O 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Al R2 Al R2 RI R2 Al A2 
El 9904 1467 15479 1459 11761 2568 20363 25817 7518 3134 
E2 2345 834 1227 229 2655 810 4795 14613 2973 731 
E3 6646 3539 4832 425 5237 783 6321 9611 4600 4973 
E4 6696 527 4591 450 5195 1098 4447 4575 5030 1159 
E5 5191 176 9822 567 5492 588 12154 14194 9825 1086 
E6 8724 1057 6225 895 7514 1224 8566 11248 7323 2142 
E7 11394 313 15019 692 16768 1414 10340 18638 8089 13341 
E8 9474 5662 8213 1467 11405 2555 5692 14908 10057 4552 
E9 9121 2123 9435 1251 6142 2680 0 59 4175 1998 
ElO 3349 653 1691 262 3411 2461 2256 3719 3344 1421 
Eli 19165 5561 15401 6046 10897 5283 6951 12304 16944 8838 
E12 3985 1149 2533 1011 6439 3426 12999 25204 5191 3285 
E14 2834 14 3183 445 4729 1954 9053 7249 1976 691 
E15 17355 1984 7280 565 6294 1614 6753 16957 7387 3994 
E16 10629 1775 13712 895 8600 991 14174 48704 18638 10825 
E17 14144 1488 14944 916 25972 650 18401 16466 27274 4063 
E18 6930 395 9760 237 10756 1244 12927 7570 8923 3299 
E20 37258 2710 36095 4559 20952 11341 29659 33725 26000 61046 
CD 20/C D45 R 0 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Al A2 Al R2 Ri R2 Ri R2 
El 102 216 0 524 101 428 92 2592 70 644 
E2 0 111 42 46 40 122 165 2136 22 56 
E3 56 416 33 177 0 92 0 1310 58 1586 
E4 38 59 38 37 96 65 0 355 48 124 
ES 33 18 0 189 30 118 241 2298 0 192 
E6 0 81 40 149 76 0 186 502 0 87 
E7 60 47 253 115 112 144 393 3232 20 2059 
E8 58 569 0 117 0 351 53 1218 42 475 
E9 54 0 147 0 86 274 0 0 0 146 
ElO 52 0 0 0 0 0 20 124 32 0 
Eli 90 105 90 223 127 829 14 504 0 482 
E12 96 65 17 107 59 297 4535 12043 48 216 
E14 29 0 0 55 0 53 36 615 0 95 
E15 93 220 0 56 24 170 65 1911 0 289 
E16 214 402 60 0 136 41 0 352 579 1390 
E17 291 88 78 50 185 109 542 568 112 373 
E18 330 71 114 34 151 78 193 426 216 508 
E20 262 0 159 380 0 525 517 1102 367 808 
Table A4.14b (continued): 
CD56 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 3264 1617 3789 859 5522 3509 3962 2254 6429 3693 
E2 868 222 665 183 776 1053 4436 5471 1461 1011 
E3 7192 7075 5969 354 8060 1797 2695 4544 8851 5739 
E4 3386 702 3104 600 2341 710 863 621 3852 1241 
E5 2411 194 3681 945 2147 784 2893 1912 4627 1279 
E6 16030 1463 13384 2539 11424 1399 7390 2647 15665 3761 
E7 4166 297 7501 2112 7920 1161 3523 3192 8182 17429 
E8 24262 11317 20306 2231 28703 4600 13005 2975 46609 16297 
E9 4805 1178 7499 750 6755 2516 0 59 5852 1560 
ElO 1957 309 1097 105 3149 1431 545 331 3113 595 
Eli 508 236 291 527 687 346 334 1672 1029 2305 
E12 1086 591 786 266 3631 1092 22390 25574 4887 7315 
E14 146 0 358 223 2333 1268 506 568 1281 1072 
E15 11207 1599 4755 621 9274 3342 6540 3761 20522 13362 
E16 7078 1487 8641 1075 4562 1652 8692 20754 7943 6472 
E17 13271 963 9657 1018 10261 1246 7740 2983 15349 2523 
E18 4455 216 4191 68 6213 738 3785 3119 5429 2031 
E20 1586 616 1856 683 1837 3979 3102 3253 5868 9026 
C 056/CD 45R0 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Ri R2 Ri R2 
El 270 151 141 149 38 598 92 764 197 731 
E2 108 111 21 46 60 203 0 1112 44 140 
E3 301 625 167 0 179 692 122 1400 155 1969 
E4 153 59 141 112 144 65 25 207 143 289 
E5 0 0 58 94 59 0 301 956 147 128 
E6 1631 407 1432 1045 782 262 991 413 1249 1487 
E7 204 31 760 614 352 291 152 1651 307 3483 
E8 130 752 110 0 249 575 32 365 231 1480 
E9 272 353 490 125 128 383 0 59 229 389 
ElO 104 0 40 53 27 45 0 42 0 46 
Eli 0 52 0 167 159 141 64 417 93 721 
E12 72 164 70 53 59 224 9886 13904 304 2528 
E14 0 0 0 lii 0 529 36 284 58 262 
E15 1995 606 414 207 843 1784 602 1662 1593 6319 
E16 262 113 270 121 78 0 97 672 169 425 
E17 364 88 78 50 185 0 542 671 157 94 
E18 247 37 227 0 41 78 71 214 216 196 
E20 49 0 0 0 127 0 392 276 367 261 
Total CD3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Hi R2 Al R2 
El 63253 6766 88200 7069 76350 13216 100227 68794 78208 22899 
E2 18210 4919 15840 2940 12834 2226 30987 52143 19469 3758 
E3 71960 25018 55159 2422 55553 4721 31175 25923 88011 43767 
E4 47979 2901 46709 2532 55651 5175 27635 17699 59244 5548 
E5 48698 1592 78167 6134 42906 3971 88877 78425 62679 6246 
E6 146158 7785 124055 9522 114085 8748 145441 89383 120571 27639 
E7 76118 2851 111623 8602 102115 10259 88286 82366 65801 102242 
E8 98675 43570 71461 6516 109152 12227 74998 69616 130883 36223 
E9 40146 7860 54112 7778 35244 11414 14501 17828 35873 12444 
ElO 28048 2662 15255 1648 26765 9500 10803 11438 29023 5616 
Eli 40428 8619 37614 9851 36093 15667 17499 24676 49213 30571 
E12 29193 5407 21734 4540 46674 10228 23054 24531 68893 39594 
E14 27363 707 29959 3395 39939 7997 39402 27966 17657 5452 
E15 168078 7610 76094 2493 79811 12736 58642 41934 155933 42014 
E16 111481 4266 158935 5530 101025 6591 162106 235718 108956 11600 
E17 166403 11116 133583 9335 140062 9512 146395 87915 149595 10754 
E18 41743 2335 46842 2947 37004 2567 14769 5625 21834 3336 
E20 61127 2959 113059 7150 69907 10282 73779 42650 257269 147389 
WOM 
Table A4.14b (continued): 
C D45RA/C D3 
CM ABC PfSE PHA PPD 
DONOR Ri R2 RI R2 RI R2 RI R2 Ri R2 
El 31431 3226 43227 3630 35395 2966 37627 31679 32993 3631 
E2 8571 2220 6988 1559 5825 671 4785 14787 8845 1138 
E3 33965 13963 24495 1164 23527 1679 8489 12018 32429 5356 
E4 27089 1427 24509 987 28491 1741 12387 8333 31405 1627 
E5 28704 1081 43394 3311 25203 2252 46628 39429 34544 3418 
E6 84049 4870 79011 6606 68142 4778 81865 59457 63755 5673 
E7 39056 2039 55330 5405 47937 3816 26218 26281 31805 28483 
E8 49301 25902 37852 4057 49139 4691 16666 19239 65903 7927 
E9 20907 3968 25512 4348 16047 3564 7051 8052 15879 2636 
ElO 14868 1479 7956 997 12859 1402 3971 4830 14175 1846 
Eli 16931 4627 18059 5240 9269 3988 7262 12415 22322 8523 
E12 5086 1136 5195 1388 5660 2536 4490 4335 11760 2842 
E14 16905 491 18701 1921 24209 1740 14157 10584 9977 1110 
E15 81278 3567 36211 1036 34615 3069 10763 14324 62258 5940 
E16 57051 2776 81523 3144 49639 3402 41581 87335 62747 6726 
E17 73631 5702 58666 5095 61363 4699 45625 25282 68868 5763 
E18 9198 679 10144 1307 7472 916 3957 2461 4016 1654 
E20 19291 1513 34026 3726 22125 2284 11610 9836 45602 11069 
CD 45 R 0/CD 3 
CM ABC PfSE PHA PPD 
DONOR Al R2 Al R2 Al R2 Ri R2 Ri R2 
El 27768 4105 40706 4576 35898 10842 53073 43393 40187 20175 
E2 7437 3479 6579 1559 4942 1494 17736 36773 8104 2847 
E3 26604 18229 20265 1568 22466 3699 16684 18314 45551 41820 
E4 14932 1974 15711 2000 18951 4080 11980 10979 20756 4402 
ES 13608 818 22956 3408 13438 2401 31943 47362 20370 3850 
E6 40405 4645 33231 4933 31125 5446 39859 29620 45476 24140 
E7 22751 1303 37895 4255 38609 7506 43490 57576 25354 84419 
E8 28582 24467 19042 3127 30529 7537 31912 40296 38778 27356 
E9 13400 4731 20635 3981 13895 8798 4930 10736 16214 10334 
ElO 8700 1615 4712 925 9629 7923 4160 5479 9390 3574 
Eli 14788 4859 17016 6202 23178 12815 8710 15192 23340 24789 
E12 21687 4780 15095 3952 39235 9147 16546 22405 51590 37595 
E14 6154 275 6394 1537 10574 6691 14530 13759 5465 4663 
E15 70141 5929 33409 2010 37275 11616 33596 30067 76408 39604 
E16 22330 1388 28114 2735 24985 5018 102362 188261 32206 8574 
E17 32825 4635 25519 3386 28152 4465 51236 46693 34166 6088 
E18 15922 1468 20004 2110 14821 1834 10534 5287 10471 3103 
E20 24457 - 	1816 49674 3785 24117 8266 44997 29990 109298 123636 
TcRu/CD3 
CM ABC -- PfSE PHA PPD 
DONOR Al R2 Al A2 Ri R2 Al R2 Ri R2 
El 1404 1399 1141 1349 604 1749 1850 9431 359 2347 
E2 273 608 104 128 20 94 533 6978 200 120 
E3 395 2437 652 348 261 498 674 5289 5991 10675 
E4 293 310 308 217 577 1321 1344 3624 700 982 
ES 130 222 174 621 168 432 8277 30364 2044 937 
E6 165 452 358 421 95 370 12364 29148 1403 4523 
E7 60 47 84 0 112 391 1001 10663 51 4255 
E8 86 853 44 54 249 490 1042 4592 105 602 
E9 163 65 147 239 128 1646 96 1842 198 887 
ElO 104 156 34 0 208 845 243 1617 210 722 
Eli 124 957 171 635 1173 2286 183 3320 1029 3508 
E12 256 382 390 410 500 908 191 3591 417 1745 
E14 0 34 0 93 75 488 181 1121 103 488 
E15 46 291 74 65 59 912 398 3252 115 571 
E16 3789 1406 4951 1535 4018 3151 87378 166995 9271 6428 
E17 5968 3189 2439 3234 3763 2376 22387 33066 4363 2881 
E18 1086 438 1918 574 1957 1090 5842 5174 3557 2535 
E20 5787 714 9044 1090 5722 7428 15370 18547 6418593303 
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Table A4.14b (continued): 
TcRcx/C D45 RO 
CM RBC PfSE PHA PPD 
DONOR Hi R2 Ri R2 Ri R2 Ri R2 Al R2 
El 744 988 606 1028 390 1374 1372 7003 266 2100 
E2 115 521 42 128 0 94 368 5726 89 120 
E3 207 2236 351 274 0 498 478 4302 3131 10561 
E4 115 310 77 177 289 1321 431 2740 287 1020 
E5 65 197 58 415 89 401 3596 21558 834 656 
E6 47 362 40 368 95 329 1734 9565 923 4309 
E7 36 47 84 0 32 336 710 9233 20 4255 
E8 0 682 22 0 0 456 568 3218 0 508 
E9 163 65 74 79 43 1587 55 1408 137 887 
ElO 52 156 17 0 153 845 94 994 32 587 
Ell 56 891 171 502 846 2276 73 3121 497 3701 
E12 232 459 239 410 500 1000 191 3957 529 2080 
E14 0 17 0 93 75 433 72 747 19 462 
E15 0 420 21 87 59 1016 306 2821 0 826 
E16 1740 1135 1920 1240 2330 3151 15049 36136 4756 6212 
E17 1480 1809 0 0 617 1003 6888 14618 1163 1976 
E18 522 344 1137 511 1191 1090 4635 5459 2332 2481 
E20 2485 - 	790 3686 800 2458 7032 6580 7654 28853 74039 
TcR-yS/CD3 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Al R2 Ri R2 Ri R2 Ri R2 
El 3050 950 3451 1089 3811 1751 2312 2138 2989 1690 
E2 423 124 319 156 161 280 232 824 319 466 
E3 979 1365 1354 194 995 269 159 332 1102 653 
E4 1362 229 1667 242 1716 502 564 223 1448 401 
ES 1553 35 1840 357 1831 422 1004 1158 2125 463 
E6 15155 1008 14895 1900 15505 1473 12323 2313 14108 2485 
E7 4046 261 5508 675 4512 448 3497 2668 3389 5996 
ER 3168 4859 2759 523 5296 2128 2210 2096 5921 7579 
E9 3572 1054 4436 659 3164 1363 399 183 3048 822 
ElO 157 55 34 58 90 376 94 341 400 313 
Eli 2651 613 2508 581 1184 652 1156 1846 3724 3279 
E12 1054 328 606 318 1294 339 714 1207 2403 600 
E14 282 0 317 133 652 422 193 362 335 176 
E15 1415 341 1199 694 606 260 667 595 2008 690 
E16 5791 1213 5341 1012 2970 2181 11092 26862 9971 5306 
E17 12591 1088 12038 1208 ND ND 8610 8063 14700 2924 
E18 8731 512 7487 676 8375 1433 7477 4103 5852 2311 
E20 5330 828 2599 473 947 2048 6580 12079 1915 5606 
TcR78/C D45 A 0 
CM ABC PfSE PHA PPD 
DONOR Al R2 RI R2 Al R2 Al R2 Ri R2 
El 911 623 944 598 1019 958 863 1412 938 1060 
E2 57 63 42 104 40 245 68 696 0 430 
E3 490 1171 485 166 343 202 86 143 464 653 
E4 229 201 231 194 385 502 133 191 191 321 
ES 65 35 116 268 59 211 141 542 98 278 
E6 496 323 1830 1210 1716 941 1321 512 1134 1072 
E7 708 209 642 462 608 336 760 1923 440 4391 
E8 720 3096 275 286 946 1467 421 983 882 5005 
E9 471 649 294 329 342 876 55 0 640 384 
ElO 78 55 0 39 0 251 55 209 200 268 
Eli 350 320 381 306 571 343 151 955 972 2056 
E12 359 328 215 293 1250 304 326 1293 977 600 
E14 0 0 0 133 188 375 72 280 84 176 
E15 580 317 562 728 309 71 343 564 1408 402 
E16 2669 1324 1500 1012 679 2018 3730 12088 5529 5824 
E17 607 415 663 493 ND ND 2419 4222 1298 2010 
E18 1540 450 938 462 1957 1328 4806 5081 2341 2451 
E20 2321 788 1140 405 735 2246 3792 7011 0 2637 
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Table A4.14b (continued): 
CD4/CD3 
DONOR Ri R2 Hi H2 Iii Hz Ill riz Ill r%L 
El 37746 5456 70171 6664 56338 12320 35469 34726 50138 19564 
E2 14100 3814 13247 2353 11891 1743 7449 20058 14376 3104 
E3 53829 18543 49307 2157 44720 3977 17921 17896 69863 41960 
E4 35326 2287 33755 1999 36973 3267 19140 12470 40860 4697 
ES 27249 1117 47830 4701 28142 3317 55990 56234 48260 4050 
E6 72370 4498 55087 5021 54678 5306 46258 30624 61640 23463 
E7 49669 2420 73593 5602 70610 8517 44719 49671 40734 87069 
E8 62160 30565 44493 4183 70289 8519 21748 24614 80894 23583 
E9 24135 4860 33967 5378 18242 8111 4696 4849 20085 9871 
ElO 17443 1484 10509 1149 19474 9043 4497 4522 16215 3947 
Eli 27659 6613 24440 6981 10442 4564 11137 18100 27920 24144 
E12 25153 4919 18368 3754 25814 6412 18541 19928 56156 35369 
E14 15385 562 20837 2231 20948 6623 17817 12779 11876 4404 
E15 110420 5333 54624 2150 56013 11288 17720 14178 110365 37619 
E16 74567 4362 115969 7519 67130 7168 76739 122032 76847 10120 
E17 112715 7966 84516 7861 94081 6952 81208 54023 107666 9433 
E18 25354 1691 23698 1450 20719 1619 8356 4892 12425 2797 
E20 41918 2717 70015 4099 39955 10159 40595 22297 193288 133470 
C D4IC D 45R0 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Rl A2 Ri A2 Ri R2 Ri R2 
El 20124 4029 39523 5554 33433 11480 21966 21919 32622 18800 
E2 5458 2262 5275 1252 4936 1411 4621 13943 5279 2297 
E3 18376 12963 16603 1348 18191 3447 10890 13205 32468 38799 
E4 12132 1715 10747 1540 13740 2509 7243 6590 14676 4143 
E5 9025 493 18733 2098 10489 2113 21817 28673 20206 2669 
E6 23572 3345 17739 3423 21398 4211 16039 12429 29004 21094 
E7 22787 1415 33435 3678 34065 6166 25458 33661 22538 73835 
E8 21757 18723 15688 2218 26728 5669 9638 14525 31996 19954 
E9 11188 2956 17131 3526 9520 6709 1212 2228 11353 8405 
ElO 5603 754 3530 718 8564 7418 2033 2386 6509 2383 
Eli 17529 5121 16233 5365 8043 4011 7426 15522 19986 22707 
E12 20282 4271 14571 3541 23388 6045 15135 19128 45630 35061 
E14 4012 375 4672 1296 8931 6008 10172 10039 5317 4002 
ElS 60025 4697 28368 1981 28927 10980 10958 10659 62512 36482 
616 17826 1877 37866 5336 23412 6150 28931 59097 27016 8596 
E17 40782 3684 31001 4082 30003 3521 35331 33624 40475 6071 
E18 16224 1230 15358 1215 13534 1584 6963 4975 7914 2638 
E20 25569 1891 42831 3168 23072 8530 28609 14214 127025 110738 
C D8/C D 3 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Al R2 Al R2 
El 20988 3858 29874 3774 24829 4434 2035 1461 21791 3940 
E2 4805 1760 3279 830 2889 898 15043 41783 3410 1042 
E3 10845 6529 7307 1140 8582 1192 8195 11596 9508 3911 
54 13430 1806 10645 1341 13740 2945 9375 8688 15312 2353 
ES 12707 909 17745 3877 11953 2184 28126 30135 19961 2474 
E6 65608 5102 52124 5240 49986 5278 91298 70331 47725 6658 
E7 21407 1470 31694 3704 27633 3237 39993 48111 17244 22986 
E8 26566 21415 19789 3506 32040 4728 52135 58230 36489 9076 
E9 12584 5288 18944 2824 11287 3266 8552 15528 12740 2822 
ElO 6934 1256 4461 1069 8049 2199 5459 6966 6152 1985 
Ell 10524 4698 9341 4578 23664 13686 4547 9929 13578 8909 
E12 4631 1969 2976 1483 17508 5781 3136 6618 8347 3160 
E14 4927 298 7345 1672 6347 2090 19273 18619 3869 1003 
E15 41022 5109 19241 1844 17480 4229 36949 35236 35988 9374 
E16 28788 2279 41407 3157 25994 3869 88772 173455 33196 7750 
E17 43305 4603 39020 3379 37365 3875 68631 50327 43429 4314 
E18 11659 1285 9391 939 10209 1454 9941 4683 10327 2579 
E20 22136 1944 35856 2392 24725 7353 44653 37177 63084 22162 
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Table A4.14b (continued): 
CD8/CD45RO 
CM RBC PfSE PHA PPD 
DONOR Al R2 Ri R2 Al R2 Al R2 RI R2 
El 2176 1777 2380 1301 2591 2637 1156 871 2016 2480 
E2 194 417 381 369 187 269 2451 10166 222 400 
63 602 2079 301 356 392 319 710 3410 522 2368 
E4 1515 556 846 564 1219 1152 1112 2145 1385 1253 
E5 760 257 1085 775 792 913 2270 7777 1095 728 
E6 8866 2395 4673 2009 5912 2638 9000 7292 4478 4017 
E7 1333 349 1318 978 1712 1364 3675 10583 1034 10448 
E8 1541 3772 1231 753 1228 1565 3462 6523 1869 4558 
E9 381 1639 1323 807 627 1051 358 2044 808 1390 
ElO 426 287 200 290 695 796 545 1094 368 678 
Eli 1105 1054 492 1377 4164 3769 233 2917 1041 4477 
612 870 903 687 621 3866 1843 809 4196 2067 2026 
E14 97 40 96 608 113 818 734 2327 129 580 
E15 6288 3034 2844 999 3206 2444 3687 6607 7064 6839 
E16 5839 1621 8191 2582 5513 3265 21277 51774 10043 6934 
617 6672 2249 6711 1707 6848 2597 26953 27440 5884 2623 
E18 4139 989 4362 777 4530 1378 6085 4683 6915 2715 
E20 2926 807 4668 776 2515 5982 21339 17529 3953 12304 
TcR V79/CO3 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Rl R2 Al R2 
El 2176 798 3747 743 6742 2157 59501 54527 2676 796 
E2 610 193 236 0 234 102 242 409 311 32 
63 1186 1416 1070 73 1012 109 355 192 947 367 
E4 815 264 1064 131 1363 315 622 386 1051 72 
65 804 18 1220 587 683 168 643 303 1128 263 
E6 4468 197 2923 392 4482 253 2725 797 3498 641 
67 2137 209 3041 327 3232 270 1647 1007 2099 999 
E8 2577 3336 1737 230 3071 434 1105 791 3527 1265 
E9 1233 808 2010 734 1254 738 151 127 1082 498 
ElO 52 115 143 111 153 69 55 78 315 152 
Eli 1726 356 1665 569 676 104 763 436 2093 711 
E12 751 338 676 269 1308 317 933 1151 2596 583 
E14 282 88 220 156 314 242 566 261 270 219 
E15 1323 314 828 61 689 106 500 273 1362 368 
E16 1525 608 3241 1526 1475 929 4184 12952 3549 3868 
E17 8297 932 5970 698 7012 1077 5244 4594 8144 1194 
618 3327 530 4149 433 3462 855 5142 3013 4367 2553 
E20 2272 607 3050 517 848 3776 2005 5894 1100 11710 
TcR V79/CD45RO 
CM ABC PfSE PHA PPD 
DONOR Al R2 Ri R2 Ri R2 Al R2 Ri R2 
El 465 345 718 357 2025 1356 8494 10331 544 465 
E2 43 97 0 0 20 0 174 308 0 32 
E3 94 884 134 48 212 55 159 0 58 156 
E4 306 264 0 78 192 157 216 141 96 72 
E5 33 18 0 84 30 101 60 230 0 52 
E6 1135 157 457 143 1106 127 970 522 519 454 
E7 408 80 321 197 352 210 596 745 174 606 
E8 144 1858 44 115 349 81 274 348 147 807 
E9 109 294 515 407 670 474 96 65 91 166 
ElO 26 29 34 22 27 34 35 27 0 114 
Ell 90 24 291 312 254 62 64 189 266 310 
E12 311 184 105 197 735 269 214 975 465 524 
E14 58 22 96 78 38 242 409 218 64 195 
E15 742 257 265 40 368 106 269 140 254 368 
E16 357 387 1650 1526 544 974 1492 6907 1835 3793 
617 1213 571 566 184 1090 502 2690 2798 962 813 
618 1031 397 1279 365 999 855 4221 3484 2647 2601 
E20 1046 644 2095 962 622 3712 1473 3628 489 7886 
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Table A4.14b (continued): 
TcR V51/CD3 
CM ABC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 RI R2 Ri R2 
El 1265 471 1859 604 1887 585 2281 1915 1865 1226 
E2 165 88 263 119 134 69 262 1105 171 26 
E3 56 191 0 27 0 26 37 53 58 54 
E4 1337 130 1257 103 1523 50 730 369 1448 397 
E5 1846 18 2693 103 1534 112 2089 496 3646 212 
E6 14020 705 12370 1034 13026 949 11374 2047 13224 2462 
E7 1945 28 3142 209 2848 237 2813 1641 2222 3362 
E8 3024 1611 2353 179 4681 1178 3462 1853 7663 9121 
E9 2448 221 4338 378 3492 1085 510 774 3154 393 
ElO 104 58 69 0 90 77 55 75 137 41 
Eli 2290 839 1756 646 2093 896 763 2932 3088 3229 
E12 264 96 198 42 368 97 202 486 609 465 
E14 58 0 179 102 151 164 361 195 64 31 
E15 650 28 478 57 427 228 797 588 946 238 
E16 2026 533 2940 787 1670 1599 9146 27726 5915 5451 
E17 4876 780 4175 172 3455 484 3580 4377 3938 1075 
E18 4661 305 4688 423 4475 892 6792 5862 5474 2996 
E20 2877 591 2864 641 1582 4456 2663 6124 2282 5677 
IcR V1/CD45RO 
CM ABC PfSE P1-IA PPD 
DONOR RI R2 Ri R2 Al R2 Al R2 Ri R2 
El 84 184 85 121 126 314 154 958 359 595 
E2 0 88 21 0 0 35 165 737 0 0 
E3 0 191 0 27 0 26 37 53 0 54 
E4 38 32 154 52 0 50 0 113 0 198 
E5 33 18 0 0 0 37 0 138 49 53 
E6 142 352 40 478 267 453 103 443 250 878 
E7 60 28 237 119 144 27 253 906 20 1348 
E8 29 487 44 67 100 413 253 522 1050 5624 
E9 54 73 0 0 43 544 0 ill 46 87 
ElO 26 0 0 0 63 77 0 0 0 0 
Eli 68 435 90 187 296 447 14 1294 162 1553 
E12 24 96 0 42 0 37 51 325 96 351 
E14 0 0 83 102 38 41 36 78 0 0 
E15 46 0 21 57 0 102 195 388 254 300 
E16 500 416 540 657 330 1400 2238 13815 3718 5779 
E17 194 275 137 43 165 132 310 1228 134 684 
E18 1072 135 796 282 1177 782 4928 6774 3214 2931 
E20 1619 691 1644 570 1159 4831 1191 3192 367 3302 
'fI 
Table A415: Complete data for percentages of cellular subsets for each immune 
individual on a) day 0, b) day 3 and c) day 7. Resting cells (Ri) and lymphoblasts (R2) 
are indicated for each stimuli (ND = not done). 
a) 
% in gate 
DONOR Ri R2 
Ii 28.88 0.90 
12 32.24 1.88 
3 10.08 0.32 
14 31.64 1.76 
15 40.44 1.68 
17 71.36 3.30 
18 59.76 4.34 
9 26.08 1.44 
lii 21.36 0.82 
112 83.34 4.70 
113 81.88 4.82 
114 46.46 3.14 
115 46.46 3.14 
116 75.04 9.16 
117 27.94 0.54 
118 29.58 0.90 
119 37.60 1.18 
120 84.86 4.60 
CD2O 
DONOR Ri R2 
Ii 3.94 6.12 
12 3.94 15.25 
13 6.32 34.21 
14 6.95 11.83 
15 2.85 20.59 
17 6.15 17.12 
18 6.95 17.24 
19 6.98 25.58 
Ill 3.18 17.86 
112 3.99 26.19 
113 5.28 21.62 
114 8.69 29.25 
115 4.39 0.00 
116 2.10 8.03 
117 1.16 15.00 
18 2.31 0.00 
119 1.03 13.33 
120 2.11 5.68 
CD56 
DONOR Hi R2 
Ii 1.61 3.40 
12 4.36 6.77 
13 2.35 5.26 
14 2.27 7.53 
15 4.61 7.84 
17 4.95 11.67 
18 6.63 21.38 
19 6.73 16.28 
11 2.29 3.57 
12 1.18 3.96 
113 3.28 7.57 
114 1.02 4.08 
115 2.61 7.40 
116 0.77 5.11 
117 0.62 5.00 
118 1.66 0.00 
119 2.78 3.33 
120 2.60 13.64 
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Table A4.15a (continued): 
CD 56/CD 3 
DONOR Ri R2 
Ii 1.43 1.36 
12 2.44 2.82 
13 1.23 0.00 
14 1.20 3.23 
5 0.54 0.98 
7 2.97 2.33 
18 2.21 2.07 
19 2.91 4.65 
Ill 0.70 0.00 
12 0.47 0.79 
13 0.76 1.62 
114 0.57 1.36 
115 0.83 3.70 
116 0.52 0.73 
17 0.21 0.00 
18 1.01 0.00 
19 0.60 0.00 
120 1.30 1.14 
Total C D 3 
DONOR Ri R2 
Il 70.55 85.71 
2 73.87 50.28 
13 75.05 63.16 
14 71.12 51.62 
5 63.93 39.22 
7 87.10 57.97 
18 83.06 54.48 
19 61.10 29.07 
Ill 66.41 57.14 
12 87.17 41.27 
113 82.21 49.73 
114 60.73 43.54 
115 68.09 77.77 
116 93.97 78.10 
117 49.08 60.00 
18 52.84 47.83 
119 46.54 30.00 




% in gate 
ABC PFSE 
DONOR Ri R2 RI R2 
Il 44.00 1.78 42.80 1.72 
12 55.26 3.24 54.92 5.27 
13 28.76 0.98 20.76 0.58 
14 43.04 2.54 42.96 2.74 
5 48.32 3.74 50.36 4.46 
7 66.84 3.42 60.20 5.80 
8 53.70 4.52 48.30 5.36 
19 38.18 1.24 35.82 1.54 
Ill 7.66 0.66 7.56 0.46 
112 50.28 1.16 50.64 1.34 
113 60.74 3.30 60.64 2.76 
114 28.68 1.24 30.68 2.18 
115 11.74 0.52 10.60 0.36 
116 42.36 1.90 41.54 1.88 
117 17.32 0.30 18.90 0.36 
118 23.66 0.22 25.38 0.42 
CD 20 
RBC PFSE 
DONOR RI R2 Ri R2 
1 2.69 16.92 2.50 12.98 
12 5.17 13.87 3.26 16.39 
13 2.16 8.33 4.05 19.23 
14 1.94 3.40 1.91 8.33 
5 4.04 16.81 3.43 14.83 
17 5.01 20.78 3.62 11.39 
18 4.96 6.33 5.05 5.06 
19 2.33 9.17 1.81 13.46 
11 1.88 18.18 0.00 0.00 
112 1.76 8.06 1.59 7.61 
113 2.21 16.67 1.07 13.77 
114 3.27 14.12 3.89 21.48 
115 1.38 3.03 0.68 5.56 
116 1.44 11.50 0.99 10.31 
117 0.45 7.69 0.10 0.00 
118 1.22 0.00 1.03 0.00 
CD56 
RBC PFSE 
DONOR Ri R2 Al R2 
Il 1.24 4.62 1.31 0.76 
12 3.02 4.01 4.31 5.25 
13 1.49 1.39 3.43 3.85 
4 1.66 0.97 5.92 8.89 
5 2.24 2.94 2.86 1.90 
17 3.32 6.93 2.92 6.40 
18 3.93 5.67 4.22 4.28 
19 4.49 10.09 3.19 3.85 
Ill 1.88 0.00 1.68 0.00 
112 1.42 4.03 1.16 0.00 
113 1.72 4.05 1.73 2.90 
114 2.42 2.35 4.11 4.44 
115 0.92 3.03 1.53 0.00 
116 1.00 0.00 0.55 1.03 
117 0.54 7.69 0.52 0.00 
118 2.03 0.00 1.50 0.00 
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Table A4.15b (continued): 
C D56/C D 3 
RBC PFSE 
DONOR Ri R2 Ri R2 
Ii 0.84 3.85 0.96 0.00 
2 2.05 2.19 2.92 2.95 
13 0.95 0.00 2.70 3.85 
14 1.17 0.97 5.19 8.33 
5 0.72 2.52 0.52 0.76 
17 2.46 3.90 1.74 2.49 
18 2.10 4.00 1.74 3.50 
19 3.30 8.26 2.29 3.85 
Ill 1.25 0.00 0.28 0.00 
112 1.02 2.42 0.77 0.00 
113 0.68 1.52 0.63 0.00 
114 1.15 2.35 2.22 0.74 
115 0.46 0.00 1.02 0.00 
116 0.86 0.00 0.40 0.00 
117 0.36 7.69 0.31 0.00 
118 1.54 0.00 0.95 0.00 
Total C D 3 
RBC PFSE 
DONOR Ri R2 Ri R2 
Ii 76.73 80.00 76.01 77.10 
12 81.14 63.50 81.77 70.49 
3 82.65 88.89 82.35 76.93 
14 69.89 69.42 68.06 69.44 
15 72.58 78.57 64.11 73.38 
17 89.01 70.57 88.38 80.43 
18 84.49 84.67 80.85 89.88 
19 71.56 70.65 67.50 63.47 
Ill 75.23 54.55 66.67 71.43 
112 88.15 76.61 90.70 79.35 
113 86.30 70.21 86.63 69.57 
114 59.61 61.17 58.08 53.33 
115 68.20 69.70 66.05 77.78 
116 93.53 76.99 93.92 75.26 
117 35.30 53.84 33.23 63.64 
118 54.87 60.00 43.29 40.00 
Table A4.15c: 
C) 
% in gate 
RBC PfSE 
DONOR Ri R2 Ri R2 
Ii 25.10 0.84 24.12 0.66 
12 46.34 3.38 45.92 4.10 
13 15.02 0.48 16.52 0.82 
14 31.46 2.00 34.20 3.02 
15 41.86 5.54 40.94 2.34 
17 57.64 3.80 55.34 3.96 
8 25.86 1.20 34.16 2.64 
19 27.26 1.24 23.02 0.72 
Ill 5.64 0.20 4.30 0.20 
112 43.46 1.02 44.92 0.64 
113 64.90 1.38 57.78 4.96 
114 30.12 0.52 34.06 4.14 
115 10.44 0.20 10.72 0.26 
116 35.22 0.54 34.74 0.32 
117 13.92 0.14 14.90 0.28 
118 15.74 0.20 18.44 0.38 
19 25.92 0.18 27.68 1.64 
120 56.54 1.00 58.04 1.98 
CD 20 
RBC PfSE 
DONOR Ri R2 Ri R2 
Ii 1.41 11.11 2.10 16.67 
12 2.38 15.33 3.21 14.08 
13 1.40 21.43 1.63 16.67 
14 1.99 12.71 1.58 7.53 
15 3.42 9.93 3.82 9.47 
17 3.61 11.11 4.45 11.18 
18 2.23 3.20 4.64 3.92 
19 1.38 3.77 2.02 0.00 
Ill 0.76 9.09 1.62 3.45 
112 2.00 7.41 1.75 14.86 
113 2.15 22.22 2.03 12.55 
114 2.86 24.53 3.71 18.56 
115 2.14 7.69 0.71 0.00 
116 0.75 19.23 0.73 27.91 
117 1.67 0.00 0.82 0.00 
118 0.51 0.00 0.78 7.69 
119 1.82 5.88 1.64 3.70 
120 0.23 0.00 0.39 4.00 
CD56 
RBC 	 PfSE 
DONOR RI R2 	Ri R2 
Il 0.29 1.85 0.70 2.08 
12 2.21 2.00 2.55 6.34 
13 1.08 21.43 1.09 4.17 
14 1.18 2.54 1.46 1.08 
15 0.64 0.35 2.12 2.96 
17 1.93 1.11 2.32 8.55 
18 2.24 1.60 2.89 3.92 
19 2.07 3.77 2.02 3.33 
Ill 5.35 9.09 3.24 3.45 
112 1.26 7.41 1.13 5.40 
113 1.02 4.94 3.61 10.59 
114 20.28 5.66 12.69 7.18 
115 1.56 0.00 2.30 5.26 
116 1.23 3.85 0.62 0.00 
117 0.91 0.00 0.98 ND 
118 1.43 0.00 1.27 3.85 
119 8.94 11.76 7.04 8.64 
120 1.80 4.00 1.18 3.00 
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Table A4.15c (continued): 
C D 56/C 0 3 
R B C PfSE 
DONOR R  R2 R  R2 
Ii 0.22 1.85 0.62 2.08 
12 1.92 1.33 1.60 4.23 
13 0.86 0.00 0.98 1.39 
14 0.81 1.69 0.90 0.00 
15 0.32 0.35 0.43 1 .1 8 
7 1.68 1.11 1.62 3.29 
18 1.74 0.80 2.20 3.92 
19 1.69 3.77 1.63 3.33 
Iii 3.82 9.09 2.27 0.00 
12 1.07 0.00 0.61 1.35 
13 0.80 2.47 1.12 5.49 
14 19.10 5.66 11.34 3.59 
115 0.39 0.00 1.24 0.00 
116 1.18 3.85 0.51 0.00 
117 0.61 0.00 0.65 ND 
18 0.92 0.00 0.78 3.85 
119 4.47 11.76 2.96 2.47 
120 1.50 3.00 0.95 2.00 
Total C D 3 
R B C PfSE 
DONOR R  R2 R  R2 
II 75.59 77.78 77.64 77.08 
2 81.72 68.00 81.96 73.24 
13 90.86 57.14 89.11 76.39 
4 69,53 64.40 74.42 67.74 
5 74.65 86.52 76.60 82.84 
7 90.57 77.22 88.86 73.03 
8 86.04 84.80 85.26 88.23 
9 74.52 81.13 74.11 80.00 
11  75.96 72.73 68.29 86.21 
12 94.20 51.85 93.00 70.27 
13 89,49 65.43 88.28 69.41 
14 79.40 62.26 73.72 68.86 
15 78.06 84.62 74.51 84.21 
16 96.00 53.85 94.77 44.19 
17 50.31 85.71 40.91 75.00 
18 52.29 60.00 42.15 53.85 
19 41.41 23.52 41.97 69.14 
20 89.72 86.00 90.24 90.00 
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Table A4.16: Complete data for total numbers of cells (per 106  cells plated on day 0) of 
cellular subsets for each immune individual on a) day 0, b) day 3 and c) day 7. Resting 
cells (Ri) and lymphoblasts (132) are indicated for each stimuli (ND = not done). 
a) 
cells in nate 
DONOR Ri R2 
Ii 288800 9000 
12 322400 18800 
13 100800 3200 
4 316400 17600 
15 404400 16800 
17 713600 33000 
18 597600 43400 
19 260800 14400 
lii 213600 8200 
112 833400 47000 
113 818800 48200 
114 464600 31400 
115 464600 31400 
116 750400 91600 
117 279400 5400 
118 295800 9000 
119 376000 11800 
20 848600 46000 
CD2O 
DONOR Ri R2 
Ii 11379 551 
12 12703 2867 
13 6371 1095 
14 21990 2082 
15 11525 3459 
17 43886 5650 
8 41533 7482 
19 18204 3684 
Ill 6792 1465 
112 33253 12309 
113 43233 10421 
114 40374 9185 
115 20396 0 
116 15758 7355 
117 3241 810 
118 6833 0 
119 3873 1573 
120 17905 2613 
CD56 
DONOR Ri R2 
Ii 4650 306 
12 14057 1273 
13 2369 168 
14 7182 1325 
15 18643 1317 
17 35323 3851 
18 39621 9279 
19 17552 2344 
Ill 4891 293 
112 9834 1861 
113 26857 3649 
114 4739 1281 
115 12126 2324 
116 5778 4681 
117 1732 270 
18 4910 0 
119 10453 393 
120 22064 6274 
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Table A4.16a (continued): 
C D56/C D3 
DONOR Ri R2 
Ii 4130 122 
12 7867 530 
3 1240 0 
4 3797 568 
15 2184 165 
17 21194 769 
8 13207 898 
9 7589 670 
Iii 1495 0 
12 3917 371 
13 6223 781 
114 2648 427 
115 3856 1162 
116 3902 669 
17 587 0 
118 2988 0 
19 2256 0 
20 11032 524 
Total CD3 
DONOR Al R2 
Il 203748 7714 
2 238157 9453 
13 75650 2021 
14 225024 9085 
5 258533 6589 
17 621546 19130 
18 496367 23644 
9 159349 4186 
Ill 141852 4685 
112 726475 19397 
113 673135 23970 
114 282152 13672 
15 316346 24420 
16 705151 71540 
17 137130 3240 
118 156301 4305 
119 174990 3540 




cells in gate 
RBC PfSE 
DONOR Ri R2 Ri R2 
Ii 140800 5696 72760 2924 
2 265248 15552 197712 18972 
3 169109 5762 14117 394 
14 180768 10668 98808 6302 
5 233869 18102 201440 17840 
17 220572 11286 210700 20300 
8 408120 34352 222180 24656 
19 83996 2728 214920 9240 
lii 45960 3960 18144 1104 
112 90504 2088 111408 2948 
113 77747 4224 99450 4526 
114 77436 3348 36816 2616 
115 22071 978 27560 936 
116 169440 7600 49848 2256 
117 10392 180 22680 432 
18 33124 308 27918 462 
CD 20 
RBC PfSE 
DONOR Ri R2 Ri R2 
Ii 3788 964 1819 380 
2 13713 2157 6445 3110 
3 3653 480 572 76 
4 3507 363 1887 525 
5 9448 3043 6909 2646 
7 11051 2345 7627 2312 
18 20243 2174 11220 1248 
9 1957 250 3890 1244 
lii 864 720 0 0 
12 1593 168 1771 224 
13 1718 704 1064 623 
14 2532 473 1432 562 
15 305 30 187 52 
16 2440 874 493 233 
17 47 14 23 0 
118 404 0 288 0 
C D56 
RBC PfSE 
DONOR Ri R2 Ri R2 
Il 1746 263 953 22 
2 8010 624 8521 996 
3 2520 80 484 15 
4 3001 103 5849 560 
5 5239 532 5761 339 
7 7323 782 6152 1299 
8 16039 1948 9376 1055 
9 3771 275 6856 356 
Ill 864 0 305 0 
12 1285 84 1292 0 
13 1337 171 1720 131 
14 1874 79 1513 116 
15 203 30 422 0 
16 1694 0 274 23 
17 56 14 118 0 
18 672 0 419 0 
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Table A4.16b (continued): 
CD56/CD3 
RBC RISE 
DONOR R  R2 R  R2 
Ii 1183 219 698 0 
12 5438 341 5773 560 
3 1607 0 381 15 
14 2115 103 5128 525 
15 1684 456 1047 136 
17 5426 440 3666 505 
8 8571 1374 3866 863 
9 2772 225 4922 356 
Ill 575 0 51 0 
12 923 51 858 0 
13 529 64 627 0 
14 891 79 817 19 
115 102 0 281 0 
116 1457 0 199 0 
117 37 14 70 0 
18 510 0 265 	- 0 
Total CD3 
RBC PISE 
DONOR Ri R2 RI R2 
Ii 108036 4557 55305 2254 
2 215222 9876 161669 13373 
3 139768 5122 11625 303 
4 126339 7406 67249 4376 
5 169742 14222 129143 13091 
7 196331 7965 186217 16327 
8 344821 29086 179633 22161 
9 60108 1927 145071 5865 
Ill 34576 2160 12097 789 
12 79779 1600 101047 2339 
13 67096 2966 86153 3149 
114 46160 2048 21383 1395 
15 15053 681 18203 728 
16 158477 5851 46817 1698 
17 3668 97 7537 275 




cells in gate (10) 
ABC PfSE 
DONOR Ri R2 Ri R2 
Ii 95456 3192 41004 1122 
12 157556 11492 183680 16400 
3 16222 518 29736 1476 
14 34606 2200 37620 3322 
15 130603 17285 80242 4586 
17 219032 14440 149418 10692 
8 41376 1920 122976 9504 
19 76328 3472 78268 2448 
lii 25944 920 12040 560 
112 182532 4284 368344 5248 
13 140184 2981 145606 12499 
114 69276 1196 78338 9522 
115 9605 184 8576 208 
116 84528 1296 41688 384 
117 33408 336 35760 672 
118 23610 300 16596 342 
119 88128 612 177152 10496 
120 135696 2400 266984 9108 
CD 20 
RBC PfSE 
DONOR Ri R2 Ri R2 
Il 1346 355 861 187 
12 3750 1762 5896 2309 
13 227 111 485 246 
14 689 280 594 250 
5 4467 1716 3065 434 
7 7907 1604 6649 1195 
8 923 61 5706 373 
9 1053 131 1581 0 
Ill 197 84 195 19 
112 3651 317 6446 780 
13 3014 662 2956 1569 
114 1981 293 2906 1767 
115 206 14 61 0 
16 634 249 304 107 
17 558 0 293 0 
18 120 0 129 26 
19 1604 36 2905 388 
120 	- 312 0 1041 364 
CD56 
ABC PfSE 
DONOR Ri R2 Ri R2 
Ii 277 59 287 23 
12 3482 230 4684 1040 
3 175 111 324 62 
4 408 56 549 36 
5 836 60 1701 136 
17 4227 160 3466 914 
18 927 31 3554 373 
9 1580 131 1581 82 
Ill 1388 84 390 19 
12 2300 317 4162 283 
13 1430 147 5256 1324 
14 14049 68 9941 684 
15 150 0 197 11 
16 1040 50 258 0 
117 304 0 350 ND 
118 338 0 211 13 
119 7879 72 12472 907 
120 2443 96 3150 273 
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Table A4.16c (continued): 
CD 56/CD 3 
ABC PfSE 
DONOR Al R2 R  R2 
Ii 210 59 254 23 
12 3025 153 2939 694 
13 140 0 291 21 
14 280 37 339 0 
15 418 60 345 54 
17 3680 160 2421 352 
18 720 15 2705 373 
19 1290 131 1276 82 
Ill 991 84 273 0 
112 1953 0 2247 71 
113 1121 74 1631 686 
114 13232 68 8884 342 
115 37 0 106 0 
116 997 50 213 0 
117 204 0 232 ND 
118 217 0 129 13 
119 3939 72 5244 259 
120 2035 72 2536 182 
Total C D 3 
R B C PfSE 
DONOR Al R2 Al R2 
Il 72155 2483 31836 865 
12 128755 7815 150544 12011 
13 14739 296 26498 1128 
4 24062 1 41 7 27997 2250 
5 97495 14955 61466 3799 
17 198377 11151 132773 7808 
18 35600 1628 104849 8385 
19 56880 2817 58004 1958 
11  19707 669 8222 483 
112 171945 2221 342560 3688 
113 125451 1950 128541 8676 
114 55005 745 57751 6557 
115 7498 156 6390 175 
16 81147 698 39508 170 
17 16808 288 14629 504 
18 12346 180 6995 184 
119 36494 144 74351 7257 
120 121746 2064 240926 8197 
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Table A4.17: Complete data for percentages of cellular subsets for each naïve 
individual used as a control in Ghana on a) day 0 and b) day 7. Resting cells (Ri) and 
lymphoblasts (R2) are indicated for each stimuli. 
a) 
% in gate 
DONOR Ri R2 
Cl 50.9 5.7 
C2 55.8 6.4 
C4 51.7 9.1 
CD2O 
DONOR Ri R2 
Cl 7.6 6.2 
C2 3.7 7.4 
C4 7.4 7.8 
CD 20/CD 45 A 0 
DONOR RI R2 
Cl 0.0 0.0 
C2 0.0 0.0 
C4 0.0 0.0 
CD56 
DONOR Ri R2 
Cl 0.8 4.6 
C2 0.3 1.9 
C4 0.5 1.3 
CD 56/CD 45 R 0 
DONOR Ri R2 
Cl 0.0 0.2 
C2 0.0 0.0 
C4 0.0 0.0 
Total CD3 
DONOR Al R2 
Cl 80.9 68.4 
C2 76.6 60.7 
C4 54.9 51.6 
CD 45 A A/CD 3 
DONOR RI R2 
Cl 57.5 41.0 
C2 46.6 22.3 
C4 23.0 15.8 
CD 45 R 0/CD 3 
DONOR Al R2 
Cl 13.7 30.7 
C2 20.7 42.1 
C4 22.2 36.9 
TcRcz3/CD3 
DONOR Ri R2 
Cl 3.5 14.9 
C2 6.3 18.9 
C4 0.7 8.1 
TcRaI3/CD45RO 
DONOR Ri R2 
Cl 0.0 0.2 
C2 0.0 0.6 
C4 0.0 0.0 
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Table A4.17a (continued): 
TcR7/CD3 
DONOR Ri R2 
Cl 7.9 11.1 
C2 1.3 3.7 
C4 1.6 3.1 
Tc Ry/C D 45 RD 
DONOR Ri R2 
Cl 0.8 2.4 
C2 0.6 0.8 
C4 0.6 0.6 
CD4ICD3 
DONOR Ri R2 
Cl 42.5 31.1 
C2 52.2 38.7 
C4 36.0 37.4 
CD4/CD45RD 
DONOR Ri R2 
Cl 1.8 2.5 
C2 8.6 13.1 
C4 6.4 5.8 
CD8/CD3 
DONOR Ri R2 
Cl 33.3 38.2 
C2 12.7 21.3 
C4 16.8 17.2 
CD8/CD45RO 
DONOR Al R2 
Cl 0.4 1.7 
C2 0.6 0.4 
C4 0.4 1.0 
TcR V79/CD3 
DONOR Ri R2 
Cl 8.3 11.7 
C2 0.7 1.5 
C4 1.4 1.0 
TcR V79/CD45RO 
DONOR Ri R2 
Cl 0.1 0.0 
C2 0.0 0.4 
C4 0.0 0.1 
TcR V51/CD3 
DONOR Ri R2 
Cl 0.6 1.4 
C2 0.6 3.8 
C4 0.4 1.1 
TcR V1/CD45RO 
DONOR Ri R2 
Cl 0.0 0.0 
C2 0.1 0.8 





DONOR Al R2 	Ri R2 	Al R2 	Ri R2 	Ri 92 
Cl 	30.66 3.10 44.63 1.83 46.41 2.07 24.22 27.49 47.98 2.14 
C2 65.12 1.79 	65.50 1.94 	59.17 7.41 	22.08 21.58 	50.60 12.73 
C4 	55.18 1.95 59.35 1.91 50.87 3.55 28.99 12.78 38.72 9.92 
O D20 
CM RBC PfSE PHA PPD 
DONOR Al 	R2 RI R2 Ri R2 Ri 	R2 Ri R2 
Cl 3.52 8.20 3.16 7.19 2.21 12.50 6.12 21.91 2.19 7.43 
C2 8.35 	27.85 8.82 19.61 4.59 9.69 1.38 	2.48 2.03 4.73 
C4 2.34 7.11 3.04 18.39 5.93 14.68 3.12 10.55 3.06 8.99 
CD20/C045R0 
CM RBC PfSE P1-IA PPD 
DONOR 	Ri R2 Ri R2 Al R2 Ri A2 Al A2 
Cl 	0.27 1.64 0.19 1.80 0.12 1.88 0.26 3.24 0.00 3.06 
C2 6.27 6.33 6.18 4.58 3.21 1.21 0.82 0.43 1.43 0.35 
C4 	0.17 3.11 0.44 11.66 1.72 8.97 0.33 2.05 1.56 3.07 
0056 
DONOR Ri 
Cl 	1.44 14.21 	1.29 8.39 	1.46 30.63 	5.38 6.02 	2.92 36.25 
02 5.20 7.59 5.69 8.50 3.42 17.36 3.59 4.89 4.62 11.37 
C4 	0.99 5.33 	0.89 11.21 	3.42 9.78 	1.84 1.57 	5.31 2.78 
CD56/CD45RO 
CM ABC PfSE PHA PPD 
DONOR 	Ri R2 Ri R2 Ri R2 RI R2 Ri R2 
Cl 	0.08 1.64 0.08 1.20 0.00 1.25 0.13 0.35 0.02 4.37 
C2 3.62 3.16 3.81 3.92 1.66 1.48 0.30 0.20 0.88 1.55 
C4 	0.10 2.22 0.24 8.07 0.76 6.52 0.20 0.47 0.78 1.28 
Total 003 
RRC PfSE PHA PPD 
Cl 	53.03 56.23 	47.81 56.93 	48.96 49.31 	62.10 88.29 	48.76 37.59 
02 79.34 67.14 81.44 71.37 76.04 70.03 60.57 94.35 70.45 83.04 
04 	51.47 31.29 	53.35 45.19 	53.45 68.36 	39.25 85.12 	63.16 88.03 
C D45R A/C D3 
DONOR Al R2 	Ri R2 	Ri A2 	Ri A2 	Ri 92 
Cl 	37.82 35.34 34.32 36.84 32.49 20.74 9.04 24.65 33.69 15.60 
02 49.83 32.39 	50.58 42.72 	45.34 13.25 	9.29 19.54 	37.90 6.59 
04 	18.90 8.50 19.38 15.30 17.76 13.03 4.35 19.06 16.29 5.83 
CD45RO/CO3 
CM 	 RBC 	 PfSE 	 PHA 	 PPD 
DONOR Ri - R2 Ri R2 Al R2 Ri A2 Ri 	A2 
Cl 14.75 	27.31 11.79 	26.79 13.49 	35.02 33.97 	67.33 11.16 26.95 
02 25.15 40.38 26.96 40.85 23.30 56.93 18.48 40.37 25.59 	79.27 
04 25.17 	21.09 24.97 	35.23 25.16 	55.59 14.85 	49.96 39.64 85.43 
TcRcx3/CD3 
191A 
DONOR RI R2 Ri R2 Ri 92 91 92 91 92 
Cl 0.17 1.02 0.10 2.56 0.10 2.27 0.52 5.06 0.55 3.61 
02 6.19 4.12 8.21 1.39 3.57 6.38 6.28 7.22 4.09 6.36 
04 0.67 3.39 1.05 12.73 3.79 10.88 1.64 6.65 2.76 5.54 
TcRo3/CD45AO 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Al R2 Al R2 Al 92 
Cl 0.00 0.68 0.04 1.92 0.00 2.27 0.30 4.68 0.05 2.41 
02 1.31 2.88 2.14 0.46 0.53 4.71 0.72 4.89 0.43 6.19 
04 0.00 1.69 0.08 2.73 0.22 2.92 0.00 4.72 0.21 4.85 
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Table A4.17b (continued): 
TcR8/CD3 
- 	CM RBC PfSE PHA PPD 
DONOR Al R2 Ri R2 Ri R2 Ri R2 Al R2 
Cl 	4.99 6.08 4.18 4.03 4.40 13.55 3.01 3.28 5.71 12.27 
C2 7.26 10.19 8.11 5.23 4.43 6.53 4.56 0.61 3.39 1.68 
C4 	1.55 7.32 2.23 12.26 4.16 10.64 1.28 1.12 3.03 2.26 
TcRy6/C D45R 0 
FU 
R2 
Cl 	1.88 6.08 	1.23 4.70 	1.73 13.55 	2.06 3.22 	1.90 11.66 
C2 2.21 6.80 2.28 4.58 1.12 5.16 0.57 0.32 0.91 1.44 
C4 	0.52 5.28 	0.44 4.72 	0.68 5.32 	0.14 0.48 	0.72 1.29 
DONOR Al R2 	Al R2 - Al R2 	Ri R2 	Ml R2 
Cl 	23.19 36.86 29.76 33.99 	26.05 35.68 19.89 51.62 27.05 35.02 
C2 59.07 49.19 	60.91 56.52 54.90 56.36 	32.35 49.23 	54.36 80.10 
C4 	38.30 26.50 35.95 27.61 	34.62 51.32 9.40 22.86 54.11 85.54 
CD 4/CD 45 R 0 
F'IIA 
DONOR Ri R2 	Al R2 	Al R2 	Al R2 	RI R2 
Cl 	7.46 13.50 10.05 18.30 8.94 26.63 11.12 37.16 8.29 29.03 
C2 16.37 34.05 	16.25 36.23 	16.99 42.39 	9.17 22.47 	21.31 78.03 
C4 	19.24 18.00 19.73 18.18 18.04 36.36 5.39 16.79 36.82 82.12 
CM 	 RBC 	 PtSE 	 PHA 	 PPL) 
Ri 
Cl 	21.94 24.59 	22.53 20.10 	19.93 23.33 	38.62 60.99 	22.28 18.77 
C2 23.01 32.35 22.46 31.31 20.15 14.47 44.32 71.01 16.49 7.18 
C4 	16.18 10.78 	16.65 18.86 	15.16 17.50 	29.57 77.54 	14.04 6.66 
C D8/C D45 R 0 
CM RBC PfSE PHA PPD 
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Table A4.18: Complete data for total numbers of cells (per 106  cells plated on day 0) of 
cellular subsets for each naïve individual used as a control in Ghana on a) day 0 and b) 
day 7. Resting cells (Ri) and lymphoblasts (R2) are indicated for each stimuli. 
a) 
cells in gate 
DONOR Hi R2 
Cl 	508900 57300 
C2 557900 63700 
C4 	516600 90600 
CD2O 
DONOR Ri R2 
Cl 	38422 3570 
C2 20419 4707 
C4 	38073 7085 
CD 20/CD 45 R 0 
DONOR Ri R2 
Cl 	 0 	0 
C2 167 0 
C4 	 0 	0 
CD56 
DONOR Al R2 
Cl 	4071 2630 
C2 1729 1204 
C4 	2480 1196 
CD56/CD45RO 
DONOR Ri R2 
Cl 	102 	92 
C2 112 0 
C4 	207 	0 
Total CD3 
DONOR Ri R2 
Cl 	411904 39176 
C2 427519 38672 
C4 	283458 46741 
CD 45 R A/CD 3 
DONOR Hi R2 
Cl 	292618 23487 
C2 260149 14192 
C4 	118766 14315 
CD 45 R 0/CD 3 
DONOR RI R2 
Cl 	69770 17614 
C2 115653 26824 
C4 	114840 33459 
TcRczfi/CD3 
DONOR Al R2 
Cl 	17557 8561 
C2 35315 12033 
C4 	3513 7357 
TcRc4/CD45R0 
DONOR Ri R2 
Cl 	 0 	120 
C2 112 382 
C4 	103 	0 
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Table A4.18a (continued): 
TcRy/CD3 
DONOR Ri R2 
Cl 	40305 6355 
C2 7253 2325 
C4 	8421 2781 
Tc Ry/C D 45 RD 
DONOR Ri R2 
Cl 	4122 1387 
C2 3292 	516 
C4 	2841 580 
CD4/CD3 
DONOR Ri R2 
Cl 	216283 17803 
C2 291224 24633 
C4 	185769 33848 
CD4/CD45RD 
DONOR Ri R2 
Cl 	9364 1433 
C2 48147 8338 
C4 	32907 5246 
CD8/CD3 
DONOR Ri R2 
Cl 	169616 21889 
C2 71076 13594 
C4 	86737 15565 
CD8/CD45RD 
DONOR RI R2 
Cl 	1883 	968 
C2 3403 261 
C4 	1963 	897 
TcR Vy9/CD3 
DONOR Ri R2 
Cl 	42239 6721 
C2 3850 949 
C4 7336 924 
TcR V-y9/CD45RD 
DONOR Ri R2 
Cl 	305 	0 
C2 167 274 
C4 	 0 	100 
TcR V1/CD3 
DONOR Ri R2 
Cl 	3155 	796 
C2 3068 2401 
C4 	1963 	997 
TcR V61/CD45RD 
DONOR Ri R2 
Cl 	 0 	0 
C2 391 535 
C4 	568 	0 
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Table A4.1 8b: 
b) 
cells in nate 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Ri R2 Hi R2 Ri R2 
Cl 153300 15500 187446 7686 185640 8280 261576 296892 143940 6420 
C2 86284 2372 124450 3686 125736 15746 82800 80925 69575 17504 




Cl 	5396 1271 	5923 553 	4103 1035 	16008 65049 	3152 477 
C2 7205 661 10976 723 5771 1526 1143 2007 1412 828 
C4 	2066 222 	2300 448 	8296 1433 	2533 3775 	3762 2831 
CD20/C045R0 
I-'IIA 
DONOR Ri R2 	Ri 92 	Hi 92 	Hi 92 	Hi H2 
Cl 	414 254 356 138 223 156 680 9619 0 196 
C2 5410 	150 	7691 	169 	4036 	191 	679 	348 	995 	61 
C4 	150 97 333 284 2406 876 268 734 1918 967 
CD56 
CM RBC PfSE PHA PPD 
DONOR Ri R2 Ri R2 Hi R2 Ri R2 Ri R2 
Cl 2208 2203 2418 645 2710 2536 14073 17873 4203 2327 
C2 4487 180 7081 313 4300 2734 2973 3957 3214 1990 
C4 874 166 673 273 4784 955 1494 562 6528 876 
0056/C D45R0 
I'tIA 
DONOR Ri R2 	Ri R2 	Ri R2 	Ri R2 	Hi R2 
Cl 	123 254 150 92 0 104 340 1039 29 281 
02 3123 	75 	4742 	144 	2087 	233 	248 	162 	612 	271 
C4 	 88 69 182 197 1063 637 162 168 959 403 
CD3 
CM 
R2 	Hi 	R2 
Cl 	81295 	8716 	89618 	4376 90889 4083 	162439 262126 	70185 2413 
C2 68458 1592 101352 2631 	95610 11027 50152 76353 49016 14535 
C4 	45442 	976 	40371 1100 74773 6674 	31860 30459 	77646 27726 
CD45RA/CD3 
CM RBC PfSE PHA PPD 
DONOR 	Ri R2 Ri R2 Hi R2 Hi R2 Ri H2 
Cl 	57978 5478 64331 2832 60314 1717 23646 73184 48493 1002 
C2 42995 768 62947 1575 57009 2086 7692 15813 26369 1153 
C4 	16686 265 14665 373 24845 1272 3531 6820 20026 1836 
CD45RO/CD3 
DONOR Ri R2 	Ri R2 	Hi R2 	Ri 92 	Hi 92 
Cl 	22612 4233 22100 2059 25043 2900 88857 199897 16064 	1130 
C2 21700 958 	33552 1506 	29297 8964 	15301 32669 	17804 13875 
04 	22222 	658 18895 	858 35197 5427 12054 17878 48732 26907 
Tc A cxrlfC 03 
CM RBC PfSE PHA PPD 
DONOR 	Ri 	R2 Ri 	R2 Ri R2 Ri R2 Ri R2 
Cl 	261 158 187 197 186 188 1360 15023 792 232 
02 5341 	98 10217 	51 4489 1005 5200 5843 2846 1113 
04 	592 106 795 310 5302 1062 1331 2380 3393 1745 
TcRczfl/CD45RO 
DONOR Hi R2 	Hi R2 	Ri R2 	Ri 92 	91 92 
Cl 	 0 105 75 148 0 188 785 13895 72 155 
02 1130 68 	2663 17 	666 742 	596 3957 	299 1083 
04 	 0 53 61 66 308 285 0 1689 258 1528 
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Table A4.18b (continued): 
TcRyS/CD3 
CM ABC PfSE PHA PPD 
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C 08/C 045 A 0 
CM ABC PfSE PHA PPD 
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Table A4.19: Complete data for percentages of IFN-y-stained cells on day 7 for each 
naïve individual. Resting cells (Ri) and lymphoblasts (R2) are indicated for each stimuli 
(arithmetic mean and SEM indicated). 
% in gate 
CM ABC PfSE SEB 
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Table A4.20: Complete data for total numbers of IFN-y-stained cells on day 7 for each 
naïve individual (per 106  cells plated on day 0). Resting cells (Ri) and lymphoblasts 
(R2) are indicated for each stimuli (arithmetic mean and SEM indicated). 
cells in aate 
CM ABC PfSE SEB 
Donor Al R2 Al R2 R  R2 Al R2 
MR 292200 11700 385600 10800 356560 48240 266520 288600 
SO 233820 7800 307360 10320 301040 21520 334800 156480 
SS 263040 13020 315120 16800 308400 42960 263640 180000 
CD56 
CM ABC PfSE SEB 
Donor Al 	R2 R 	R2 Al R2 Al R2 
MR 58 152 116 223 535 5511 0 17662 
SO 70 	310 246 	99 331 3478 201 13841 
SS 289 1278 158 2127 802 12119 395 20232 
CD56/IFN- 
CM ABC PfSE SEB 
Donor Al 	A2 Al 	R2 Al A2 Hi 	A2 
MR 0 152 0 127 178 4742 0 20693 
50 0 	310 0 	119 0 3478 0 	16024 
SS 132 1298 158 2233 278 12158 105 23220 
CD3 
CM RBC PfSE SEB 
Donor Al R2 Al R2 R  R2 Al A2 
MR 253026 10089 338467 9660 312287 40333 255375 167893 
SO 220239 6943 289502 9665 278577 17155 326558 123862 
SS 242510 10724 287295 14267 280243 36789 258293 136344 
CD3/IFN-y 
CM ABC PfSE SEB 
Donor Al R2 Al R2 Al R2 R 	R2 
MR 17050 5696 19087 6404 20288 30497 11181 113910 
SO 9446 2627 19425 6247 12162 8987 24206 100937 
SS 29329 6141 43108 8069 28512 27834 15752 112518 
TcF1cz 
CM RBC PfSE SEB 
Donor R  R2 Al R2 Al R2 R  R2 
MR 218653 8203 297143 8665 288707 29084 154808 69639 
SO 185092 4645 248885 7412 224260 12303 218775 98496 
SS 222400 9484 261959 13176 259920 33994 185985 95040 
TcRc3/lFN-y 
CM RBC PfSE SEB 
Donor Al R2 Al R2 Al R2 Al R2 
MR 14844 5129 18432 6653 16651 23884 11620 70534 
SO 3577 2103 15952 5530 7436 7825 26282 99678 
SS 24436 7631 28298 9662 27633 29282 15054 96786 
TcR 
uonor Ni 114 	 111 KZ 	 K  KZ 	 Ni 112 
MR 	1797 	311 2969 	524 2496 7805 0 28355 
SO 6547 448 	10942 1056 	5599 3501 	1222 53649 
SS 	3946 1223 4995 1808 3531 11341 514 72027 
T c Ry/l F N 
MR 	117 335 	386 559 	107 8674 	 0 16450 
50 561 	493 430 1137 241 3859 0 41436 
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Individuals living in malaria endemic areas eventually develop clinical immunity to Plasmodium 
falciparum. That is, they are able to limit blood parasite densities to extremely low levels and fail 
to show symptoms of infection. As the clinical symptoms of malaria infection are mediated in 
part by pro-inflammatory cytokines it is not clear whether the acquisition of clinical immunity is 
due simply to the development of anti-parasitic mechanisms or whether the ability to regulate 
inflammatory cytokine production is also involved. We hypothesise that there is a correlation 
between risk of developing clinical malaria and the tendency to produce IFN-1 in response to 
malaria infection. In order to test this hypothesis, we have compared the ability of PBMC from 
malaria naive, malaria-exposed (but not clinically immune) and malaria-immune adult donors to 
proliferate and to secrete IFN-y in response to P. falciparum schizont extract (PfSE). In order to 
determine how PfSE-induced IFN-y production is regulated, we have also measured production 
of IL-12p40 and IL-10 from PfSE-stimulated PBMC and investigated the role of neutralising 
antibody to IL-12 in modulating IFN-'y production. Our results show that cells from naive donors 
produce moderate amounts of IFN-y in response to PfSE and that IFN-y production is strongly 
IL- 12 dependent. Cells from malaria-exposed donors produce much higher levels of IFN-y but 
this response is only partially IL-12 dependent. In complete contrast, cells from clinically 
immune donors produce minimal amounts of IFN-y. No significant differences were detected 
between the groups in IL- 10 production, suggesting that this cytokine does not play a major role 
in regulating malaria-induced lEN-I production. The data from this study thus strongly support 
the hypothesis that down-regulation of inflammatory cytokine production is a component of 
acquired clinical immunity to malaria. 
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Introduction 
Malaria, particularly Plasmodiumfalciparum, is responsible for more deaths than any other 
parasitic disease and malaria-related morbidity constitutes a significant constraint on 
development in tropical countries. Vaccines offer a potential means of long term malaria control 
but, as the clinical symptoms of malaria infection are mediated in part by pro-inflammatory 
cytokines (1), the design of a safe and effective vaccine requires identification of the mechanisms 
of anti-malarial immunity and differentiation of protective from pathogenic responses (2). 
Work on murine malarias suggests that innate immune mechanisms, mediated by IIFN-y derived 
from natural killer (NK) cells and/or y6 T cells, limits the initial phase of parasite replication (3) 
and that adaptive responses (mediated by c43 T cells and B cells) are required for parasite 
elimination (4). IFN-y is essential for resolution of primary infections (5). TNF-a and lEN-I act 
synergistically to optimize nitric oxide (NO) production (6), which may be involved in parasite 
killing (7). The difference between lethal and non-lethal malaria infections can be explained, in 
part, by the ability of mice to mount an early IL- 12, IFN-'y or TNF-cx response (8-11). However, 
IFN-y also plays a role in the acute symptoms of infection, such as fever, anorexia and weight 
loss, through induction of TNF-o and other endogenous pyrogens. Over-production of IFN-7 or 
TNF-c predisposes to severe pathology (11-13) and, in lethal infections, neutralisation of IL- 12, 
blocking the IFN-y pathway or down-regulation of TNF-cx by administration of rTGF-f3 
abrogates mortality (12,14-16). 
In humans, sterilising immunity to malaria rarely, if ever, develops but individuals living in 
endemic areas become clinically immune; i.e. they are able to control circulating parasite 
densities to within tolerable limits and show no significant clinical symptoms of infection. 
Although IFN-i responses to some defined malaria antigens correlate with protective immunity 
(17,18), plasma IFN-y concentrations are higher in symptomatic than in asymptomatic infections 
(19) and there is a temporal association between IFN-y secretion and fever (20). Similarly, 
plasma TNF-a and nitrogen oxide levels are associated with rapid resolution of fever and 
parasite clearance (21,22) but severe P. falciparum malaria is accompanied by high levels of 
circulating cytokines, including TNF-c (23-26). Taken together, these observations suggest that 
there is a critical balance to be found in the inflammatory response to malaria infection and that 
the ability to regulate cytokine levels, within quite precise limits, may be a component of clinical 
immunity. 
We have previously shown that although peripheral blood mononuclear cells (PBMC) from 
malaria-immune African adults make strong IFN-y responses to certain purified malaria antigens, 
IFN-y responses to crude parasite extracts are low or non-existent (27). Similar findings have 
been reported elsewhere (28). In contrast, cells from malaria-naive, European adults (who are at 
high risk of developing severe malaria if infected) produce significant amounts of IFN-y after 
stimulation with P. falciparum schizont extracts (PfSE) or live malaria parasites (29,30). 
Although the majority of cells being activated in naive donors are TCR43+ CD45RO+ or 
TCR'y+ Tcells (29,30), the source of the IFN-y has not been determined. The basis for this 
strong recall antigen response appears to be priming of malaria-reactive, memory T cells by 
exposure to cross-reacting antigens expressed on a wide variety of commensal organisms and 
common pathogens (31,32). 
We hypothesise that there is a correlation between the risk of developing clinical malaria and the 
ability to produce IFN-y in response to malaria infection, and that this can be assessed in vitro as 
the ability of PBMC to produce IFNy when reactivated by PfSE. In order to test this hypothesis, 
we have compared the ability of PBMC from malaria naive, malaria-exposed (but not clinically 
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immune) and malaria-immune adult donors, to proliferate and to secrete IFN-y in response to 
PfSE stimulation in vitro. In order to determine how PfSE-induced IIFN-y production is 
regulated, we have also measured production of IL-12 and IL-10 from PfSE-stimulated PBMC 
and investigated the role of neutralising antibody to IL-12 in modulating IFN-y production. 
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Subjects and Methods 
Subjects 
Malaria naive donors (n = 19, aged 20-41 years, 11 male, 8 female) were recruited from 
Edinburgh, Scotland, UK. None of the donors had knowingly been infected with malaria and the 
majority had never visited a malaria-endemic area. Malaria-immune donors (n = 20, aged 30-47 
years, 8 male, 12 female) were recruited from the village of Dodowa, approximately 40 miles 
inland from Accra, Ghana, where malaria transmission is highly endemic (33) and the majority 
of adults show no clinical symptoms when infected with malaria. Malaria-exposed donors (n = 
20, aged 21-60 years, 17 male, 3 female) were recruited from the Greater Accra district where 
levels of malaria transmission are much lower than in rural areas (33) and many adults still 
develop clinical symptoms when infected by malaria. 
A questionnaire was completed for each donor, giving information on prior exposure to malaria 
and use of anti-malarial drugs. Up to thirty mis of venous blood were collected into heparinised 
containers. An aliquot of plasma was removed for serology and Giemsa-stained blood films from 
all the African donors were examined for the presence of malaria parasites. A highly sensitive 
PCR method, based on the multicopy 7H8/6 gene sequence (34), was used to detect very low 
level P. falcipa rum infections. Details of the PCR method are given elsewhere (35). 
P. falcipa rum schizont antigens 
P. falciparum clone 3137 (36) was maintained in continuous culture (37). Cultures were routinely 
screened for mycoplasma using a commercial PCR kit (BioWhittaker, Wokingham, UK) and 
shown to be free of contamination. When parasitaemia reached approx 6-8%, mature schizonts 
were separated on a 60% Percoll gradient (Pharmacia, Uppsala, Sweden), washed three times in 
serum-free RPMI 1640 (Gibco, Paisley, UK), pelleted by microcentrifugation and resuspended at 
a concentration of 10 infected erythrocytes per ml. The suspension was freeze-thawed three 
times by immersion in liquid N2 .The entire extract (designated PfSE) was used in cell culture 
experiments. A portion of the extract was spun to remove the cellular debris; the supernatant was 
saved and used for serology (designated soluble Pf antigen). Both antigen preparations were 
aliquoted and stored at -80°C until required. Freeze thaw preparations of uninfected erythrocytes 
(108/ml) (uRBC) were used as controls. 
Serology 
Plasma from all donors was tested for anti-malarial antibodies by ELISA. Immulon IV microtitre 
plates (Dynex, Billingshurst, UK) were coated with an optimal concentration of soluble Pf 
antigen (determined by titration) diluted in carbonate/bicarbonate buffer and incubated overnight 
at 4°C. Plates were blocked for 3 hours at room temperature with PBS containing 0.5% Tween 20 
(Sigma, Poole, UK) and I% non-fat milk powder (blocking buffer). Plasma samples, diluted 
1:1000 in blocking buffer, were added to duplicate wells, and incubated for 3 hours at RT. Bound 
antibody was detected with rabbit anti-human IgG-horse radish peroxidase (Dako, High 
Wycombe, UK) and o-phenylenediamine/H202 as described previously (35). Optical density was 
measured at 492nm. Samples were designated positive for anti-malarial antibody if the OD was 
greater than the mean plus 2SD of the OD values of 22 control European plasmas. Ab levels are 
expressed as a % of the value obtained for a pool of hyperinunune plasma from African adults 
tested on the same plate. 
Cell cultures 
Mononuclear cells were separated from heparmnised blood by centrifugation through 
Lymphoprep® (Pharmacia, Uppsala, Sweden), washed in RPMI 1640 and resuspended at a 
concentration of 106  viable cells per ml in complete culture medium (RPMI 1640 with 2m1V1 L- 
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glutamine, 100U/ml penicillin, 0.1 mg/mi streptomycin, 30mM HEPES and 0.22% (v/v) sodium 
bicarbonate; all Sigma) with 10% heat-inactivated, non-immune human serum. For lymphocyte 
proliferation assays, cells were aliquoted (lO011lJwell) into sterile, round-bottomed, 96 well 
microtitre plates. Antigens, at optimal concentration in complete medium, or the mitogen PHA (2 
ig/ml, Sigma) were added to triplicate wells and plates incubated at 37°C in 5% CO. for 2,4,6 or 
8 days. Eighteen hours before harvesting, 100111 of supernatant was removed from each well and 
reserved for cytokine analaysis. lpCi 3H- thymidine (Amersham, UK) in lOOjil fresh culture 
medium was added to each well. Cells were harvested onto cellulose filters and incorporation of 
radio-labelled thymidine assessed by scintillation counting. The geometric mean counts per 
minute (cpm) were determined for each antigen and the stimulation index (SI) calculated as the 
ratio of PfSE-stimulated cpm to control (uRBC-stimulated) cpm. SI values ~! 2.5 were considered 
positive (38). 
In order to determine the interaction between WN-y production and IL- 12, a neutralising 
antibody to human IL-12 (R&D Systems, Abingdon, UK)) or a control, isotype-matched murine 
IgG (R&D Systems) were added to the cultures at a final concentration of 5 .tg/ml. Antibodies 
were added at the beginning of the culture period (2, 4 or 6 days) and remained throughout. 
Supernatants were collected and tritiated thymidine incorporation assessed as described above. 
For intracellular cytokine staining, 2 x 106 PBMC were aliquoted into each well of a 24 well, 
flat-bottomed culture plate and incubated for 7 days. PfSE or uRBC were added to duplicate or 
triplicate wells at the concentrations given above; the superantigen staphylococcal enterotoxin B 
(SEB) (2 jig/ml, Sigma) was used as a positive control. 
Cytokine assays 
Cell culture supernatants were tested for presence of IFN-'y, IL- 12p4O and IL- 10 by two site 
capture ELISA. Flat-bottomed, 96 well microtitre plates (Immulon IV) were coated overnight 
with lOOj.tl per well of an optimal concentration of capture antibody diluted in PBS. Plates were 
washed 4 times with PBS plus 0.05% Tween 20, blocked with 200 Ill/well blocking buffer (PBS 
plus 4% bovine serum albumin, Sigma) for 1 hour at 37°C and washed three more times. Culture 
supernatants or cytokine standards (1 OOjil/well) were added to duplicate wells and incubated at 
room temperature for 3 hours. After washing four times, 100111 /well of biotinylated capture 
antibody (diluted in PBS) was added and incubated for 1 hour at room temperature. Plates were 
washed 6 times, avidin-labelled horse-radish peroxidase (1 jig/ml, Sigma) added for 30 minutes 
at room temperature and after a final 8 washes, plates were developed for 15 minutes at room 
temperature with hydrogen peroxide as substrate and o-phenylenediamine as chromagen. The 
reaction was stopped with 2M H2SO4 and absorbance read at 492 nm. 
Antibody pairs for IL- 10 and IFN-y, and all cytokine standards, were obtained from Endogen, 
Woburn, MA, USA. The anti-IL-12 antibody pair was obtained from R&D systems. Coating 
antibodies for IL- 10 and IFN-y were used at 2 jig/ml, coating antibody for IL- 12p4O was used at 
4 jig/mi. Biotinylated antibody to IIL-10 and IFN-y were used at 0.05 jig/mi, antibody to IL-12p40 
was used at 0.3 jig/nil. 
Cytokine concentrations were calculated from standard curves using best fit formulae. The lower 
limit of detection (LLD) was defined as 2 SD above the mean of the negative control (culture 
medium alone). Limited volumes of culture supernatants precluded the evaluation of additional 
cytokines. 
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Intracellular cytokine staining 
Eighteen hours prior to staining, 3Ig/ml Brefeldin A (Sigma) was added to cell cultures to block 
secretion of cytokine from the endoplasmic reticulum. Cells were washed with PBS, resuspended 
at 2x106 cells/mi in PBS with 1% foetal bovine serum (FBS, Sigma) and 0.1% NaN3, and double-
stained with labelled antibodies to CD3 (tricolour) and either CD56 (PE), TcRc3 (FITC) or 
TcR1 (FITC) (all from T Cell Sciences, Claydon, UK). Cells were incubated at 4°C for 40 
minutes, washed in PBS, resuspended in 3001.11 PBS with 4% paraformaldehyde (BDH, Poole, 
UK) and incubated in the dark, at room temperature for 15minutes. After washing, cells were 
resuspended in 300p.l PBS with 1% FBS, 0.3% saponin (BDH) and 0.1% NaN3 containing 2 ig 
of anti-IFN-y antibody, labelled with either FITC JCS) or PE (Becton-Dickinson, London UK), 
and incubated in the dark for 30 minutes at 4°C. Finally, cells were washed once in saponin/PBS 
and resuspended in 0.5m1 PBS for analysis by three colour flow cytometry (FACscan, Becton-
Dickinson). 
Statistical methods 
Differences between groups were assessed by Student's t test on log-transformed data. 
Differences in response to different treatments within a group, were assessed by paired t tests 
comparing treated and control cells from the same donors. For antigen-specific responses, where 
background or uRBC values were subtracted and thus some negative values were obtained, the 
non-parametric Mann Whitney U test was used. 
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Results 
The three groups of donors were clearly distinguishable on the basis of their clinical history, 
malaria infection rates and serological responses to soluble malaria antigens (Table I). The naive 
donors had no previous history of malaria infection and antibody levels were within the normal 
range defined by non-immune sera. The majority of the exposed but non-immune donors 
reported a clinical malaria infection (confirmed by microscopy and treated with anti-malarial 
drugs) within the last five years. Only one of the donors had a subclinical malaria infection at the 
time of blood sampling. Several donors had anti-malarial antibody levels below the cut-off level 
defined by non-immune sera and the mean antibody titre was only 41% of the hyperimmune 
control serum. In contrast, in the clinically immune group, only one donor reported a confirmed 
clinical malaria attack in the past five years, 8 donors were subclinically infected at the time of 
sampling (two detected by blood film, and 6 by PCR), all donors were seropositive and mean 
antibody titers were 87% of the hyperimmune control. 
Lymphoproliferative responses 
Proliferative responses were assessed after 3, 5 and 7 days. Cells from all donors proliferated 
strongly to PHA, showing that cells were viable (data not shown). In all three groups, the 
geometric mean SI for PfSE/uRBC increased steadily with time (Figure 1), but there was no 
significant difference in the mean SI between the groups. The only noticeable difference between 
the groups was that responses appeared slightly earlier in the exposed group than in the other two 
groups (cells from 13/19 donors gave an SI ~! 2.5 at day 2 compared to 6/19 naives and 8/18 
immunes). 
IFN- yproduction 
IFN-y in cell supernatants was measured after 2, 4 and 6 days (Figure 2). For naive donors, IFN-y 
levels in cultures stimulated with PfSE rose steadily over time, reaching a geometric mean value 
of 224 pg/ml at day 6. IFN-y levels in PfSE cultures were significantly higher than in uRBC 
cultures on days 4 and 6 (paired t ~!, df =18, P <0.002). For malaria-exposed donors, PfSE-
specific IFN-y levels rose to a mean of > 900 pg/ml at 6 days, were significantly higher than in 
uRBC-stimulated cultures on days 2,4 and 6 (paired t ~! 3.46, df> 17 P <0.003 on all days) and 
were significantly higher than for naive donors at both 4 and 6 days (Mann-Whitney U = 253, df 
= 35, p <0.001). In contrast, for immune donors, geometric mean IFN-y levels increased only 
marginally over time and the difference between uRBC-stimulated and PfSE-stimulated cultures 
was minimal. Malaria specific IFN-y levels were significantly lower in immune donors than in 
either the naive or the exposed group at both day 4 and day 6 (Mann-Whitney U, W> 230, df> 
29, P < 0.008 at day 4, P <0.001 at day 6). 
However, despite the clear differences between the groups in mean IFN-y levels, it is worth 
noting that not all naïve donors cells produced IFN-y and that a proportion of "clinically-
immune" donors cells did produce IFN-'y, albeit transiently and at low levels. The number of 
IFN-y responders (defined as donors whose cells produced at least twice as much IFN-y in PfSE-
stimulated cultures as in uRBC cultures on at least one of the days tested) was highest for 
exposed donors (19/20, 95%), intermediate for naïve donors (14/19, 74%) and lowest for 
immune donors (5/20, 25 %). 
IL-12 production 
IL- 12 p40 was measured by ELISA in 1, 2, 4, 6 and 8 day supernatants of PfSE-stimulated 
cultures. As IL-12 levels peaked at day 2 in all donors, only day 2 data is shown (Figure 3). 
Overall, levels of PfSE-specific IL-12 in supernatants were very low. Cells from exposed donors 
produced up to 530 pg/ml PfSE-specific IL-12, but levels varied widely between individuals. 
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Median IL- 12 levels were not significantly different between the groups and values obtained for 
PfSE-stimulated cells were not significantly different from values for uRBC-stimulated cultures 
(paired t tests in all 3 groups). However, when individuals are classified as either responders or 
non-responders (where a responder is defined as PfSE IL-12 - uRBC IL-12 > 20 pg/ml) then 
only 11% of naïve donors (2/18) were responders but 45% (9/20) of exposed and 35% (7/20) of 
immune donors responded. 
Relationship betwen IL-12 and IFN-yproduction. 
When IL- 12 and IFN-y production were compared in individual donors it was clear that the peak 
in IL- 12 production preceded the rise in IFN-y production; IL- 12 levels tended to peak at day 1 
or day 2 whilst IFN-y levels typically began to increase at day 4 (data not shown). To determine 
whether there was a causal association between IL-12 and IFN-y levels, neutralising antibodies to 
IL-12 (or control, isotype-matched antibodies) were added to PfSE-stimulated or uRBC-
stimulated cell cultures and IFN-1 levels were measured (Figure 4). 
Addition of anti-IL-12 or control IgG had no significant effect on lymphoproliferative responses 
(data not shown), but reduced IFN-1 production in all groups of donors. 
As described above, cells from naive donors produced modest, but significant, amounts of IFN-y. 
In the presence of neutralising antibody to IL-12, IFN-y levels were reduced to background levels 
(Fig 4a), indicating that IFN-y production from naive cells is IL-12 dependent. Differences in 
IFN-1 production between anti-IL- 12 treated and control cultures were significant on days 2, 4 
and 6 but the effect was most marked at day 6 (paired t = 3.05, df= 13, p = 0.009). Cells from 
exposed donors produced much higher levels of IFN-y than cells from naïve donors and in the 
presence of anti-IL- 12, IFN-1 levels were also significantly reduced at all time points (paired t > 
3.4 1, df =19, P 0.003 on all days) (Fig 4b). However, anti-IL-12 did not completely inhibit 
IFN-y production and at day 6 IFN-y levels were still significantly higher than in unstimulated 
cultures (t = 5.2, df= 16, P <0.001) or in PfSE-stimulated cultures of naive cells (t =4.56, df= 
32, p < 0.001). These data indicate that, in malaria-exposed donors, IFN-y production may derive 
from more than one cellular source, only one of which is IL- 12 dependent. Cells from malaria-
immune donors made very little IFN-y, nevertheless the addition of anti-IL-12 reduced IFN-y 
levels to background values and the difference between control and anti-EL- 12 cultures was 
marginally significant at day 6 (paired t = 2.18, df =19, P = 0.042) (Fig 4c). 
Cellular source of IFN-y 
In order to determine the cellular source of IFN-y in PfSE-stimulated cell cultures, cells from 
three naïve donors were cultured for 7 days in the presence of PfSE, uRBC, or (as a positive 
control) the superantigen SEB, stained for cell surface markers CD3, CD56, TcRc43 and 
TcRyö, permeabilised and counterstained for intracellular IFN-y. Labelled cells were analysed by 
three colour flow cytometry. Resting lymphocytes and lymphoblasts were gated and analysed 
separately. As can be seen from Figure 5, the majority of the [FN-y positive cells were in the 
lymphoblast population, so these cells were examined in detail (Table II). In all donors, the 
proportion and absolute number of lymphoblasts was higher in PfSE-stimulated cultures than in 
control uRBC cultures (mean, SD, 4.70 ± 1.77% compared with 1.58 ± 0.45%). Of the PfSE-
induced lymphoblasts, 11-28% were CD3-, CD56+ (i.e. NK cells) and 85-100% of these cells 
were also positive for IFN-y. Sixty to 80% of lymphoblasts were TCRc4+ and 70-95% of these 
cells were IFN-y-i-. Sixteen to 26% of lymphoblasts were TCRy+ and 100% of these cells were 
IFN-y-i-. Thus, the IFN-y-producing cells appear to be a mixed population of NK cells, c43 T cells 
and y8 T cells with approx 60% of the cells being a13  T cells. 
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IL-10 production 
The finding that cells from clinically immune individuals produce minimal amounts of IFN-y in 
response to malaria antigen stimulation is consistent with our hypothesis that clinical immunity 
to malaria is associated with down-regulation of the inflammatory cytokine response, but does 
not tell us how this down-regulation occurs. Also, the fact that cells from malaria-exposed 
individuals produce markedly higher levels of IFN-y than naïve donors, but are not obviously at 
greater risk of severe malaria, suggests that they may have developed mechanisms for 
ameliorating the impact of these high IFN-y levels. Therefore, we measured levels of the anti-
inflammatory cytokine IL-10 in cell supernatants to determine whether differences in IL-10 
production might explain either the down-regulation of the IFN-y response or the ability of 
exposed individuals to avoid severe consequences of malaria in the presence of a strong pro-
inflammatory response. 
Overall, levels of malaria-specific IL-10 were extremely low in all cultures on all days. There 
were no significant differences between the three groups in mean EL-10 levels (Table III) but 
when individuals were classified as either IL- 10 responders or non-responders to PfSE, the 
highest number of responders was seen in the exposed group and the lowest number of IL- 10 
responders was seen in the immune group. This same pattern was observed in PHA-induced IL-




Clinical immunity to malaria is characterised by the ability to limit blood parasite densities to 
extremely low levels and by the failure to show symptoms of infection. The mechanisms by 
which parasite numbers are controlled are not entirely clear but recent evidence supports a role 
for antibody-dependent cell-mediated inhibition of parasite growth (ADC), which involves both 
parasite-specific antibodies and the release of inflammatory cytokines from 
monocyte/macrophages (39). The clinical symptoms of malaria are related to the presence of 
circulating pro-inflammatory cytokines such as TNF-a (1) but the risk of clinical disease also 
increases with increasing parasite density (40). It is therefore not clear whether the acquisition of 
clinical immunity is due simply to the development of anti-parasitic mechanisms which keep 
parasite densities below a critical threshold or whether the ability to regulate inflammatory 
cytokine production is also involved. One piece of clinical evidence that points to the importance 
of the latter is that parasite densities which are well tolerated by immune individuals can be 
accompanied by severe febrile symptoms in non-immunes (40). 
For many years it was believed that glycophospholipid components of the parasite, possibly 
derived from the membrane anchors of surface antigens (41), directly induced macrophages to 
secrete TNF-a (42,43) but the notion that this is sufficient to mediate the pathology of malaria 
has recently been questioned (44). We have postulated that IFN-y is required to induce 
sufficiently high levels of inflammatory mediators to cause disease and that the ability to down-
regulate IFN-'y production (or its effects) may be a pre-requisite for clinical immunity (32). To 
date, this hypothesis is supported only by two small studies showing that levels of malaria-
induced IFN-y are lower in African adults than in European adults living in Africa (27,28). 
In this study, we have directly addressed the relationship between clinical immunity to malaria 
and the tendency of PBMC to produce either pro-inflammatory or anti-inflammatory cytokines in 
response to stimulation with a crude preparation of malaria antigens - an antigen preparation 
which we believe closely represents the pool of circulating antigen released into the peripheral 
circulation at the time of schizont rupture. The selection of peripheral blood as the source of 
leucocytes is dictated by practical constraints but has been validated in many previous studies: 
although malaria-reactive T cells tend to disappear from the peripheral circulation during an 
acute infection (probably migrating to the spleen and liver) they are released back into the 
periphery upon resolution of the infection (45) and it is thus realistic to assume that, in healthy 
individuals, the peripheral T cell population is representative of the total malaria-reactive T cell 
pool. 
Subjects were allocated to naive, exposed or immune groups according to their place of residence 
and before any laboratory analyses (parasite detection, serology or cellular assays) were 
performed. Parasite detection and serology confirmed our allocation of individuals to appropriate 
groups, with the possible exception of one person in the exposed group (who had a low density, 
asymptomatic infection at the time of sampling and might therefore be regarded as clinically 
immune) and one person in the immune group (who reported a clinical attack of malaria 9 
months previously and might therefore be considered exposed but non-immune). However, to 
avoid selection bias, neither of these subjects were reallocated to alternative groups. 
The most marked differences in cellular immune responses between the groups were in the 
amounts of IFNi produced following in vitro stimulation with PfSE. The low mean levels of 
IFN-y production by cells from immune donors (and the complete lack of malaria-induced IFN-'y 
production by 75% of these donors) strongly supports the hypothesis that clinical immunity to 
malaria is accompanied by down-regulation of the pro-inflammatory immune response. 
The mechanism by which IFN-y levels are down-regulated in immune donors is not clear. Direct 
antagonism by IL-10 seems unlikely given the failure to detect significant levels of IL-10 in 
PfSE-stimulated cell supernatants; another recent study also failed to find significant induction of 
IL- 10 from PBMC by P.falciparum extracts (46). Plasma levels of IL- 10 are raised during 
clinical malaria episodes, and are higher in severe cases than in uncomplicated cases (47-49) but 
levels are not raised in children with asymptomatic malaria infections, suggesting that EL- 10 is 
upregulated in parallel with pro-inflammatory cytokines but that it does not, in fact, play a major 
anti-inflammatory role. 
The lack of detectable cytokine production in response to PfSE in immune individuals is not due 
to T cell anergy; PBMC from immune individuals proliferated in response to PfSE to the same 
extent as cells from other donors and thus, presumably, produce [L-2. It remains to be seen 
whether these proliferating cells produce any other cytokines which may down-regulate 
inflammatory responses. A prime candidate for such a cytokine would be TGF-3: we have 
recently shown a causal association between low TGF-3 levels and severity of malaria in mice 
(16) and the plasma of acute P. falciparum patients contains lower than normal levels of 
circulating TGF-f3 (50). A potential mechanism of TGF-f3 action is down-regulation of IL- 12-
mediated IFN-y induction by inhibiting expression of the IL-12 receptor on T cells (51). 
Although we could not detect significant levels of free IL- 12 in most PfSE-stimulated PBMC 
supernatants, and IL- l2p40 mRNA could not consistently be detected by RT-PCR (data not 
shown), neutralisation of IL-12 with antibody had a significant effect on IFNy production, 
demonstrating that this cytokine does play a role in the inflammatory cytokine response to 
malaria parasites. 
Cells from naïve donors produced moderate levels of IFN-y, commensurate with the known risk 
of non-immune adults developing clinical malaria during their first infection. The IFN-y response 
appeared to be strongly IL- 12 dependent suggesting that NK cells may be the prime source of 
IFN-y in these donors. However, there was some variation between donors in the effects of anti-
IL-12 and in some naïve individuals anti-IL-12 only partially blocked IFN-y production. 
Intracellular cytokine staining of PfSE-activated PBMC's from naïve donors indicated that IFN-y 
is produced by a mixed population of blasting cells, predominantly c43 T cells but with 
significant numbers of NK cells and y8 T cells. These data correlate well with previous 
observations that in naïve donors PfSE activates mainly CD3+ TCRc43+ cells, that 'y+ T cells 
can also be activated under certain circumstances and that both populations can produce IFN-y 
(29-31,52). The c43 T cells are believed to have been primed by cross-reacting antigens present in 
a number of commensal organisms and common pathogens (53) whereas y8 T cells recognise 
phosphorylated non-protein antigens (54). Cytokine production by malaria-activated human NK 
cells has not previously been reported, although activation of NK cells by during malaria 
infection has been observed (55). 
Interestingly, cells from malaria-exposed donors produced very much higher levels of IFN-y than 
naïve donors and this response was only partly IL-12-dependent. The most plausible explanation 
for this would be that malaria-exposed donors possess an additional population of IFN-y-
producing T cells, specifically primed by malaria antigens rather than cross-reacting antigens. 
Further experiments are required to determine the cellular source of IFN-1 in this population. 
Despite producing very high levels of IFN-y in response to malaria antigens, exposed donors are 
not expected to be at any greater risk of severe malaria than naïve donors and their risk may 
indeed be lower. This suggests that the downstream effects of IFN-y production - for example 
induction of TNF-a - may be being inhibited to avert serious pathology. As in immune donors, 
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malaria antigens did not appear to induce significant levels of IL-10 (although cells from almost 
half the exposed donors did produce some IL- 10 after stimulation with PfSE) but other 
cytokines, such as TGF-, may a play role in controlling the down-stream effects of IFN-y In 
mice infected with malaria, TGF-3 inhibited TNFa production without any significant effect on 
IFN-y levels (16). 
In summary, we have shown that there is strong association between IFN-y production by PBMC 
in response to malaria antigen stimulation and the immune status of the donor. Specifically, 
PBMC from malaria-immune individuals, who are able to resolve malaria infections without 
developing clinical disease, produce negligible levels of IFN-y. In contrast both T cells and NK 
cells from non-immune individuals produce moderate levels of ffN- in an IL- 12-dependent 
manner. Intriguingly, the highest levels of IFN-y were observed in partially-immune donors who 
develop clinical symptoms of infection but are at relatively low risk of severe disease. Further 
studies are required to elucidate the mechanisms by which IFN-'y production is down-regulated in 
malaria-immune individuals. 
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FIGURE 1: Lymphoproliferative responses 
Lymphoproliferative responses to P. falciparum schizont extract (PfSE) in PBMC from malaria 
naïve (•), exposed (A) and immune (0) donors. Geometric mean SI (PfSE/uRBC), 95% Cl. 
FIGURE 2: Interferon-7 production 
PfSE-specific (PfSE-uRBC) IFN-y production (pg/mi) by PBMC from malaria naïve (U), 
exposed (A) and immune () donors (median and 75" percentile). 
FIGURE 3: IL-12 p40 production 
PfSE-specific (PfSE-uRBC) IL-12 p40 (pg/mi) in 48 hour PBMC supernatants from malaria 
naïve, exposed and immune donors. Figures indicate median values for each group. 
FIGURE 4: Effect of neutralising antibodies to IL-12 on IFN-y production. 
Effect of neutralising antibodies to IL- 12 (5ig/m1) on PfSE-induced IFN-'y production (pg/mi) 
from PBMC from (a) naïve, (b) exposed and (c) immune donors. (Mean, upper 95% Q. 
FIGURE 5: Intracellular staining for IFN-y 
Intracellular cytokine staining to determine the cellular source of IFN-y in PBMC from a malaria 
naïve donor cultured for 7 days with either SEB (panels a,d,g), PfSE (b,e,h) or uRBC (c,f,i). 
Lymphocytes were divided into resting cells (R 1) and lymphoblasts (R2) on the basis of forward 
and side scatter (panels a to c) and. and stained for CD3 (vertical axis) and IFN-y (horizontal 
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axis) (panels d-i). Few WN-y+ cells were seen in the resting population (panels d-f) but TFN-y+ 
cells were seen in the blasting population (panels g-i). In PfSE-stimulated cultures, IFN-y+ cells 
were predominantly CD3+ but some CD3 cells were also IFN-y-i-. 
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Table I: Details of blood donors 
Naive (UK) Exposed (Accra) Immune (Dodowa) 
N 19 20 20 
Age range (years) 20-41 21-60 30-47 
Pf Blood film + (%) 0(0%) 0(0%) 2(10%) 
Pf PCR + (%) 0(0%) 1(5%) 6(30%) 
Antibody + (%) 0(0%) 13(68%) 20(100%) 
Mean Ab*  (SEM) 0.05 (0.004) 0.41 (0.06) 0.87 (0.08) 
Range 0.04-0.08 0.13-1.01 0.24-1.43 
Confirmed clinical 	 0(0%) 	 14(70%) 	 1(5%) 
malaria in the last 5 
years? (%) 
*Individual Ab OD values are expressed as a ratio of the value of a high titre pool of malaria 
immune serum from African donors. 
Table II: Phenotyping of IFN-secreting cells by flow cytometry. 
Absolute numbers of lymphoblasts (x 10) after 7 days stimulation of 2 x 106  PBMC from 
malaria naïve donors. (Mean ± SE, n = 3). 
PfSE uRBC SEB 
Total 38±8.1 13±2.3 208±40.5 
CD3+ 31±6.9 11± 1.7 143±23 
CD3+[FN-y+ 22±6.9 7±0.6 109±4.1 
CD56+ 7±2.3 1±0.6 17± 1.7 
CD56+IFN-y-i- 7±2.3 1±0.6 20±2.3 
TCR c43+ 25 ± 6.4 10±1.7 88 ± 9.3 
TCR ctI3+IFN-y+ 20±6.4 7±1.2 89±9.3 
TCR yö+ 8 ± 2.3 1 ± 0.6 51 ± 12.7 
TCRy&-WN-y+ 8±2.3 1±0.6 38±11.6 
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Table III: IL-JO concentration (pg/mi) in PBMC supernatants after 2 days in culture. 
uRBC 
PfSE PHA 
Naïve (n = 19) 
Mean 
68.7 68.4 194.7 
SE 
10.5 9.3 28.0 
responders %  21.1 100.0 
Exposed (n = 20) Mean 74.1 70.8 201.5 
SE 8.9 7.7 33.4 
responders %  45.0 95.0 
Immune (n = 18) Mean 41.5 43.2 70.3 
SE 0.5 1.5 7.3 
responders %  11.1 94.4 
Responder: PfSE-induced IL-10 ~! 5 pg/mi higher than control (uRBC) value. 
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